

00859737-24-00002010-Q HOLGIC INC 212573020420730166064160604 0 0000859737-24-000020 10-Q 109 20240629 20240730 20240730 HOLGIC INC 0000859737 3844
042902449 DE 0928 10-Q 34 001-36214 INC 241157355 250 CAMPUS DRIVE MARLBOROUGH MA 01752 5082632900 250 CAMPUS DRIVE MARLBOROUGH MA 01752 10-Q 1 holx-20240629.htm
10-Q holx-20240629false2024Q300008597379-28P3MP1YPIYP1YPIY156xbri:sharesiso4217:USDiso4217:USDxbri:sharesxbri:pureholx:Segment00008597372023-10-012024-06-
2900008597372024-07-250000859737us-gaap:ProductMember2022-03-312024-06-290000859737us-gaap:ProductMember2023-04-022023-07-010000859737us-gaap:ProductMember2023-10-
012024-06-290000859737us-gaap:ProductMember2022-09-252022-07-010000859737us-gaap:ServiceMember2024-03-312024-06-290000859737us-gaap:ServiceMember2023-04-022023-07-
010000859737us-gaap:ServiceMember2023-10-012024-06-290000859737us-gaap:ServiceMember2022-09-252022-07-0100008597372024-03-312024-06-2900008597372023-04-022023-07-
0100008597372022-09-252022-07-0100008597372024-06-2900008597372023-09-300000859737us-gaap:CommonStockMember2022-09-240000859737us-
gaap:AdditionalPaidInCapitalMember2022-09-240000859737us-gaap:RetainedEarningsMember2022-09-240000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-
240000859737us-gaap:TreasuryStockCommonMember2022-09-2400008597372022-09-240000859737us-gaap:CommonStockMember2022-09-252022-12-310000859737us-
gaap:AdditionalPaidInCapitalMember2022-09-252022-12-3100008597372022-09-252022-12-310000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-252022-12-
310000859737us-gaap:TreasuryStockCommonMember2022-09-252022-12-310000859737us-gaap:CommonStockMember2022-12-310000859737us-gaap:AdditionalPaidInCapitalMember2022-12-
310000859737us-gaap:RetainedEarningsMember2022-12-310000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000859737us-
gaap:TreasuryStockCommonMember2022-12-3100008597372022-12-310000859737us-gaap:CommonStockMember2023-01-012023-04-010000859737us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-04-0100008597372023-01-012023-04-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-04-
010000859737us-gaap:TreasuryStockCommonMember2023-01-012023-04-010000859737us-gaap:CommonStockMember2023-04-010000859737us-gaap:AdditionalPaidInCapitalMember2023-04-
010000859737us-gaap:RetainedEarningsMember2023-04-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-010000859737us-
gaap:TreasuryStockCommonMember2023-04-0100008597372023-04-010000859737us-gaap:CommonStockMember2023-04-022023-07-010000859737us-
gaap:AdditionalPaidInCapitalMember2023-04-022023-07-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-022023-07-010000859737us-
gaap:TreasuryStockCommonMember2023-04-022023-07-010000859737us-gaap:CommonStockMember2023-07-010000859737us-gaap:AdditionalPaidInCapitalMember2023-07-
010000859737us-gaap:RetainedEarningsMember2023-07-010000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-010000859737us-
gaap:TreasuryStockCommonMember2023-07-0100008597372023-07-010000859737us-gaap:CommonStockMember2023-07-022023-09-300000859737us-
gaap:AdditionalPaidInCapitalMember2023-07-022023-09-3000008597372023-07-022023-09-300000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-022023-09-
300000859737us-gaap:TreasuryStockCommonMember2023-07-022023-09-300000859737us-gaap:CommonStockMember2023-09-300000859737us-gaap:AdditionalPaidInCapitalMember2023-
09-300000859737us-gaap:RetainedEarningsMember2023-09-300000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000859737us-
gaap:TreasuryStockCommonMember2023-09-300000859737us-gaap:CommonStockMember2023-10-012023-12-300000859737us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-
3000008597372023-10-012023-12-300000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-300000859737us-gaap:TreasuryStockCommonMember2023-10-
012023-12-300000859737us-gaap:AdditionalPaidInCapitalMemberholx:AcceleratedShareRepurchaseAgreementMember2023-10-012023-12-300000859737us-
gaap:TreasuryStockCommonMemberholx:AcceleratedShareRepurchaseAgreementMember2023-10-012023-12-300000859737holx:AcceleratedShareRepurchaseAgreementMember2023-10-
012023-12-300000859737us-gaap:CommonStockMember2023-12-300000859737us-gaap:AdditionalPaidInCapitalMember2023-12-300000859737us-gaap:RetainedEarningsMember2023-12-
300000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-300000859737us-gaap:TreasuryStockCommonMember2023-12-3000008597372023-12-300000859737us-
gaap:CommonStockMember2023-12-312024-03-300000859737us-gaap:AdditionalPaidInCapitalMember2023-12-312024-03-300000859737us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-312024-03-300000859737us-gaap:AdditionalPaidInCapitalMemberholx:AcceleratedShareRepurchaseAgreementMember2023-
12-312024-03-300000859737us-gaap:TreasuryStockCommonMemberholx:AcceleratedShareRepurchaseAgreementMember2023-12-312024-03-
300000859737holx:AcceleratedShareRepurchaseAgreementMember2023-12-312024-03-300000859737us-gaap:CommonStockMember2024-03-300000859737us-
gaap:AdditionalPaidInCapitalMember2024-03-300000859737us-gaap:RetainedEarningsMember2024-03-300000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-
300000859737us-gaap:TreasuryStockCommonMember2024-03-3000008597372024-03-300000859737us-gaap:CommonStockMember2024-03-312024-06-290000859737us-
gaap:AdditionalPaidInCapitalMember2024-03-312024-06-290000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-312024-06-290000859737us-
gaap:TreasuryStockCommonMember2024-03-312024-06-290000859737us-gaap:CommonStockMember2024-06-290000859737us-gaap:AdditionalPaidInCapitalMember2024-06-
290000859737us-gaap:RetainedEarningsMember2024-06-290000859737us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-290000859737us-
gaap:TreasuryStockCommonMember2024-06-290000859737holx:SSIUltrasoundImagingBusinessMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-09-
300000859737us-gaap:ScenarioPlanMemberholx:EndomagneticsLtdMember2024-04-262024-04-260000859737country:USHolx:DiagnosticsMemberholx:CytologyPerinatalMember2024-03-
312024-06-290000859737holx:DiagnosticsMemberholx:CytologyPerinatalMemberholx:InternationalMember2024-03-312024-06-
290000859737holx:DiagnosticsMemberholx:CytologyPerinatalMember2024-03-312024-06-290000859737country:USHolx:DiagnosticsMemberholx:CytologyPerinatalMember2023-04-022023-07-
010000859737holx:DiagnosticsMemberholx:CytologyPerinatalMemberholx:InternationalMember2023-04-022023-07-010000859737holx:DiagnosticsMemberholx:CytologyPer

[illegible]

[illegible]

from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and nine months ended June 29, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 28, 2024. Fiscal 2023 was a 53-week fiscal year, and the additional week was included in the first quarter of fiscal 2023 consistent with the Company’s historical fiscal calendar. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three and nine months ended June 29, 2024. On April 26, 2024, the Company executed an agreement to acquire Endomagnetics Ltd (‘‘Endomag’’) for a purchase price of approximately \$310.0A million, subject to working capital and other customary adjustments. Endomag, located in the UK, develops and sells breast surgery localization and lymphatic tracing technologies. The transaction closed on July 25, 2024. Table of Contents (2) Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customers (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: A A A Three Months Ended June 29, 2024 Three Months Ended July 1, 2023 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal \$73.3A \$48.9A \$122.2A \$79.7A \$47.1A \$126.8A Molecular Diagnostics 245.4A 65.3A 310.7A 240.2A 62.0A 302.2A Blood Screening 7.9A 9A 17.9A 7.9A 10.7A 18.6A Total \$326.6A \$114.2A \$440.8A \$330.6A \$109.1A \$439.7A Breast Health: Breast Imaging 240.4A \$68.8A \$309.2A \$220.7A \$65.4A \$286.1A Interventional Breast Solutions 60.1A 15.7A 75.8A 59.2A 15.0A 74.2A Total \$300.5A \$84.5A \$385.0A \$279.9A \$80.4A \$360.3A GYN Surgical 125.8A 40.8A \$166.6A \$122.9A \$34.4A \$157.3A Skeletal Health 12.4A \$6.6A \$19.0A \$16.7A \$10.4A \$27.1A \$765.3A \$246.1A \$1,011.4A \$750.1A \$234.3A \$984.4A Nine Months Ended June 29, 2024 Nine Months Ended July 1, 2023 Business (in millions) United States International Total United States International Total Diagnostics: Cytology & Perinatal \$213.7A \$149.0A \$362.7A \$226.9A \$138.5A \$365.4A Molecular Diagnostics 748.4A 204.8A 953.2A 831.5A 238.2A 1,069.7A Blood Screening 22.8A 9A 31.8A 22.8A 28.5A 51.3A Total \$984.9A \$353.8A \$1,338.7A \$1,086.9A \$376.7A \$1,463.6A Breast Health: Breast Imaging 703.7A \$213.6A \$917.3A \$666.5A \$195.6A \$862.1A Interventional Breast Solutions 181.6A 48.4A 230.0A 176.7A 41.1A 217.8A Total \$885.3A \$262.0A \$1,147.3A \$843.2A \$236.7A \$1,079.9A GYN Surgical \$366.6A \$118.2A \$484.8A \$359.6A \$96.6A \$456.2A Skeletal Health \$41.6A \$29.9A \$71.5A \$52.8A \$32.6A \$85.4A \$2,278.4A \$763.9A \$3,042.3A \$2,342.5A \$742.6A \$3,085.1A Table of Contents Three Months Ended Nine Months Ended Geographic Regions (in millions) June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 United States \$765.3A \$750.1A \$2,278.4A \$2,342.5A Europe 127.9A 128.5A 407.7A 427.3A Asia-Pacific 65.0A 62.9A 193.2A 191.9A Rest of World \$52.3A 42.9A 163.0A 123.4A \$1,011.4A \$984.4A \$3,042.3A \$3,085.1A The following table provides revenue recognized by source: Three Months Ended Nine Months Ended Revenue by type (in millions) June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Disposables \$623.2A \$609.0A \$1,871.0A \$1,963.3A Capital equipment, components and software 188.0A 190.1A 596.2A 559.6A Service 196.8A 180.4A 560.6A 546.7A Other 3.4A 4.9A 14.5A 15.5A \$1,011.4A \$984.4A \$3,042.3A \$3,085.1A The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of 1) Table of Contents the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company’s financial statements. Remaining Performance Obligations As of June 29, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately \$880.0 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 14% of this amount as revenue in fiscal 2024, 42% in fiscal 2025, 25% in fiscal 2026, 12% in fiscal 2027, and 7% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of \$22.8A million and \$124.4A million in the three and nine months ended June 29, 2024, respectively, that was included in the contract liability balance at September 30, 2023. The Company recognized \$21.0A million and \$122.2A million in the three and nine months ended July 1, 2023, respectively, that was included in the contract liability at September 24, 2022. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts. 12 Table of Contents (3) Leases Lessor Activity - Leases where Hologic is the Lessor Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company’s consolidated revenue for all periods presented. (4) Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in money market funds, United States Treasury bills and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents on the Consolidated Balance Sheets. The Company also has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs. The following table summarizes certain fair value information at June 29, 2024 and September 30, 2023 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments. 13 Table of Contents A Fair Value at Reporting Date Using A Fair Value Quoted Prices in Active Market A Identical Assets (Level 1) Significant Other Observable Inputs A (Level 2) Significant Unobservable Inputs A (Level 3) June 29, 2024 Assets: Money market mutual funds \$371.2A \$371.2A \$A A U.S. Treasury bills 398.1A 398.1A A A Commercial paper 49.5A 49.5A A A Interest rate swaps 14.7A 14.7A A A Forward foreign currency contracts 2.6A 2.6A A A Total \$836.1A \$818.8A \$17.3A A Liabilities: Contingent consideration \$1.1A \$A A A Forward foreign currency contracts 0.4A A A A Total \$1.5A \$A A A \$0.4A \$1.1A September 30, 2023 Assets: Interest rate swaps \$26.9A \$A A A \$26.9A A A Forward foreign currency contracts 3.4A A A A Total \$35.3A \$A A A \$35.3A A A Liabilities: Contingent consideration \$2.0A \$A A A \$2.0A Total \$2.0A \$A A A \$2.0A Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and nine month periods ended June 29, 2024 and July 1, 2023 were as follows: Three Months Ended Nine Months Ended June 29, 2024 July 1, 2023 June 29, 2023 July 1, 2023 Balance at beginning of period \$1.1A \$3.4A \$2.0A \$23.4A Contingent consideration recorded at acquisition A 1.1A A 1.1A Fair value adjustments A A 1.7A (12.4) Payments A A (2.6) (7.6) Balance at end of period \$1.1A \$4.5A \$1.1A \$4.5A Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, primarily comprised of property, plant and equipment, intangible assets and goodwill. During the third quarter of fiscal 2024, the Company recorded intangible asset impairment charges of \$13.3A million and \$0.4A million, respectively, related to its BioZorb developed technology and trade name intangible assets acquired in the Focal acquisition, which is within the Breast Health reportable segment, reducing the carrying value of the assets to zero. During the second quarter of fiscal 2024, the Company recorded intangible asset impairment charges of \$25.9A million and \$0.9A million, respectively, related to its BioZorb developed technology and trade name intangible assets reducing the carrying value of the assets to \$13.9A million and \$0.5A million, respectively. See Note 18 for further discussion. During the first quarter of fiscal 2024, the Company recorded a \$12.5A million impairment charge for right-of-use lease assets related to the closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying 14 Table of Contents value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a \$4.3A million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to \$22.4A million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded impairment charges aggregating \$186.9A million, of which \$174.8A million was allocated to intangible assets and \$12.1A million was allocated to property, plant and equipment. Subsequent to the impairment charges, the carrying value of the definite-lived intangible assets and property, plant and equipment was \$65.8A million and \$4.6A million, respectively. See Note 18 for additional information. In addition, the Company recorded a \$10.5A million impairment charge for an in-process research and development project from the Mobidiag acquisition, and the resulting carrying value was \$26.5A million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its SSI ultrasound imaging business and recorded impairment charges aggregating \$26.4A million, of which \$20.6A million was allocated to intangible assets and \$5.8A million was allocated to equipment. Subsequent to the impairment charges, the carrying value of these assets was zero. There were no other remeasurements in the three and nine months ended June 29, 2024 and July 1, 2023. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury bills, commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s United States Treasury bills, commercial paper, interest rate swaps and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. The Company’s cash and cash equivalents, including current marketable securities, as of June 29, 2024 are as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash \$1,620.3A \$A A \$1,620.3A \$A A \$1,620.3A \$A A Money market mutual funds 371.2A A A A 371.2A 371.2A A A U.S. Treasury bills 398.1A A A 398.1A 398.1A A A Commercial paper 49.5A A A A 49.5A 49.5A A A Total \$2,439.1A \$A A \$2,439.1A \$A A \$2,439.1A \$A A The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the three and nine months ended June 29, 2024. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference

between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the three and nine months ended June 29, 2024. The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and nine months ended June 29, 2024 and July 1, 2023, respectively. There were no sales of available-for-sale securities during the three and nine months ended June 29, 2024. The fair value of the available-for-sale securities by contractual maturity as of June 29, 2024 and September 30, 2023 are as follows:

Table of Contents	June 29, 2024	September 30, 2023
in millions	Fair Value	Fair Value
Due in three months or less	\$447.6Å	\$447.6Å
Total available-for-sale securities	\$447.6Å	\$447.6Å

Amounts outstanding under the Company's 2021 Credit Agreement of \$1.2 billion aggregate principal as of June 29, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company's 5.625% Senior Notes due 2028 (the 2028 Senior Notes) and 3.250% Senior Notes due 2029 (the 2029 Senior Notes) had fair values of \$382.9Å million and \$853.3Å million, respectively, as of June 29, 2024 based on their trading prices, representing a Level 1 measurement. (5) Business Combinations

Fiscal 2024 Acquisitions

Endomag

On April 26, 2024, the Company executed an agreement to acquire Endomag Ltd (Endomag) for a purchase price of approximately \$310.0Å million, subject to working capital and other customary adjustments. Endomag, located in the UK, develops and sells breast surgery localization and lymphatic tracing technologies. The transaction closed on July 25, 2024.

Fiscal 2023 Acquisitions

JW Medical

On July 3, 2023, the Company completed the acquisition of assets from JW Medical Corporation (JW Medical) for a purchase price of \$6.7Å million. JW Medical was a long-standing distributor of the Company's Breast Health products in South Korea. The majority of the purchase price was allocated to a customer relationship intangible asset with a useful life of 5 years.

Normedi

On April 3, 2023, the Company completed the acquisition of Normedi Nordic AS (Normedi) for a purchase price of \$7.7Å million. Normedi was a long-standing distributor of the Company's Surgical products in the Nordics region of Europe. The purchase price included \$1.1Å million for contingent consideration based on incremental revenue growth over a 2-year measurement period. The Company allocated \$3.0Å million of the purchase price to a customer relationship intangible asset with a useful life of 5 years, and the excess of the purchase price over the net assets acquired was recorded to goodwill.

Contingent Consideration

The Company's primary contingent consideration liability was related to its acquisition of Acesa Health, Inc. (Acesa), which was acquired in August 2020. Acesa developed the ProVu laparoscopic radiofrequency ablation system. The Company estimated the fair value of this liability to be \$81.8Å million as of the acquisition date. The contingent payments were based on a multiple of annual incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. There was no maximum earnout. Pursuant to ASC 805, Business Combinations (ASC 805), the Company recorded its estimate of the fair value of the contingent consideration liability utilizing the Monte Carlo simulation based on future revenue projections of Acesa, revenue growth rates of comparable companies, implied volatility and applying a risk adjusted discount rate. Each quarter the Company was required to remeasure the fair value of the liability as assumptions change, and such adjustments were recorded in operating expenses. This fair value measurement was based on significant inputs not observable in the market and thus represented a Level 3 measurement as defined in ASC 820, Fair Value Measurements. This fair value measurement was directly impacted by the Company's estimate of future incremental revenue growth of the business. Accordingly, if actual revenue growth were higher or lower than the estimates within the fair value measurement, the Company would record additional charges or gains. During the second quarter of fiscal 2023, the Company updated its forecasted revenue and recorded a gain of \$12.4Å million to record the liability at its fair value. The reduction in fair value was due to a decrease in forecasted revenues over the remaining measurement period at that time. During the three months ended December 30, 2023, the third and final measurement period was completed, and the Company recorded a loss of \$1.7Å million to increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. The Company made a final payment of \$2.6Å million during the second quarter of fiscal 2024.

Table of Contents

(6) Strategic Investment

Maverix Medical

On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (KKR Comet), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (Maverix), is managed by Ajax Health. As part of this strategic investment, the Company contributed \$24.5Å million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that this investment should be accounted for under the equity method, which requires the Company to record its proportional share of the entity's net income (loss). This investment is recorded within Other Assets in the Consolidated Balance Sheets, and the Company's proportionate share of Maverix's net loss for the three and nine months ended June 29, 2024 was immaterial. (7) Disposition

Sale of SuperSonic Imagine Ultrasound Imaging Business

On September 29, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH Holdings Limited for a sales price of \$1.9Å million in cash. Under the terms of the contract, the Company agreed to fund the SSI business with \$33.2Å million of cash. The sale was completed on October 3, 2023. The Company also agreed to provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of \$51.7Å million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC 360, Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets. The assets and liabilities of the disposed business at the date of disposition were as follows:

| Assets | Cash
 | \$33.2Å
 | Accounts receivable

 | 4.5 | Inventory
 | 16.2 | Prepaid expenses and other assets

 | 8.6 | Valuation allowance | (50.6) | Total assets disposed | \$11.9Å | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
--
--

--
--|-------------------
--
---|--------------
--
--|---------------|---------------------|--|-----------------------|---------|----------|--------------------------------|---------|---|--|--------------------------------|------------------------|-------------------------------|--------------------------|-------------------|---------|---------------------|---------|---------------------|--------------|----------------------------------|------------|------------|------------------------|------------------|------------|--------------------|-------------------|---------------|--------------|--|--------------|------------------|---------|---------|---------|--------------------------------|-------|-------|-------|--------------------------------|-------|-------|-------
---|--------------------|-------------------|---------------|--------------|--|--------------|------------------|---------|---------|---------|--------|---------|---------|---------|--|--------------------------------|------------------------|-------------------------------|--------------------------|---------------|---------|--------|---------|---------|--------------|---------|--------|---------|---------|------------------|
| Liabilities | Accounts payable <td>\$3.1Å</td> <td>Accrued expenses<td>5.1</td><td>Total liabilities disposed<td>\$8.2Å</td><td>The valuation allowance of \$50.6Å million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company's operations and financial results. (8) Restructuring<p>Table of Contents</p><p>During the first quarter of fiscal 2024, the Company further refined its strategy for the MobiDigi business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company's San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of \$7.2Å million and a lease asset impairment charge of \$12.5Å million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of \$1.8Å million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately \$13.1Å million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. During the three and nine months ended June 29, 2024, the Company recorded severance charges of \$3.9Å million and \$7.9Å million, respectively. This action is expected to be completed by the second quarter of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance charges of \$0.9Å million and \$2.7Å million during the three and nine months ended June 29, 2024, respectively, and \$0.4Å million and \$1.4Å million during the three and nine months ended July 1, 2023, respectively. The Company estimates that total severance charges, including retention, will be approximately \$7.5Å million. (9) Borrowings and Credit Arrangements</p><p>The Company's borrowings consisted of the following:</p><table border="1"><thead><tr><th>June 29, 2024</th><th>September 30, 2023</th></tr></thead><tbody><tr><td>Current debt obligations, net of debt discount and deferred issuance costs</td><td>Term Loan</td></tr><tr><td>\$37.5Å</td><td>\$287.0Å</td></tr><tr><td>Total current debt obligations</td><td>\$37.5Å</td></tr><tr><td>Long-term debt obligations, net of debt discount and issuance costs</td><td>Term Loan</td></tr><tr><td>\$1,168.0Å</td><td>\$1,195.6Å</td></tr><tr><td>2028 Senior Notes</td><td>397.3Å</td></tr><tr><td>2029 Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>Total long-term debt obligations</td><td>\$2,505.6Å</td></tr><tr><td>\$2,531.2Å</td><td>Total debt obligations</td></tr><tr><td>\$2,543.1Å</td><td>\$2,818.2Å</td></tr></tbody></table><p>Table of Contents</p><p>2021 Credit Agreement</p><p>On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the 2021 Credit Agreement) by entering into a Refinancing Amendment (the 2021 Credit Agreement). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (SOFR), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a \$1.5Å billion secured term loan facility (the 2021 Term Loan) and a \$2.0Å billion revolving credit facility (the 2021 Revolver). As of June 29, 2024, the principal amount outstanding under the 2021 Term Loan was \$1.2Å billion, and the interest rate was 6.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a \$250.0Å million voluntary prepayment on the 2021 Term Loan.</p><p>Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$21.1Å</td></td></tr><tr><td>\$24.3Å</td><td>\$64.9Å</td><td>Weighted average interest rate</td><td>6.43Å</td></tr><tr><td>6.17Å</td><td>6.43Å</td><td>Interest rate at end of period</td><td>6.44Å</td></tr><tr><td>6.20Å</td><td>6.44Å</td><td>The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants.<p>2028 Senior Notes</p><p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p><p>2029 Senior Notes</p><p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p><p>Table of Contents</p><p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table><p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are
applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p><table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table><p>Interest Rate Swaps - Cash Flow Hedge</p><p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p><p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p><p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p><p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions</p></td></tr></tbody></table></td></td></td> | \$3.1Å
 | Accrued expenses <td>5.1</td> <td>Total liabilities disposed<td>\$8.2Å</td><td>The valuation allowance of \$50.6Å million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company's operations and financial results. (8) Restructuring<p>Table of Contents</p><p>During the first quarter of fiscal 2024, the Company further refined its strategy for the MobiDigi business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company's San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of \$7.2Å million and a lease asset impairment charge of \$12.5Å million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of \$1.8Å million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately \$13.1Å million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. During the three and nine months ended June 29, 2024, the Company recorded severance charges of \$3.9Å million and \$7.9Å million, respectively. This action is expected to be completed by the second quarter of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance charges of \$0.9Å million and \$2.7Å million during the three and nine months ended June 29, 2024, respectively, and \$0.4Å million and \$1.4Å million during the three and nine months ended July 1, 2023, respectively. The Company estimates that total severance charges, including retention, will be approximately \$7.5Å million. (9) Borrowings and Credit Arrangements</p><p>The Company's borrowings consisted of the following:</p><table border="1"><thead><tr><th>June 29, 2024</th><th>September 30, 2023</th></tr></thead><tbody><tr><td>Current debt obligations, net of debt discount and deferred issuance costs</td><td>Term Loan</td></tr><tr><td>\$37.5Å</td><td>\$287.0Å</td></tr><tr><td>Total current debt obligations</td><td>\$37.5Å</td></tr><tr><td>Long-term debt obligations, net of debt discount and issuance costs</td><td>Term Loan</td></tr><tr><td>\$1,168.0Å</td><td>\$1,195.6Å</td></tr><tr><td>2028 Senior Notes</td><td>397.3Å</td></tr><tr><td>2029 Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>Total long-term debt obligations</td><td>\$2,505.6Å</td></tr><tr><td>\$2,531.2Å</td><td>Total debt obligations</td></tr><tr><td>\$2,543.1Å</td><td>\$2,818.2Å</td></tr></tbody></table><p>Table of Contents</p><p>2021 Credit Agreement</p><p>On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the 2021 Credit Agreement) by entering into a Refinancing Amendment (the 2021 Credit Agreement). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in
U.S. dollars were converted to a variant of the secured overnight financing rate (SOFR), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a \$1.5Å billion secured term loan facility (the 2021 Term Loan) and a \$2.0Å billion revolving credit facility (the 2021 Revolver). As of June 29, 2024, the principal amount outstanding under the 2021 Term Loan was \$1.2Å billion, and the interest rate was 6.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a \$250.0Å million voluntary prepayment on the 2021 Term Loan.</p><p>Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$21.1Å</td></td></tr><tr><td>\$24.3Å</td><td>\$64.9Å</td><td>Weighted average interest rate</td><td>6.43Å</td></tr><tr><td>6.17Å</td><td>6.43Å</td><td>Interest rate at end of period</td><td>6.44Å</td></tr><tr><td>6.20Å</td><td>6.44Å</td><td>The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants.<p>2028 Senior Notes</p><p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p><p>2029 Senior Notes</p><p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p><p>Table of Contents</p><p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table><p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p><table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table><p>Interest Rate Swaps - Cash Flow Hedge</p><p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p><p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p><p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p><p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign
currency contracts are entered into to support transactions</p></td></tr></tbody></table></td></td> | 5.1 | Total liabilities disposed <td>\$8.2Å</td> <td>The valuation allowance of \$50.6Å million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company's operations and financial results. (8) Restructuring<p>Table of Contents</p><p>During the first quarter of fiscal 2024, the Company further refined its strategy for the MobiDigi business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company's San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of \$7.2Å million and a lease asset impairment charge of \$12.5Å million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of \$1.8Å million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately \$13.1Å million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. During the three and nine months ended June 29, 2024, the Company recorded severance charges of \$3.9Å million and \$7.9Å million, respectively. This action is expected to be completed by the second quarter of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance charges of \$0.9Å million and \$2.7Å million during the three and nine months ended June 29, 2024, respectively, and \$0.4Å million and \$1.4Å million during the three and nine months ended July 1, 2023, respectively. The Company estimates that total severance charges, including retention, will be approximately \$7.5Å million. (9) Borrowings and Credit Arrangements</p><p>The Company's borrowings consisted of the following:</p><table border="1"><thead><tr><th>June 29, 2024</th><th>September 30, 2023</th></tr></thead><tbody><tr><td>Current debt obligations, net of debt discount and deferred issuance costs</td><td>Term Loan</td></tr><tr><td>\$37.5Å</td><td>\$287.0Å</td></tr><tr><td>Total current debt obligations</td><td>\$37.5Å</td></tr><tr><td>Long-term debt obligations, net of debt discount and issuance costs</td><td>Term Loan</td></tr><tr><td>\$1,168.0Å</td><td>\$1,195.6Å</td></tr><tr><td>2028 Senior Notes</td><td>397.3Å</td></tr><tr><td>2029 Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>Total long-term debt obligations</td><td>\$2,505.6Å</td></tr><tr><td>\$2,531.2Å</td><td>Total debt obligations</td></tr><tr><td>\$2,543.1Å</td><td>\$2,818.2Å</td></tr></tbody></table><p>Table of Contents</p><p>2021 Credit Agreement</p><p>On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the 2021 Credit Agreement) by entering into a Refinancing Amendment (the 2021 Credit Agreement). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (SOFR), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a \$1.5Å billion secured term loan facility (the 2021 Term Loan) and a \$2.0Å billion revolving credit facility (the 2021 Revolver). As of June 29, 2024, the principal amount outstanding under the 2021 Term Loan was \$1.2Å billion, and the interest rate was 6.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a \$250.0Å million voluntary prepayment on the 2021 Term Loan.</p><p>Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$21.1Å</td></td></tr><tr><td>\$24.3Å</td><td>\$64.9Å</td><td>Weighted average interest rate</td><td>6.43Å</td></tr><tr><td>6.17Å</td><td>6.43Å</td><td>Interest rate at end of period</td><td>6.44Å</td></tr><tr><td>6.20Å</td><td>6.44Å</td><td>The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants.<p>2028 Senior Notes</p><p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p><p>2029 Senior Notes</p><p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p><p>Table of Contents</p><p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table><p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables
with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p><table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table><p>Interest Rate Swaps - Cash Flow Hedge</p><p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p><p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p><p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p><p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions</p></td></tr></tbody></table></td> | \$8.2Å | The valuation allowance of \$50.6Å million was recorded to appropriately reflect the assets held-for-sale classification in the Consolidated Balance Sheet in the fourth quarter of fiscal 2023 relative to the loss recorded and the net tangible assets disposed. The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company's operations and financial results. (8) Restructuring <p>Table of Contents</p> <p>During the first quarter of fiscal 2024, the Company further refined its strategy for the MobiDigi business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company's San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of \$7.2Å million and a lease asset impairment charge of \$12.5Å million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of \$1.8Å million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately \$13.1Å million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees will cease employment in phases. During the three and nine months ended June 29, 2024, the Company recorded severance charges of \$3.9Å million and \$7.9Å million, respectively. This action is expected to be completed by the second quarter of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactures its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services are in the process of being transferred to the Company's Newark, Delaware facility. The transition is expected to be completed by the third quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions have been transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance charges of \$0.9Å million and \$2.7Å million during the three and nine months ended June 29, 2024, respectively, and \$0.4Å million and \$1.4Å million during the three and nine months ended July 1, 2023, respectively. The Company estimates that total severance charges, including retention, will be approximately \$7.5Å million. (9) Borrowings and Credit Arrangements</p> <p>The Company's borrowings consisted of the following:</p> <table border="1"><thead><tr><th>June 29, 2024</th><th>September 30, 2023</th></tr></thead><tbody><tr><td>Current debt obligations, net of debt discount and deferred issuance costs</td><td>Term Loan</td></tr><tr><td>\$37.5Å</td><td>\$287.0Å</td></tr><tr><td>Total current debt obligations</td><td>\$37.5Å</td></tr><tr><td>Long-term debt
obligations, net of debt discount and issuance costs</td><td>Term Loan</td></tr><tr><td>\$1,168.0Å</td><td>\$1,195.6Å</td></tr><tr><td>2028 Senior Notes</td><td>397.3Å</td></tr><tr><td>2029 Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>3.250% Senior Notes</td><td>940.3Å</td></tr><tr><td>Total long-term debt obligations</td><td>\$2,505.6Å</td></tr><tr><td>\$2,531.2Å</td><td>Total debt obligations</td></tr><tr><td>\$2,543.1Å</td><td>\$2,818.2Å</td></tr></tbody></table> <p>Table of Contents</p> <p>2021 Credit Agreement</p> <p>On September 27, 2021, the Company refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the 2021 Credit Agreement) by entering into a Refinancing Amendment (the 2021 Credit Agreement). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (SOFR), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a \$1.5Å billion secured term loan facility (the 2021 Term Loan) and a \$2.0Å billion revolving credit facility (the 2021 Revolver). As of June 29, 2024, the principal amount outstanding under the 2021 Term Loan was \$1.2Å billion, and the interest rate was 6.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a \$250.0Å million voluntary prepayment on the 2021 Term Loan.</p> <p>Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows:</p> <table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$21.1Å</td></td></tr><tr><td>\$24.3Å</td><td>\$64.9Å</td><td>Weighted average interest rate</td><td>6.43Å</td></tr><tr><td>6.17Å</td><td>6.43Å</td><td>Interest rate at end of period</td><td>6.44Å</td></tr><tr><td>6.20Å</td><td>6.44Å</td><td>The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants.<p>2028 Senior Notes</p><p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p><p>2029 Senior Notes</p><p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p><p>Table of Contents</p><p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p><table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table><p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p><table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table><p>Interest Rate Swaps - Cash Flow Hedge</p><p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p><p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap
fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p><p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p><p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions</p></td></tr></tbody></table> | June 29, 2024 | September 30, 2023 | Current debt obligations, net of debt discount and deferred issuance costs | Term Loan | \$37.5Å | \$287.0Å | Total current debt obligations | \$37.5Å | Long-term debt obligations, net of debt discount and issuance costs | Term Loan | \$1,168.0Å | \$1,195.6Å | 2028 Senior Notes | 397.3Å | 2029 Senior Notes | 940.3Å | 3.250% Senior Notes | 940.3Å | 3.250% Senior Notes | 940.3Å | Total long-term debt obligations | \$2,505.6Å | \$2,531.2Å | Total debt obligations | \$2,543.1Å | \$2,818.2Å | Three Months Ended | Nine Months Ended | June 29, 2024 | July 1, 2023 | June 29, 2024 <td>July 1, 2023</td> <td>Interest expense</td> <td>\$21.1Å</td> | July 1, 2023 | Interest expense | \$21.1Å | \$24.3Å | \$64.9Å | Weighted average interest rate | 6.43Å | 6.17Å | 6.43Å | Interest rate at end of period | 6.44Å | 6.20Å | 6.44Å | The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants. <p>2028 Senior Notes</p> <p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p> <p>2029 Senior Notes</p> <p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p> <p>Table of Contents</p> <p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p> <table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table> <p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p> <table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table> <p>Interest Rate Swaps - Cash Flow Hedge</p> <p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p> <p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at
offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p> <p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p> <p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions</p> | Three Months Ended | Nine Months Ended | June 29, 2024 | July 1, 2023 | June 29, 2024 <td>July 1, 2023</td> <td>Interest expense</td> <td>\$13.0Å</td> | July 1, 2023 | Interest expense | \$13.0Å | \$13.0Å | \$39.1Å | Totals | \$13.0Å | \$39.1Å | \$40.1Å | (10) Trade Receivables and Allowance for Credit Losses | Balance at Beginning of Period | Credit Loss Write-offs | Payments and Foreign Exchange | Balance at End of Period | June 29, 2024 | \$38.5Å | \$5.8Å | (\$2.9) | \$41.4Å | July 1, 2023 | \$37.7Å | \$2.2Å | (\$0.8) | \$39.1Å | (11) Derivatives |
| June 29, 2024 | September 30, 2023
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Current debt obligations, net of debt discount and deferred issuance costs | Term Loan
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$37.5Å | \$287.0Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total current debt obligations | \$37.5Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Long-term debt obligations, net of debt discount and issuance costs | Term Loan
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$1,168.0Å | \$1,195.6Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2028 Senior Notes | 397.3Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 2029 Senior Notes | 940.3Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3.250% Senior Notes | 940.3Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 3.250% Senior Notes | 940.3Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total long-term debt obligations | \$2,505.6Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$2,531.2Å | Total debt obligations
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$2,543.1Å | \$2,818.2Å
 |
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | Nine Months Ended
 | June 29, 2024
 | July 1, 2023

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 29, 2024 <td>July 1, 2023</td> <td>Interest expense</td> <td>\$21.1Å</td> | July 1, 2023
 | Interest expense
 | \$21.1Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$24.3Å | \$64.9Å
 | Weighted average interest rate
 | 6.43Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6.17Å | 6.43Å
 | Interest rate at end of period
 | 6.44Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 6.20Å | 6.44Å
 | The Company's effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants: a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants. <p>2028 Senior Notes</p> <p>A 5Å A 5Å As of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the 2028 Senior Notes) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 1, 2028.</p> <p>2029 Senior Notes</p> <p>As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the 2029 Senior Notes) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries and mature on February 15, 2029.</p> <p>Table of Contents</p> <p>Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:</p> <table border="1"><thead><tr><th>Three Months Ended</th><th>Nine Months Ended</th><th>June 29, 2024</th><th>July 1, 2023</th></tr></thead><tbody><tr><td>June 29, 2024<td>July 1, 2023</td><td>Interest expense</td><td>\$13.0Å</td></td></tr><tr><td>\$13.0Å</td><td>\$39.1Å</td><td>Totals</td><td>\$13.0Å</td></tr><tr><td>\$39.1Å</td><td>\$40.1Å</td><td>(10) Trade Receivables and Allowance for Credit Losses</td></tr></tbody></table> <p>The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the
portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023:</p> <table border="1"><thead><tr><th>Balance at Beginning of Period</th><th>Credit Loss Write-offs</th><th>Payments and Foreign Exchange</th><th>Balance at End of Period</th></tr></thead><tbody><tr><td>June 29, 2024</td><td>\$38.5Å</td><td>\$5.8Å</td><td>(\$2.9)</td></tr><tr><td>\$41.4Å</td><td>July 1, 2023</td><td>\$37.7Å</td><td>\$2.2Å</td></tr><tr><td>(\$0.8)</td><td>\$39.1Å</td><td>(11) Derivatives</td></tr></tbody></table> <p>Interest Rate Swaps - Cash Flow Hedge</p> <p>The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (AOCI) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest 20Table of Contents</p> <p>payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company's SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024.</p> <p>Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts</p> <p>The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions</p> | Three Months Ended

 | Nine Months Ended | June 29, 2024
 | July 1, 2023 | June 29, 2024 <td>July 1, 2023</td> <td>Interest expense</td> <td>\$13.0Å</td>

 | July 1, 2023 | Interest expense | \$13.0Å | \$13.0Å | \$39.1Å | Totals | \$13.0Å | \$39.1Å | \$40.1Å | (10) Trade Receivables and Allowance for Credit Losses | Balance at Beginning of Period | Credit Loss Write-offs | Payments and Foreign Exchange | Balance at End of Period | June 29, 2024 | \$38.5Å | \$5.8Å | (\$2.9) | \$41.4Å | July 1, 2023 | \$37.7Å | \$2.2Å | (\$0.8) | \$39.1Å | (11) Derivatives | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended | Nine Months Ended
 | June 29, 2024
 | July 1, 2023

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 29, 2024 <td>July 1, 2023</td> <td>Interest expense</td> <td>\$13.0Å</td> | July 1, 2023
 | Interest expense
 | \$13.0Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$13.0Å | \$39.1Å
 | Totals
 | \$13.0Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$39.1Å | \$40.1Å
 | (10) Trade Receivables and Allowance for Credit Losses
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Balance at Beginning of Period | Credit Loss Write-offs
 | Payments and Foreign Exchange
 | Balance at End of Period

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| June 29, 2024 | \$38.5Å
 | \$5.8Å
 | (\$2.9)

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| \$41.4Å | July 1, 2023
 | \$37.7Å
 | \$2.2Å

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (\$0.8) | \$39.1Å
 | (11) Derivatives
 |

 | |
 | |

 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. As of JuneÂ 29, 2024, the notional amount was \$97.2Â million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net.Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three and nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively, were as follows:Three Months EndedNine Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Amount of realized gain (loss) recognized in incomeForward foreign currency contracts\$1.7Â \$1.4Â \$3.5Â \$(1.3)Foreign currency option contracts\$â€”Â \$(1.2)â€”Â \$(2.7)\$1.7Â \$0.2Â \$3.5Â \$(4.0)Amount of unrealized gain (loss) recognized in incomeForward foreign currency contracts\$(0.5)â€”Â \$(6.2)\$(13.8)Foreign currency option contractsâ€”Â \$1.0Â â€”Â \$(6.8)\$(0.5)\$1.0Â \$(6.2)\$(20.6)Amount of gain (loss) recognized in incomeTotal\$1.2Â \$1.2Â \$(2.7)\$(24.6)21Table of ContentsFinancial Instrument PresentationThe table below presents the fair value of the Companyâ€™s derivative financial instruments as well as their classification on the balance sheet as of JuneÂ 29, 2024: Balance Sheet LocationJune 29, 2024September 30, 2023Assets:Derivative instruments designated as a cash flow hedge:Interest rate swap contractsPrepaid expenses and other current assets\$8.5Â \$16.2Â Interest rate swap contractsOther assets\$6.2Â 10.7Â \$14.7Â \$26.9Â Derivatives not designated as hedging instruments:Forward foreign currency contractsPrepaid expenses and other current assets\$2.6Â \$8.4Â \$2.6Â \$8.4Â Liabilities:Derivatives not designated as hedging instruments:Forward foreign currency contractsAccrued expenses\$0.4Â \$â€”Â The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods:Three Months EndedNine Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Amount of gain (loss) recognized in other comprehensive income, net of taxes:Interest rate swaps\$0.3Â \$3.7Â \$(9.3)\$(5.6)Total\$0.3Â \$3.7Â \$(9.3)\$(5.6)(12) Commitments and ContingenciesLitigation and Related MattersOn November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of 88 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter.Â Â Â The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution of which are reasonably likely based upon managementâ€™s assessment, to have a material adverse effect on its financial condition or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at 22Table of Contentseach reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies (ASC 450). Legal costs are expensed as incurred. (13) Net Income (Loss) Per ShareA reconciliation of basic and diluted share amounts is as follows:Â Three Months EndedNine Months EndedÂ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Basic weighted average common shares outstanding23,604Â 246,908Â 236,373Â 247,319Â Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units1,862Â â€”Â 1,708Â 2,074Â Diluted weighted average common shares outstanding236,466Â 246,908Â 238,081Â 249,393Â Weighted-average anti-dilutive shares related to:Outstanding stock options and restricted stock units933Â 2,936Â 1,372Â 1,786Â In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock optionsâ€™ combined exercise price and average unrecognized stock compensation expense is greater than the average stock price during the period. In those reporting periods in which the Company has a net loss, diluted loss per share is equal to basic loss per share because the effect of potentially dilutive securities would be anti-dilutive.(14) Stock-Based CompensationThe following presents stock-based compensation expense in the Companyâ€™s Consolidated Statements of Income:Â Three Months EndedNine Months EndedÂ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Cost of revenues\$2.6Â \$2.1Â \$8.5Â \$7.7Â Research and development2.2Â 2.1Â 8.4Â 8.6Â Selling and marketing3.5Â 2.9Â 10.4Â 9.2Â General and administrative6.3Â 9.8Â 41.8Â 35.1Â \$14.6Â \$16.9Â \$69.1Â \$60.6Â The Company granted options to purchase 0.6 million and 0.5 million shares of the Companyâ€™s common stock during the nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively, with weighted-average exercise prices of \$72.32 and \$74.67, respectively. There were 4.5 million options outstanding at JuneÂ 29, 2024 with a weighted-average exercise price of \$54.62.23Table of ContentsThe Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:Â Three Months EndedNine Months EndedÂ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Risk-free interest rate4.4Â %4.3Â %4.4Â %4.3Â %Expected volatility33.4Â %33.9Â %33.4Â %33.9Â %Expected life (in years)4.84.84.84.8Dividend yieldâ€”Â %â€”Â %â€”Â %â€”Â %Â Weighted average fair value of options granted\$26.44Â \$30.51Â \$25.06Â \$25.95Â The Company granted 0.7 million and 0.6 million restricted stock units (â€œRSUsâ€) during the nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively, with weighted-average grant date fair values of \$72.03 and \$74.58 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (â€œPSUsâ€) during the nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively, to members of its senior management team, which have a weighted-average grant date fair value of \$71.92 and \$74.35 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Companyâ€™s common stock at the end of a three-year performance period, provided that the Companyâ€™s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1Â million of FCF PSUs based on a three-year cumulative free cash flow measure (â€œFCF PSUsâ€) to members of its senior management team, which had a grant date fair value of \$71.92 and \$74.35 per unit during the nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Companyâ€™s common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (â€œMSUsâ€) to members of its senior management team during the nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Companyâ€™s common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at \$88.06 and \$97.91 per share using the Monte Carlo simulation model in fiscal 2024 and 2023, respectively. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At JuneÂ 29, 2024, there was 1.7 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding. At JuneÂ 29, 2024, there was \$12.4 million and \$55.5 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.3 and 1.8 years, respectively.24Table of Contents(15) Other Balance Sheet InformationJune 29, 2024September 30, 2023InventoriesRaw materials\$263.2Â \$238.6Â Work-in-process58.4Â 66.3Â Finished goods343.9Â 312.7Â \$665.5Â \$617.6Â Property, plant and equipmentEquipment\$388.4Â \$380.0Â Equipment under customer usage agreements507.7Â 508.1Â Building and improvements243.7Â 230.0Â Leasehold improvements42.0Â 44.4Â Land40.8Â 41.1Â Furniture and fixtures23.6Â 19.2Â Finance lease right-of-use asset8.4Â 8.2Â \$1,254.6Â \$1,231.0Â Less â€” accumulated depreciation and amortization(725.8) (714.0) \$528.8Â \$517.0Â During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded impairment charges of \$12.1Â million to property, plant and equipment. In addition, during the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its SSI ultrasound imaging business and recorded impairment charges of \$5.8Â million related to property, plant and equipment. See Note 18 for additional information.(16) Business Segments and Geographic InformationThe Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. 25Table of ContentsIdentifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023. Segment information is as follows:Â Three Months EndedNine Months EndedÂ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Total revenues:Diagnostics\$440.8Â \$439.7Â \$1,338.7Â \$1,463.6Â Breast Health385.0Â 360.3Â 1,147.3Â 1,079.9Â GYN Surgical166.6Â 157.3Â 484.8Â 456.2Â Skeletal Health19.0Â 27.1Â 71.5Â 85.4Â \$1,011.4Â \$984.4Â \$3,042.3Â \$3,085.1Â Income from operations:Diagnostics\$89.7Â \$(113.5) \$210.1Â \$142.8Â Breast Health102.4Â 63.3Â 296.2Â 233.7Â GYN Surgical56.7Â 48.5Â 144.3Â 149.6Â Skeletal Health(4.8) 3.1 2.0Â 9.8Â \$244.0Â \$1.4Â \$652.6Â \$535.9Â Depreciation and amortization:Diagnostics\$51.0Â \$56.8Â \$168.3Â \$172.9Â Breast Health9.3Â 12.2Â 29.6Â 38.7Â GYN Surgical11.9Â 11.9Â 36.1Â 35.8Â Skeletal Health0.1Â 0.3Â 0.4Â 0.5Â \$72.3Â \$81.2Â \$234.4Â \$247.9Â Capital expenditures:Diagnostics\$17.7Â \$22.6Â \$61.7Â \$58.7Â Breast Health10.4Â 8.0Â 25.1Â 22.0Â GYN Surgical4.8Â 4.5Â 11.5Â 11.2Â Skeletal Health0.7Â â€”Â 1.1Â 0.2Â Corporate0.3Â 1.4Â 0.5Â \$6.6Â \$33.9Â \$36.5Â \$99.9Â \$97.7Â Â June 29, 2024September 30, 2023Identifiable assets:Diagnostics\$2,476.3Â \$2,596.4Â Breast Health1,217.6Â 1,170.1Â GYN Surgical1,429.8Â 1,455.4Â Skeletal Health35.6Â 33.7Â Corporate\$730.8Â 3,883.7Â \$8,890.1Â \$9,139.3Â The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended JuneÂ 29, 2024 and JulyÂ 1, 2023. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Companyâ€™s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Companyâ€™s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The â€œRest of Worldâ€ designation includes Canada, Latin America and the Middle East.26Table of ContentsRevenues by geography as a percentage of total revenues were as follows:Â Â Three Months EndedNine Months EndedÂ June 29, 2024July 1, 2023June 29, 2024July 1, 2023United States75.7Â %76.2Â %74.9Â %75.9Â %Europe12.6Â %13.4Â %13.9Â %13.9Â %Asia-Pacific6.4Â %6.4Â %6.4Â %6.2Â %Rest of Worlds3.3Â %4.3Â %5.3Â %4.0Â %100.0Â %100.0Â %100.0Â %100.0Â % (17) Income TaxesIn accordance with ASC 740, Income Taxes, each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.For the three months ended June 29, 2024, the Company recorded income tax expense of \$46.2Â million resulting in an effective tax rate of 19.2%. For the nine months ended June 29, 2024, the Company recorded income tax expense of \$32.6Â million, resulting in an effective tax rate of 5.1%. The effective tax rate for the three months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Companyâ€™s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits. The effective tax rate for the nine months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to a discrete tax benefit of \$107.2Â million related to a worthless stock deduction on an investment in one of the Companyâ€™s international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Companyâ€™s international subsidiaries, and federal and state tax credits. The Company recorded income tax expense of \$52.6Â million and \$165.1Â million for the three and nine months ended July 1, 2023, resulting in effective tax rates of 434.7% and 31.1%, respectively. The effective tax rates for the three and nine months ended JulyÂ 1, 2023 were higher than the U.S. statutory tax rate primarily due to the tax effect of impairment charges recorded for assets acquired in the Mobidiag acquisition and the impairment of the Companyâ€™s SSI ultrasound imaging assets, income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Companyâ€™s international subsidiaries.Non-Income Tax MattersThe Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. Such amounts were not material for any of the periods presented. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.27Table of Contents(18) Intangible AssetsIntangible assets consisted of the following:Â DescriptionAs of June 29, 2024As of September 30, 2023GrossCarryingValueAccumulatedAmortizationGrossCarryingValueAccumulatedAmortizationAcquired intangible assets:DevelopedA technologies\$4,375.4Â \$3,786.6Â \$4,411.0Â \$3,649.5Â In-process research and development21.9Â â€”Â 25.7Â â€”Â A Customer relationships600.6Â 564.4Â 600.0Â 550.6Â Trade names252.5Â 222.9Â 253.6Â 212.8Â Total acquired intangible assets\$5,250.4Â \$4,573.9Â \$5,290.3Â \$4,412.9Â Internal-use software25.5Â 20.0Â 24.0Â 17.8Â Capitalized software embedded in products29.7Â 24.1Â 27.4Â 22.7Â Total intangible assets\$5,305.6Â \$4,618.0Â \$5,342.0Â \$4,453.4Â The estimated remaining amortization expense of the Companyâ€™s acquired intangible assets as of JuneÂ 29, 2024 for each of the five succeeding fiscal years was as follows:Remainder of Fiscal 2024\$47.2Â Fiscal 2025\$180.6Â Fiscal 2026\$150.6Â Fiscal 2027\$63.6Â Fiscal 2028\$60.5Â During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant and Equipment - Overall, to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis, the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of \$26.8Â million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: \$25.9Â million to developed technology and \$0.9Â million to trade names, which reduced the carrying value of the assets to \$13.9Â million and \$0.5Â million respectively. During the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb Marker as a Class I recall. This was the technical classification of a prior safety notice only, not a product removal. Following this, the Company lowered its forecasts for this product line, which is an indicator of impairment. Accordingly, the Company performed an undiscounted cash flow analysis, and the cash flows were not sufficient to recover the carrying value of the asset group. The Company performed a fair value analysis and determined that the fair value of the asset group was de minimus. As a result, the Company recorded an impairment charge of \$13.3Â million and \$0.4Â million to developed technology and trade names, respectively, to fully write-off the assets.During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a \$4.3Â million impairment charge, reducing the fair value of this asset to \$22.4Â million. 28Table of ContentsThe reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of \$7.3Â million to bring the net carrying values to zero.During the third

quarter of fiscal 2023, in connection with its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Mobidiag business, including product design and manufacturing requirements, the Company reassessed its short-term and long-term commercial plans for this business. The Company made certain operational and strategic decisions to invest and focus more on the long-term success of this business, which resulted in the Company significantly reducing its forecasted revenues and operating results. As a result, the Company determined indicators of impairment existed and performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the Mobidiag business over the estimated remaining useful life of its primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a DCF. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows were based on the Company's most recent strategic plan at the time and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used is intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 17.0%. As a result of this analysis, the fair value of the Mobidiag asset group was below its carrying value. Prior to calculating and allocating the impairment charge, the Company assessed the only in-process research and development intangible asset in this asset group for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a \$10.5 million impairment charge, reducing the fair value of this asset to \$26.5 million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project to focus on other projects. To record the asset group to fair value, the Company recorded an impairment charge of \$186.9 million during the third quarter of fiscal 2023. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: \$153.7 million to developed technology, \$10.4 million to customer relationships, \$10.7 million to trade names, and \$12.1 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. Actual operating results and the related cash flows of the asset group could differ from the estimated operating results and related cash flows. In the event the asset group does not meet its forecasted projections, additional impairment charges could be recorded in the future. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary at that time. During the third quarter of fiscal 2023, the Company also identified indicators of impairment associated with its SSI ultrasound imaging assets. As a result, the Company recorded an impairment charge of \$26.4 million, of which \$20.6 million was allocated to intangible assets, primarily developed technology, and \$5.8 million was allocated to equipment. (19) Product Warranties Product warranty activity was as follows: A Balance at Beginning of Period Provisions Settlements / Adjustments Balance at End of Period Nine Months Ended: June 29, 2024 \$8.3 \$7.2 \$ (6.3) \$9.2 July 1, 2023 \$8.0 \$4.9 \$ (5.4) \$7.5 29 Table of Contents (20) Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended June 29, 2024 Nine Months Ended June 29, 2024 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance \$(147.8) \$0.3 \$10.5 \$(137.0) \$(168.0) \$0.3 \$20.1 \$(147.6) Other comprehensive income (loss) before reclassifications (2.8) \$ 0.3 \$ (2.5) 17.4 \$ 9.3 8.1 Ending Balances (150.6) \$0.3 \$10.8 \$(139.5) \$(150.6) \$0.3 \$10.8 \$(139.5) Three Months Ended July 1, 2023 Nine Months Ended July 1, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance \$(138.1) \$(0.3) \$20.0 \$(118.4) \$(267.2) \$(0.3) \$29.3 \$(238.2) Other comprehensive income (loss) before reclassifications 1.1 \$ 3.7 4.8 130.2 \$ (5.6) 124.6 Ending Balances (137.0) \$(0.3) \$23.7 \$(113.6) \$(137.0) \$(0.3) \$23.7 \$(113.6) (21) Share Repurchase On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to \$1.0 billion of the Company's outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous \$1.0 billion authorization. Exclusive of shares repurchased pursuant to the accelerated share repurchase agreement described below, during the three and nine months ended June 29, 2024, the Company repurchased 1.4 million and 3.5 million shares of its common stock under the authorization for total consideration of \$100.0 million and \$250.0 million, respectively. As of June 29, 2024, \$44.6 million remained available under this authorization. On November 6, 2023, the Board of Directors authorized the Company to repurchase up to \$500 million of the Company's outstanding shares pursuant to an accelerated share repurchase (the ASR) agreement. On November 15, 2023, the Company executed the ASR agreement with Goldman Sachs & Co. (the Goldman Sachs) pursuant to which the Company agreed to repurchase \$500 million of the Company's common stock. In connection with the launch of the ASR, on November 17, 2023, the Company paid Goldman Sachs an aggregate of \$500 million and received approximately 5.6 million shares of the Company's common stock, representing 80% of the transaction value based on the Company's closing share price on November 14, 2023. On February 27, 2024, the ASR agreement was completed, and the Company received an additional 1.4 million shares for the final settlement. This final settlement was based on the total transaction value and the volume-weighted average share price of the Company's common stock during the term of the agreement. (22) New Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures. The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial position and results of operations. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures. The FASB issued this Update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. 30 Table of Contents In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material. Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. The Company is monitoring SEC developments and evaluating the impact of the new rule to its financial statements. 31 Table of Contents Item 2. A A Management's Discussion and Analysis of Financial Condition and Results of Operations CAUTIONARY STATEMENTS Some of the statements contained in this report and documents incorporated by reference herein are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding: the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, such as inflation, bank failures, rising interest rates and availability of capital markets, wars, other economic disruptions and U.S. and global recession concerns, on our customers and suppliers and on our business, financial condition, results of operations and cash flows and our ability to draw down our revolver; the effect of the worldwide political and social uncertainty and divisions, including the impact on trade regulations and tariffs, that may adversely impact the cost and sale of our products in certain countries, or increase the costs we may incur to purchase materials, parts and equipment from our suppliers; the ability to execute acquisitions and the impact and anticipated benefits of completed acquisitions and acquisitions we may complete in the future; the development of new competitive technologies and products; our ability to predict accurately the demand for our products, and products under development and to develop strategies to address markets successfully; continued demand for our COVID-19 assays; potential cybersecurity threats and targeted computer crime; the ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, as well as cost inflation in materials, packaging and transportation; the possibility of interruptions or delays at our manufacturing facilities, or the failure to secure alternative suppliers if any of our sole source third-party manufacturers fail to supply us; the ability to consolidate certain of our manufacturing and other operations on a timely basis and within budget, without disrupting our business and to achieve anticipated cost synergies related to such actions; the ability to successfully manage ongoing organizational and strategic changes, including our ability to attract, motivate and retain key employees and maintain engagement and efficiency in remote work environments; our ability to obtain and maintain regulatory approvals and clearances for our products, including the implementation of the European Union Medical Device and In Vitro Diagnostic Regulation requirements, and maintain compliance with complex and evolving regulations and quality standards, as well as the uncertainty of costs required to obtain and maintain compliance with such regulatory and quality matters; the coverage and reimbursement decisions of third-party payors; the uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on our business and results of operations; the guidelines, recommendations, and studies published by various organizations relating to the use of our products; the effect of consolidation in the healthcare industry; our ability to meet production and delivery schedules for our products; the effect of any future public health pandemic or other crises, including the timing, scope and effect of U.S. and international governmental, regulatory, fiscal, monetary and public health responses to such crises; our ability to protect our intellectual property rights; the possibility that products may contain undetected errors or defects or otherwise not perform as anticipated; the anticipated development of markets we sell our products into and the success of our products in these markets; the anticipated performance and benefits of our products; business strategies; anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations; estimated asset and liability values; 32 Table of Contents the impact of future tax legislation; conducting business internationally; the impact and costs and expenses of investigative and legal proceedings and compliance risks we may be subject to now or in the future; potential negative impacts resulting from climate change or other environmental, social, and governance and sustainability related matters; our compliance with covenants contained in our debt agreements; and our liquidity, capital resources and the adequacy thereof. In some cases, you can identify forward-looking statements by terms such as may, will, should, could, would, expect, anticipate, believe, estimate, project, predict, likely, future, strategy, potential, seek, goal and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial results include the cautionary statements set forth herein and in our other filings with the Securities and Exchange Commission, including the Risk Factors set forth or incorporated by reference in Part II, Item 1A of this Quarterly Report on Form 10-Q, as well as those described in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 or any other of our subsequently filed reports. We qualify all of our forward-looking statements by these cautionary statements. OVERVIEW We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products focused on women's health and well-being through early detection and treatment. We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives. We operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Through our Diagnostics segment, we offer a wide range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. Our primary Diagnostics products include our molecular diagnostic assays, which run on our advanced instrumentation systems (Panther and Panther Fusion), our ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. Our Aptima family of molecular diagnostic assays is used to detect, among other things, the infectious microorganisms that cause common sexually transmitted diseases, or STDs, such as chlamydia and gonorrhea, or CT/NG; certain high-risk strains of human papillomavirus, or HPV; Trichomonas vaginalis, the parasite that causes trichomoniasis; Mycoplasma genitalium; and Herpes Simplex viruses 1 and 2. We also offer viral load tests for the quantitation of Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, or HIV-1, and human cytomegalovirus, or CMV, for use on our Panther instrument system. In addition, we offer bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year. Our assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or GBS, that are run on the Panther Fusion system, a field upgradeable instrument addition to the base Panther system. In response to the COVID-19 pandemic, we developed and launched the Aptima SARS-CoV-2 assay and the Aptima SARS-CoV-2/Flu assay (each of which runs on our standard Panther system) and the Panther Fusion SARS-CoV-2 assay (which runs on our Panther Fusion system). In May 2022, we CE-marked two new molecular assays, Panther Fusion EBV Quant assay for quantitation of Epstein-Barr virus, and the Panther Fusion BKV Quant assay for quantitation of the BK virus. These two new assays are the first quantitative real-time PCR assays on the Panther Fusion system. These assays, along with the Aptima CMV Quant assay already available in Europe, expand our menu of transplant monitoring assays. The ThinPrep System is primarily used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test assists physicians in assessing the risk of pre-term birth. We also generate service revenues from our CLIA-certified laboratory for testing related to breast cancer and all metastatic cancers. Our Breast Health segment offers a broad portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. These solutions include 3D digital mammography systems, image analytics software utilizing artificial intelligence, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site 3D markers, localization, specimen radiology, connectivity solutions and breast conserving surgery products. Our most advanced breast imaging platforms, the 3Dimensions and Selenia 3D Dimensions systems, utilize tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast, which we refer to as the Genius 3D Mammography exam. Our GYN Surgical products include our MyoSure hysteroscopic tissue removal system, or MyoSure, our NovaSure endometrial ablation system, or NovaSure, our Fluent fluid management system, or Fluent, our Access ProVu laparoscopic radiofrequency ablation system, or Access ProVu, as well as our CoolSeal vessel sealing portfolio and our JustRight surgical stapler. The MyoSure suite of devices offers four options to provide incision-less removal of fibroids, polyps, and other pathology within the uterus. The NovaSure portfolio is comprised of the NovaSure CLASSIC device, NovaSure ADVANCED device and the NovaSure V5 device for the treatment of abnormal uterine bleeding. The Fluent system is a fluid management system that provides liquid distention during diagnostic and operative hysteroscopic procedures. The Access ProVu system is a fully integrated system that uses laparoscopic ultrasound, guidance mapping and radiofrequency ablation to treat nearly all types of fibroids. The CoolSeal portfolio includes the Trinity, Reveal, and Mini advanced bipolar vessel sealing devices. The JustRight 5 mm stapler features a smaller instrument profile and is used for laparoscopic general and pediatric surgery. Our Skeletal Health segment's products include the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body composition assessments, and the Fluoroscanner Insight FD mini C-arm, which assists in performing minimally invasive orthopedic surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. Unless the context otherwise requires, references to we, us, Hologic or our company refer to Hologic, Inc. and its consolidated subsidiaries. Trademark Notice Hologic is a trademark of Hologic, Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, 3D Mammography, 3D, 3DQuorum, Access, Access ProVu, Affirm, Ampliadiag, Aptima, ATEC, BioZorb, Brevera, Celero, Hologic Clarity HD, CoolSeal, C-View, Directray, Dimensions, Eviva, Faxitron, Fluent, Fluorscan, Focal Therapeutics, Genius 3D, Genius, Genius AI, Hologic, Horizon, InSight, Intelligent 3D, ImageChecker, JustRight, Localizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, Progensia, Quanta, Rapid

[illegible]

\$439.4A 14.4% \$455.7A 14.8% % (16.3) (3.6)% General and administrative\$94.0A 9.3A %90.2A 9.2A %3.8A 4.2A %306.2A 10.1A %299.5A 9.7A %6.7A 2.2A %Amortization of intangible assets\$25.3A 0.5A %67.1A 0.7A % (1.8) (25.4)%24.3A 0.8A %21.9A 0.7A %2.4A 11.0A %Impairment of intangible assets and Equipment\$4.4A €€ "A €44.3A 4.5A % (43.9)**5.6A 0.2A %44.3A 1.4A % (38.7) (87.4)%Contingent consideration - fair value adjustment€ "A €€ "A €€ "A **1.7A 0.1A % (12.4) (0.4)%14.1A 113.7A %Restructuring charges\$6.2A 0.6A %2.1A 0.2A %4.1A **34.8A 1.1A %4.9A 0.2A %29.9A **\$316.3A 31.3A %\$366.1A 37.2A %\$(49.8) (13.6)%\$1,017.5A 33.4A %\$1,035.3A 33.6A %\$(17.8) (1.7)%** Percentage not meaningfulResearch and Development Expenses. Research and development expenses decreased 11.7% and 7.2% in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to a decrease in compensation and benefits from lower headcount, primarily in Breast Health and Diagnostics, a decrease in project spend, and the elimination of expenses from our SSI ultrasound business of \$2.7 and \$8.7 million, respectively, as a result of its divestiture. These decreases were partially offset by a decrease in credits of \$3.2 million and \$5.5 million, respectively, recorded for funds received from the Biomedical Advanced Research and Development Authority (BARDA) grant to obtain FDA approval of our SARS-CoV-2 in the current three and nine month periods compared to the corresponding periods in the prior year. In addition, in the current nine month period expenses were lower as the prior year period included an extra week of expenses, partially offset by a \$10.0 million charge related to the purchase of intellectual property to be used in a development project in Diagnostics that has no future alternative use. At any point in time, we have a number of different research projects and clinical trials being conducted and the timing of these projects and related costs can vary from period to period. Selling and Marketing Expenses. Selling and marketing expenses decreased 2.3% and 3.6%, respectively, in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to lower spending on advertising and marketing initiatives, primarily from our sponsorship of the Women's Tennis Association, the elimination of 39Table of Contentsexpenses from our SSI ultrasound business of \$1.5 and \$5.2 million, respectively, and lower travel expenses partially offset by an increase in international headcount and higher meeting expense. In addition, in the current nine month period expenses were lower as the prior year period included an extra week of activity. General and Administrative Expenses. General and administrative expenses increased 4.2% and 2.2% in the current three and nine month periods compared to the corresponding periods in the prior year. The increase in the current three month period compared to the corresponding period in the prior year was primarily due to an increase in legal expenses, compensation and benefits from higher headcount and acquisition transaction costs, partially offset by lower stock compensation. The increase in the current nine month period compared to the corresponding period in the prior year was primarily due to higher compensation and benefits from stock compensation as a result of the equity plan's retirement provision and higher expense from our deferred compensation plan, an increase in legal expenses as the prior year included a benefit of \$7.4 million from a settlement awarded in the Minerva litigation and an increase in bad debt expense of \$3.6 million. This increase in the current nine month period was partially offset by a decrease of \$10.0 million in charitable contributions, an \$8.9 million charge for a business dispute in connection with terminating the Mobidiag joint venture agreement in China in the prior year period, lower IT infrastructure spend and lower expenses from one less week of activity. Amortization of Intangible Assets. Amortization of intangible assets primarily results from customer relationships and trade names related to our acquisitions. These intangible assets are generally amortized over their estimated useful lives of between 5 and 30 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows. Amortization expense decreased in the current three month period compared to the corresponding period in the prior year primarily due to lower Mobidiag intangible asset values from impairment charges recorded in the third quarter of fiscal 2023 and accelerated amortization recorded in the first quarter of fiscal 2024. Amortization expense increased in the current nine month period compared to the corresponding period in the prior year primarily due to accelerated amortization of customer relationship and trade name intangible assets acquired in the Mobidiag acquisition.Impairment of Intangible Assets and Equipment. During the second quarter of fiscal 2024, as discussed above, we recorded an impairment charge of \$26.8 million related to our BioZorb product line of which \$0.9 million was allocated to trade names. During the third quarter of fiscal 2024, as discussed above, we recorded an additional impairment charge related to our BioZorb product line of \$13.7 million of which \$0.4 million was allocated to trade names. During the first quarter of fiscal 2024, as discussed in Note 4 to the consolidated financial statements, we recorded an impairment charge of \$4.3 million to record our only IPR&D asset from the Mobidiag acquisition to fair value. The reduction in fair value was primarily due to a reduction in forecasted revenues and timing of completing the project.During the third quarter of fiscal 2023, as discussed above, we recorded an aggregate impairment charge of \$197.4 million related to our Mobidiag acquisition and \$26.4 million related to our SSI ultrasound imaging assets. The impairment charges were allocated to the long-lived assets and written off to operating expenses as follows: Mobidiag - \$10.5 million to IPR&D, \$10.4 million to customer relationships, \$10.7 million to trade names, and \$3.0 million to equipment; Ultrasound Imaging - \$2.4 million to customer relationships, \$1.7 million to trade names, and \$5.6 million to equipment.Contingent Consideration Fair Value Adjustments. In connection with the acquisition of Accessa Health Inc., or Accessa, we were obligated to make contingent earn-out payments based on achieving incremental revenue growth over a three-year period ending annually in December of each of 2021, 2022, and 2023. As of the acquisition date, we recorded a contingent consideration liability for the estimated fair value of the amount we expected to pay to the former shareholders of the acquired business. As of the end of the first quarter of fiscal 2024, the third and final measurement period was completed, and we recorded a loss of \$1.7A million to increase the contingent consideration liability to fair value based on actual revenue results in the final earn-out period. During the second quarter of fiscal 2023, we updated our forecasted revenue and recorded a gain of \$12.4 million to record the liability at its fair value. The reduction in fair value was due to a decrease in forecasted revenues over the remaining measurement period at that time.Restructuring Charges. During the first quarter of fiscal 2024, we further refined our strategy for the Mobidiag business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of facilities in Finland and France, and to move the development activities and operations to our San Diego, California location. As such, we determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of \$7.2 million and a lease asset impairment charge of \$12.5 million. In addition, during the first quarter of fiscal 2024, we recorded the minimum statutory severance benefit for the affected French employees of \$1.8 million. During the second quarter of fiscal 2024, we finalized negotiations with the respective Works Councils. We estimate that the total charge for severance benefits will be approximately \$13.1 million, the majority of which will be recognized over the service period to receive such benefits. In the second and third quarters of fiscal 2024, we recorded severance charges of \$4.0 million and \$3.9 million, respectively, related to this action. This action is expected to be completed by the second quarter of fiscal 2025. For additional information on restructuring actions, please refer to Note 8 to our consolidated financial statements.Interest IncomeA Three Months EndedNine Months EndedJune 29,2024July 1,2023ChangeJune 29,2024July 1,2023ChangeAmountAmount%Interest Income\$28.4A \$32.5A \$(4.1) (12.6)%\$80.3A \$84.6A \$(4.3) (5.1)%Interest income decreased in the current three and nine month periods compared to the corresponding periods in the prior year due to lower average cash balances in the current year periods compared to the corresponding periods in the prior year partially offset by higher interest rates in the current year periods as the U.S. Federal Reserve continually raised the Federal Funds Rate throughout our fiscal 2023 year.Interest ExpenseA Three Months EndedNine Months EndedJune 29,2024July 1,2023ChangeJune 29,2024July 1,2023ChangeAmountAmount%Interest expense consists primarily of the cash interest costs and the related amortization of the debt discount and deferred issuance costs on our outstanding debt. Interest expense increased in the current three and nine month periods compared to the corresponding periods in the prior year, primarily due to the increase in the variable interest rate under our 2021 Credit Agreement and a decrease in amounts received under interest rate swap agreements primarily due to a decrease in our overall hedged principal amount from \$1.0 billion to \$500 million and an increase in the fixed SOFR component under those agreements. These decreases were partially offset by a lower principal balance outstanding under our 2021 Credit Agreement as we voluntarily prepaid \$250.0 million during the first quarter of fiscal 2024.Other Income (Expense), netA Three Months EndedNine Months EndedJune 29,2024July 1,2023ChangeJune 29,2024July 1,2023ChangeAmountAmount%Other Income (Expense), net\$0.2A \$5.9A \$(5.7) (96.6)%\$0.8A \$(7.0)\$7.8A **For the current three month period, this account primarily consisted of a gain of \$0.9 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market gain and net foreign currency exchange gains of \$0.4 million primarily from the mark-to-market of foreign currency contracts used to hedge operating results, partially offset by a \$0.9 million ownership share loss from our investment in Maverix Medical. For the third quarter of fiscal 2023, this account primarily consisted of net foreign currency exchange gains of \$3.4 million and a gain of \$2.4 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market gains.For the current nine month period, this account primarily consisted of a gain of \$10.9 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market gains. This gain was partially offset by net foreign currency exchange losses of \$7.2 million primarily from the mark-to-market of foreign currency contracts used to hedge operating results, and a \$2.3 million ownership share loss from our investment in Maverix Medical. For the corresponding nine month period in the prior year, this account primarily consisted of net foreign currency exchange losses of \$15.0 million, primarily from the mark-to-market of foreign currency contracts used to hedge operating 41Table of Contentsresults, partially offset by a gain of \$7.7 million from the change in cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market gains.Provision for Income TaxesA Three Months EndedNine Months EndedJune 29,2024July 1,2023ChangeJune 29,2024July 1,2023ChangeAmountAmount%Provision for Income Taxes\$46.2A \$52.6A \$(6.4) (12.2)%\$32.6A \$165.1A \$(132.5) (80.3)%Our effective tax rates for the three and nine months ended June 29, 2024 were 19.2% and 5.1%, respectively, compared to 434.7% and 31.1% for the corresponding periods in the prior year. Our effective tax rate for the three months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Company's international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits. Our effective tax rate for the nine months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to a discrete tax benefit of \$107.2 million related to a worthless stock deduction on the investment in one of the Company's international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Company's international subsidiaries, and federal and state tax credits. Our effective tax rates for the three and nine months ended July 1, 2023 were higher than the U.S. statutory tax rate primarily due to the tax effect of impairment charges recorded for assets acquired in the Mobidiag acquisition and the impairment of the Company's SSI ultrasound imaging assets, income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Company's international subsidiaries.Segment Results of OperationsWe operate in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The accounting policies of the segments are the same as those described in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. We measure segment performance based on total revenues and operating income. Revenues from product sales of each of these segments are described in further detail below. The discussion that follows is a summary analysis of total revenues and the primary changes in operating income or loss by segment.DiagnosticsA Three Months EndedNine Months EndedJune 29,2024July 1,2023ChangeJune 29,2024July 1,2023ChangeAmountAmount%Total Revenues\$440.8A \$439.7A \$1.1A 0.3A %\$1,338.7A \$1,463.6A \$(124.9) (8.5)%Operating Income\$89.7A \$(113.5)\$203.2A (179.0)%\$210.1A \$142.8A \$67.3A 47.1A %Operating Income as a % of Segment Revenue20.3A % (25.8)%15.7A %9.8A %Diagnostics revenues increased in the current three month period compared to the corresponding period in the prior year primarily due to an increase in lab testing revenue from our Biotheranostics business, partially offset by a decrease in product revenues as discussed above. Diagnostic revenues decreased in the current nine month period compared to the corresponding period in the prior year primarily due to a decrease in product revenues as discussed above. Operating income for this business segment increased in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to an increase in gross profit and a decrease in operating expenses. Gross margin was 53.1% and 52.2% in the current three and nine month periods, respectively, compared to 15.5% and 44.2% in the corresponding periods in the prior year, respectively. The increase in gross margin in the current three and nine month periods 42Table of Contentswas primarily due an impairment charge of \$162.8 million related to Mobidiag recorded in the prior year, lower intangible asset amortization expense, lower manufacturing costs from the shut-down of the Mobidiag Finland facility, an increase in sales volume of Women's Health Aptima and Fusion assays and an increase in Biotheranostics lab testing revenue which has higher margins. These increases were partially offset by lower sales volumes of our SARS-CoV-2 assays, which have a higher margin than our core products.Operating expenses decreased in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to impairment charges of \$34.6 million related to Mobidiag recorded in the prior year and to a lesser extent a decrease in marketing initiative spend and R&D project spend, partially offset by an increase in restructuring in the current three and nine month periods of \$3.9 million and \$3

current nine month period compared to the corresponding period in the prior year primarily due to a gain of \$12.4 million recorded in the prior year period to decrease the Acesa contingent consideration liability to fair value and a \$7.4 million settlement awarded to us in the Minerva litigation in the prior year. Partially offsetting these increases was a decrease in commissions expense, research and development project spend and travel expense.

Skeletal Health	Three Months Ended	Nine Months Ended	June 29, 2024	July 1, 2023	Change	June 29, 2024	July 1, 2023	Change						
Amount	Amount	Amount	Total Revenues	\$19.0	\$27.1	(\$8.1)	(29.9)%	\$71.5	\$85.4	(\$13.9)	(16.3)%			
Operating Income	(4.8)	\$3.1	(\$7.9)	(25.4.8)%	\$2.0	\$9.8	(\$7.8)	(79.6)%	Operating Income as a % of Segment Revenue	(25.2)	11.4	%2.8	11.5	%

Skeletal Health revenues decreased in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to the decrease in product revenues discussed above. Operating income for this business segment decreased in the current three and nine month periods compared to the corresponding periods in the prior year primarily due to a decrease in gross profit and an increase in operating expenses. Gross margin was 4.9% and 27.9% in the current three and nine month periods, respectively, compared to 30.2% and 32.1% in the corresponding periods in the prior year, respectively. The decrease in gross margin was primarily due to a \$5.0 million charge recorded in the current quarter to repair certain Horizon DXA units in the field due to a non-conformance pertaining to electromagnetic compatibility requirements and to a lesser extent a decrease in volume of Horizon DXA systems due to the temporary stop-ship implemented in the current quarter. Operating expenses increased slightly in the current three and nine month periods compared to the corresponding periods in the prior year. LIQUIDITY AND CAPITAL RESOURCES At June 29, 2024, we had \$2,994.6 million of working capital and our cash and cash equivalents totaled \$2,439.1 million. Our cash and cash equivalents decreased by \$316.6 million during the first nine months of fiscal 2024 primarily due to cash used in investing and financing activities primarily related to repurchases of our common stock and debt repayments, partially offset by cash generated from operating activities. In the first nine months of fiscal 2024, our operating activities provided cash of \$918.2 million, primarily due to net income of \$610.9 million, non-cash charges for depreciation and amortization aggregating \$234.4 million, stock-based compensation expense of \$69.1 million, intangible asset impairment charges of \$44.8 million and a lease asset impairment charge of \$12.5 million. These adjustments to net income were partially offset by a decrease in net deferred income taxes of \$44.8 million primarily due to the amortization of intangible assets and to a lesser extent the capitalization of research expenditures under the tax rules. Cash provided by operations included a net cash outflow of \$22.8 million from changes in our operating assets and liabilities. This cash outflow was primarily driven by an increase in prepaid income taxes of \$73.9 million primarily due to the worthless stock deduction and to a lesser extent the timing of tax payments relative to the provision for income taxes, and an increase in inventory of \$47.1 million to meet expected demand across our primary product lines and the build of Breast Health capital equipment prior to the transfer of manufacturing to Newark, Delaware from Danbury, Connecticut. These cash outflows were partially offset by an increase of \$58.5 million in accrued expenses and other liabilities primarily due to an increase in income tax reserves, accrued interest due to the timing of payments and professional fees partially offset by lower compensation accruals, an increase of \$26.5 million in accounts payable primarily due to the timing of payments, and an increase in deferred revenue of \$19.9 million primarily due to billings for annual service contracts under our expanded installed base of digital mammography systems. In the first nine months of fiscal 2024, our investing activities used cash of \$185.3 million primarily due to capital expenditures of \$99.9 million, which primarily consisted of the placement of equipment under customer usage agreements and purchase of manufacturing equipment and building improvements at our Newark and San Diego facilities, \$42.5 million for strategic investments and a \$31.3 million net payment to sell our SSI ultrasound business. In the first nine months of fiscal 2024, our financing activities used cash of \$1,051.8 million primarily due to \$776.8 million for repurchases of our common stock, including a \$500 million accelerated share repurchase program, \$278.1 million for debt principal payments under our 2021 Credit Agreement, including a \$250.0 million voluntary prepayment, and \$16.6 million for the payment of employee taxes withheld for the net share settlement of vested restricted stock units. Partially offsetting these uses of cash were proceeds of \$25.2 million from our equity plans. Debt We had total recorded debt outstanding of \$2.54 billion at June 29, 2024, which was comprised of amounts outstanding under our 2021 Credit Agreement of \$1.21 billion (principal of \$1.21 billion), 2029 Senior Notes of \$940.3 million (principal of \$950.0 million), and 2028 Senior Notes of \$397.3 million (principal of \$400.0 million). 2021 Credit Agreement On September 27, 2021, we refinanced our then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the "2021 Credit Agreement") by entering into a Refinancing Amendment (the "2021 Credit Agreement"). Borrowings under the 2021 Credit Agreement are secured by first-priority liens on, and a first priority security interest in, substantially all of our and our Subsidiary Guarantors' U.S. assets. The credit facilities (the "2021 Credit Facilities") under the 2021 Credit Agreement consist of: a secured term loan in the initial principal amount of \$1.5 billion (the "2021 Term Loan") with a stated maturity date of September 25, 2026; and a secured revolving credit facility (the "2021 Revolver") under which the Borrowers may borrow up to \$2.0 billion, subject to certain sublimits, with a stated maturity date of September 25, 2026. As of June 29, 2024, there were no borrowings under the 2021 Revolver. Borrowings under the 2021 Credit Agreement bear interest, at our option, at the Base Rate, at the Term SOFR Rate, at the Alternative Currency Daily Rate, or at the Daily SOFR Rate, in each case plus the Applicable Rate. The Applicable Rate in regard to the Base Rate, the Term SOFR Rate, the Alternative Currency Daily Rate, the Alternative Currency Term Rate and the Daily SOFR Rate is subject to change depending on the Total Net Leverage Ratio (as defined in the 2021 Credit Agreement). As of June 29, 2024, the interest rate under the 2021 Term Loan was 6.44% per annum. We are required to make scheduled principal payments under the 2021 Term Loan in increasing amounts, which currently range from \$9.375 million per three-month period to \$18.75 million per three-month period commencing with the three-month period ending on December 26, 2025. The remaining scheduled balance of \$1.085 billion (or such lesser aggregate principal amount of the Term Loans then outstanding) on the 2021 Term Loan and any amounts outstanding under the 2021 Revolver are due at their respective maturities. In addition, subject to the terms and conditions set forth in the 2021 Credit Agreement, we may be required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances (excluding permitted debt) and insurance recoveries (subject to certain investment rights). Certain mandatory prepayments are subject to reduction or elimination if certain financial covenants are met. Subject to certain limitations, we may voluntarily prepay any of the 2021 Credit Facilities without premium or penalty. As of June 29, 2024, the outstanding principal balance of the 2021 Term Loan was \$1.21 billion. The 2021 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including the requirement that we maintain two financial ratios (a total net leverage ratio and an interest coverage ratio) measured as of the last day of each quarter for the previous twelve-month period. As of June 29, 2024, we were in compliance with these covenants. 2028 Senior Notes The total aggregate principal balance of the 2028 Senior Notes is \$400.0 million. The 2028 Senior Notes are general senior unsecured obligations and are guaranteed on a senior unsecured basis by certain of our domestic subsidiaries. The 2028 Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on February 1 and August 1 of each year. We have the option to redeem the 2028 Senior Notes on or after: February 1, 2024 through February 1, 2025 at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and thereafter at 100% of par. In addition, if there is a change of control coupled with a decline in ratings, as provided in the indenture, we will be required to make an offer to purchase each holder's 2028 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. 2029 Senior Notes The total aggregate principal balance of the 2029 Senior Notes is \$950.0 million. The 2029 Senior Notes are general senior unsecured obligations and are guaranteed on a senior unsecured basis by certain domestic subsidiaries. The 2029 Senior Notes mature on February 15, 2029 and bear interest at the rate of 3.250% per year, payable semi-annually on February 15 and August 15 of each year. We have the option to redeem the 2029 Senior Notes on or after: September 28, 2023 through September 27, 2024 at 101.625% of par; September 28, 2024 through September 27, 2025 at 100.813% of par; and September 28, 2025 and thereafter at 100% of par. In addition, if there is a change of control coupled with a decline in ratings, as provided in the indenture, we will be required to make an offer to purchase each holder's 2029 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date. Stock Repurchase Program On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to \$1.0 billion of our outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous \$1.0 billion authorization. As of June 29, 2024, \$248.6 million remained available under this authorization. The timing of the share repurchases will be based upon our continuing analysis of market, financial, and other factors. Repurchases under the authorized share repurchase plan may be made using a variety of methods, which may include, but are not limited to, open market purchases, privately negotiated transactions, accelerated share repurchase agreements, or purchases pursuant to a Rule 10b5-1 plan under the Exchange Act. The authorized share repurchase plan may be suspended, delayed or discontinued at any time. Acquisition On April 26, 2024, we executed an agreement to acquire Endomagics Ltd (the "Endomag") for a purchase price of approximately \$310.0 million, subject to working capital and other customary adjustments. The transaction closed on July 25, 2024. Legal Contingencies We are currently involved in several legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of our business. In connection with these legal proceedings, claims, inspections, inquiries or investigations, management periodically reviews estimates of potential costs to be incurred by us in connection with the adjudication or settlement, if any, of these proceedings. These estimates are developed, as applicable in consultation with outside counsel, and are based on an analysis of potential litigation outcomes and settlement strategies. In accordance with ASC 450, Contingencies, loss contingencies are accrued if, in the opinion of management, an adverse outcome is probable and such financial outcome can be reasonably estimated. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings. Information with respect to this disclosure may be found in Note 12 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which information is incorporated herein by reference. Future Liquidity Considerations We expect to continue to review and evaluate potential strategic transactions that we believe will complement our current or future business. Subject to the "Risk Factors," if any, set forth or incorporated by reference in Part II, Item 1A of this Quarterly Report on Form 10-Q, as well as those described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 or any other of our subsequently filed reports, and the general disclaimers set forth in our "Cautionary Statement" regarding forward-looking statements at the outset of this Item 2, we believe that our cash and cash equivalents, including marketable securities, cash flows from operations, and the cash available under our 2021 Revolver will provide us with sufficient funds in order to fund our expected normal operations and debt payments over the next twelve months. Our longer-term liquidity is contingent upon future operating performance. We may also require additional capital in the future to fund capital expenditures, repayment of debt, acquisitions, strategic transactions or other investments. As described above, we have significant indebtedness outstanding under our 2021 Credit Agreement, 2028 Senior Notes, and 2029 Senior Notes. These capital requirements could be substantial. For a description of risks to our operating performance and our indebtedness, see the "Risk Factors" set forth or incorporated by reference in Part II, Item 1A of this Quarterly Report on Form 10-Q, as well as those described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. CRITICAL ACCOUNTING POLICIES AND ESTIMATES The discussion and analysis of our financial condition and results of operations are based upon our interim consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition for multiple element arrangements, allowance for doubtful accounts, reserves for excess and obsolete inventories, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, contingent liabilities, tax reserves and recoverability of our net deferred tax assets and related valuation allowances. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates if past experience or other assumptions do not turn out to be substantially accurate. Any differences may have a material impact on our financial condition and results of operations. For a discussion of how these and other factors may affect our business, see the "Cautionary Statement" regarding forward-looking statements set forth at the outset of this Item 2 and the "Risk Factors" set forth or incorporated by reference in Part II, Item 1A of this Quarterly Report on Form 10-Q as well as those described in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023 or any other of our subsequently filed reports. The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this report are described in Management's Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. Item 3. A. A Quantitative and Qualitative Disclosures About Market Risk. 47 Table of Contents Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments. Financial instruments consist of cash and cash equivalents, including money market funds, United States Treasury bills and commercial paper, accounts receivable, equity investments, foreign currency derivative contracts, interest rate swap agreements, insurance contracts, accounts payable and debt obligations. Except for our outstanding 2028 and 2029 Senior Notes, the fair value of these financial instruments approximate their carrying amount. The fair values of our 2028 and 2029 Senior Notes were approximately \$382.9 million and \$853.3 million, respectively, as of June 29, 2024. Amounts outstanding under our 2021 Credit Agreement of \$1.2 billion aggregate principal as of June 29, 2024 are subject to variable rates of interest based on current market rates, and as such, we believe the carrying amount of these obligations approximates fair value. Primary Market Risk Exposures. Our primary market risk exposure is in the areas of interest rate risk and foreign currency exchange rate risk as well as our investments in money market funds, United States Treasury bills and commercial paper. We consider these investments to be low risk as they are highly rated securities, highly liquid and short term in nature. We incur interest expense on borrowings outstanding under our 2028 and 2029 Senior Notes, and 2021 Credit Agreement. The 2028 and 2029 Senior Notes have fixed interest rates. Borrowings under our 2021 Credit Agreement bear interest at the SOFR Rate plus SOFR Adjustment of 0.10% plus the applicable margin of 1.00% per annum. As of June 29, 2024, there was \$1.2 billion of aggregate principal outstanding under the 2021 Credit Agreement. Since this debt obligation is a variable rate instrument, our interest expense associated with the instrument is subject to change. A hypothetical 10% adverse movement (increase in the SOFR rate) would increase annual interest expense by approximately \$3.8 million, which is net of the impact of our interest rate swap hedge. We previously entered into interest rate swap agreements to help mitigate the interest rate volatility associated with the variable rate interest on the amounts outstanding under our credit facilities. The critical terms of the interest rate swaps were designed to mirror the terms of our SOFR-based borrowings under the 2021 Credit Agreement, and therefore the interest rate swap is highly effective at offsetting the cash flows being hedged. We designated these derivative instruments as a cash flow hedge of the variability of the Term SOFR-based interest payments on \$500 million of principal. The return from cash and cash equivalents, including marketable securities, will vary as short-term interest rates change. A hypothetical 10% increase in market interest rates would increase annual interest income by approximately \$11.2 million based on our current cash balances. Foreign Currency Exchange Risk. Our international business is subject to risks, including, but not limited to unique economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. Accordingly, our future results could be materially adversely impacted by changes in these or other factors. We conduct business worldwide and maintain sales and service offices outside the U.S. as well as manufacturing facilities in Costa Rica and the United Kingdom. Our international sales are denominated in a number of currencies, primarily the Euro, U.S. dollar, UK Pound, Australian dollar, Canadian dollar, Chinese Yuan and Japanese Yen. The majority of our foreign subsidiaries functional currency is the local currency, although certain foreign subsidiaries functional currency is the U.S. dollar based on the nature of their operations or functions. Our revenues denominated in foreign currencies are positively affected when the U.S. dollar weakens against them and adversely affected when the U.S. dollar strengthens. Fluctuations in foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses. In addition, currency devaluations can result in a loss if we hold deposits in that currency. We have executed forward foreign currency contracts to hedge a portion of results denominated in the Euro, UK Pound, Australian dollar, Japanese Yen, Canadian dollar and Chinese Yuan. These contracts do not qualify for hedge accounting. As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of unrealized gains and losses reported in other income (expense), net on the mark-to-market of outstanding contracts and (ii) realized gains and losses recognized in other

income (expense), net, whereas the offsetting economic gains and losses are reported in the line item of the underlying cash flow, for example, revenue. We believe that the operating expenses of our international subsidiaries that are incurred in local currencies will not have a material adverse effect on our business, results of operations or financial condition. Our operating results and certain assets and liabilities that are denominated in foreign currencies are affected by changes in the relative strength of the U.S. dollar against those currencies. Our expenses, denominated in foreign currencies, are positively affected when the U.S. dollar strengthens against those currencies and adversely affected when the U.S. dollar weakens. However, we believe that the foreign currency exchange risk is not significant. We believe a hypothetical 10% increase or decrease in foreign currencies that we transact in would not have a material adverse impact on our financial condition or results of operations. 48Table of ContentsItem 4.Â A A A Controls and Procedures.We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.As of June 29, 2024, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules13A-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of June29, 2024. An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.49Table of ContentsPART II â€” OTHER INFORMATIONItem1.1 A A A Legal Proceedings.Information with respect to this Item may be found in Note 12 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.Additional information on our commitments and contingencies can be found in our Annual Report on Form 10-K for our fiscal year ended September130, 2023.Item1A. Risk Factors.There are no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K for our fiscal year ended September130, 2023 or any of our subsequently filed reports. 50Table of ContentsItem2. Unregistered Sales of Equity Securities and Use of Proceeds.Issuerâ€™s Purchases of Equity SecuritiesPeriod of RepurchaseAverage PricePaid Per Share(\$)(1) TotalNumber ofShares Purchased As Part of PubliclyAnnounced Plans or Programs(#)(1) MaximumNumber (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under OurPrograms (in millions) (\$) (1) March 31, 2024 â€” April 27, 2024\$â€” A â€” A \$348.6A April 28, 2024 â€” May 25, 202474.52A 434,120A 316.3A May 26, 2024 â€” June 29, 202473.79A 917,207A 248.6A Totals74.02A 1,351,327A \$248.6A (1) On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to \$1.0 billion of the Companyâ€™s outstanding common stock, effective as of the close of trading on September 23, 2022. As of June 29, 2024, \$248.6 million remained unused under this program. The program does not obligate the Company to acquire a minimum amount of shares. Under the program, shares may be repurchased in privately negotiated and/or open market transactions, including under plans complying with Rule 10b5-1 under the Exchange Act. For additional information regarding the Companyâ€™s repurchase programs, please see â€œManagement's Discussion and Analysis of Financial Condition and Results of Operations â€” Liquidity and Capital Resources â€” Stock Repurchase Program.â€œItem 5. Other InformationRule 10b5-1 Trading PlansDuring the third quarter of fiscal 2024, Karleen Oberton, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on May 30, 2024 to sell up to 62,679 shares of our common stock (following the exercise of options) between August 29, 2024 and February 3, 2025, the date this plan expires. The trading plan will cease upon the earlier of February 3, 2025 or the sale of all shares subject to the trading plan.During the third quarter of fiscal 2024, none of our other directors or executive officers adopted Rule 10b5-1 trading plans and none of our directors or executive officers terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).51Table of ContentsItem 6.Â A A A Exhibits.(a) Exhibits (a) Incorporated byReferenceExhibitNumberExhibit DescriptionFormFilingÂ Date/Period EndDate31.1*Certification of Hologicâ€™s CEO pursuant to Item6 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.31.2*Certification of Hologicâ€™s CFO pursuant to Item6 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.32.1*Certification of Hologicâ€™s CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2*Certification of Hologicâ€™s CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCH*Inline XBRL Taxonomy Extension Schema Document.101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.101.DEF*Inline XBRL Taxonomy Extension Definition.104*Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). * Filed herewith.**A A A Furnished herewith.52Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Â A Hologic, Inc.Â (Registrant)Date:July 30, 2024 /s/Â A A A Stephen P. MacMillanÂ A A A A A A A A Stephen P. MacMillanChairman, President and Chief Executive Officer(Principal Executive Officer)Date:July 30, 2024 /s/Â A A A Karleen M. ObertonÂ A A A A A A A A Karleen M. ObertonÂ Chief Financial Officer(Principal Financial Officer)53 EX-31.1 2 holx_q3-2024ex311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Stephen P. MacMillan, certify that:1.I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: JulyÂ 30, 2024 /s/Â A A A Stephen P. MacMillanÂ A A A A A A A A Stephen P. MacMillanChairman, President and Chief Executive Officer EX-31.2 3 holx_q3-2024ex312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Karleen M. Oberton, certify that:1.I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: JulyÂ 30, 2024 /s/Â A A A Karleen M. ObertonKarleen M. ObertonChief Financial Officer EX-32.1 4 holx_q3-2024ex321.htm EX-32.1 DocumentExhibit 32.1CertificationPursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002(Subsections (a)Â and (b)Â of SectionÂ 1350, Chapter 63 of Title 18, United States Code)I, Stephen P. MacMillan, Chief Executive Officer of Hologic, Inc., a Delaware corporation (the â€œCompanyâ€), do hereby certify, pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)Â and (b)Â of SectionÂ 1350, Chapter 63 of Title 18, United States Code), that:(1)The Quarterly Report on Form 10-Q for the quarter ended JuneÂ 29, 2024 (the â€œForm 10-Qâ€) of the Company fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.Â Dated: JulyÂ 30, 2024/s/Â A A A Stephen P. MacMillanÂ A A A A A A A A Stephen P. MacMillanChairman, President and Chief Executive OfficerA SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST. EX-32.2 5 holx_q3-2024ex322.htm EX-32.2 DocumentExhibit 32.2CertificationPursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002(Subsections (a)Â and (b)Â of SectionÂ 1350, Chapter 63 of Title 18, United States Code)I, Karleen M. Oberton, Chief Financial Officer of Hologic, Inc., a Delaware corporation (the â€œCompanyâ€), do hereby certify, pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)Â and (b)Â of SectionÂ 1350, Chapter 63 of Title 18, United States Code), that:(1)The Quarterly Report on Form 10-Q for the quarter ended JuneÂ 29, 2024 (the â€œForm 10-Qâ€) of the Company fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2)The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.Â Dated: JulyÂ 30, 2024/s/Â A A A Karleen M. ObertonKarleen M. ObertonChief Financial OfficerA SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST. EX-101.SCH 6 holx-20240629.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000002 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000006 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000007 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000011 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000014 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000015 - Disclosure - Strategic Investment link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000016 - Disclosure - Disposition link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000017 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000018 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000019 - Disclosure - Trade Receivables and Allowance for Credit Losses link:presentationLink link:calculationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000022 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000023 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000024 - Disclosure - Other Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000025 - Disclosure - Business Segments and Geographic Information link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000026 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000027 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000028 - Disclosure - Product Warranties link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000029 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000030 - Disclosure - Share Repurchase link:presentationLink link:calculationLink link:definitionLink link:definitionLink 0000031 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954471 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954472 - Disclosure - Revenue from Contract with Customer (Policies) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954473 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954474 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954475 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954476 - Disclosure - Disposition (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954477 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954478 - Disclosure - Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954480 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954481 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954482 - Disclosure - Other Balance Sheet

Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Business Segments and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Product Warranties (Tables) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Revenue - Business Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Revenue - Geographical Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Revenue - Revenue by Type (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Revenue - Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Additional Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Fair Value Measurements - Roll Forward (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Fair Value Measurements - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Fair Value Measurements - Available for Sale Debt Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Business Combination (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Strategic Investment (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Disposition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Disposition - Schedule of Disposition Related Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Trade Receivables and Allowance for Credit Losses (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Derivatives - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Net Income (Loss) Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Other Balance Sheet Information - Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Other Balance Sheet Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Business Segments and Geographic Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - Business Segments and Geographic Information - Segment Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - Business Segments and Geographic Information - Revenues by Geography (Detail) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - Product Warranties - Product Warranty Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - Share Repurchase (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 holx-20240629_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 holx-20240629_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 holx-20240629_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Fair value adjustments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Revolving credit facility borrowings Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Maverix Medical LLC Maverix Medical LLC [Member] Maverix Medical LLC Equipment under customer usage agreements Equipment Under Customer Usage Agreements Gross amount at the balance sheet date of long-lived, depreciable asset that are equipment placed at customer locations for which title is not transferred to the Company's customers. Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Intangible assets, current Intangible Assets, Current Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Interest rate at end of period Line of Credit Facility, Interest Rate at Period End Borrowings and Credit Arrangements Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Impairment of intangible assets Impairment of Intangible Assets, Finite-Lived Equity Method Investments and Joint Ventures [Abstract] Deferred income tax liabilities Deferred Income Tax Liabilities, Net MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Table] Performance Shares Performance Shares [Member] Breast Health Breast Health [Member] Breast health. Foreign Exchange Option Foreign currency option contracts Foreign Exchange Option [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Impairment of intangible assets and equipment Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Insider Trading Policies and Procedures [Line Items] Lease asset impairment charges Other Asset Impairment Charges Accelerated Share Repurchase Agreement Accelerated Share Repurchase Agreement [Member] Accelerated Share Repurchase Agreement Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Deferred revenue Deferred Revenue, Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Share Repurchase Equity [Text Block] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Settlements/ Adjustments Standard and Extended Product Warranty Accrual, Decrease for Payments Provisions Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Revenues Percentage Of Revenues Percentage of revenues. Revenue Revenue [Policy Text Block] Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, \$0.01 par value â€¢ 1,623 shares authorized; 0 shares issued Preferred Stock, Value, Issued Intersegment Intersegment Eliminations [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Annual incremental revenue growth period Annual Incremental Revenue Growth Period Annual Incremental Revenue Growth Period Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Payment for Contingent Consideration Liability, Financing Activities Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Impairment, assets held-for-use Impairment, Long-Lived Asset, Held-for-Use Diluted (in usd per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Treasury stock, at cost â€¢ 68,731 and 58,231 shares, respectively Treasury Stock, Value Accounts receivable, less reserves Accounts Receivable, after Allowance for Credit Loss, Current Land Land 2028 Senior Notes 2028 Senior Notes [Member] 2028 Senior Notes [Member] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputsâ€ (Levelâ€ 3) Fair Value, Inputs, Level 3 [Member] Treasury stock (in shares) Balance (in shares) Balance (in shares) Treasury Stock, Common, Shares Share-based compensation, stock options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Proceeds from the Department of Defense Proceeds received from government grants for capacity expansion Proceeds received from government grants for capacity expansion Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Restructuring Plan [Domain] Restructuring Plan [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Weighted-average exercise prices (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Total Investments, Fair Value Disclosure Weighted average fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Leases Lessee, Operating Leases [Text Block] Breast Imaging Breast Imaging [Member] Breast Imaging [Member] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Costs of revenues: Cost of Revenue [Abstract] Balance (in shares) Balance (in shares) Shares, Issued LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Stock Repurchased During Period, Value Stock Repurchased During Period, Value Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Prepaid income taxes Prepaid Taxes Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Amount of gain (loss) recognized in other comprehensive income, net of taxes: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Danbury closure Danbury closure [Member] Danbury closure Reconciliation of Basic and Diluted Share Amounts Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenue Cost of Goods and Services Sold Income Tax Contingency [Table] Income Tax Contingency [Table] Secured Term Loan Secured Term Loan [Member] Secured Term Loan Executive Category: Executive Category [Axis] Intangible assets useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Forward foreign currency contracts Foreign Exchange Contract [Member] Quotedâ€ Pricesâ€ in Activeâ€ Marketâ€ for Identicalâ€ Assets (Levelâ€ 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Goodwill Goodwill Other Balance Sheet Information of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Developedâ€ technology Developed Technology [Member] Developed technology, Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Building and improvements Buildings and Improvements, Gross Maximum eligible percentage to receive target number of shares of company's common stock Maximum Target Number Of Shares Issued Based On Stock Performance In Percent Maximum target number percentage of shares issued based on stock performance. Revenues by Geography Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Customer relationships Customer Relationships Contracts [Member] Customer relationships contracts. Underlying Securities Award Underlying Securities Amount Interventional Breast Solutions Interventional Breast Solutions [Member] Interventional Breast Solutions [Member] Entity Small Business Entity Small Business Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Weighted-average anti-dilutive shares related to: Weighted Average Number of Shares Outstanding, Basic [Abstract] Fiscal 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Derivative notional amount Derivative, Notional Amount Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Accrued expenses Accrued Liabilities [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Stock-Based Compensation Expense in Consolidated Statements of Operations Schedule Of Share Based Compensation Expense [Table Text Block] Schedule of share-based compensation expense. Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Market Based Awards Market Based Awards [Member] Market Based Awards [Member] Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items] Forward foreign currency contracts Foreign Exchange Forward [Member] Europe Europe [Member] BioZorb BioZorb [Member] BioZorb Revenues Total revenues Revenues Payment of minimum tax withholdings on net share settlements of equity awards Payment For Tax Withholding Related To Vested And Released Restricted Stock Units The payment of minimum statutory tax withholdings to taxing authorities on the behalf of employees from the net share settlement upon vesting of restricted stock units. This payment is not an expense of the Company nor an operating activity. Credit Agreement Credit Agreement [Member] Credit agreement. Equipment Manufacturing Equipment And Software Gross amount as of the balance sheet date of long-lived, depreciable assets that include manufacturing and other equipment with finite lives used to produce goods and services, and computer equipment and software. Borrowed principal Principal Amount Of Borrowings Represents the aggregate outstanding principal of amounts borrowed under the Credit Agreement. Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount JW Medical JW Medical [Member] JW Medical Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Interest Rate Swap, 2023 Interest Rate Swap, 2023 [Member] Interest Rate Swap, 2023 Award Type [Axis] Award Type [Axis] Weighted-average anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Shares granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Hedging Designation [Axis] Hedging Designation [Axis]

Cytology & Perinatal Cytology & Perinatal [Member] Cytology & Perinatal [Member] Property, plant and equipment, gross Property, Plant and Equipment, Gross Schedule Of Interest Expense Under Credit Agreement Schedule Of Interest Expense Under Credit Agreements [Table Text Block] Schedule Of Interest Expense Under Credit Agreements Remainder of Fiscal 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Trading Arrangement: Trading Arrangement [Axis] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Leases Lessee, Finance Leases [Text Block] share repurchase plan [Line Items] share repurchase plan [Line Items] [Line Items] for share repurchase plan [Table] Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Schedule Of Geographical Segments [Line Items] Schedule Of Geographical Segments [Line Items] Schedule Of Geographical Segments [Line Items] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract] Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract] Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Table] Deferred revenue, net of current portion Deferred Revenue, Noncurrent Common stock issued under the employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Amortization of acquired intangible assets Amortization of Intangible Assets Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Finite-lived intangibles Finite-Lived Intangible Assets, Net New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Performance stock units vesting period Shared Based Compensation Arrangement Restricted Stock Vesting Period Period of time that must lapse in order for the restricted stock units to vest. Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Asset Class [Axis] Asset Class [Axis] September 22, 2022 September 22, 2022 [Member] September 22, 2022 Vesting of restricted stock units, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Fair value of debt instrument Debt Instrument, Fair Value Disclosure Total acquired intangible assets Acquired intangible assets [Member] Acquired intangible assets [Member] Subsequent Events Consideration Subsequent Events, Policy [Policy Text Block] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Restructuring Costs [Abstract] Common stock, issued (in shares) Common Stock, Shares, Issued Consideration transferred Business Combination, Consideration Transferred Gross profit Gross Profit Severance costs Severance Costs Weighted-Average Assumptions Utilized to Value Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Total debt obligations Long-Term Debt Right of use asset Right of use asset [Member] Right of use asset Skeletal Health Skeletal Health [Member] Skeletal health. Internal-use software Internal-use software [Member] Internal-use software [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Stock option plans Share-Based Payment Arrangement, Option [Member] Weighted-average period for recognition of unrecognized stock-based compensation, years Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Depreciation and amortization Depreciation, Amortization and Accretion, Net Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Normedi Normedi [Member] Normedi Document Type Document Type Blood Screening Blood Screening [Member] Blood Screening [Member] Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Weighted average interest rate Line of Credit Facility, Interest Rate During Period Tabular List, Table Tabular List [Table Text Block] Minimum eligible percentage to receive target number of shares of company's common stock Minimum Target Number Of Shares Issued On Stock Performance In Percent Minimum target number percentage of shares that would be issued based on stock price performance. Entity Address, Address Line One Entity Address, Address Line One Interest Rate Swap, Agreement One Interest Rate Swap, Agreement One [Member] Interest Rate Swap, Agreement One Other Balance Sheet Information Details Of Certain Balance Sheet Accounts [Text Block] Details of certain balance sheet accounts. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other adjustments and non-cash items Other Noncash Income (Expense) Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions . [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Revenue, Remaining Performance Obligation, Percentage Revenue, Remaining Performance Obligation, Percentage Balance At Beginning of Period Balance At End of Period Accounts Receivable, Allowance for Credit Loss, Current Derivative [Table] Derivative [Table] Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Cash Cash [Member] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Revenues Revenue from Contract with Customer, Including Assessed Tax Leasehold improvements Leasehold Improvements, Gross Prepaid income taxes Increase (Decrease) in Prepaid Taxes Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Restructuring Cost and Reserve [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Assets: Fair Value Cash and Cash Equivalents, Fair Value Disclosure Long term debt obligations. excluding convertible notes Long Term Debt Obligations Without Convertible Notes Long term debt obligations without convertible notes. Business Combinations Business Combination Disclosure [Text Block] PSU Free Cash Flow [Member] PSU Free Cash Flow [Member] PSU Free Cash Flow [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Molecular Diagnostics Molecular Diagnostics [Member] Molecular Diagnostics [Member] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Accounts, Notes, Loans and Financing Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Schedule of Interest Expense Under Convertible Notes Schedule Of Interest Expense Under Convertible Notes [Table Text Block] Schedule of interest expense under convertible notes. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number December 11, 2020 December 11, 2020 [Member] December 11, 2020 Equity Method Investments Equity Method Investments Inventory Inventories Inventory, Net Lease revenue as a percentage of total (percentage) Lease Revenue, Percentage Of Total Revenue Lease Revenue, Percentage Of Total Revenue Access Health Access Health [Member] Access Health Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Disposition Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Entity Interactive Data Current Entity Interactive Data Current 2021 Revolver 2021 Revolver [Member] 2021 Revolver Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Segment Reporting Disclosure [Line Items] Segment Reporting Disclosure [Line Items] Segment Reporting Disclosure [Line Items] Total Shareholder Return Amount Total Shareholder Return Amount Repurchases of common stock Payments for Repurchase of Common Stock Product Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Unrealized Gains Cash and Cash Equivalents, Unrealized Gain Cash and Cash Equivalents, Unrealized Gain Other assets Other Assets [Member] Segments [Domain] Segments [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name 2021 Term Loan 2021 Term Loan [Member] 2021 Term Loan Accelerated amortization Accelerated amortization Accelerated amortization Senior notes, face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Schedule Of Geographical Segments [Table] Schedule Of Geographical Segments [Table] Schedule Of Geographical Segments [Table] Interest Rate Swap, Agreement Two Interest Rate Swap, Agreement Two [Member] Interest Rate Swap, Agreement Two Assets held-for-sale - current assets Disposal Group, Including Discontinued Operation, Assets Disposal Group, Including Discontinued Operation, Assets Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Derivative Assets at Fair Value Schedule of Derivative Assets at Fair Value [Table Text Block] Fiscal 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Payment of deferred acquisition consideration Payment of deferred acquisition consideration Payment of deferred acquisition consideration Disposal Group Name [Domain] Disposal Group Name [Domain] Indefinite-lived intangibles, fair value Indefinite-Lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure PEO PEO [Member] Capital equipment, components and software Capital Equipment, Components and Software [Member] Capital Equipment, Components and Software [Member] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Repurchase of common stock Treasury Stock, Value, Acquired, Par Value Method Asset Class [Domain] Asset Class [Domain] Derivative Asset, Subject to Master Netting Arrangement, before Offset Derivative Asset, Subject to Master Netting Arrangement, before Offset 2029 Senior Notes 2029 Senior Notes [Member] 2029 Senior Notes Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Fair Value, Off-balance Sheet Risks [Table] Schedule of Fair Value, Off-Balance-Sheet Risks [Table] Other Balance Sheet Information of Inventories Schedule of Inventory, Current [Table Text Block] Interest Rate Swap Interest rate swap Interest Rate Swap [Member] Debt Instrument [Axis] Debt Instrument [Axis] Disposal Group, Including Discontinued Operation, Liabilities Disposal Group, Including Discontinued Operation, Liabilities Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Company's effective tax rate Effective Income Tax Rate Reconciliation, Percent Repayments of Debt Repayments of Debt Diagnostics Diagnostics [Member] Diagnostics. Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Service Service [Member] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Sales price Disposal Group, Including Discontinued Operation, Consideration Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Total AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Disposal Group, Including Discontinued Operation, Accrued Liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities All Executive Categories All Executive Categories [Member] Corporate Corporate Segment [Member] Cash Flow Hedge Derivative Instrument Assets at Fair Value Cash Flow Hedge Derivative Instrument Assets at Fair Value Cash Flow Hedge Derivative Instrument Assets at Fair Value Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Pension Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Disposed of by Sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Number of reportable segments Number of Reportable Segments Net income (loss) per common share: Earnings Per Share [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Selling and marketing Selling and Marketing Expense Common stock, \$0.01 par value â€¢ 750,000 shares authorized; 300,787 and 299,940 shares issued, respectively Common Stock, Value, Issued Contingent consideration - fair value adjustments Contingent consideration - fair value adjustments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Names Trade names Trade Names [Member] Total 2028 and 2029 Senior Notes [Member] 2028 and 2029 Senior Notes Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Senior Notes Senior Notes [Member] Total current assets Assets, Current Contingent consideration Contingent Consideration [Member] Contingent Consideration Intangible asset and equipment impairment charges Asset impairment charges Asset Impairment Charges Contingent consideration Business Combination, Contingent Consideration, Liability Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Amortization of acquired intangible assets Amortization Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Subsegments [Domain] Subsegments [Domain] Current Fiscal Year End Date Current Fiscal Year End Date Stock Repurchase Program, Authorized Amount Stock Repurchase Program, Authorized Amount Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares New Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Schedule of Unrealized Loss Recognized in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Payments under finance lease obligations Payments under finance lease obligations Payments under finance lease obligations Asia-Pacific Asia Pacific [Member] Changes in Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Ultrasound imaging assets Ultrasound imaging assets [Member] Ultrasound imaging assets Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Unrealized Losses Cash and Cash Equivalents, Unrealized Loss Cash and Cash Equivalents, Unrealized Loss Karleen Oberton [Member] Karleen Oberton Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Forward Contracts Forward Contracts [Member] Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Strategic Investment Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Disposal Group, Including Discontinued Operation, Accounts Payable Disposal Group, Including Discontinued Operation, Accounts Payable Strategic investments Payments to Acquire Other Investments Derivatives Derivatives and Fair Value [Text Block] Other Other Type of Revenue [Member] Other Type of Revenue [Member] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Balance At Beginning Of Period Balance At End Of Period Standard and Extended Product Warranty Accrual Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Commercial Paper Commercial Paper [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Impairment of intangible assets and equipment Cost Of Goods Sold Impairment Of Intangible Assets and Equipment The amount of impairment loss recognized in cost of product sales in the period resulting from the write-down of the carrying amount of an intangible asset to fair value. Deferred revenue Increase (Decrease) in Deferred Revenue SSI Ultrasound Imaging Business SSI Ultrasound Imaging Business [Member] SSI Ultrasound Imaging Business Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Notational Amount Notational Amount Notational Amount Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Subsegments [Axis] Subsegments [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name

[Domain] Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Accelerated share repurchase agreement Accelerated share repurchase agreement Accelerated share repurchase agreement Purchase of intellectual property Payments to Acquire Intangible Assets Disposables Consumables [Member] Consumables [Member] Percentage of share repurchase program Percentage of share repurchase program Percentage of share repurchase program Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Restructuring and Related Activities Disclosure Restructuring and Related Activities Disclosure [Text Block] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, before Tax, Attributable to Parent Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable InputsA (LevelA 2) Fair Value, Inputs, Level 2 [Member] Measurement input Intangible Asset, Measurement Input Intangible Asset, Measurement Input Entity Emerging Growth Company Entity Emerging Growth Company Mobidiag Mobidiag [Member] Mobidiag Endomag Endomagnetics Ltd [Member] Endomagnetics Ltd Capital expenditures Payments to Acquire Productive Assets Guarantees [Abstract] Guarantees [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) GYN Surgical Gyn Surgical [Member] GYN surgical. Product Warranty Activity Schedule of Product Warranty Liability [Table Text Block] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Derivative Instruments, Gain (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Interest Rate Swap, 2024 Interest Rate Swap, 2024 [Member] Interest Rate Swap, 2024 Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Outstanding Stock Options and stock units Share-Based Payment Arrangement [Member] Title Trading Arrangement, Individual Title Weighted-average exercise price of options outstanding (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Foreign Tax Authority Foreign Tax Authority [Member] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income (Loss) Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Accelerated Share Repurchases, Settlement (Payment) or Receipt Accelerated Share Repurchases, Settlement (Payment) or Receipt Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Receivables [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Other comprehensive income activity Other Comprehensive Income (Loss), Net of Tax Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] US Treasury Securities US Treasury Securities [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Contingent consideration recorded at acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Other activity Payments for (Proceeds from) Other Investing Activities Developed technology Developed Technology Rights [Member] Retained Earnings Retained Earnings [Member] Current portion of long-term debt Long-Term Debt, Current Maturities Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Property, Plant and Equipment Property, Plant and Equipment [Member] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic (in usd per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Common stock issued under the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Product Warranties Product Warranty Disclosure [Text Block] Expected cost Restructuring and Related Cost, Expected Cost Arrangement Duration Trading Arrangement Duration In-process research and development In Process Research and Development [Member] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Principal of Consolidation Consolidation, Policy [Policy Text Block] Proceeds from swap Proceeds from swap Proceeds from swap Restructuring charges Restructuring Charges Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Cash Divested from Deconsolidation Cash Divested from Deconsolidation Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Interest expense Interest Expense, Borrowings Business Combinations [Abstract] Business Combinations [Abstract] Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Furniture and fixtures Furniture and Fixtures, Gross Accounts payable Increase (Decrease) in Accounts Payable Common stock, authorized (in shares) Common Stock, Shares Authorized Rest of World Rest of World [Member] Rest of World [Member] Total available-for-sale securities Debt Securities, Available-for-Sale International International [Member] International [Member] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Rest of World All Other Countries [Member] All other countries. Finite-lived intangible assets, fair value Finite-Lived Intangible Assets, Fair Value Disclosure Compensation Amount Outstanding Recovery Compensation Amount Credit Loss Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in-capital Additional Paid in Capital Deferred income taxes Deferred Income Tax Expense (Benefit) Restructuring Plan [Axis] Restructuring Plan [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] RSU, PSU, MSU RSU, PSU, MSU [Member] RSU, PSU, MSU [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Fiscal 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships Insider Trading Arrangements [Line Items] Term Loan Term Loan [Member] Term Loan [Member] Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Sale of business, net of cash disposed Proceeds from Divestiture of Businesses, Net of Cash Divested Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Fiscal 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenues Cost of Sales [Member] Contingent consideration - fair value adjustments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less â€” accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Fair Value Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Cash Disposal Group, Including Discontinued Operation, Cash Repayment of long-term debt Repayments of Long-Term Debt Finance lease obligations, net of current portion Finance Lease, Liability, Noncurrent Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Ultrasound imaging assets, developed technology Ultrasound imaging assets, developed technology [Member] Ultrasound imaging assets, developed technology Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Liabilities: Liabilities, Fair Value Disclosure [Abstract] Amount of realized gain (loss) recognized in income Derivative, Gain (Loss) on Derivative, Net Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Value Finite-Lived Intangible Assets, Gross Provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Revolver Revolver [Member] Revolver [Member] Derivative instruments designated as a cash flow hedge Designated as Hedging Instrument [Member] Income Tax Authority [Domain] Income Tax Authority [Domain] Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance Lease, Right-of-Use Asset, after Accumulated Amortization Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Name Trading Arrangement, Individual Name Net income Net income Net income attributable to Hologic Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Amortization of acquired intangible assets Cost, Amortization Equity [Abstract] Equity [Abstract] share repurchase plan [Table] share repurchase plan [Table] share repurchase plan [Table] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Intangible Assets and Goodwill Intangible Assets Disclosure [Text Block] Amount of unrealized gain (loss) recognized in income Unrealized Gain (Loss) on Derivatives Money Market Funds Money Market Funds [Member] Cash and cash equivalents Cost Cash and Cash Equivalents, at Carrying Value Senior notes Senior Notes Disposal Group, Including Discontinued Operation, Prepaid and Other Assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets Property, plant, and equipment, fair value Property, Plant, and Equipment, Fair Value Disclosure Changes in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Translation adjustment, net tax, excluding amounts reclassified from AOCI Other Comprehensive Income (Loss), Foreign Currency Translation adjustment, net tax, excluding amounts reclassified from AOCI Assets: Assets, Fair Value Disclosure [Abstract] Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Disposal Group, Including Discontinued Operation, Inventory Disposal Group, Including Discontinued Operation, Inventory Total Obligations, Fair Value Disclosure Assets held-for-sale - current liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net of current portion Total long-term debt obligations Long-Term Debt, Excluding Current Maturities Selling and marketing Selling and Marketing Expense [Member] Diluted (in shares) Diluted weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Income from Operation of Disposed Business Disposal Groups, Including Discontinued Operations [Table Text Block] Operating expenses: Operating Expenses [Abstract] Agreement Scenario, Plan [Member] Capital expenditures Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Gain (loss) recognized in other comprehensive income (loss), net Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Vesting of restricted stock units, net of shares withheld for employee taxes (in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Identifiable assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Share Repurchase Program [Axis] Share Repurchase Program [Axis] Cover [Abstract] Cover [Abstract] Equipment [Member] Equipment [Member] Trade Receivables and Allowance for Credit Losses Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Increase in equipment under customer usage agreements Payments To Manufacture Equipment Under Customer Usage Agreements The cash outflow related to equipment placed at customer locations for which title is not transferred to the Company's customers. Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Capitalized software embedded in products Capitalized software [Member] Capitalized software [Member] Operating expenses Operating Expenses Business Segments and Geographic Information Segment Reporting Disclosure [Text Block] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Variable interest rate Derivative, Variable Interest Rate FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Ultrasound imaging assets, equipment Ultrasound imaging assets, equipment [Member] Ultrasound imaging assets, equipment Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Finance lease obligations Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Basic (in shares) Basic weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Income from operations Income (loss) from operations Operating Income (Loss) Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Revenues: Revenues [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Proceeds from issuance of common stock pursuant to employee stock plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Write-offs, Payments and Foreign Exchange Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease) Disposal Group, Including Discontinued Operation, Other Assets Disposal Group, Including Discontinued Operation, Other Assets Disposal Group, Including Discontinued Operation, Contra Assets Disposal Group, Including Discontinued Operation, Contra Assets Scenario [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Company's Borrowings Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer Relationships Customer Relationships [Member] Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] EX-101.PRE 10 holx-20240629_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2 Cover Page - shares 9 Months Ended Jun. 29, 2024 Jul. 25, 2024 Cover [Abstract] A Title of 12(b) Security Common Stock, \$0.01 par value A Document Transition Report false A Document Quarterly Report true A Entity Incorporation, State or Country Code DE A Entity Address, Postal Zip Code 01752 A Entity File Number 1-36214 A Document Type 10-Q A Amendment Flag false A Document Period End Date Jun. 29, 2024 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Entity Registrant Name HOLOGIC, INC A Entity Central Index Key 0000859737 A Current Fiscal Year End Date --09-28 A Entity Filer Category Large Accelerated Filer A Entity Emerging Growth Company false A Entity Small Business false A Entity Common Stock, Shares Outstanding A 232,271,906 Entity Shell Company false A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A City Area Code (508) A Local Phone Number 263-2900 A Entity Tax Identification Number 04-2902449 A Entity Address, Address Line One 250 Campus Drive, A Entity Address, City or Town Marlborough, A Entity Address, State or Province MA A Trading Symbol HOLX A Security Exchange Name NASDAQ A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type:

duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei CoverAbstract Namespace Prefix: dei Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format -MM-DD. + ReferencesNo definition available. + Details Name: dei CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei DocumentFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei DocumentFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei DocumentPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:

units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 15: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 6: [http://www.xbrl.org/2003/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 19: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.1.2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3) + Details Name: us-gaap_ImpairmentOffintangibleAssetsIndefinitelivedExcludingGoodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479557/942-235-S99-1)Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481913/940-20-25-1>Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1) + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB TOPIC 6.1.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.1.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 8:

Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 12](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 12): <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 13>: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-10Reference 14>: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483581/946-220-45-7Reference 15>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1Reference 16](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1Reference 16): <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 17>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1Reference 18): [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 19](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 19): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20): [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(v\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28): [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30): [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 31): [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 32): <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 33>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 34): <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 35>: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 37](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 37): [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 38](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 38):

SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after loss of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT V.24.2 Consolidated Statements of Comprehensive Loss (Parenthetical) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Statement of Comprehensive Income [Abstract] Á Á Á Á Tax \$ 0.1 \$ 1.2 \$ (2.9) \$ (1.7) X - DefinitionAmount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT V.24.2 Consolidated Balance Sheets - USD (\$) \$ in Millions Jun. 29, 2024 Sep. 30, 2023 Current assets: Á Á Cash and cash equivalents \$ 2,439.1 \$ 2,722.5 Accounts receivable, less reserves 628.5 625.6 Inventory 665.5 617.6 Prepaid expenses and other current assets 158.4 175.3 Prepaid income taxes 105.5 31.6 Assets held-for-sale - current assets 0.0 11.9 Total current assets 3,997.0 4,184.5 Property, plant and equipment, net 528.8 517.0 Intangible assets, net 687.6 888.6 Goodwill 3,291.1 3,281.3 Other assets 385.6 267.9 Total assets 8,890.9 9,139.3 Current liabilities: Á Á Current portion of long-term debt 37.5 287.0 Accounts payable 202.0 175.2 Accrued expenses 540.7 534.6 Deferred revenue 219.0 199.2 Finance lease obligations 3.2 3.1 Assets held-for-sale - current liabilities 0.0 8.2 Total current liabilities 1,002.4 1,207.3 Long-term debt, net of current portion 2,505.6 2,531.2 Finance lease obligations, net of current portion 12.9 15.3 Deferred income tax liabilities 17.8 20.2 Deferred revenue, net of current portion 14.8 13.8 Other long-term liabilities 385.7 334.6 Stockholders' equity: Á Á Preferred stock, \$0.01 par value â€ 1,623 shares authorized; 0 shares issued 0.0 0.0 Common stock, \$0.01 par value â€ 750,000 shares authorized; 300,787 and 299,940 shares issued, respectively 3.0 3.0 Additional paid-in-capital 6,213.1 6,141.2 Retained earnings 2,667.2 2,056.3 Treasury stock, at cost â€ 68,731 and 58,231 shares, respectively (3,792.9) (3,036.0) Accumulated other comprehensive loss (139.5) (147.6) Total stockholders' equity 4,950.9 5,016.9 Total liabilities and stockholders' equity \$ 8,890.1 \$ 9,139.3 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 26: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7) + Details Name: us-gaap AssetsCurrentNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C](http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11> + Details Name: us-gaap AssetsOffDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(SX 210.5-02\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/21474834](http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)

[illegible]

10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <https://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02.29.30\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29.30) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_TreasuryStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Balance Sheets (Parenthetical) - \$ / shares shares in Thousands Jun. 29, 2024 Sep. 30, 2023 Statement of Financial Position [Abstract]

Preferred stock, par value (in dollars per share)	\$ 0.01	\$ 0.01	Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0	Common stock, par value (in dollars per share)	\$ 0.01	\$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000	Common stock, issued (in shares)	300,787,000	299,940,000
Treasury stock	68,731,000	58,231,000			

 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Stockholders' Equity - USD (\$) shares in Thousands, \$ in Millions Total Accelerated Share Repurchase Agreement Common Stock Additional Paid-in Capital Additional Paid-in Capital Accelerated Share Repurchase Agreement Retained Earnings Total Treasury Stock Treasury Stock Accelerated Share Repurchase Agreement Increase (Decrease) in Stockholders' Equity [Roll Forward]

Beginning balance	\$ 4,876.2	\$ 3.0	\$ 6,042.6	\$ 1,600.3	\$ (238.2)	\$ (2,531.5)
Exercise of stock options	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3
Vesting of restricted stock units, net of shares withheld for employee taxes	\$ 23.0	\$ (23.0)	\$ 0.0	\$ 0.0	\$ 0.0	\$ 0.0
Common stock issued under the employee stock purchase plan	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2
Stock-based compensation expense	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Repurchase of common stock	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Net income (loss)	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9

 X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Stockholders' Equity - USD (\$) shares in Thousands, \$ in Millions Total Accelerated Share Repurchase Agreement Common Stock Additional Paid-in Capital Additional Paid-in Capital Accelerated Share Repurchase Agreement Retained Earnings Total Treasury Stock Treasury Stock Accelerated Share Repurchase Agreement Increase (Decrease) in Stockholders' Equity [Roll Forward]

Beginning balance	\$ 4,876.2	\$ 3.0	\$ 6,042.6	\$ 1,600.3	\$ (238.2)	\$ (2,531.5)
Exercise of stock options	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3
Vesting of restricted stock units, net of shares withheld for employee taxes	\$ 23.0	\$ (23.0)	\$ 0.0	\$ 0.0	\$ 0.0	\$ 0.0
Common stock issued under the employee stock purchase plan	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2
Stock-based compensation expense	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Repurchase of common stock	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Net income (loss)	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9

 X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1> + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Stockholders' Equity - USD (\$) shares in Thousands, \$ in Millions Total Accelerated Share Repurchase Agreement Common Stock Additional Paid-in Capital Additional Paid-in Capital Accelerated Share Repurchase Agreement Retained Earnings Total Treasury Stock Treasury Stock Accelerated Share Repurchase Agreement Increase (Decrease) in Stockholders' Equity [Roll Forward]

Beginning balance	\$ 4,876.2	\$ 3.0	\$ 6,042.6	\$ 1,600.3	\$ (238.2)	\$ (2,531.5)
Exercise of stock options	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3	\$ 267.4	\$ 10.3
Vesting of restricted stock units, net of shares withheld for employee taxes	\$ 23.0	\$ (23.0)	\$ 0.0	\$ 0.0	\$ 0.0	\$ 0.0
Common stock issued under the employee stock purchase plan	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2	\$ 171.4	\$ 10.2
Stock-based compensation expense	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Repurchase of common stock	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9
Net income (loss)	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9	\$ 187.4	\$ 11.9

 X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

<https://asc.fasb.org/1943274/2147481877/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.Fact.2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.Fact.1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.1.7) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479360/740-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9> + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespaces Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481877/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidTaxes Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483581/946-220-45-7>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483586/944-220-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483575/946-220-S99-3>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 32: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 37: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1>Reference 38: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 39: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section

S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483589/942-20-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrli.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the cash inflow during the period from the sale of a component of the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2 Consolidated Statements of Cash Flows (Parenthetical) - USD (\$) in Millions Sep. 30, 2023 Sep. 28, 2023 Disposed of by Sale | SSI Ultrasound Imaging Business A Cash \$ 33.2 \$ 33.2 X - DefinitionAmount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCash Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=holx_SSIUltrasoundImagingBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2 Basis of Presentation 9 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Basis of Presentation Basis of PresentationThe unaudited consolidated financial statements of Hologic, Inc. (â€œHologicâ€ or the â€œCompanyâ€) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the â€œSECâ€) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (â€œGAAPâ€) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended SeptemberÂ 30, 2023 included in the Companyâ€™s annual report on FormÂ 10-K filed with the SEC on NovemberÂ 21, 2023. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Companyâ€™s financial position, results of operations and cash flows for the periods presented. The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from managementâ€™s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and nine months ended JuneÂ 29, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending SeptemberÂ 28, 2024. Fiscal 2023 was a 53-week fiscal year, and the additional week was included in the first quarter of fiscal 2023 consistent with the Companyâ€™s historical fiscal calendar.Subsequent Events ConsiderationThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three and nine months ended JuneÂ 29, 2024. On April 26, 2024, the Company executed an agreement to acquire Endomagnetics Ltd (â€œEndomagâ€) for a purchase price of approximately \$310.0Â million, subject to working capital and other customary adjustments. Endomag, located in the UK, develops and sells breast surgery localization and lymphatic tracing technologies. The transaction closed on July 25, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2 Leases 9 Months Ended Jun. 29, 2024 Leases [Abstract] A Leases LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Companyâ€™s consolidated revenue for all periods presented. Leases LeasesLessor Activity - Leases where Hologic is the LessorCertain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Companyâ€™s consolidated revenue for all periods presented. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeFinanceLeasesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrli.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements 9 Months Ended Jun. 29, 2024 Fair Value Disclosures [Abstract] A Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value MeasurementsAssets/Liabilities Measured and Recorded at Fair Value on a Recurring BasisThe Company has investments in money market funds, United States Treasury bills and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents on the Consolidated Balance Sheets.The Company also has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs.The following table summarizes certain fair value information at JuneÂ 29, 2024 and SeptemberÂ 30, 2023 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments. A Fair Value at Reporting Date UsingÂ Fair ValueQuoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) June 29, 2024 Assets: Money market mutual funds \$371.2Â \$371.2Â A \$â€ A U.S. Treasury bills \$398.1Â \$398.1Â A A Commercial paper \$49.5Â \$49.5Â A A Interest rate swaps \$14.7Â \$14.7Â A A Forward foreign currency contracts \$2.6Â \$2.6Â A A Total \$836.1Â \$818.8Â A \$17.3Â A Liabilities: Contingent consideration \$1.1Â \$â€ A \$â€ A \$1.1Â Forward foreign currency contracts \$0.4Â \$0.4Â A A Total \$1.5Â \$â€ A \$0.4Â A \$1.1Â September 30, 2023 Assets: Interest rate swaps \$26.9Â \$â€ A \$26.9Â A Forward foreign currency contracts \$8.4Â \$â€ A \$8.4Â A Total \$35.3Â \$â€ A \$35.3Â A Liabilities: Contingent consideration \$2.0Â \$â€ A \$â€ A \$2.0Â Total \$2.0Â \$â€ A \$â€ A \$2.0Â Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three and nine month periods ended JuneÂ 29, 2024 and July 1, 2023 were as follows: Three Months Ended Nine Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Balance at beginning of period \$1.1Â \$3.4Â \$2.0Â \$23.4Â Contingent consideration recorded at acquisition â€ A 1.1Â â€ A 1.1Â Fair value adjustments â€ A â€ A 1.7Â (12.4) Payments â€ A â€ A (2.6) (7.6) Balance at end of period \$1.1Â \$4.5Â \$1.1Â \$4.5Â Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, primarily comprised of property, plant and equipment, intangible assets and goodwill. During the third quarter of fiscal 2024, the Company recorded intangible asset impairment charges of \$13.3Â million and \$0.4Â million, respectively, related to its BioZorb developed technology and trade name intangible assets acquired in the Focal acquisition, which is within the Breast Health reportable segment, reducing the carrying value of the assets to zero. During the second quarter of fiscal 2024, the Company recorded intangible asset impairment charges of \$25.9Â million and \$0.9Â million, respectively, related to its BioZorb developed technology and trade name intangible assets reducing the carrying value of the assets to \$13.9Â million and \$0.5Â million, respectively. See Note 18 for further discussion. During the first quarter of fiscal 2024, the Company recorded a \$12.5Â million impairment charge for right-of-use lease assets related to the closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a \$4.3Â million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to \$22.4Â million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded impairment charges aggregating \$186.9Â million, of which \$174.8Â million was allocated to intangible assets and \$12.1Â million was allocated to property, plant and equipment. Subsequent to the impairment charges, the carrying value of the definite-lived intangible assets and property, plant and equipment was \$65.8Â million and \$4.6Â million, respectively. See Note 18 for additional information. In addition, the Company recorded a \$10.5Â million impairment charge for an in-process research and development project from the Mobidiag acquisition, and the

resulting carrying value was \$26.5Å million. During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its SSI ultrasound imaging business and recorded impairment charges aggregating \$26.4Å million, of which \$20.6Å million was allocated to intangible assets and \$5.8Å million was allocated to equipment. Subsequent to the impairment charges, the carrying value of these assets was zero. There were no other remeasurements in the three and nine months ended JuneÅ 29, 2024 and JulyÅ 1, 2023.Disclosure of Fair Value of Financial InstrumentsThe CompanyÅ™’s financial instruments mainly consist of cash and cash equivalents, United States Treasury bills, commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the CompanyÅ™’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The CompanyÅ™’s United States Treasury bills, commercial paper, interest rate swaps and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. The CompanyÅ™’s cash and cash equivalents, including current marketable securities, as of JuneÅ 29, 2024 are as follows:ValuationBalance Sheet Classificationin millionsCostUnrealized GainsUnrealized LossesFair ValueCash and cash equivalentsInvestmentsCash\$1,620.3Å \$Å€”A \$Å€”A \$1,620.3Å \$1,620.3Å \$Å€”A Money market mutual funds371.2Å \$Å€”A \$Å€”A 371.2Å 371.2Å \$Å€”A U.S. Treasury bills398.1Å \$Å€”A \$Å€”A 398.1Å \$Å€”A Commercial paper49.5Å \$Å€”A \$Å€”A 49.5Å 49.5Å \$Å€”A Totals\$2,439.1Å \$Å€”A \$Å€”A \$2,439.1Å \$2,439.1Å \$Å€”A The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the three and nine months ended JuneÅ 29, 2024. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the three and nine months ended JuneÅ 29, 2024. The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and nine months ended JuneÅ 29, 2024 and JulyÅ 1, 2023, respectively. There were no sales of available-for-sale securities during the three and nine months ended JuneÅ 29, 2024.The fair value of the available-for-sale securities by contractual maturity as of JuneÅ 29, 2024 and SeptemberÅ 30, 2023 are as follows:June 29, 2024September 30, 2023in millionsFair ValueFair ValueDue in three months or less\$447.6Å \$Å€”A Total available-for-sale securities\$447.6Å \$Å€”A Amounts outstanding under the CompanyÅ™’s 2021 Credit Agreement of \$1.2 billion aggregate principal as of JuneÅ 29, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The CompanyÅ™’s 5.4625% Senior Notes due 2028 (the Å€œ2028 Senior NotesÅ”) and 3.250% Senior Notes due 2029 (the Å€œ2029 Senior NotesÅ”) had fair values of \$382.9Å million and \$853.3Å million, respectively, as of JuneÅ 29, 2024 based on their trading prices, representing a Level 1 measurement. X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders’ equity, which may be measured on a recurring or nonrecurring basis, + ReferencesReference 1:

in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the “2018 Credit Agreement”) by entering into a Refinancing Amendment (the “2021 Credit Agreement”). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (the “SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a \$1.5Å billion secured term loan facility (the “2021 Term Loan”) and a \$2.0Å billion revolving credit facility (the “2021 Revolver”). As of June 29, 2024, the principal amount outstanding under the 2021 Term Loan was \$1.2Å billion, and the interest rate was 6.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. During the first quarter of fiscal 2024, the Company made a \$250.0Å million voluntary prepayment on the 2021 Term Loan. Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended Nine Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Interest expense \$21.1Å \$24.3Å \$64.9Å \$67.2Å Weighted average interest rate 6.43Å % 6.17Å % 6.43Å % 5.65Å % Interest rate at end of period 6.44Å % 6.20Å % 6.44Å % 6.20Å % The Company’s effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on \$1.0Å billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixes the SOFR component of the variable interest rate on \$500Å million of aggregate principal under the 2021 Term Loan at 3.46% commencing on December 17, 2023 and terminating on December 27, 2024, resulted in the Company receiving \$2.4Å million and \$14.4Å million during the three and nine months ended June 29, 2024, respectively, and \$9.8Å million and \$25.0Å million during the three and nine months ended July 1, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of June 29, 2024, the Company was in compliance with these covenants. 2028 Senior Notes Å Å Å of June 29, 2024, the Company had 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) outstanding in the aggregate principal balance of \$400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of June 29, 2024, the Company had 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) outstanding in the aggregate principal balance of \$950Å million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 15, 2029. Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Nine Months Ended Interest Rate June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 2028 Senior Notes 4.625Å % \$4.8Å \$4.8Å \$14.4Å \$14.8Å 2029 Senior Notes 3.250Å % 8.2Å 8.2Å 24.7Å 25.3Å Totals \$13.0Å \$13.0Å \$39.1Å \$40.1Å X - References No definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap DebtDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2 Trade Receivables and Allowance for Credit Losses 9 Months Ended Jun. 29, 2024 Receivables [Abstract] Å Trade Receivables and Allowance for Credit Losses Trade Receivables and Allowance for Credit Losses The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity, such as the ongoing and possible future effects of global challenges including macroeconomic uncertainties, such as inflation, rising interest rates and availability of capital markets, and other economic disruptions. To date, the Company has not experienced significant customer payment defaults, or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of June 29, 2024 compared to July 1, 2023: Balance at Beginning of Period Credit Loss Write-offs, Payments and Foreign Exchange Balance at End of Period Nine Months Ended: June 29, 2024 \$38.5Å \$5.8Å (2.9) \$41.4Å July 1, 2023 \$37.7Å \$2.2Å (0.8) \$39.1Å X - Definition The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContent + Details Name: us-gaap LoansNotesTradeAndOtherReceivablesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap ReceivablesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2 Derivatives 9 Months Ended Jun. 29, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Å Derivatives Derivatives Interest Rate Swaps - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (the “AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform, in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was \$1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on \$1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is \$500 million, and the first interest rate swap fixes the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on \$500Å million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of these swaps was an asset position of \$14.7Å million as of June 29, 2024. Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company’s cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts; however, the Company may seek to apply hedge accounting in future scenarios. As of June 29, 2024, the notional amount was \$97.2Å million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three and nine months ended June 29, 2024 and July 1, 2023, respectively, were as follows: Three Months Ended Nine Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Amount of realized gain (loss) recognized in income Forward foreign currency contracts \$1.7Å \$1.4Å \$3.5Å \$(1.3) Foreign currency option contracts \$6.1Å \$(1.2) \$6.1Å \$(2.7) \$1.7Å \$0.2Å \$3.5Å \$(4.0) Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts \$(0.5) \$6.1Å \$(6.2) \$(13.8) Foreign currency option contracts \$6.1Å \$1.0Å \$6.1Å \$(6.8) \$(0.5) \$1.0Å \$(6.2) \$(20.6) Amount of gain (loss) recognized in income Total \$1.2Å \$1.2Å \$(2.7) \$(24.6) Financial Instrument Presentation The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of June 29, 2024: Balance Sheet Location June 29, 2024 September 30, 2023 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets \$8.5Å \$16.2Å Interest rate swap contracts Other assets \$2.1Å \$10.7Å \$14.7Å \$26.9Å Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets \$2.6Å \$8.4Å \$2.6Å \$8.4Å Liabilities: Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses \$0.4Å \$6.1Å The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended Nine Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swaps \$0.3Å \$3.7Å \$(9.3) \$(5.6) Totals \$0.3Å \$3.7Å \$(9.3) \$(5.6) X - References No definition available. + Details Name: us-gaap Derivative Instruments And Hedging Activities Disclosure Abstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for derivatives and fair value of assets and liabilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent + Details Name: us-gaap Derivatives And Fair Value TextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2 Commitments and Contingencies 9 Months Ended Jun. 29, 2024 Commitments and Contingencies Disclosure [Abstract] Å Commitments and Contingencies (12) Commitments and Contingencies Litigation and Related Matters On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of 88 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter. Å Å Å The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution of which are reasonably likely based upon management’s assessment, to have a material adverse effect on its financial condition or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies (ASC 450). Legal costs are expensed as incurred. X - References No definition available. + Details Name: us-gaap Commitments And Contingencies Disclosure Abstract Namespace Prefix: us-gaap Data Type: xbrl:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480327/954-440-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-

gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2 Net Income (Loss) Per Share 9 Months Ended Jun. 29, 2024 Earnings Per Share [Abstract] A Net Income (Loss) Per Share Net Income (Loss) Per ShareA reconciliation of basic and diluted share amounts is as follows: A Three Months EndedNine Months EndedA June 29, 2024July 1, 2023June 29, 2024July 1, 2023Basic weighted average common shares outstanding234,604A 246,908A 236,373A 247,319A Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units1,862A 2,170A 1,708A 2,074A Diluted weighted average common shares outstanding236,466A 246,908A 238,081A 249,393A Weighted-average anti-dilutive shares related to:Outstanding stock options and restricted stock units933A 2,936A 1,372A 1,786A In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options' combined exercise price and average unrecognized stock compensation expense is greater than the average stock price during the period. In those reporting periods in which the Company has a net loss, diluted loss per share is equal to basic loss per share because the effect of potentially dilutive securities would be anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_ EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3> + Details Name: us-gaap_ EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2 Stock-Based Compensation 9 Months Ended Jun. 29, 2024 Share-Based Payment Arrangement [Abstract] A Stock-Based Compensation Stock-Based CompensationThe following presents stock-based compensation expense in the Company's Consolidated Statements of Income: A Three Months EndedNine Months EndedA June 29, 2024July 1, 2023June 29, 2024July 1, 2023Cost of revenues\$2.6A \$2.1A \$8.5A \$7.7A Research and development2.2A 2.1A 8.4A 8.6A Selling and marketing3.5A 2.9A 10.4A 9.2A General and administrative6.3A 9.8A 41.8A 35.1A \$14.6A \$16.9A \$69.1A \$60.6A The Company granted options to purchase 0.6 million and 0.5 million shares of the Company's common stock during the nine months ended JuneA 29, 2024 and JulyA 1, 2023, respectively, with weighted-average exercise prices of \$72.32 and \$74.67, respectively. There were 4.5 million options outstanding at JuneA 29, 2024 with a weighted-average exercise price of \$54.62.The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: A Three Months EndedNine Months EndedA June 29, 2024July 1, 2023June 29, 2024July 1, 2023Risk-free interest rate4.4A %4.3A %4.4A %4.3A %Expected volatility33.4A %33.9A %33.4A %33.9A %Expected life (in years)4.84.84.8Dividend yield2A %2A %2A %2A %Weighted average fair value of options granted\$26.44A \$30.51A \$25.06A \$25.95A The Company granted 0.7 million and 0.6 million restricted stock units (aRSTUs) during the nine months ended JuneA 29, 2024 and JulyA 1, 2023, respectively, with weighted-average grant date fair values of \$72.03 and \$74.56 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (aPSTUs) during the nine months ended JuneA 29, 2024 and JulyA 1, 2023, respectively, to members of its senior management team, which have a weighted-average grant date fair value of \$71.92 and \$74.35 per unit, respectively. Each recipient of PSTUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of a three-year performance period, provided that the Company's defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 1A million of FCF PSTUs based on a three-year cumulative free cash flow measure (aFCF PSTUs) to members of its senior management team, which had a grant date fair value of \$71.92 and \$74.35 per unit during the nine months ended JuneA 29, 2024 and JulyA 1, 2023, respectively. Each recipient of FCF PSTUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the three-year measurement period. The PSTUs and FCF PSTUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (aMSTUs) to members of its senior management team during the nine months ended JuneA 29, 2024 and JulyA 1, 2023, respectively. Each recipient of MSTUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSTUs were valued at \$88.06 and \$97.91 per share using the Monte Carlo simulation model in fiscal 2024 and 2023, respectively. The MSTUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSTUs ratably over the service period. At JuneA 29, 2024, there was 1.7 million in aggregate unvested RSUs, PSTUs, FCF PSTUs and MSTUs outstanding. At JuneA 29, 2024, there was \$12.4 million and \$55.5 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSTUs, FCF PSTUs and MSTUs), respectively, to be recognized over a weighted-average period of 2.3 and 1.8 years, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap_ DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2 Other Balance Sheet Information 9 Months Ended Jun. 29, 2024 Balance Sheet Related Disclosures [Abstract] A Other Balance Sheet InformationJune 29, 2024September 30, 2023InventoriesRaw materials\$263.2A \$238.6A Work-in-process58.4A 66.3A Finished goods343.9A 312.7A \$665.5A \$617.6A Property, plant and equipmentEquipment\$388.4A \$380.0A Equipment under customer usage agreements507.7A 508.1A Building and improvements243.7A 230.0A Leasehold improvements42.0A 44.4A Land40.8A 41.1A Furniture and fixtures23.6A 19.2A Finance lease right-of-use asset8.4A 8.2A \$1,254.6A \$1,231.0A Less accumulated depreciation and amortization(725.8)(714.0)\$528.8A \$517.0A During the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its Mobidiag business and based on the fair value of the asset group recorded impairment charges of \$12.1A million to property, plant and equipment. In addition, during the third quarter of fiscal 2023, the Company identified indicators of impairment related to its long-lived assets of its SSI ultrasound imaging business and recorded impairment charges of \$5.8A million related to property, plant and equipment. See Note 18 for additional information. X - DefinitionDetails of certain balance sheet accounts. + ReferencesNo definition available. + Details Name: holx_DetailsOfCertainBalanceSheetAccountsTextBlock Namespace Prefix: holx_ Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2 Business Segments and Geographic Information 9 Months Ended Jun. 29, 2024 Segment Reporting [Abstract] A Business Segments and Geographic InformationBusiness Segments and Geographic InformationThe Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and nine months ended JuneA 29, 2024 and JulyA 1, 2023. Segment information is as follows: A Three Months EndedNine Months EndedA June 29, 2024July 1, 2023June 29, 2024July 1, 2023Total revenues:Diagnostics\$440.8A \$439.7A \$1,338.7A \$1,463.6A Breast Health385.0A 360.3A 1,147.3A 1,079.9A GYN Surgical166.6A 157.3A 484.8A 456.2A Skeletal Health19.0A 27.1A 71.5A 85.4A \$1,011.4A \$984.4A \$3,042.3A \$3,085.1A Income from operations:Diagnostics\$89.7A \$(113.5)\$210.1A \$142.8A Breast Health102.4A 63.3A 296.2A 233.7A GYN Surgical56.7A 48.5A 144.3A 149.6A Skeletal Health(4.8)3.1 2.0A 9.8A \$244.0A \$1.4A \$652.6A \$535.9A Depreciation and amortization:Diagnostics\$51.0A \$56.8A \$168.3A \$172.9A Breast Health9.3A 12.2A 29.6A 38.7A GYN Surgical11.9A 11.9A 36.1A 35.8A Skeletal Health0.1A 0.3A 0.4A 0.5A \$72.3A \$81.2A \$234.4A \$247.9A Capital expenditures:Diagnostics\$17.7A \$22.6A \$61.7A \$58.7A Breast Health10.4A 8.0A 25.1A 22.0A GYN Surgical4.8A 4.5A 11.5A 11.2A Skeletal Health0.7A 0.6A 1.1A 0.2A Corporate0.3A 1.4A 0.5A 5.6A \$33.9A \$36.5A \$99.9A \$97.7A A June 29, 2024September 30, 2023Identifiable assets:Diagnostics\$2,476.3A \$2,596.4A Breast Health1,217.6A 1,170.1A GYN Surgical1,429.8A 1,455.4A Skeletal Health35.6A 33.7A Corporate3,730.8A 3,883.7A \$8,890.1A \$9,139.3A The Company had no customers that represented greater than 10% of consolidated revenues during the three and nine months ended JuneA 29, 2024 and JulyA 1, 2023. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company's sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company's sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The Rest of World designation includes Canada, Latin America and the Middle East.Revenues by geography as a percentage of total revenues were as follows: A Three Months EndedNine Months EndedA June 29, 2024July 1, 2023June 29, 2024July 1, 2023United States75.7A %76.2A %74.9A %75.9A %Europe12.6A %13.1A %13.4A %13.9A %Asia-Pacific6.4A %6.4A %6.4A %6.2A %Rest of World5.3A %4.3A %5.3A %4.0A %100.0A %100.0A %100.0A %100.0A % X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2 Income Taxes 9 Months Ended Jun. 29, 2024 Income Tax Disclosure [Abstract] A Income Taxes Income TaxesIn accordance with ASC 740, Income Taxes, each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.For the three months ended June 29, 2024, the Company recorded income tax expense of \$46.2A million resulting in an effective tax rate of 19.2%. For the nine months ended June 29, 2024, the Company recorded income tax expense of \$32.6A million, resulting in an effective tax rate of 5.1%.The effective tax rate for the three months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Company's international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits. The effective tax rate for the nine months ended June 29, 2024 was lower than the U.S. statutory tax rate primarily due to a discrete tax benefit of \$107.2A million related to a worthless stock deduction on an investment in one of the Company's international subsidiaries recorded in the first quarter of fiscal 2024, the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Company's international subsidiaries, and federal and state tax credits. The Company recorded income tax expense of \$52.6A million and \$165.1A million for the three and nine months ended July 1, 2023, resulting in effective tax rates of 434.7% and 31.1%, respectively. The effective tax rates for the three and nine months ended JulyA 1, 2023 were higher than the U.S. statutory tax rate primarily due to the tax effect of impairment charges recorded for assets acquired in the Mobidiag acquisition and the impairment of the Company's SSI ultrasound imaging assets, income tax reserves, the global intangible low-taxed income inclusion, and state income taxes, partially offset by the impact of the U.S. deduction for foreign derived intangible income, and the geographic mix of income earned by the Company's international subsidiaries.Non-Income Tax MattersThe Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. Such amounts were not material for any of the periods presented. In the

normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future. X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Dislosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(h)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/7740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 21-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 270-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482526/740-270-50-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 17-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SAB TOPIC 6.1.5.Q1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SAB TOPIC 6.1.5.Q1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SAB TOPIC 11.C\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SAB TOPIC 11.C)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2) + Details Name: us-gaap IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2 Intangible Assets and Goodwill 9 Months Ended Jun. 29, 2024

Goodwill and Intangible Assets Disclosure [Abstract] Â Intangible Assets and Goodwill Intangible AssetsIntangible assets consisted of the following:Â DescriptionAs of June 29, 2024As of September 30, 2023GrossCarryingValueAccumulatedAmortizationGrossCarryingValueAccumulatedAmortizationAcquired intangible assets:DevelopedA technology\$4,375.4A \$3,786.6A \$4,411.0A \$3,649.5A In-process research and development21.9A â€”A 25.7A â€”A Customer relationships600.6A 564.4A 600.0A 550.6A Trade names252.5A 222.9A 253.6A 212.8A Total acquired intangible assets\$5,250.4A \$4,573.9A \$5,290.3A \$4,412.9A Internal-use software25.5A 20.0A 24.0A 17.8A Capitalized software embedded in products29.7A 24.1A 27.7A 22.7A Total intangible assets\$5,305.6A \$4,618.0A \$5,342.0A \$4,453.4A The estimated remaining amortization expense of the Companyâ€™s acquired intangible assets as of JuneÂ29, 2024 for each of the five succeeding fiscal years was as follows:Remainder of Fiscal 2024\$47.2A Fiscal 2025\$180.6A Fiscal 2026\$150.6A Fiscal 2027\$63.6A Fiscal 2028\$60.5A During the second quarter of fiscal 2024, in connection with commencing its company-wide annual strategic planning process, the Company identified indicators of impairment in its BioZorb product line, which was part of the Focal acquisition. As a result, the Company performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant and Equipment - Overall, to determine if the cash flows expected to be generated by the BioZorb product line over the remaining estimated useful life of the primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis, the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. Therefore, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculated the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Based on this analysis, the fair value of the BioZorb asset group was below its carrying value and the Company recorded an impairment charge of \$26.8A million during the second quarter of fiscal 2024. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: \$25.9A million to developed technology and \$0.9A million to trade names, which reduced the carrying value of the assets to \$13.9A million and \$0.5A million respectively. During the third quarter of fiscal 2024, the Federal Drug Administration classified a prior safety notice for the BioZorb Marker as a Class I recall. This was the technical classification of a prior safety notice only, not a product removal. Following this, the Company lowered its forecasts for this product line, which is an indicator of impairment. Accordingly, the Company performed an undiscounted cash flow analysis, and the cash flows were not sufficient to recover the carrying value of the asset group. The Company performed a fair value analysis and determined that the fair value of the asset group was de minimus. As a result, the Company recorded an impairment charge of \$13.3A million and \$0.4A million to developed technology and trade names, respectively, to fully write-off the assets.During the first quarter of fiscal 2024, the Company assessed its only in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a \$4.3A million impairment charge, reducing the fair value of this asset to \$22.4A million. The reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of \$7.3A million to bring the net carrying values to zero.During the third quarter of fiscal 2023, in connection with its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Mobidiag business, including product design and manufacturing requirements, the Company reassessed its short-term and long-term commercial plans for this business. The Company made certain operational and strategic decisions to invest and focus more on the long-term success of this business, which resulted in the Company significantly reducing its forecasted revenues and operating results.As a result, the Company determined indicators of impairment existed and performed an undiscounted cash flow analysis pursuant to ASC 360 to determine if the cash flows expected to be generated by the Mobidiag business over the estimated remaining useful life of its primary asset were sufficient to recover the carrying value of the asset group. Based on this analysis the undiscounted cash flows were not sufficient to recover the carrying value of the long-lived assets. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value of the asset group, the Company utilized the income approach, which is based on a DCF. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows were based on the Company's most recent strategic plan at the time and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used is intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 17.0%. As a result of this analysis, the fair value of the Mobidiag asset group was below its carrying value. Prior to calculating and allocating the impairment charge, the Company assessed the only in-process research and development intangible asset in this asset group for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the DCF model and recorded a \$10.5A million impairment charge, reducing the fair value of this asset to \$26.5A million. The reduction in fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project to focus on other projects.To record the asset group to fair value, the Company recorded an impairment charge of \$186.9A million during the third quarter of fiscal 2023. The impairment charge was allocated to the long-lived assets on a pro-rata basis as follows: \$153.7A million to developed technology, \$10.4A million to customer relationships, \$10.7A million to trade names, and \$12.1A million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. Actual operating results and the related cash flows of the asset group could differ from the estimated operating results and related cash flows. In the event the asset group does not meet its forecasted projections, additional impairment charges could be recorded in the future. The Company also re-evaluated the remaining useful lives of the intangible assets and concluded no changes were necessary at that time.During the third quarter of fiscal 2023, the Company also identified indicators of impairment associated with its SSI ultrasound imaging assets. As a result, the Company recorded an impairment charge of \$26.4A million, of which \$20.6A million was allocated to intangible assets, primarily developed technology, and \$5.8A million was allocated to equipment. X - ReferencesNo definition available. + Details Name: us-gaap GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/350-30/tableOfContent+Details Name: us-gaap IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2 Product Warranties 9 Months Ended Jun. 29, 2024Guarantees [Abstract] Â Product Warranties Product WarrantiesProduct warranty activity was as follows:Â BalanceÂ at BeginningÂ of a PeriodProvisionsSettlementsAdjustmentsBalanceÂ at EndÂ of a PeriodNine Months Ended:June 29, 2024\$8.3A \$7.2A \$(6.3)\$9.2A July 1, 2023\$8.0A \$4.9A \$(5.4)\$7.5A X - ReferencesNo definition available. + Details Name: us-gaap GuaranteesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)\(5\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)(5)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 460-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482425/460-10-50-4) + Details Name: us-gaap ProductWarrantyDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2 Accumulated Other Comprehensive Income (Loss) 9 Months Ended Jun. 29, 2024

Accumulated Other Comprehensive Income [Abstract] Â Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented:Three Months Ended June 29, 2024Nine Months Ended June 29, 2024Foreign Currency TranslationPension PlansHedged Interest Rate SwapsTotalForeign Currency TranslationPension PlansHedged Interest Rate SwapsTotalBeginning Balances\$(147.8)\$0.3A \$10.5A \$(137.0)\$ (168.0)\$0.3A \$20.1A \$(147.6)Other comprehensive income (loss) before reclassifications(2.8)â€”A 0.3A (2.5)17.4A â€”A (9.3)8.1A Ending Balances\$(150.6)\$0.3A \$10.8A \$(139.5)\$ (150.6)\$0.3A \$10.8A \$(139.5)Three Months Ended July 1, 2023Nine Months Ended July 1, 2023Foreign Currency TranslationPension PlansHedged Interest Rate SwapsTotalForeign Currency TranslationPension PlansHedged Interest Rate SwapsTotalBeginning Balances\$(138.1)\$ (0.3)\$20.0A \$(118.4)\$ (267.2)\$ (0.3)\$29.3A \$(238.2)Other comprehensive income (loss) before reclassifications1.1A â€”A 3.7A 4.8A 130.2A â€”A (5.6)12.6A Ending Balances\$(137.0)\$ (0.3)\$23.7A \$(113.6)\$ (137.0)\$ (0.3)\$23.7A \$(113.6) X - DefinitionAccumulated Other Comprehensive Income [Abstract] + ReferencesNo definition available. + Details Name: holx AccumulatedOtherComprehensiveIncomeAbstract Namespace Prefix: holx_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(21\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-599-1)Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/220/tableOfContent+Details Name: us-gaap ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2 Share Repurchase 9 Months Ended Jun. 29, 2024Equity [Abstract] Â Share Repurchase Share RepurchaseOn September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to \$1.0A billion of the Companyâ€™s outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous \$1.0A billion authorization. Exclusive of shares repurchased pursuant to the accelerated share repurchase agreement described below, during the three and nine months ended JuneÂ29, 2024, the Company repurchased 1.4A million and 3.5A million shares of its common stock under the authorization for total consideration of \$100.0A million and \$250.0A million, respectively. As of JuneÂ29, 2024, \$248.6A million remained available under this authorization. On November 6, 2023, the Board of Directors authorized the Company to repurchase up to \$500A million of the Companyâ€™s outstanding shares pursuant to an accelerated share repurchase (â€œacSRâ€) agreement. On November 15, 2023, the Company executed the ASR agreement with Goldman Sachs & Co. (â€œGoldman Sachsâ€) pursuant to which the Company agreed to repurchase \$500A million of the Companyâ€™s common stock. In connection with the launch of the ASR, on November 17, 2023, the Company paid Goldman Sachs an aggregate of \$500A million and received approximately 5.6A million shares of the Companyâ€™s common stock, representing 80% of the transaction value based on the Companyâ€™s closing share price on November 14, 2023. On February 27, 2024, the ASR agreement was completed, and the Company received an additional 1.4A million shares for the final settlement. This final settlement was based on the total transaction value and the volume-weighted average share price of the Companyâ€™s common stock during the term of the agreement. X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481062/946-235-50-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147481004/946-505-50-6>Reference 7:

45-28Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fashb.org/1943274/2147483589/942-220-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fashb.org/1943274/2147483621/220-10-599-2) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2 Insider Trading Arrangements 3 Months Ended 9 Months Ended Jun. 29, 2024 shares Jun. 29, 2024 shares Trading Arrangements, by Individual A A Non-Rule 10b5-1 Arrangement Adopted false A Rule 10b5-1 Arrangement Terminated false A Non-Rule 10b5-1 Arrangement Terminated false A Rule 10b5-1 Arrangement Terminated false A Rule 10b5-1 Arrangement Terminated false A Trading Arrangements, by Individual A A Material Terms of Trading Arrangement A During the third quarter of fiscal 2024, Karleen Oberton, our Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on May 30, 2024 to sell up to 62,679 shares of our common stock (following the exercise of options) between August 29, 2024 and February 3, 2025, the date this plan expires. The trading plan will cease upon the earlier of February 3, 2025 or the sale of all shares subject to the trading plan. Name Karleen Oberton A Title Chief Financial Officer A Rule 10b5-1 Arrangement Adopted true A Adoption Date May 30, 2024 A Arrangement Duration 158 days A Aggregate Available 62,679 62,679 X - ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fashb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmtdFlag Namespace Prefix: ecd_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=holt KarleenObertonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2 Basis of Presentation (Policies) 9 Months Ended Jun. 29, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] A Basis of Presentation Basis of PresentationThe unaudited consolidated financial statements of Hologic, Inc. (â€œHologicâ€ or the â€œCompanyâ€) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the â€œSECâ€) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (â€œGAAPâ€) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended SeptemberÂ 30, 2023 included in the Companyâ€™s annual report on FormÂ 10-K filed with the SEC on NovemberÂ 21, 2023. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Companyâ€™s financial position, results of operations and cash flows for the periods presented. Principal of ConsolidationThe unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from managementâ€™s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and nine months ended JuneÂ 29, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending SeptemberÂ 28, 2024. Fiscal 2023 was a 53-week fiscal year, and the additional week was included in the first quarter of fiscal 2023 consistent with the Companyâ€™s historical fiscal calendar. Subsequent Events ConsiderationSubsequent Events ConsiderationThe Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three and nine months ended JuneÂ 29, 2024. On April 26, 2024, the Company executed an agreement to acquire Endomagetics Ltd (â€œEndomagâ€) for a purchase price of approximately $310.0Â million, subject to working capital and other customary adjustments. Endomag, located in the UK, develops and sells breast surgery localization and lymphatic tracing technologies. The transaction closed on July 25, 2024. X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: <a href=)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fashb.org/1943274/2147481203/810-10-50-1> + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reporting subsequent events. + ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2 Revenue from Contract with Customer (Policies) 9 Months Ended Jun. 29, 2024 Revenue from Contract with Customer [Abstract] A Revenue (2) RevenueThe Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customers (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Companyâ€™s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:Â A A A Three Months Ended June 29, 2024Three Months Ended July 1, 2023Business (in millions)United StatesInternationalTotalUnited StatesInternationalTotalDiagnostics:Cytology & Perinatal\$73.3Â \$48.9Â \$122.2Â \$79.7Â \$47.1Â \$126.8Â Molecular Diagnostics245.4Â 65.3Â 310.7Â 240.2Â 62.0Â 302.2Â Blood Screening7.9Â â€“ 7.9Â 10.7Â â€“ 10.7Â Total\$326.6Â \$114.2Â \$440.8Â \$330.6Â \$109.1Â \$439.7Â Breast Health:Breast Imaging240.4Â \$68.8Â \$309.2Â \$220.7Â \$65.4Â \$286.1Â Interventional Breast Solutions60.1Â 15.7Â 75.8Â 59.2Â 15.0Â 74.2Â Total\$300.5Â \$84.5Â \$385.0Â \$279.9Â \$80.4Â \$360.3Â GYN Surgical\$125.8Â \$40.8Â \$166.6Â \$122.9Â \$34.4Â \$157.3Â Skeletal Health\$12.4Â \$6.6Â \$19.0Â \$16.7Â \$10.4Â \$27.1Â \$765.3Â \$246.1Â \$1,011.4Â \$750.1Â \$234.3Â \$984.4Â Nine Months Ended June 29, 2024Nine Months Ended July 1, 2023Business (in millions)United StatesInternationalTotalUnited StatesInternationalTotalDiagnostics:Cytology & Perinatal\$213.7Â \$149.0Â \$362.7Â \$226.9Â \$138.5Â \$365.4Â Molecular Diagnostics748.4Â 204.8Â 953.2Â 831.5Â 238.2Â 1,069.7Â Blood Screening22.8Â â€“ 22.8Â 28.5Â â€“ 28.5Â Total\$984.9Â \$353.8Â \$1,338.7Â \$1,086.9Â \$376.7Â \$1,463.6Â Breast Health:Breast Imaging\$703.7Â \$213.6Â \$917.3Â \$666.5Â \$195.6Â \$862.1Â Interventional Breast Solutions181.6Â 48.4Â 230.0Â 176.7Â 41.1Â 217.8Â Total\$885.3Â \$262.0Â \$1,147.3Â \$843.2Â \$236.7Â \$1,079.9Â GYN Surgical\$366.6Â \$118.2Â \$484.8Â \$359.6Â \$96.6Â \$456.2Â Skeletal Health\$41.6Â \$29.9Â \$71.5Â \$52.8Â \$32.6Â \$85.4Â \$2,278.4Â \$763.9Â \$3,042.3Â \$2,342.5Â \$742.6Â \$3,085.1Â Three Months EndedNine Months EndedGeographic Regions (in millions)June 29, 2024July 1, 2023June 29, 2024July 1, 2023United States\$765.3Â \$750.1Â \$2,278.4Â \$2,342.5Â Europe127.9Â 128.5Â 407.7Â 427.3Â Asia-Pacific65.0Â 62.9Â 193.2Â 191.9Â Rest of World53.2Â 42.9Â 163.0Â 123.4Â \$1,011.4Â \$984.4Â \$3,042.3Â \$3,085.1Â The following table provides revenue recognized by source:Three Months EndedNine Months EndedRevenue by type (in millions)June 29, 2024July 1, 2023June 29, 2024July 1, 2023Disposables\$623.2Â \$609.0Â \$1,871.0Â \$1,963.3Â Capital equipment, components and software188.0Â 190.1Â 596.2Â 559.6Â Service196.8Â 180.4Â 560.6Â 546.7Â Other3.4Â 4.9Â 14.5Â 15.5Â \$1,011.4Â \$984.4Â \$3,042.3Â \$3,085.1Â The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contractâ€™s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Companyâ€™s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Companyâ€™s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services.The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized.The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement.Revenue from laboratory testing services, which is generated by the Companyâ€™s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors.Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable ConsiderationThe Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Companyâ€™s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Companyâ€™s financial statements.Remaining Performance ObligationsAs of JuneÂ 29, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately \$880.0 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Companyâ€™s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 14% of this amount as revenue in fiscal 2024, 42% in fiscal 2025, 25% in fiscal 2026, 12% in fiscal 2027, and 7% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.Contract Assets and LiabilitiesThe Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to

the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of \$22.8Å million and \$124.4Å million in the three and nine months ended JuneÅ 29, 2024, respectively, that was included in the contract liability balance at SeptemberÅ 30, 2023. The Company recognized \$21.0Å million and \$122.2Å million in the three and nine months ended JulyÅ 1, 2023, respectively, that was included in the contract liability at SeptemberÅ 24, 2022.Practical ExpedientsThe Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts. X - ReferencesNo definition available. + Details Name: us-gaap RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 15: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 16: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 17: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(j\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (j) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(k\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(l\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 21: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(m\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (m) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 22: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(n\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (n) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(o\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 24: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(p\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (p) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 25: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(q\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (q) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 26: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(r\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (r) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 27: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(s\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (s) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(t\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (t) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 29: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(u\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (u) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 30: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(v\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 31: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(w\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (w) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 32: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(x\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (x) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 33: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(y\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (y) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 34: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(z\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (z) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 35: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 36: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(ab\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (ab) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 37: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(ac\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (ac) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 38: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(ad\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (ad) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 39: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(ae\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (ae) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 40: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (af) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)

discount and deferred issuance costs:Term Loans\$37.5Å \$287.0Å Total current debt obligations\$37.5Å \$287.0Å Long-term debt obligations, net of debt discount and issuance costs:Term Loan\$1,168.0Å \$1,195.6Å 2028 Senior Notes\$397.3Å 396.8Å 2029 Senior Notes\$940.3Å 938.8Å Total long-term debt obligations\$2,505.6Å \$2,531.2Å Total debt obligations\$2,543.1Å \$2,818.2Å Schedule Of Interest Expense Under Credit Agreement Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows:Å Three Months EndedNine Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Interest expenses\$21.1Å \$24.3Å \$64.9Å \$67.2Å Weighted average interest rate6.43Å %6.17Å %6.43Å %6.56Å %Interest rate at end of period6.44Å %6.20Å %6.44Å %6.20Å % Schedule of Interest Expense Under Convertible NotesTotal Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows:Three Months EndedNine Months EndedInterest RateJune 29, 2024July 1, 2023June 29, 2024July 1, 20232028 Senior Notes4.625Å %\$4.8Å \$4.8Å \$14.4Å \$14.8Å 2029 Senior Notes3.250Å %8.2Å 8.2Å 24.7Å 25.3Å Total\$13.0Å \$13.0Å \$39.1Å \$40.1Å X - DefinitionSchedule of interest expense under convertible notes. + ReferencesNo definition available. + Details Name: holx ScheduleOfInterestExpenseUnderConvertibleNotesTableTextBlock Namespace Prefix: holx Data Type: dtr-types:1:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Interest Expense Under Credit Agreements + ReferencesNo definition available. + Details Name: holx ScheduleOfInterestExpenseUnderCreditAgreementsTableTextBlock Namespace Prefix: holx Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DebtDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2 Trade Receivables and Allowance for Credit Losses (Tables) 9 Months Ended Jun. 29, 2024 Receivables [Abstract] Å Schedule of Accounts, Notes, Loans and Financing Receivable The following is a rollforward of the allowance for credit losses as of JuneÅ 29, 2024 compared to JulyÅ 1, 2023:BalanceÅ atBeginningOfPeriodCredit LossWrite-offs,Payments and Foreign ExchangeBalanceÅ atEndOfPeriodNine Months Ended:June 29, 2024\$38.5Å \$5.8Å \$(2.9)\$41.4Å July 1, 2023\$37.7Å \$2.2Å \$(0.8)\$39.1Å X - ReferencesNo definition available. + Details Name: us-gaap ReceivablesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02.3.4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2 Derivatives (Tables) 9 Months Ended Jun. 29, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Å Derivative Instruments, Gain (Loss) Three Months EndedNine Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Amount of realized gain (loss) recognized in incomeForward foreign currency contracts\$1.7Å \$1.4Å \$3.5Å \$(1.3)Foreign currency option contracts\$6.1Å \$(1.2)\$6.1Å \$(2.7)\$1.7Å \$0.2Å \$3.5Å \$(4.0)Amount of unrealized gain (loss) recognized in incomeForward foreign currency contracts\$(0.5)\$6.2Å \$(13.8)Foreign currency option contracts\$6.1Å 1.0Å \$6.1Å \$(6.8)\$0.5Å 1.0Å \$(6.2)\$20.6Amount of gain (loss) recognized in incomeTotals1.2Å \$1.2Å \$(2.7)\$(24.6) Schedule of Derivative Assets at Fair Value The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of JuneÅ 29, 2024: Balance Sheet LocationJune 29, 2024September 30, 2024Assets:Derivative instruments designated as a cash flow hedge:Interest rate swap contractsPrepaid expenses and other current assets\$8.5Å \$16.2Å Interest rate swap contractsOther assets6.2Å 10.7Å \$14.7Å \$26.9Å Derivatives not designated as hedging instruments:Forward foreign currency contractsPrepaid expenses and other current assets\$2.6Å \$8.4Å \$2.6Å \$8.4Å Liabilities:Derivatives not designated as hedging instruments:Forward foreign currency contractsAccrued expenses\$0.4Å \$6.1Å Schedule of Unrealized Loss Recognized in AOCI The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods:Three Months EndedNine Months EndedJune 29, 2024July 1, 2023June 29, 2024July 1, 2023Amount of gain (loss) recognized in other comprehensive income, net of taxes:Interest rate swaps\$0.3Å \$3.7Å \$(9.3)\$(5.6)Totals\$0.3Å \$3.7Å \$(9.3)\$(5.6) X - ReferencesNo definition available. + Details Name: us-gaap DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C) + Details Name: us-gaap ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of derivative assets at fair value. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfDerivativeAssetsAtFairValueTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: <http://www.xbrli.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A) + Details Name: us-gaap ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2 Net Income (Loss) Per Share (Tables) 9 Months Ended Jun. 29, 2024 Earnings Per Share [Abstract] Å Reconciliation of Basic and Diluted Share Amounts A reconciliation of basic and diluted share amounts is as follows:Å Three Months EndedNine Months EndedÅ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Basic weighted average common shares outstanding234,604Å 246,908Å 236,373Å 247,319Å Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units1,862Å 1,708Å 2,074Å Diluted weighted average common shares outstanding236,466Å 246,908Å 238,081Å 249,393Å Weighted-average anti-dilutive shares related to:Outstanding stock options and restricted stock units933Å 2,936Å 1,372Å 1,786Å X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: [http://www.xbrli.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrli.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) + Details Name: us-gaap ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2 Stock-Based Compensation (Tables) 9 Months Ended Jun. 29, 2024 Share-Based Payment Arrangement [Abstract] Å Stock-Based Compensation Expense in Consolidated Statements of Operations The following presents stock-based compensation expense in the Company's Consolidated Statements of Income:Å Three Months EndedNine Months EndedÅ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Cost of revenues\$2.6Å \$2.1Å \$8.5Å \$7.7Å Research and development2.2Å 2.1Å 8.4Å 8.6Å Selling and marketing3.5Å 2.9Å 10.4Å 9.2Å General and administrative6.3Å 9.8Å 41.8Å 35.1Å \$14.6Å \$16.9Å \$69.1Å \$60.6Å Weighted-Average Assumptions Utilized to Value Stock Options The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:Å Three Months EndedNine Months EndedÅ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Risk-free interest rate4.4Å %4.3Å %4.4Å %4.3Å %Expected volatility33.4Å %33.9Å %33.4Å %33.9Å %Expected life (in years)4.84.84.84.8Dividend yield4.6Å %4.6Å %4.6Å %4.6Å %Weighted average fair value of options granted\$26.44Å \$30.51Å \$25.06Å \$25.95Å X - DefinitionSchedule of share-based compensation expense. + ReferencesNo definition available. + Details Name: holx ScheduleOfShareBasedCompensationExpenseTableTextBlock Namespace Prefix: holx Data Type: dtr-types:1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph \(f\)\(2\) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2 Other Balance Sheet Information (Tables) 9 Months Ended Jun. 29, 2024 Balance Sheet Related Disclosures [Abstract] Å Other Balance Sheet Information of Inventories June 29, 2024September 30, 2023InventoriesRaw materials\$263.2Å \$238.6Å Work-in-process58.4Å 66.3Å Finished goods343.9Å 312.7Å \$665.5Å \$617.6Å Other Balance Sheet Information of Property, Plant and Equipment Property, plant and equipmentEquipment\$388.4Å \$380.0Å Equipment under customer usage agreements507.7Å 508.1Å Building and improvements243.7Å 230.0Å Leasehold improvements42.0Å 44.4Å Land40.8Å 41.1Å Furniture and fixtures23.6Å 19.2Å Finance lease right-of-use asset\$4.8Å 8.2Å \$1,254.6Å \$1,231.0Å Less Å accumulated depreciation and amortization(725.8)(714.0)\$528.8Å \$517.0Å X - ReferencesNo definition available. + Details Name: us-gaap BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1> + Details Name: us-gaap ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2 Business Segments and Geographic Information (Tables) 9 Months Ended Jun. 29, 2024 Segment Reporting [Abstract] Å Segment Information egment information is as follows:Å Three Months EndedNine Months EndedÅ June 29, 2024July 1, 2023June 29, 2024July 1, 2023Total revenues:Diagnostics\$440.8Å \$439.7Å \$1,338.7Å \$1,463.6Å Breast Health385.0Å 360.3Å 1,147.3Å 1,079.9Å GYN Surgical166.6Å 157.3Å 484.8Å 456.2Å Skeletal Health19.0Å 27.1Å 71.5Å 85.4Å \$1,011.4Å \$984.4Å \$3,042.3Å \$3,085.1Å Income from operations:Diagnostics\$89.7Å \$(113.5)\$210.1Å \$142.8Å Breast Health102.4Å 63.3Å 296.2Å 233.7Å GYN Surgical56.7Å 48.5Å 144.3Å 149.6Å Skeletal Health(4.83)Å 1.2Å 0.0Å 9.8Å \$244.0Å \$1.4Å \$652.6Å \$535.9Å Depreciation and amortization:Diagnostics\$51.0Å \$56.8Å \$168.3Å \$172.9Å Breast Health9.3Å 12.2Å 29.6Å 38.7Å GYN Surgical11.9Å 11.9Å 36.1Å 35.8Å Skeletal Health0.1Å 0.3Å 0.4Å 0.5Å \$72.3Å \$81.2Å \$234.4Å \$247.9Å Capital expenditures:Diagnostics\$17.7Å \$22.6Å \$61.7Å \$58.7Å Breast Health10.4Å 8.0Å 25.1Å 22.0Å GYN Surgical4.8Å 4.5Å 11.5Å 11.2Å Skeletal Health0.7Å 4.6Å 1.1Å 0.2Å Corporate0.3Å 1.4Å 0.5Å 5.6Å \$33.9Å \$36.5Å \$99.9Å \$97.7Å Å June 29, 2024September 30, 2023Identifiable assets:Diagnostics\$2,476.3Å \$2,596.4Å Breast Health1,217.6Å 1,170.1Å GYN Surgical1,429.8Å 1,455.4Å Skeletal Health35.6Å 33.7Å Corporate3,730.8Å 3,883.7Å \$8,890.1Å \$9,139.3Å Revenues by Geography Revenues by geography as a percentage of total revenues were as follows:Å Å Three Months EndedNine Months EndedÅ June 29, 2024July 1, 2023June 29, 2024July 1, 2023United States75.7Å %76.2Å %74.9Å %75.9Å %Europe12.6Å %13.1Å %13.4Å %13.9Å %Asia-Pacific6.4Å %6.4Å %6.4Å %6.2Å %Rest of World5.3Å %4.3Å %5.3Å %4.0Å %100.0Å %100.0Å %100.0Å %100.0Å % X - DefinitionTabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03.1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30> + Details Name: us-gaap ScheduleOfSegmentReportingInformationBySegmentTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap SegmentReportingAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.2 Intangible Assets and Goodwill (Tables) 9 Months Ended Jun. 29, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Å Schedule of Intangible Assets Intangible assets consisted of the following:Å DescriptionAs of June 29, 2024As of September 30, 2023GrossCarryingValueAccumulatedAmortizationGrossCarryingValueAccumulatedAmortizationAcquired intangible assets:DevelopedÅ technology\$4,375.4Å \$3,786.6Å \$4,411.0Å \$3,649.5Å In-process research and development21.9Å \$4.2Å 25.7Å 4.6Å Å Customer relationships600.6Å 564.4Å 600.0Å 550.6Å Trade names252.5Å 222.9Å 253.6Å 212.8Å Total acquired intangible assets\$5,250.4Å \$4,573.9Å \$5,290.3Å \$4,412.9Å Internal-use software25.5Å 20.0Å 24.0Å 17.8Å Capitalized software embedded in products29.7Å 24.1Å 27.7Å 22.7Å Total intangible assets\$5,305.6Å \$4,618.0Å \$5,342.0Å \$4,453.4Å Å Schedule of Estimated Amortization Expense The estimated remaining amortization expense of the Company's acquired intangible assets as of JuneÅ 29, 2024 for each of the five succeeding fiscal years was as follows:Remainder of Fiscal 2024\$47.2Å Fiscal 2025\$180.6Å Fiscal 2026\$150.6Å Fiscal 2027\$63.6Å Fiscal 2028\$60.5Å X -

ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2> + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.2 Product Warranties (Tables) 9 Months Ended Jun. 29, 2024 Guarantees [Abstract] A Product Warranty Activity Product warranty activity was as follows: A Balance at Beginning of a PeriodProvisionsSettlements/AdjustmentsBalance at End of a PeriodNine Months Ended:June 29, 2024\$8.3A \$7.2A \$(6.3)\$9.2A July 1, 2023\$8.0A \$4.9A \$(5.4)\$7.5A X - ReferencesNo definition available. + Details Name: us-gaap_GuaranteesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482425/460-10-50-8> + Details Name: us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.2 Accumulated Other Comprehensive Income (Loss) (Tables) 9 Months Ended Jun. 29, 2024 Accumulated Other Comprehensive Income [Abstract] A Changes in Accumulated Other Comprehensive Income The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented:Three Months Ended June 29, 2024Nine Months Ended June 29, 2024Foreign Currency TranslationPension PlansHedged Interest Rate SwapsTotalForeign Currency TranslationPension PlansHedged Interest Rate SwapsTotalBeginning Balances(147.8)\$0.3A \$10.5A \$(137.0)(168.0)\$0.3A \$20.1A \$(147.6)Other comprehensive income (loss) before reclassifications(2.8)A 0.3A (2.5)17.4A A 9(3.8)1A Ending Balances(150.6)0.3A \$10.8A \$(139.5)\$(150.6)0.3A \$10.8A \$(139.5)Three Months Ended July 1, 2023Nine Months Ended July 1, 2023Foreign Currency TranslationPension PlansHedged Interest Rate SwapsTotalForeign Currency TranslationPension PlansHedged Interest Rate SwapsTotalBeginning Balances\$(138.1)\$(0.3)\$20.0A \$(118.4)\$(267.2)\$(0.3)\$29.3A \$(238.2)Other comprehensive income (loss) before reclassifications1.1A A 3.7A 4.8A 130.2A A 5(6)124.6A Ending Balances\$(137.0)\$(0.3)\$23.7A \$(113.6)\$(137.0)\$(0.3)\$23.7A \$(113.6) X - DefinitionAccumulated Other Comprehensive Income [Abstract] + ReferencesNo definition available. + Details Name: holx_AccumulatedOtherComprehensiveIncomeAbstract Namespace Prefix: holx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481674/830-30-50-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481694/830-30-45-20> + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.2 Basis of Presentation (Details) \$ in Millions Apr. 26, 2024 USD (\$) Endomag | Agreement A Subsequent Event [Line Items] A Consideration transferred \$ 310.0 X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479637/805-30-30-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479581/805-30-50-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479637/805-30-30-7> + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481674/830-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483399/855-10-50-2> + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=holx_EndomagneticsLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.2 Revenue - Business Revenue (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Disaggregation of Revenue [Line Items] A A A Revenues 1,011.4 \$ 984.4 \$ 3,042.3 \$ 3,085.1 United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 765.3 750.1 2,278.4 2,342.5 International A A A Disaggregation of Revenue [Line Items] A A A Revenues 246.1 234.3 763.9 742.6 Diagnostics A A A Disaggregation of Revenue [Line Items] A A A Revenues 440.8 439.7 1,338.7 1,463.6 Diagnostics | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 114.2 109.1 353.8 376.7 Diagnostics | CytoLOGY & Perinatal A A A Disaggregation of Revenue [Line Items] A A A Revenues 122.2 126.8 362.7 365.4 Diagnostics | CytoLOGY & Perinatal | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 73.3 79.7 213.7 226.9 Diagnostics | CytoLOGY & Perinatal | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 48.9 47.1 149.0 138.5 Diagnostics | Molecular Diagnostics A A A Disaggregation of Revenue [Line Items] A A A Revenues 310.7 302.2 953.2 1,069.7 Diagnostics | Molecular Diagnostics | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 245.4 240.2 748.4 831.5 Diagnostics | Molecular Diagnostics | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 65.3 62.0 204.8 238.2 Diagnostics | Blood Screening A A A Disaggregation of Revenue [Line Items] A A A Revenues 7.9 10.7 22.8 28.5 Diagnostics | Blood Screening | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 7.9 10.7 22.8 28.5 Diagnostics | Blood Screening | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 0.0 0.0 0.0 0.0 Breast Health A A A Disaggregation of Revenue [Line Items] A A A Revenues 385.0 360.3 1,147.3 1,079.9 Breast Health | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 300.5 279.9 885.3 843.2 Breast Health | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 84.5 80.4 262.0 236.7 Breast Health | Breast Imaging A A A Disaggregation of Revenue [Line Items] A A A Revenues 309.2 286.1 917.3 862.1 Breast Health | Breast Imaging | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 240.4 220.7 703.7 666.5 Breast Health | Breast Imaging | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 68.8 65.4 213.6 195.6 Breast Health | Interventional Breast Solutions A A A Disaggregation of Revenue [Line Items] A A A Revenues 75.8 74.2 230.0 217.8 Breast Health | Interventional Breast Solutions | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 60.1 59.2 181.6 176.7 Breast Health | Interventional Breast Solutions | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 15.7 15.0 48.4 41.1 GYN Surgical A A A Disaggregation of Revenue [Line Items] A A A Revenues 166.6 157.3 484.8 456.2 GYN Surgical | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 125.8 122.9 366.6 359.6 GYN Surgical | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 40.8 34.4 118.2 96.6 Skeletal Health A A A Disaggregation of Revenue [Line Items] A A A Revenues 19.0 27.1 71.5 85.4 Skeletal Health | United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 12.4 16.7 41.6 52.8 Skeletal Health | International A A A Disaggregation of Revenue [Line Items] A A A Revenues 6.6 \$ 10.4 \$ 29.9 \$ 32.6 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91> + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 18: <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479557/942-235-S99-1> + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=holx_InternationalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=holx_DiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=holx_MolecularDiagnosticsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt ProductOrServiceAxis=holtz BloodScreeningMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
gaap StatementBusinessSegmentsAxis=holtz BreastHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt ProductOrServiceAxis=holtz BreastImagingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:
srt ProductOrServiceAxis=holtz InterventionalBreastSolutionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap StatementBusinessSegmentsAxis=holtz GynSurgicalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-
gaap StatementBusinessSegmentsAxis=holtz SkeletalHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R53.htm IDEA: XBRL DOCUMENT v3.24.2 Revenue -
Geographical Revenue (Details) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Disaggregation of Revenue [Line Items] A A A
A Revenues \$ 1,011.4 \$ 984.4 \$ 3,042.3 \$ 3,085.1 United States A A A Disaggregation of Revenue [Line Items] A A A Revenues 765.3 750.1 2,278.4 2,342.5 Europe A A A
Disaggregation of Revenue [Line Items] A A A Revenues 127.9 128.5 407.7 427.3 Asia-Pacific A A A Disaggregation of Revenue [Line Items] A A A Revenues 65.0 62.9 193.2 191.9
Rest of World A A A Disaggregation of Revenue [Line Items] A A A Revenues \$ 53.2 \$ 42.9 \$ 163.0 \$ 123.4 X - DefinitionLine items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI>
<https://asc.fasb.org/1943274/2147479806/606-10-50-5Rreference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 ->
[Paragraph 91 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -](Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -)
[Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4:](Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4:)
[http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 ->
[Paragraph 91 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -](Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -)
[Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7:](Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7:)
[http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 ->
[Paragraph 91 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix:](Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap DisaggregationOfRevenueLineItems Namespace Prefix:)
<us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other>
<activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue,>
[and sales and trading gain \(loss\). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -](and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -)
[Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -](Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -)
[Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-](Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-)
[3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI](3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section>
[S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic](S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic)
[470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI](470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification ->
[Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 7:](Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 7:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher)

ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-8> + Details Name: us-gaap ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-13> + Details Name: us-gaap RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.2 Revenue - Remaining Performance Obligation (Details) Jun. 29, 2024 Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29 Á Disaggregation of Revenue [Line Items] Á Revenue, Remaining Performance Obligation, Percentage 14.00% Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 months Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29 Á Disaggregation of Revenue [Line Items] Á Revenue, Remaining Performance Obligation, Percentage 42.00% Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-03-29 Á Disaggregation of Revenue [Line Items] Á Revenue, Remaining Performance Obligation, Percentage 25.00% Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-03-29 Á Disaggregation of Revenue [Line Items] Á Revenue, Remaining Performance Obligation, Percentage 12.00% Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-03-29 Á Disaggregation of Revenue [Line Items] Á Revenue, Remaining Performance Obligation, Percentage 7.00% Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479777/606-10-55-91> + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-13> + Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPercentage of remaining performance obligation to total remaining performance obligation not recognized as revenue. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-13> + Details Name: us-gaap RevenueRemainingPerformanceObligationPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-03-29 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-03-29 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-03-29 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-03-29 Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-03-29 Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.2 Leases - Additional Lease Information (Details) 3 Months Ended Jun. 29, 2024 Leases [Abstract] Á Lease revenue as a percentage of total (percentage) 0.03 X - DefinitionLease Revenue, Percentage Of Total Revenue + ReferencesNo definition available. + Details Name: holx_LeaseRevenuePercentageOfTotalRevenue Namespace Prefix: holx_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) - USD (\$) in Millions Jun. 29, 2024 Sep. 30, 2023 Assets: Á Assets: \$ 2,439.1 Á Total 836.1 \$ 35.3 Liabilities: Á Á Total 1.5 2.0 Money Market Funds Á Assets: Á Assets: 371.2 Á US Treasury Securities Á Assets: Á Assets: 398.1 Á Commercial Paper Á Assets: Á Assets: 49.5 Á Interest Rate Swap Á Assets: Á Total 14.7 26.9 Forward foreign currency contracts Á Assets: Á Total 2.6 8.4 Prepaid expenses and other current assets | Forward foreign currency contracts | Derivatives not designated as hedging instruments Á Assets: Á Cash Flow Hedge Derivative Instrument Assets at Fair Value Á 8.4 Contingent consideration Á Liabilities: Á Á Total 1.1 2.0 Forward foreign currency contracts Á Liabilities: Á Á Total 0.4 Á QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) Á Assets: Á Á Total 818.8 0.0 Liabilities: Á Á Total 0.0 0.0 QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Money Market Funds Á Assets: Á Assets: 371.2 Á QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | US Treasury Securities Á Assets: Á Assets: 398.1 Á QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Commercial Paper Á Assets: Á Assets: 49.5 Á QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Interest Rate Swap Á Assets: Á Á Total 0.0 0.0 QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Forward foreign currency contracts Á Assets: Á Á Total 0.0 0.0 QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Contingent consideration Á Liabilities: Á Á Total 0.0 0.0 QuotedÁ PricesÁ in ActiveÁ MarketÁ for IdenticalÁ Assets (LevelÁ 1) | Forward foreign currency contracts Á Liabilities: Á Á Total 0.0 Á Significant Other Observable InputsÁ (LevelÁ 2) Á Assets: Á Á Total 17.3 35.3 Liabilities: Á Á Total 0.4 0.0 Significant Other Observable InputsÁ (LevelÁ 2) | Money Market Funds Á Assets: Á Assets: 0.0 Á Significant Other Observable InputsÁ (LevelÁ 2) | US Treasury Securities Á Assets: Á Assets: 0.0 Á Significant Other Observable InputsÁ (LevelÁ 2) | Commercial Paper Á Assets: 0.0 Á Significant Other Observable InputsÁ (LevelÁ 2) | Prepaid expenses and other current assets | Forward foreign currency contracts | Derivatives not designated as hedging instruments | Forward foreign currency contracts Á Assets: Á Cash Flow Hedge Derivative Instrument Assets at Fair Value Á 8.4 Significant Other Observable InputsÁ (LevelÁ 2) | Contingent consideration Á Liabilities: Á Á Total 0.0 0.0 Significant Other Observable InputsÁ (LevelÁ 2) | Forward foreign currency contracts | Prepaid expenses and other current assets | Forward foreign currency contracts | Derivatives not designated as hedging instruments Á Assets: Á Cash Flow Hedge Derivative Instrument Assets at Fair Value 2.6 Á Significant Unobservable InputsÁ (LevelÁ 3) Á Assets: Á Á Total 0.0 0.0 Liabilities: Á Á Total 1.1 2.0 Significant Unobservable InputsÁ (LevelÁ 3) | Money Market Funds Á Assets: Á Assets: 0.0 Á Significant Unobservable InputsÁ (LevelÁ 3) | US Treasury Securities Á Assets: Á Assets: 0.0 Á Significant Unobservable InputsÁ (LevelÁ 3) | Commercial Paper Á Assets: Á Assets: 0.0 Á Significant Unobservable InputsÁ (LevelÁ 3) | Interest Rate Swap Á Assets: Á Á Total 0.0 0.0 Significant Unobservable InputsÁ (LevelÁ 3) | Forward foreign currency contracts Á Assets: Á Á Total 0.0 0.0 Significant Unobservable InputsÁ (LevelÁ 3) | Contingent consideration Á Liabilities: Á Á Total 1.1 \$ 2.0 Significant Unobservable InputsÁ (LevelÁ 3) | Forward foreign currency contracts Á Liabilities: Á Á Total 0.0 Á X - ReferencesNo definition available. + Details Name: us-gaap AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesNo definition available. + Details Name: us-gaap CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of all asset derivatives designated as cash flow hedging instruments. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480434/815-10-50-4B> + Details Name: us-gaap CashFlowHedgeDerivativeInstrumentAssetsAtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of obligations measured on a recurring basis. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap FairValueLiabilitiesMeasuredOnRecurringBasisObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByAssetClassAxis=us-gaap ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BalanceSheetLocationAxis=us-gaap PrepaidExpensesAndOtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DerivativeInstrumentRiskAxis=us-gaap ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap HedgingDesignationAxis=us-gaap NondesignatedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinancialInstrumentAxis=holx ContingentConsiderationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FinancialInstrumentAxis=us-gaap ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FairValueByFairValueHierarchyLevelAxis=us-gaap FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Roll Forward (Details) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Fair Value Disclosures [Abstract] Á Á Á Beginning balance \$ 1.1 \$ 3.4 \$ 2.0 \$ 23.4 Contingent consideration recorded at acquisition 0.0 1.1 0.0 1.1 Fair value adjustments 0.0 0.0 1.7 (12.4) Payments 0.0 0.0 (2.6) (7.6) Ending balance \$ 1.1 \$ 4.5 \$ 1.1 \$ 4.5 X - ReferencesNo definition available. + Details Name: us-gaap FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Additional Information (Detail) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Mar. 30, 2024 Dec. 30, 2023 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Á Á Á Á Impairment of intangible assets Á Á Á 174.8 Á Á Intangible asset and equipment impairment charges Á Á Á 186.9 \$ 44.8 \$ 223.8 Impairment of intangible assets and equipment \$ 0.4 Á Á 44.3 5.6 44.3 Impairment, assets held-for-use Á Á Á 12.1 Á Á Finite-lived intangible assets, fair value Á Á Á 65.8 Á 65.8 Property, plant, and equipment, fair value Á Á Á 4.6 Á 4.6 Ultrasound imaging assets Á Á Á Á Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Á Á Á Á Intangible asset and equipment impairment charges Á Á Á 26.4 Á Á Ultrasound imaging assets, equipment Á Á Á Á Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Á Á Á Á Intangible asset and equipment impairment charges Á Á Á 5.8 Á Á Mobidiag | Right of use asset Á Á Á Á Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Á Á Á Á Intangible asset and equipment impairment charges Á Á 12.5 Á Á In-process research and development Á Á Á Á Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Á Á Á Á

[illegible]

[illegible]

Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCash Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=holx_SSIUltrasoundImagingBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDiscontinuedBySaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2 Restructuring (Details) - USD (\$) \$ in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Dec. 30, 2023 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Mobidiag Á Á Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Á Á Accelerated depreciation Á \$ 7.2 Á Á Lease asset impairment charges Á 12.5 Á Á Severance costs \$ 3.9 \$ 1.8 Á \$ 7.9 Á Expected cost 13.1 Á Á 13.1 Á Danbury closure Á Á Á Á Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Á Á Á Á Severance costs 0.9 Á \$ 0.4 2.7 Á Á Expected cost \$ 7.5 Á Á \$ 7.5 Á X - DefinitionThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2 + Details Name: us-gaap_OtherAssetImpairmentCharges Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount expected to be recognized in earnings for the specified restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostExpectedCost1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Section 50 -Paragraph 1 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveAcceleratedDepreciation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=holx_MobidiagMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=holx_DanburyClosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.2 Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD (\$) \$ in Millions Jun. 29, 2024 Sep. 30, 2023 Debt Instrument [Line Items] Á Á Current portion of long-term debt \$ 37.5 \$ 287.0 Total long-term debt obligations 2,505.6 2,531.2 Total debt obligations 2,543.1 2,818.2 Term Loan Á Á Debt Instrument [Line Items] Á Á Current portion of long-term debt 37.5 287.0 Long term debt obligations, excluding convertible notes 1,168.0 1,195.6 2028 Senior Notes Á Á Debt Instrument [Line Items] Á Á Long term debt obligations, excluding convertible notes 397.3 396.8 2029 Senior Notes Á Á Debt Instrument [Line Items] Á Á Long term debt obligations, excluding convertible notes \$ 940.3 \$ 938.8 X - DefinitionLong term debt obligations without convertible notes. + ReferencesNo definition available. + Details Name: holx_LongTermDebtObligationsWithoutConvertibleNotes Namespace Prefix: holx_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-11 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -

[Topic 20 - Name Accounting Standards Codification - Section 55 - Paragraph 69B - Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3:](#)

[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\) -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 6:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1Reference 7:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebtNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium \(discount\) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium \(discount\) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=holt_LoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=holt_A2028SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=holt_A2029SeniorNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.2 Borrowings and Credit Arrangements - Additional Information \(Detail\) - USD \(\\$\) in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Dec. 30, 2023 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Aug. 25, 2022 Sep. 27, 2021 Interest Rate Swap, Agreement One A A A A A Debt Instrument \[Line Items\] A A A A A Derivative notional amount \\$ 1,000.0 A A \\$ 1,000.0 A A Variable interest rate 1.23% A A 1.23% A A Interest Rate Swap, Agreement Two A A A A A Debt Instrument \[Line Items\] A A A A A Derivative notional amount \\$ 500.0 A A \\$ 500.0 A A Variable interest rate 3.46% A A 3.46% A A Interest Rate Swap A A A A A Debt Instrument \[Line Items\] A A A A A Derivative notional amount A A A A \\$ 1,000.0 A A Variable interest rate A A A A 1.23% A A Proceeds from swap \\$ 2.4 A A \\$ 9.8 A A 14.4 A A 25.0 A A Secured Term Loan | 2021 Term Loan A A A A A Debt Instrument \[Line Items\] A A A A A Senior notes, face amount 1,200.0 A A 1,200.0 A A \\$ 1,500.0 Repayments of Debt A A \\$ 250.0 A A A Revolver | 2021 Revolver A A A A A Debt Instrument \[Line Items\] A A A A A Revolving credit facility borrowings A A A A A \\$ 2,000.0 Senior Notes | 2028 Senior Notes A A A A A Debt Instrument \[Line Items\] A A A A A Senior notes, face amount \\$ 400.0 A A \\$ 400.0 A A Stated interest rate 4.625% A A 4.625% A A Senior Notes | 2029 Senior Notes A A A A A Debt Instrument \[Line Items\] A A A A A Stated interest rate 3.25% A A 3.25% A A Senior notes \\$ 950.0 A A \\$ 950.0 A A X - DefinitionProceeds from swap + ReferencesNo definition available. + Details Name: holt_ProceedsFromSwap Namespace Prefix: holt_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace \(par\) amount of debt instrument at time of issuance. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1BReference 2:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4:](#)

[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2:](#) [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02.22\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1BReference 2:](#) [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69AReference 6:](#)

[http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI](#)

[https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9:](#)

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11:](#) [http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12:](#) [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1](#)

2028 Senior Notes $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Line of Credit Facility [Line Items] $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Stated interest rate 4.625% $\text{\AA}$ 4.625% $\text{\AA}$ Interest expense $\text{\$}$ 4.8 $\text{\$}$ 4.8 $\text{\$}$ 14.4 $\text{\$}$ 14.8 2029 Senior Notes $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Line of Credit Facility [Line Items] $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Stated interest rate 3.25% $\text{\AA}$ 3.25% $\text{\AA}$ Interest expense $\text{\$}$ 8.2 $\text{\$}$ 8.2 $\text{\$}$ 24.7 $\text{\$}$ 25.3 Total $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Line of Credit Facility [Line Items] $\text{\AA}$ $\text{\AA}$ $\text{\AA}$ Interest expense $\text{\$}$ 13.0 $\text{\$}$ 13.0 $\text{\$}$ 39.1 $\text{\$}$ 40.1 X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: [\text{\\\$}\) in Millions Jun. 29, 2024 Mar. 23, 2023 Aug. 25, 2022 Interest rate swap \$\text{\AA}\$ \$\text{\AA}\$ Derivative \[Line Items\] \$\text{\AA}\$ \$\text{\AA}\$ Derivative notional amount \$\text{\AA}\$ \$\text{\AA}\$ \$\text{\\$}\$ 1,000.0 Variable interest rate \$\text{\AA}\$ \$\text{\AA}\$ 1.23% Forward Contracts \$\text{\AA}\$ \$\text{\AA}\$ Derivative \[Line Items\] \$\text{\AA}\$ \$\text{\AA}\$ Notational Amount \$\text{\\$}\$ 97.2 \$\text{\AA}\$ \$\text{\AA}\$ Interest Rate Swap, 2023 \$\text{\AA}\$ \$\text{\AA}\$ Derivative \[Line Items\] \$\text{\AA}\$ \$\text{\AA}\$ Derivative notional amount \$\text{\AA}\$ \$\text{\\$}\$ 500.0 \$\text{\AA}\$ Variable interest rate \$\text{\AA}\$ \$\text{\AA}\$ 3.46% \$\text{\AA}\$ Cash Flow Hedge Derivative Instrument Assets at Fair Value \$\text{\\$}\$ 14.7 \$\text{\AA}\$ \$\text{\AA}\$ Interest Rate Swap, 2024 \$\text{\AA}\$ \$\text{\AA}\$ Derivative \[Line Items\] \$\text{\AA}\$ \$\text{\AA}\$ Derivative notional amount \$\text{\AA}\$ \$\text{\\$}\$ 500.0 \$\text{\AA}\$ Variable interest rate \$\text{\AA}\$ \$\text{\AA}\$ 2.98% \$\text{\AA}\$ X - DefinitionNotational Amount + ReferencesNo definition available. + Details Name: holt_NotationalAmount Namespace Prefix: holt_Data Type: xbrli:monetaryItem Balance Type: debit Period Type: instant X - DefinitionFair value of all asset derivatives designated as cash flow hedging instruments. + ReferencesReference 1:](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Balance Type: na Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivableRollforward Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <a href=)

XBRL DOCUMENT v3.24.2 Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD (\$) \$ in Millions 3 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Derivative Instruments, Gain (Loss) [Line Items] Á Á Á Amount of gain (loss) recognized in other comprehensive income, net of taxes: \$ 0.3 \$ 3.7 \$ (9.3) \$ (5.6) Interest Rate Swap Á Á Á Derivative Instruments, Gain (Loss) [Line Items] Á Á Á Amount of gain (loss) recognized in other comprehensive income, net of taxes: \$ 0.3 \$ 3.7 \$ (9.3) \$ (5.6) X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4E + Details> Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480627/815-20-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480627/815-20-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A + Details) Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.2 Net Income (Loss) Per Share (Detail) - shares shares in Thousands 3 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Earnings Per Share [Line Items] Á Á Á Basic weighted average common shares outstanding 234,604 246,908 236,373 247,319 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,862 0 1,708 2,074 Diluted weighted average common shares outstanding 236,466 246,908 238,081 249,393 Outstanding Stock Options and stock units Á Á Á Weighted-average anti-dilutive shares related to: Á Á Á Weighted-average anti-dilutive shares (in shares) 933 2,936 1,372 1,786 X - DefinitionEarnings Per Share [Line Items] + ReferencesNo definition available. + Details Name: holx_EarningsPerShareLineItems Namespace Prefix: holx_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details) Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A + Details) Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details) Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details) Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.2 Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD (\$) \$ in Millions 3 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Stock-based compensation expense \$ 14.6 \$ 16.9 \$ 69.1 \$ 60.6 Cost of revenues Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Stock-based compensation expense 2.6 2.1 8.5 7.7 Research and development Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Stock-based compensation expense 2.2 2.1 8.4 8.6 Selling and marketing Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Stock-based compensation expense 3.5 2.9 10.4 9.2 General and administrative Á Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Á Stock-based compensation expense \$ 6.3 \$ 9.8 \$ 41.8 \$ 35.1 X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details) Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(01\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(01\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(02\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(03\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(2\)\(iii\)\(04\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\)\(2\)\(v\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details) Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.2 Stock-Based Compensation - Additional Information (Detail) - USD (\$) \$ / shares in Units, shares in Millions, \$ in Millions 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Stock option plans Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Options granted (in shares) 0.6 0.5 Weighted-average exercise prices (in dollars per share) \$ 72.32 \$ 74.67 Share-based compensation, stock options outstanding (in shares) 4.5 Á Weighted-average exercise price of options outstanding (in dollars per share) \$ 54.62 Á Unrecognized compensation expense \$ 12.4 Á Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years 3 months 18 days Á Restricted stock units Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Shares granted (in shares) 0.7 0.6 Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) \$ 72.03 \$ 74.58 Unrecognized compensation expense \$ 55.5 Á Weighted-average period for recognition of unrecognized stock-based compensation, years 1 year 9 months 18 days Á Performance Shares Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Shares granted (in shares) 0.1 0.1 Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) \$ 71.92 \$ 74.35 PSU Free Cash Flow [Member] Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Shares granted (in shares) 0.1 0.1 Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) \$ 71.92 \$ 74.35 Minimum eligible percentage to receive target number of shares of company's common stock 0.00% Á Maximum eligible percentage to receive target number of shares of company's common stock 200.00% Á Performance stock units vesting period 3 years Á Market Based Awards Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Shares granted (in shares) 0.1 0.1 Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share) \$ 88.06 \$ 97.91 Minimum eligible percentage to receive target number of shares of company's common stock 0.00% Á Maximum eligible percentage to receive target number of shares of company's common stock 200.00% Á Performance stock units vesting period 3 years Á RSU, PSU, MSU Á Á Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Á Á Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares) 1.7 Á X - DefinitionMaximum target number percentage of shares issued based on stock performance. + ReferencesNo definition available. + Details Name: holx_MaximumTargetNumberOfSharesIssuedBasedOnStockPerformanceInPercent Namespace Prefix: holx_ Data Type: dtr-type:percentItemType Balance Type: na Period Type: duration X - DefinitionMinimum target number percentage of shares that would be issued based on stock price performance. + ReferencesNo definition available. + Details Name: holx_MinimumTargetNumberOfSharesIssuedOnStockPerformanceInPercent Namespace Prefix: holx_ Data Type: dtr-type:1:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time that must lapse in order for the restricted stock units to vest. + ReferencesNo definition available. + Details Name:

holx_SharedBasedCompensationArrangementRestrictedStockVestingPeriod Namespace Prefix: holx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1:

-Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480581/330-10-S99-2> + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480581/330-10-S99-2> + Details Name: us-gaap_InventoryWorkInProcessNetOfReserves Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.2 Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD (\$) in Millions Jun. 29, 2024 Sep. 30, 2023 Balance Sheet Related Disclosures [Abstract] Å Å Equipment \$ 388.4 \$ 380.0 Equipment under customer usage agreements 507.7 508.1 Building and improvements 243.7 230.0 Leasehold improvements 42.0 44.4 Land 40.8 41.1 Furniture and fixtures 23.6 19.2 Finance Lease, Right-of-Use Asset, after Accumulated Amortization 8.4 8.2 Property, plant and equipment, gross 1,254.6 1,231.0 Less a€" accumulated depreciation and amortization (725.8) (714.0) Property, plant and equipment, net \$ 528.8 \$ 517.0 X - DefinitionGross amount at the balance sheet date of long-lived, depreciable asset that are equipment placed at customer locations for which title is not transferred to the Company's customers. + ReferencesNo definition available. + Details Name: holx_EquipmentUnderCustomerUsageAgreements Namespace Prefix: holx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionGross amount as of the balance sheet date of long-lived, depreciable assets that include manufacturing and other equipment with finite lives used to produce goods and services, and computer equipment and software. + ReferencesNo definition available. + Details Name: holx_ManufacturingEquipmentAndSoftware Namespace Prefix: holx_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/214749440/944-210-S99-1Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_BuildingsAndImprovementsGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap_FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_FurnitureAndFixturesGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depletion of real estate held for productive use, excluding land held for sale. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_Land Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation of additions or improvements to assets held under a lease arrangement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_LeaseholdImprovementsGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2:> <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 4:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480842/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2:> <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 4:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480842/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 92 R81.htm IDEA: XBRL DOCUMENT v3.24.2 Other Balance Sheet Information - Additional Information (Detail) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Segment Reporting Information [Line Items] Å Å Å Asset impairment charges \$ 186.9 \$ 44.8 \$ 223.8 Mobidig | Property, Plant and Equipment Å Å Å Segment Reporting Information [Line Items] Å Å Å Asset impairment charges 12.1 Å Å SSI Ultrasound Imaging Business | Property, Plant and Equipment Å Å Å Segment Reporting Information [Line Items] Å Å Å Asset impairment charges \$ 5.8 Å Å X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2:> <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsegmentsAxis=holx_MobidigMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsegmentsAxis=holx_SSIUltrasoundImagingBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 93 R82.htm IDEA: XBRL DOCUMENT v3.24.2 Business Segments and Geographic Information - Additional Information (Detail) 3 Months Ended 6 Months Ended 9 Months Ended Jun. 29, 2024 USD (\$) Jul. 01, 2023 USD (\$) Mar. 30, 2024 Segment Jun. 29, 2024 USD (\$) Jul. 01, 2023 USD (\$) Segment Reporting Disclosure [Line Items] Å Å Å Number of reportable segments | Segment Å Å Å Revenues \$ 1,011,400,000 \$ 984,400,000 Å \$ 3,042,300,000 \$ 3,085,100,000 Intersegment Å Å Å Segment Reporting Disclosure [Line Items] Å Å Å Revenues \$ 0 \$ 0 \$ 0 X - DefinitionSegment Reporting Disclosure [Line Items] + ReferencesNo definition available. + Details Name: holx_SegmentReportingDisclosureLineItems Namespace Prefix: holx_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-18> + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 4:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 5:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 6:> <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 7:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 8:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 9:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 10:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 11:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 12:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 13:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 14:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 15:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 16:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 17:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 18:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 19:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 21:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 22:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23:> <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479557/942-235-S99-1> + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 94 R83.htm IDEA: XBRL DOCUMENT v3.24.2 Business Segments and Geographic Information - Segment Information (Detail) - USD (\$) in Millions 3 Months Ended 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Jun. 29, 2024 Jul. 01, 2023 Segment Reporting Information [Line Items] Å Å Å Total revenues \$ 1,011.4 \$ 984.4 \$ 3,042.3 \$ 3,085.1 Å Income (loss) from operations 244.0 1.4 652.6 535.9 Å Depreciation and amortization 72.3 81.2 234.4 247.9 Å Capital expenditures 33.9 36.5 99.9 97.7 Å Identifiable assets 8,890.1 Å 8,890.1 Å \$ 9,139.3 Diagnostics Å Å Å Segment Reporting Information [Line Items] Å Å Å Total revenues 440.8 439.7 1,338.7 1,463.6 Å Income (loss) from operations 89.7 (113.5) 210.1 142.8 Å Depreciation and amortization 51.0 56.8 168.3 172.9 Å Capital expenditures 17.7 22.6 61.7 58.7 Å Identifiable assets 2,476.3 Å 2,476.3 Å 2,596.4 Breast Health Å Å Å Segment Reporting Information

[Line Items] $\bar{A} \bar{A} \bar{A} \bar{A}$ Total revenues 385.0 360.3 1,147.3 1,079.9 $\bar{A}$ Income (loss) from operations 102.4 63.3 296.2 233.7 $\bar{A}$ Depreciation and amortization 9.3 12.2 29.6 38.7 $\bar{A}$ Capital expenditures 10.4 8.0 25.1 22.0 $\bar{A}$ Identifiable assets 1,217.6 $\bar{A}$ 1,217.6 $\bar{A}$ 1,170.1 GYN Surgical $\bar{A} \bar{A} \bar{A} \bar{A}$ Segment Reporting Information [Line Items] $\bar{A} \bar{A} \bar{A} \bar{A}$ Total revenues 166.6 157.3 484.8 456.2 $\bar{A}$ Income (loss) from operations 56.7 48.5 144.3 149.6 $\bar{A}$ Depreciation and amortization 11.9 11.9 36.1 35.8 $\bar{A}$ Capital expenditures 4.8 4.5 11.5 11.2 $\bar{A}$ Identifiable assets 1,429.8 $\bar{A}$ 1,429.8 $\bar{A}$ 1,455.4 Skeletal Health $\bar{A} \bar{A} \bar{A} \bar{A}$ Segment Reporting Information [Line Items] $\bar{A} \bar{A} \bar{A} \bar{A}$ Total revenues 19.0 27.1 71.5 85.4 $\bar{A}$ Income (loss) from operations (4.8) 3.1 2.0 9.8 $\bar{A}$ Depreciation and amortization 0.1 0.3 0.4 0.5 $\bar{A}$ Capital expenditures 0.7 0.0 1.1 0.2 $\bar{A}$ Identifiable assets 35.6 $\bar{A}$ 35.6 $\bar{A}$ 33.7 Corporate $\bar{A} \bar{A} \bar{A} \bar{A}$ Segment Reporting Information [Line Items] $\bar{A} \bar{A} \bar{A} \bar{A}$ Capital expenditures 0.3 $\bar{A}$ 1.4 0.5 $\bar{A}$ 5.6 $\bar{A}$ Identifiable assets $\bar{A}$ 3,730.8 $\bar{A}$ $\bar{A}$ 3,730.8 $\bar{A}$ $\bar{A}$ 3,883.7 $\bar{X}$ - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(12\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479440/944-210-599-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.6-04\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.6-04(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-599-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.5-02\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 22: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 26: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.9-03\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-599-1) + Details Name: us-gaap Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant $\bar{X}$ - DefinitionThe aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap DepreciationAmortizationAndAccretionNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration $\bar{X}$ - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) + Details Name: us-gaap OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration $\bar{X}$ - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration $\bar{X}$ - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 15:

https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: us-gaap IncomeTaxContingencyLiabilities Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-50-11> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-50-9](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483586/944-220-50-9) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1) + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - Details Name: us-gaap IncomeTaxAuthorityAxis=us-gaap ForeignCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 97 R86.htm IDEA: XBRL DOCUMENT v3.24.2 Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD (\$) \$ in Millions Jun. 29, 2024 Sep. 30, 2023 Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 5,305.6 5,342.0 Accumulated Amortization 4,618.0 4,453.4 Developed technology A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 4,375.4 4,411.0 Accumulated Amortization 3,786.6 3,649.5 In-process research and development A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 21.9 25.7 Accumulated Amortization 0.0 0.0 Customer relationships A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 600.6 600.0 Accumulated Amortization 564.4 550.6 Trade names A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 252.5 253.6 Accumulated Amortization 222.9 212.8 Total acquired intangible assets A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 5,250.4 5,290.3 Accumulated Amortization 4,573.9 4,412.9 Internal-use software A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 25.5 24.0 Accumulated Amortization 20.0 17.8 Capitalized software embedded in products A A Finite-Lived Intangible Assets [Line Items] A A Gross Carrying Value 27.7 27.7 Accumulated Amortization \$ 24.1 22.7 X - Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(SX 210.5-02\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2) + Details Name: us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483147/928-340-50-1> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2) + Details Name: us-gaap FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=holt_DevelopedTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=holt_CustomerRelationshipsContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=holt_AcquiredIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=holt_InternalUseSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap FiniteLivedIntangibleAssetsByMajorClassAxis=holt_CapitalizedSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 98 R87.htm IDEA: XBRL DOCUMENT v3.24.2 Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) \$ in Millions Jun. 29, 2024 USD (\$) Goodwill and Intangible Assets Disclosure [Abstract] A Remainder of Fiscal 2024 \$ 47.2 Fiscal 2025 180.6 Fiscal 2026 150.6 Fiscal 2027 63.6 Fiscal 2028 \$ 60.5 X - Definition Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + References Reference 1

gaap_BusinessAcquisitionAxis=holx_SSIUltrasoundImagingBusinessMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=holx_CapitalEquipmentComponentsandSoftwareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=holx_UltrasoundImagingAssetsDevelopedTechnologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 100 R89.htm IDEA: XBRL DOCUMENT v3.24.2 Product Warranties - Product Warranty Activity (Detail) - USD (\$) in Millions 9 Months Ended Jun. 29, 2024 Jul. 01, 2023 Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward] Å BalanceÅ at BeginningÅ of Period Å 8.3 Å 8.0 Provisions 7.2 4.9 Settlements/ Adjustments (6.3) (5.4) BalanceÅ at EndÅ ofÅ Period Å 9.2 Å 7.5 X - DefinitionÅa roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-13.5(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ProductWarrantyAccrual Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualPayments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in the standard and extended product warranty accrual from warranties issued. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 101 R90.htm IDEA: XBRL DOCUMENT v3.24.2 Accumulated Other Comprehensive Income (Loss) (Detail) - USD (\$) in Millions 3 Months Ended Jun. 29, 2024 Jul. 01, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Å Å Å Beginning balance Å Å \$ 5,016.9 Å Other comprehensive income (loss) before reclassifications \$ (2.5) \$ 4.8 8.1 \$ 124.6 Ending balance 4,950.9 Å 4,950.9 Å Total Å Å Å Accumulated Other Comprehensive Income (Loss) [Line Items] Å Å Å Beginning balance (137.0) (118.4) (147.6) (238.2) Ending balance (139.5) (113.6) (139.5) (113.6) Foreign Currency Translation Å Å Å Accumulated Other Comprehensive Income (Loss) [Line Items] Å Å Å Beginning balance (147.8) (138.1) (168.0) (267.2) Other comprehensive income (loss) before reclassifications (2.8) (3.1) 1.7 1.4 3.2 Ending balance (150.6) (137.0) (150.6) (137.0) Pension Plans Å Å Å Accumulated Other Comprehensive Income (Loss) [Line Items] Å Å Å Beginning balance 0.3 (0.3) 0.3 (0.3) Other comprehensive income (loss) before reclassifications 0.0 0.0 0.0 0.0 Ending balance 0.3 (0.3) 0.3 (0.3) Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent Interest Rate Swap Å Å Å Accumulated Other Comprehensive Income (Loss) [Line Items] Å Å Å Beginning balance 10.5 20.0 20.1 29.3 Other comprehensive income (loss) before reclassifications 0.3 3.7 (9.3) (5.6) Ending balance \$ 10.8 \$ 23.7 \$ 10.8 \$ 23.7 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 102 R91.htm IDEA: XBRL DOCUMENT v3.24.2 Share Repurchase (Details) - USD (\$) 3 Months Ended 9 Months Ended Feb. 27, 2024 Nov. 17, 2023 Jun. 29, 2024 Jun. 29, 2024 Nov. 15, 2023 Nov. 06, 2023 Sep. 23, 2022 share repurchase plan [Line Items] Å Å Å Å Stock Repurchased During Period, Value Å Å \$ 100,000,000 Å 250,000,000 Å Å Accelerated share repurchase agreement Å Å Å Å \$ 500,000,000 Å Accelerated Share Repurchases, Settlement (Payment) or Receipt Å \$ 500,000,000 Å Å \$ 500,000,000 Å Percentage of share repurchase program Å 80.00% Å Å Å Å Repurchase of common stock (in shares) 1,400,000 5,600,000 Å Å Å September 22, 2022 Å Å Å Å share repurchase plan [Line Items] Å Å Å Å Å Stock Repurchase Program, Authorized Amount Å Å Å Å \$ 1,000,000,000 Å Stock Repurchased During Period, Shares Å Å 1,400,000 3,500,000 Å Å Å Stock Repurchase Program, Remaining Authorized Repurchase Amount Å Å \$ 248,600,000 Å 248,600,000 Å Å December 11, 2020 Å Å Å Å share repurchase plan [Line Items] Å Å Å Å Å Stock Repurchase Program, Authorized Amount Å Å \$ 1,000,000,000 Å 1,000,000,000 Å Å X - DefinitionAccelerated share repurchase agreement + ReferencesNo definition available. + Details Name: holx_AcceleratedShareRepurchaseAgreement Namespace Prefix: holx Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPercentage of share repurchase program + ReferencesNo definition available. + Details Name: holx_PercentageOfShareRepurchaseProgram Namespace Prefix: holx Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Definition[Line Items] for share repurchase plan [Table] + ReferencesNo definition available. + Details Name: holx_ShareRepurchasePlanLineItems Namespace Prefix: holx Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 25 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481138/505-30-25-5 + Details Name: us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of stock repurchase plan authorized. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount remaining of a stock repurchase plan authorized. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. +

[illegible]

[illegible]

[illegible]

M4 \Y%*%DP.O.#!G?%0OVUSNAR4K,NOZ7?U=%%?G9POPAUQ[W7OWNMCT@|G]!"1 M_X,8j8^~5&-UDYM(NN=I:N33=4/-INI%U] J6;Y7+QK
MOVK;R3OE0H(H0W1I~NJK6=M%>OE1U,|@%*%O)DK"KTEM2R(W)1K3U.ZL:~1MNH MHA-10BEJ)/7/-4/66-00%+1E^ Y 5VFX(R:[\$P1@7HSTW|^ [74#]]3G1OM(
MOMP#AFKGV2^K&134R>+5WT5D[1I1U41F;E4U.2I=EI]081)U=>>4F9*4+~#7R' MN,-8~>M7? 5A=C]3&[+DP;P;7&54L/MX<-(V-QF[@+2;FAWKXOB7Z^N1[1]9 M:QODX%
V9IR,[\$@P9R6PCE4E3[,@?%PG \L8;1)G?%HJ2Z]](H89) C.5BORZGOGA7[;Q5[L8*9159Q|PVT5C]4C#/M<27X.M-13IY &JNFUOL3Y**&612%QM;-OME,881NS
5[~(C%CL8 ->8M6 M@JZG7\$=J%>%QPH8P2ID^&Y&-A]5*3G;[BOAQ]) M 0-U1E*-,0?%PEY* MU5U.7.#,A=1=K;7Q7:OTX^4H<,(CMOLF2P8,8,->D83>PO? GDS(="K7&\1[2
M1P+(C/C#T;P;IWUW15V9%#N4G%K;9QJ]P(O(1+^E8BZMJ6G60+13R)GL3' MX/N<C/5VYG2T1T2Z3#; JHF.EK9;A^E8CKY<3 A.#9;\$,R5+J\$=U3@)4&4
MK8Z&CTNLUMJ\$B\$]]NC\$M5'R;04]L+=1\$K4PY0.Z=\$W*/ MH.;9BN=XDA.;59> 9 ON.7\U;U#YJDH+5T)2K\$O4KTL^LU%4=FIA MH.'8%GG;;@+<2< V<->9(K.D VK2-2V:9J8);-; 0\$!784T=GH
="7;Y(U M,^Q20B,XOM/(D#H7;4C^C06,-VSJ ->L^D'0LOL3P^VGASOAWM1J4\$8^2WV MGBJ9 MHXFEX7V1/8L7,FQ50=75SG;;HV8/EPEGS#5YE >8 /JZZ1,W3?>?HT3?3/ MZ
\$KB,0'.\L&4QOAH+;48;5774WEJ+@/@OHIYOW2V9XWCMY !=:7A@F508 MM2;RZ02@JT G9XL9V/M<8LM25>X\$;-.%2+8+V:~ FHMJ13#515DR2Z]P= MT NO .A:&PO=V]R:W-H965T-V6
M_QY=V]F]T\$;VQOQ9L@?#M1FB;.[+DB% _JM?4U4D)7G1 ?7EZZU=;L;M1N6>U/@R;L(KK&9;6Y M=^O^Z(PW[?++=#2.7>ZT+2X^ON=1=[7]V53Y[8P=Y5S6ZG]^<;DY>/RZ2
MBW#CLJVL[.IQ?^?J7F _O.E V=J5N+J,5#^[X6S9;:sJL YP<9V/O9G0>EJP M5VL>7>=>WDF69?F%+CYE^RY&Q) #)S:HF!A!_LRMR7,B!#; ^Y6E@Q^'.48 =W MHY[EAVR+44SMV7^<
Y05YVP]GH\$5;5N0IS^>?@X^6K9QU5F30^YCSBW^VLG M0JT:5Y<[QOD<[&PA? 63UT@P6V]T9D/J-Z,3,MO\$5^7ZO: WQ254^JH16@QK] M8%Y=YSB1GEOJ[P]U@?; ?&S>3!8Q)2ZG?<
JMB\$J]B!# 56W?+1IE*O[K<K^MKJQQ;JY2UB3=ENZ/T;H9^>H7^E@+1K5, _Y&Q)'OLOP6M2,T.WZ00SO&Q M4P05>C50Z2B=O\$014P96KC T1]A>_KJ_SU^#J3T_OIJ_ZZ05Z9#Q>(<
M&F>J1W/Q(=O?);/1NQ>XGT3N)R]1#JR8NOEC. 3-RJ(O/60+?=7A?B)5 MV12U4XAW!|TLV#>5;W11JIAU >W-C.;#=1)Q;F^YIQZ!=> 4;K(U,841M^U M<-9\$T[Z[!@-.Y4>5:6=#85V76@-@<
ORQRAN+3^?;O]R MK4P.HIE:08BR,0^>W7;ENG[4EIFH5.1-4;K.A0LJ^X^U< K9KVRJ#5/K-N73 M3B !2M\$P@RH^T9W^6&Z2^7990Z1CTE;I MGHV^O^>HMQV.J]^++&RK)Y935F673+<[-;\$ 946E31U^Z=JUYW M04P7=65WB#P8+W E0B3^YKM3WVT2.1+K1LJW00H.M^*W YND2;S=ZTWB^= MF6<=A0=N-Q?7(=SS&[SKQHOD R1#HFLB5.;5?<
#PYV/!=#V7QJ2R70X4;J(R3\$7.EDQ% _S+=A2(U.1.TF+TNPNH)R M^*CF.(E)+VW^OWE7N,\$7(L\$K<-<Y.SH F3!7\$Y!>T/WQ2.Z/KIB R9C8000F^M\$ XP6MP1^0+BE[?R, M06RL?<
OS[G]5R]M^DBESZ25.9EX3J JM^4JX.S*=8^OJ^V P.E%\$YV4B]>R MYX.3&8N9R&^I6';.2B;X.S.32U@2V(+Y=,1W4AQ%ZX6=,ABX; ON?RIYR<[J] MON/P UU 3Y.QZ&\$B.AG#4^?<
L1C.)@%P3,7^<-KGYXB6^22^#97T\$5LOA@G M V)5B;THZG+; _O@J3+>?>?L7^1T5]]!%L2-SL9U-G^@S%HSU5^""@T//<6 M4QF8UCJ. X^XGDI 'RBZMDSI=;P>=>F]"=30K^ 1KX><
QS@GS+ J1\$Y>3.82N,@R8A#XR 6QLYXD6G@<\$5(AAA MQX+X(ETAL?P3!)^_J03=6/A!M12\$=G' B'=+1[3H56!6 M287P1B1 M.MC(IOP#N24VG^ Q^Q;<
O+9RXLXG^'TFIN^GA43RVHB,1ME^A^+T%1H M.9\$C/FRVTU<=<I)=2F;Y=E9 =Z=7=@U>9Y2Q9I1SDBNR575XJ=G8!>JQ7K M^X %#H J^KX^6X CIG6)3S^62.[K.;5W5,)#!6A+&\$ 36%_H] <
(+)%VPI^XG MR^<QV@O+P[2&4+WWP[3?>?1PA+^IZEXLSD4^S@P5<3Y=3:S-BXWNJ])8D7N^4?&O >X,KFB01QPX9C.J.A)QOZ?R&8 M4CM\$#82^C#H1M- <
_PP@/IRP(1.2B _K4M+PTRNB)@<#XWMPQ; _J^G7[!J^ MEAP521R9^JW8BVU TPCL183BK,"55-2&8F%3,+ID7BHYHQ2,CIN\YL?^62Q>+>+?2]OJ@+&+5]F^ MXWR&#A:*W-5H&W!<9F F- <
.DWGZ?2AW8B36U1E7#=#1L5D93E1;@;TAF#JT_ M9ARJZ]#L,B/%;#=#@M,D1?(" +1\$!:-[MP>T^L\$7XJ5G,N75>+1,01R+>6 M1)~?>A.D43BR\$?UW77_13V6DR^V,=Q9 J_U^Q3SL6@=2^*<
%Q13H16=(51A6=L;U6=#C=CACI%>X% M=H-#TYUJC]5QJQ,QA2E,8V@C[;_JXA%YTCT<+GW5921V46HFC\$C-];J W M18<@Q C]J>#Y[-@&K1M\$+U5M: ^00EM>Z+107KJ6W2,]FTU.GJ <
M12F2V+&E+ZYW^HPGW-U4+BF@O^LZ3&DRLBZ&A4U1-8V9UYFY<+>2XB]J] M#212]XQ/62U^9Q6VFFSA@<\$9?J7^*,W3HL<90+2>;Z>+J^P/V^Z-V8^)+?1 M9B9475\$SH\$!+>+0:IZZ!<
[0401A]GTV1A[NZ?>^Y30,515(W#80SYZ,DMRB MBZRH3^Q5QEO=^Y.15%8<4G;4A^&X/T(^X7QM&ZYRE.;)PR[XOMB2S6?>3X7^X]GBD,AKL^4V.#_~!!H! M 4Q1A^~1]BIU;B;45UY- <
1=IQO.^#3R1O9CECB)B1UC0I2]BQM^Z!WD^DY1 MC#A@W#7@'HM^U&+R][+@&*(GV+!|;EU#G M#E,-?DF14+5[-BK^&[\$1\$^H<,"8CE+.(A46AF^6SB3>?>.U5.2DN&_K8R\$Z <
M%Z6C_@Z.1QTTB?2%?!LR)

H 40;?HY*&.-SW=)DE)YR%/'3 MF955*%P??<^UG(G:RLBS4J)[R=-&5D]@KRNZ< 8.G6GW*840^CB7N/M2R\$S((M9=)1@HG).HV>B+22& PE?<
1(8RNNR/ CBE);B7N\$-GAD^C^W+PPK5Z2^*^U MM&>G^M;A.#N,7 <1>I-DST^VD^<_#JF;QD"[M^@+1%)6]"-8;-<V9!T1SER MJJ;HH#P^#VOA&+O0!9- <
2&[CN_FCB'.H04:##=47\$0K/50^I+@[P0,]3 FXR@ M>G>!--WMK/!II5Z3._?9V975_I6"\1\$QS/O;)D9^U%+WP.4X+@%97B >?>?J2 MCJ)UO74%.*<
<&^&N^*,SAWT3OIE6G003OS6I/!LPC(-JY)Y?9P^H^WK3KN30H;[MLQO+=K(2A,0]J^Z,83@H%=O H^C7^ZAWT?>Y.8-10/CW?%YORO^U3?V7 <
M."(&^W)D#&=#U&?1%KWA-S!+K%N^C!>R28:51& BHY%SVJ>|Y;=\$ ' M.VLW!> NMMFN6;_1/3O!K7ZURZV\..O<.(N4Q>E6^8Y)=SM:UDO/T?I^C M< <
M% CFB0^T!^K152V5(OL511FRDE _.@]E|>_0 5775G>?MOK^M^O-4/4^' X M MIDQ^Q;PTWD.@T5->3,P2.U^\$?^?>NUTUEN30@P[6@=D^/VWAB^* <
(P14V M%-^0C75EVG=S6J O4>^NN&S+^FBM]M21Z[4H>A^@&O^&118#PS/+W+>@ DP#];<=W4,L+A,1%[C_0Y?iV,<<9F051\$SG5@]CA%<^O^KS?<
2G2:1,9G=K%)\$R MD..T%>:>@T<E&TRXSEKWR#F0><-Z>=>9;FV,R+>+3=N6;15F=2LQA@^S. MTNN4B^ECTC^];KI?;(J@YKA/GY287^X+8^M <
T+:=R4L;N%N^%<0^2DB\$^!F# M;?&E(BANPT,=YHZ>]EQAT[M?>?;1,10)H<.(# EJ^W88HLQ6W(WATY)Y^ZFY[5 M,((=)^(N4UE@N30@P[6@=D^/VWAB^* <
'_TH2 %CAZ?>=&SQ>PG M/AA.^6J)H)=: EU12[|MZ.8<^?;,+>=&%6#DW4NGNHV=[K|IXZV' M;[T]OR>RD9W9M GS-12M^F@/@F3RC91PFC+**<
(S*P1K;V1B^"F&FZ3?;].- M8+=IP;W9 (CBX^Y@ G3^C7PKPCT3!#V!&U0<;^=HSU/X#<KQNXQ8^&S^Y M:V.I&ML:W7@,0K(3<^HV2%<(- <
/I@!>D@6L\$EL_#P: KMV@<Y\$B#^ Y(L);(> M9/>+4D5+GX)UID9.8(OHOYH^<^N5U 7G>@ (UJ|F);#;W:8REZ ?3AKXVU(65USLL|CBE M#<^"!|:@.LJ?<
#L5/A6C(1FV/@:/:J\$S4(VNH%E|[F39V7^A^Z#&3"[5^W^..: M^,X.XV&C^>Y^*A\$W/FH;=<^/6_:(NEZ]0+%^~T|W1%;,)XONTN\$/U_0&[M1_IT+V6]- <
@/Y|QNX/JIW/[C^CSH^U0.^B5X.^A4.60\$1S3G;[GJ]TQW] M;.,_2EIUO M^O^/L07WXXS^=)2N]OPRU C+3PA/VW.XR9T13^41QL+@T^W_1F M4?<
<_.R]#8LN&K^*807>[&L;F\$_.GK|+2O\$]3MH &#&A]L^|+A;]^W B M08J\$4<8(ID-U1L8]-8C<6N]PE(3EO)(1=%~+CADRD7W7K <
M+1PW\$^!QJHR^@BSYFX2X!W+RWK<=(AT6HP!^Y&QX&U4-RL<50625QHB[5GXG MX[%O1+VBJ]<[3RK1^0PPV[=Q16" X^!&_?#4-JF7G<_KH:(- <
M R<^GA<4M7QI^ ^Z=P+9.GM/OE/SQI &B(4YNUM@Z&LZG^U+^#PD5=[OE M_659PQ[&PO=V]R:W-H965TH <
"0S+;1^!E/WJSLV=^2%Y\$G60^L[L]^*PLM MT)>?>2?D]G|V=LCCU<=ZKSYG#014%L9?#_(0JK>CD4]R+I4?VHH-9;6E2K;M <
MU64C7SE6:4PBJ#%D/^X]^I4V@]E5^+MWLRM;AT;OG?DZ]4;G0#A=N<#TX' MW<="SO@/ Z/95:4R7G#X4MT@]O(UZE%27;+RVAAROK@?<
ST[I]^HP?D)<#0S;=<% (S&M):S&\$ _1^3N/W^H^V+M]E&6I M/-:XE>=AOQZ<#F@E%>+|L^*W^S,;3WG@I?8PL=?VC2Q4ZR8U#|8LDW&>ZE- <
M^Z>+6AWV\$B[SR1,VH1)Y-TL%Y^F^4T-KIS-D)-HH,E#+#5F@YPV1T1%<C)C5 MR NSS!|MGB2V-D&;C.Z=-7A.&+H^3R_N;?3S?|EU2A<-0;Y <
M#7VRJN2>WIN4T^ S1V#94YUT5&F1P\$ UF9(DSV3-X M^V6W9=)OJ24^E&Y 5#!#=[T,]YLG|>^4@E?H] _/LU+H^8_G#Z>OS3\$;;3 <
MGNWT&/KQ1ATB>Q\$NSM!GN^9RR4[T]^NAD#-JF^JN2^M2\$#./LJ^% M^2TXD]7H@20K(HD7C]2"4TNR IKJR< \$?!-M&[67?>([I9/"^AKBT) > <
ML5Y6ZU2A^"SO&[66<<3I@T A #JE#&62U^Z1Z 6N#((:SHU8^X^Y6K-I-);G11^Y-B,4SJDBKVM1C MUX<?>T9(6S,#^C^MV6%IBJGH9GC(I;<- <
L1)OF.HD>A^ M][T^8YD^RTCS;<6\$0V;[SVZST^? >#&^Z1=SP8^1<I^*G09^N^Z3XN^<(OVN49V^YH)P^X,M 5,ELD6J.(XGF>4*9 <
M8[C^UNA^IG^XE%&A/^,0@^PS7+?A]9RH8.JI!&5.#D80^K6^+R[1]Q6^U/B A MFD?8L2^!<1!DN.?|CG%CL@V|V- <
9HIZIRY:4/TMCG#SOIAFM^U!DMO2:30.MN E;#;Q@: Y-DATY/#BM121\$)UMNN^:(L3&2/@;|IBJX^;VH^;8WS, <
<55G)P&87UD;NA=9#&_S.X\$4\$1\$!10 (< N^ EA M7^#NP04 (9 >+PO=V]R:W-H965T?5LUK3L9+;WOCJ935R12U2KFJZ70+*PMC <
M5[K#T^93UUFMYJ2T;J8BBM+I2M7M:'9,J5;5YN66;TX&9WRHS.)B3P M>ZTW;N^;820WQGS!P^OYR2A^AW2C2X!(^EZW^EPW#0*!&U]JS- <
%A47WOW?H MOU\$&L,N-C@.(1F^N^60C^?TFS>Z3Z>1?#%SAZLDV0A=E(FE6OG MS:I7@]6=10>ZEN?ASV9%|J@N@51/D=#)7KY57LV-K-LRB- <
*#A1X5^VN!< MW6)1KKR^U1KT_Q2W^IVK=G+;W73/?3=0#^JY-RQ!E;(^R 4I(-=Q M-M^U XY^BC484>OEY 9TT|SUFW%|/+&==;<
MUG,-7>7NK)/G0NY^_O<.<7:S93=K!|<8ZJ=LTJ;RJN68-3NB^OH?W8 _X2 M/<=6JMT1NUY:K>|QB\$^]]5#_PP+EG%:C]G9SO)+5K?0(4T#!AW[B7UJ: <
[1S MY<<8^&?;|KVU+^50-NS8>GD]+O^Y5U1KGZQ^76A@;@SA M/6=9/(GA)?- 2]NQ\$3@;#?)<#;=<I-)SD\$ _OO1NE^G^VYL)F4PD2Q- B7D\$ M6D)& <
&^*2<3B^".&F^U12T6^A,K#TXEDNN^A^WZ2UFZ!!B. YB1^NBO:Y M)M4O^PLSO/WFG5^_71;OA^12J^IPAQ@C)9\$M\$,%H <
M4>1H1B,0]C^*UH_R/@IPO^?^!<#GF0(2TQ,24C&J2A ^(\%(OX<C)CS&72+ MA@DU^9(8JAX/G0\$] K,(A0GGP,|ZBHYE&D.EG^)_%H7(,0/(BX)G5- <
D4N)403Q^:SR\$C3W< SSE(MAT1 .T,DSN2@ZX Y^R(O<|]CM&@>@/YR&2SG.^XM&_AB;@UONN%>=\$>GH=M <
M(O)>A@Z^M^"PF),4EA^V@^2T+&+399R^342 "\$?DOO?((LL#<R&CE..O)\$7P M?AS#%ZIF,BC1&NCQ0]O^PS9X>W>P> <
+!G7#70J])_ KFD:7[G7^7T4;_C^M M(GBSMG QACV^E^B8GPRK^W LIR26OU^H\$O: _6S>Y>[!\$;X[P=UPA^M^=FJJM _|C <
M=^N<6=M2^SQ^Z9I=X\$";|^%H. O._MXW^MZ8P+MPW^H^A\$XG\$;]-CO.@6+A MJTCQ^@U778V\$U^_7=0<_!7X,Y%659UKX#+ <
<.99@HRS4),Q@066+BF0S@EQ M_1:L2YAO<#F-/!D:1X^"826^_HP^AD8WN@C;],AFXR8#7<8>!--M1?1@/^A6D?_2_A)TQ8%8^UAC^-T,^PVS? <
[U!+ P04 ^" |@/Y8G+!| M84%# #!#P &O ^AL+W=OP^9=9%S-M,NYP,NPM MFQO@J6?^9ON=;MC O5&MWXM02;=- <
+W^#M3WG) _1TOHO6Y:T@[C%DL(ZG:V948-/j+/ M?ZW]\$\$ _T<8XC5#/[4N#_):ON..CVZ,7C)#U^B-!MY4SXW^*45!F3B#NP+Y MW.@#%X9]Y[(<
[A6X+0R@QYUE)X]^*L>=WK0=GD^P[60M;Z4&1^1>J.F^N46 MEKU7^2[M4W4KE(QWJAX^S<*^RHB,679RSNQ/T&>;W^Y)Z7U_M_D])FTA- <
M5EOVUJ4.W.H^?>O.YE)DOUXD90Z&Z^C^_S3 1.4??.&;(+ODN6?>G11 M5?>Q,LQLXL4D9UDZL^H118!M^E^Y9@AA#4+ <
(NC044>CA^U0W5>LV^0@!KCOSN, MAOCO7D2]P-O !%=HAZ^08/[2 5:D@%1Z2A,V+^305>7."_3L1/V**1QO].RB <
MLT^Q1%,^GT#N(NB6WL=^>9>6=8Z;[YF2^ZW)&UM _8;@!AL;.;7OG.UX M6^B16^H<I2M^M+YK9F^H^IP316M4E1XL+4HE^VG^1LO."HH<[TMP <
V(+G MDGR&O7-#?QG8;40?;J]("(^1+>4^M0%4&I^U>4\$ X L@6>_TC^T7(EDPJR7[<
M5>D52_F.AR7^O^6W=IZQM/#ZD^YN80^POH+&3#;0J\$QW8^ZR^Z1(-/+ M19;7<-IB2!BW"(@)-XQ,&^7F38AMCO)MG95? <
HCL^&K7LNN4I#9S^7^A^ M9J#9I<5]IO4 _O QS0Y^B(31)DG/PMAA5^O^DIOL^RN;D/(TW_P@E!&<+10 M=;\$,G73C]^*OBJGN8\$^X1.[F@;V <
7^KS&HKY.VXH]=5WWMO+&O3?^&MF1;28W3,[<^U@>H_Q_01M^ZKGUBJWO7X^<(^SS.58^C9A !U,4 NGFOA^A^LWF(>SO!D- <
4AOE^H<<3O!@] MMSGG.,MWX,RFVR9#<<5^#^VLZE&4^O!P?O@Wv6]80AA^! YO*474+8BVJN19 M6<_U8?H|H>M^OX)^+ <
A2&>9F.P^YZD+;#IY5B+BY?SQBV="^""WQC@R\$^W)J] MO^%O^W1 j6H?_0=02P,^C @_NX#^6+8)1^6 @ / 8 ID IX;^JW M;W)K&UL? <
55M;|HP\$XKIZR:6FE^+R,D^^B^= M5@VU7?=>AV>3?2J8V>V ^V_WJF@O^7*E43VW3WV^?>S9;11^LD4B!>2R^F- <
M^JLK898K(^(2V9B5:SDRU+IBEQ:ZE5B^HTL|T?E2^6JY^4C,MH,OJGSKO/W^H^<^9@#4]OJdGM[G]Q^U+&4\$!F74(C%YKO\$A^!#1 M^+? <
%C])V+O!PO4/_XK63E@4S>^7\$;YI;8AP-(LAQR61A][3F&V]U|Q>IH3Q M3]@SWUXO@JRV5I7;8&]0]^E;AX. 0>N<^0;D^K>(9%G>T9NE)P^UC^&]_ <
!I^>V>P.LT,CL<K _V MS(P8K^P)_PEA[?+>W6^""GN/Q/^X^4W^M,1AQ^=<^ZC5D^?OVOW6Q J,NHV^|BGR3J^>R;P6^H)-S(3)<2JW(OR!F^ M^)<
(JXPW&6W-;Q SS2K#;_"BC+K?>_!W(=)N10>92,IDAD!>=718UWU,M,1QZ^J]S^NE!&[C\$C0_C.E 4\$6L#!!0 @ _N_E@-C05 M&00_X^9 >+&PO=V]R:W- <
H965TDZX?=/M 6;.LJD1D)Q>IU19+IEQ1(>3M9 ET[24T]5 M\$EEFE)ZYES^DP6B9&W G_EN%/_YF!NLA3B MFUE<93/-PYA@2MM\$!@-JWB116& <
R(U_JYA.^H|(H|/T^W>Z>1+)<G^O! MS3.]G3FI QFN65WH&|^I^ _?W&1J^E2B4 8=!(SN,^%C52HMRKTP>E^EO1O.P^M^X=G^_JE_OB^<*X36I|:0]?*2:3? <
2K\$#<:0)S4S15:TV.9=S\$Y1|>+>DT)ST] M7PA)&CG?#& @PN6)6:[A7^K&TB/BKQ76I?>?IXYF@T;6^W^1%PUX>=)1)M^#)\$UUL^ <
[WF&V;&^1V9;._#MXNP%_!\$S5T(OP,(_3#NP80:VT<6+SJ]=XE+ M#9>Y6A5^U1+A _ETI^8^D_791NLN!O+9,|\$56R%,X?20Z&1V?^?JDV0^_JZ <
M/(U;3^,^I/F%""O&^W]6[12Q^A][4;]I0-LB;^?ODG#8/1P?)*BM!&:@T M9B#6H^EY+8^K^GDV XH\$V^K=8:2R7^""R!W!12TG4HP>R>QY^N+(M^PDXJ) <
J)\$M^,'8@X\$>7=0D9HA^B82DE\$N5,WX^L^NTFTF]=RA+^&8M.(1NZOAC=N3V<^M^Q3Z?C^*73Y<+&622?/09#WYBQLRAPU@2MV+M4NJV <
8PM6>X^?B6CHZ^&^PFCX]WVB0P18E6Q2-1PBRBOJ.7-S7!"IJB MQ42+;TAB=VRWO:~^C0.+&\$^Q\$0\$R^@UT15X8T7+U^EN,G(>^8ZH1^H_JT <
MZN%,TG(F^6^<\$?TB6GRHHLT05:ZJ]J]KJZ4YA&Z%XEH&/OZ>7=\$ MA!_FOFOUQKSV_V/;&=U=B-PE+.,JHEK;_0>S&S=1572(W)JOFNPW/V+5",< <
(A M4:LI&Z08->6K&^Q1_5I^*56GC/>HP2Y<9V4N;K0,6R:3^?W;99.VJZE^?Q MIM/[Q.OFIT)5X)I4?7=^\$4VW5^ST^*R^&PO=V]R:W^H <
M965TBF4KI@E5;B4VMDN3>J1]3\$6E4,2Z#=#.KO;G0Z56LKN.O; M#69=54R _+%(HS2SH1^7MWQ56G<11=..K? _J8_Z11,6M2PYKU :KB1H+&;! <
MO#=#9#!S> WYRW)&5&5PF2Z4>G?(MGP6Q^P@%9M8Q,I)/>(^Y",(^*X^&6VA= M.L/N^97IPN=.N2R9P7,E^G^ANRUDP^B#@[Jv^O56;KJ<C <
9^CX,B6,~_FP9J^& M 61K8U6U-&8^BX;R9ZV_ZC^,K^<(-D);#NQI&A/C.S+UJMO^M21,3F#CY5 M;TW!<>F^YX&EGR|UBB;MKT?A^WO <
UABLE;6G@B]PQW[6]^XV^_0U^\$5RD#^| M6H:0%&@B9!|^Y^<X^S/ZG]_IE_W_R+XW5U^2_JR7| SV[!A!FIB:93@+&M^,(ZB,T,@_O>J?QIP- <
1#MHH!X8TSL:S^PM\$%0^I9R3:VG-"5PKBRON^9-- M#2^X1 IRN>I4=U|JYWM3^6^<=(WA=L31<_C^2F3JE0W3N8O+^H+M^%6-)H <
MFH@9AZ&Z85L_R%15,T^5I?20B7]^G^_H36#^#A>9SC]B(^&I|QHRH^RKL^N=84 M=CIM[I^C]J^?A4,2P^F\$WZ,D^!^<3/3/P8YCS!SP+ST@D8>? <
<3ARP/XXI,&^& MOD=;=.Q0K RV,1>U(QD>JLNM^DQM @S3;BGK%9J^""^S^PI-A +K9,(UB M5>VG>JDL[0A ^&DIHW8 >B4<16<0!<9 _!51+ P04 ^" <
[@/Y8]+)9 M9X,\$ \$#\$ &O ^AL+W=OX[T=^-5YL _/:4265GG=2Y?+KV3B^C-M YZ!P9:5-QAT. MS;IGDM2^YOT=][W]7);=P <

MJ>50(G\I'K<:80FL>""=G=Y@,J?>[65EK_9)M2=HS"<6&=SBIEM" 3JGSS MIRH<873\ 6%]%*(O-WE1M[***[X?&KTAAF21C3Z*YZ;31.*\$K*O3.X*E#/MS: B5=>D;&L^!7\$N51M<.O<F9=>[<85R4]>\$Z'+/S!>=JUDU\H24V!+=L21 WJ!9>.V< (1;-!JT?9P(MM!U(#L=,|BN*|,)%BG4&3%<(FWX229A MV'R07@H)80RH^>)G%: IEQ;*WK!^<^<.O<GX-@A,|N/Q@F/ M^-0/PIU'8!+=P=-: SH*W'3K>_ZJ =EQXGJL;j'6C(=*UU/>HKN|1:RG> MX_F3%|+(HD:M+ZP#8JY[C][DP| N71R1J|U;PP1|2|Y%:H%L28<5R04)APN MK&BW1J|]-**92YVWE7*W|O^<6SP->B-70G\$5*PR2:8;RS9X_-;|1|\$NEMQ: ML1(QITG\$^`NN41E8.6AC`XWQZO)NRB\$KGW(C>Z MAGWSWD#K(E(MQST MP9LTJXDT, &+Q<4=)ANWY2SF-F4K">6F8@T3;#0, "B.&11B=L/S1N7=&LB Y M2!@X8W!0ME=-7IDJG(E9WSRWK)3SZ<^5F [YB>O7JF1=#\LV3[TKV@#BN>3A^-0_\QH>'3#L;|] [+*Y=7A^B8CL^L6ZEY]5891:#DWQ[S7M5E M:6^O=,?;./K*.3ZP:C+_R7@RWY4%8:M2Q4!*>=U|/ M4>|JZQR!5W;|B2KJG[PITS PQQ6QHWM&QR"^1|3?MTW[18E(M=)KW"PS,M,Q?|9H'SI27C+KV? J*OBAOICOQW|_D1NL<^&LE57;;MLP#;T5P@& M?>?JQW:=RY(R2Y8BUV*>=EL^ACTH-A,+E:5,DION[T?]B9=N28")")%IXC M2O1XH_2|J1 M/-9"FDE06;L>19\$*|JR9.5=KE+2S5+IFEDR|BLQ:(RM|4BVB M)([S|J&9:ZY>! PC>/&|*W/5*5DH>=^_RW(2Q(X0 M"BRLOV*Q"X"O40@1#1^;C&#KJ1+W%_OT-|Y|:1EP0R^5N*.E[:!(, 2ERR M1M@;M7F/6ST7#|J|OPOA?V+2QW\$ 16.1J|K?)Q*FLOUGC|MSV\$L8\$M(M@F) MY|T6|BS?;,NF82TVH?TTH;F%G^JSB1R7KBFV5M,NISP|_41|OY2Q%JA%>?%## MG,\$U:KBMF";%|80; [&D:5*+CXJMJCS%4Y@CJ\$CTK:RL;66+Y-#BAAW- M9\$=SGIP\$O&KD.23\$#)(XR4@[I9WL_U..E1_#>,BVY7)D]M=|G^V,UW9(?A_2V M<-EA,/=R1F;- "IP\$)#0,Z<@,IL^?|+XU0F964YW*68VO)K*P,WP PL ME M?>7;D;PI=*(3RX#?+23SW47/3-O6K\$+^B%_SI:O1O_Q"B!:"FB0%T;6NB MY1D8H)C+&#COD*29F\$>9Y|D>3B,|V3G8=I|R>Z:6(>=>|KKN 7V_% M=(66M4DB8861>,CZH(=?"!AJ|U.QGC3X13%.)6WR5"50/"Y /;"0GM%XX MR!-X_FR0|))79/4=MS#N9UTC_TMD'F9YOB=R\$,#MG#,!VFGH43!7SZH1?-Y#_U??\$4W#E,XU*8YZ4G[B5,UR.'008_VYE2->N6G ML2&%=7:D=5YNX\$|^?|7?7V7A+L VE|[97>&*|]|]+_ 51+ P04 ""|[Y89T&6.8#_! 'M"0^&_!A+W=OQ3? 1&-GSO,X#""E2SQN[|_]I)RYP90%> B|]M,M,KOZ >2X MR&+6PCVK\$|[T->?(\$\$L:7L&EB>VD 66VL*G?)Q#E>Z#DLJ9(VX=CA+Z>86\$Y>0 M>-[-1]|E|V;9>#C5!K2+|C37%)J]- I^CTFW*S&KZEU.>^<^LRE8W4]*5P|TJ M:;-\\OU|HG-!9IWP/C2-"XXRG:0TP8RNO Y@|J^VL+ 1YEC?IH?;T#QV3/ M<9I(+34N3|>3V5>O^DFK=V>N4?D^OAOX:GOB<^&Z_&|2\$5#(</ M,)|KL876^_ \W"MC:S&-(6P<71|J;9"ZWIM DK",1B"AM0RA:H:0^\$#V,Y M'6CNK.9N)NB&;OKI0|JBMHWQ1|J9|7|J\$9LKZ_|8#>FP2PMNZAS[5P|<);4K,EG6VMW!-<_ M^7W@:YXC?F+>4>3@CV9R=|>6PCVWRZL_NU7- +EZ]+H?7*#*6Z'8<=Y^6D M\$;=IAYTSHZ.GK<2M1+_X0;NE=J:9MW[C|Z^\$J8-(_C2WCSB?&%Z24G.@(7 ME!J'/7*L;I|MIF-5Y9_~N;+T|IF05|Z]M?T_];JORNX|;H+~#M|X%U!+_ P04 M ""|[Y8L2F+&V8#_!N|P &0_!A+W=O,YWOG/E?*_ T5|, 6/+4"FD606-M=Q-%|F|@9294 M'4B|V2K=,HM'O8M,IX'57JD5\$8WC(FH9E)R|O^M|J?N>BNXA+4FI|;IK^O M0*CI|(DB"PX| @OFNL^Q\$MYQW;P0|8HW|NUQE,TH=2|6FXDD3#=#A^<)>KW,E| M@3|G|,W1GCA|-DI|=8>|J2*('2\$04%F'P'!YA+<@A_-"&M|&S& RZ12|P?T M.^ \[-K)A|MX|877MED\$94|JV+>V^NU_P'C/Y|@I83Q7|(?9(L|(%5OK&|_ M9630E\$U8B|&#I M^C7Y+2.MC'DO:RA_E\$_018357|@N|JG 7_I94CH|26A,Q#&D0><5,|97H-AQOYNS#68^<^=Z:>9TKO|_! ML'S#BGB-V>X9Q/W|!SZ?Z9;-?X-(_JS<&8Gv6_S1[3_#X!#Q 9Z'=(C,T MOCPV1,|9|J03@N9,&|(3H44<A<F95B0+|B5U?>=5158 S)RS C11&FY(Y+ MCD5BN=9BZ?C^6RCFVS P<:S-?0+5VDW|J^)=&C-CZVEQS&! MF| @["55LIP<-08XGF\$|\$|@,\$|+JN:BYW'DSO,4NUY!|Q<-N^9/UG4-3S%1RC;G'S/HH^P=, MM!N25VI|U>.&8.1=YZ5ODB22YIGJ_=-W:>+98)6?E72)'F# |JYJVW|HTAHP MC!&4?TN4LU9IR_>A|,YF%Y@6N2A?%# N:T|X8|G0|TLH.IJA&,N=?RD, MJ50O[3!_I|_38W0|S.|G>\$E^|STCDN#+F|1- OYGG|MTZ>|V&@U=6=G|93%Q M2MO@PK.">#15BE|_#=#T|Q|_ =02P,\$% @ NX#^6 +S|J1BY!_%PL M!D !X;|JW;W)K&ULM59;;QHY%/XK1S2M&FD6 MQO9<4X*42|=-I5912+=.K?;!# 9&F1E3VX1D?_V>XP\$*:@|JV9?Q!9_/WW=N MN+_ 4YL'.E'+P5%>- />_G,N?|7JVF'E:VJZ>JP9_F6A32X+=;_W9N5%R|W MJL?&|.G5LEPZ@|]?NS6#OEZXJF\$4K0&|J&MIGB|5I9?G'=99;|R5TYFCC=Z@ M/Y=3- 53N^_ S6X*JW01F7M6L|JLP.G+>N6|GES&=|P?^*72.LVIE(RT?|J#% MS2B\$Q(A\$G"\$8+\$X5%=|J:HB*(3Q2BFLD5S84E*\$S^&N)=FYPN;"X M8RT,U11|I2S(9@R?E)X:.9^5!=PT;>3)A>_OY:A2|K3?/,U|TM^/@/#+HND"SP/@(8^_X(F-'X3'\$Z_@ MK>3#G9IKX|IF"G|=C*PSF#5_!Y+;HD6'T:B2SNQ<6#N|@Z5BE7E4G<&|(-RP) M/QSA&FVX1L?0-URW0G.(XE&OPQ17P.56S\$O," L736'YVC.XGQFE=H)WQ|Y M=P>#HWQPOBRJ9V#!_L|=K+^HGY43A(A|4IIXVKBPLG\$ 4A=V,1I^W4QQ9 M(\$2VFD6)Z"9PB0W.(OBL9.5F(+*X&X) (P|J| \$RQ_1BF>3>3'W|@<^""3,L" M+V|@|L8LI@-1%N\$E49QT.0P2L\$T04@RQ|&IUT&*>O&@/"1OSQDS,|RM*51 M!&(\$\$,|L7+|6V4|ZEOJ8'-8!?'_KF,B|< "<9Y0?%&|.GMOAQ|.*L': MSWYVA8CY|DW&?^&_B<=*"ZTP<8CG?>JV\$|5|+E@N',;\$JSS_TJ|J;NAJJ MN5/U|D080 W8ZSB5'E!>;83R(;&NBERHC@C(Y))Q2|O5N M@(*4_);@&%-IO!0HB+=/TE^R!) *JFH19)GPOLV"+&S^@&_8H*0XTAOC36^& MC_&NU5+@="SYE_L_5!W_.PTSA,4O6-0%NA=2+* GX'8:2&D54?|O_S> ME X#AVZTD(HP?|0DK- (<\$@M;=+P<6|P|U|@|AB5.Q^B-J|CES84OYV M*PO,D (2_\ONEU#0%"8#"ORA337&112X%. GO>AX28A@>+P%M+?U6*F5F?HG MF85"+QK7OELVNYM7WT7|V/EUO^TR? I68D(V%2DW0%,L^@VK:9UB|<KJGSXC M[? AY:&PO=V|JR-W.H965TFEF8>5->LYYU%DB@H;D+5HJ2=M=(M_B2H-Y%I^?+2 M.S5UQ.X)%#5%;"KK#- 6# MUOC-W|J|HW5|]0-*5H4|J&|&A&U9.3_C+AXOL^"U;_P|< F:0!69ZQ|>VZDH|&R_=_/NWLX@)C\$ M_SPHGO/SNGLBK_*6|Z8;4% [4X3FEOX4+TWB1/2)>7>:MH5Y&<77Z3EZ24|"?A|T-@TS-@,A#LN|@|7|U=3*.I)8!TM+9"6*N:FEO(S3EX^ MM%#H52'PN;JZ+RI=%V8/22|@2\ (IO^W80F|):X^<ARKK6|(\$E| M2L8+O/OY..4+QM-HV+1F5D2'2ME#+7#JH3,(1JWME%#DWQB=9)81C_!F^BO M^<N(5/P@ON&@2U)9>@5_ U1V17\$S%05/C@FPL5LQ^ND%|>9QOGONWD?)@| MV3+FD23ZPL|@|7|D0S/D_|L9;HP535(SC=)6_!Y/O|G&F8&CW7&2>SCG?% MI8#4D48W ZD)@|J28D^Y;Y4KU;1L M/VTN@TG^TC8FVRA|89HX4TSE=2RCT<@&HH;9^~L7BB=M/W,&JS#Q%_V@<[G M?YSX2O7&R\$-U+@FUS@<4P)U/X+ |ZM;_69RE)W^F5%7RVHW0|>7RME|P*_ M8@>6OP+4\$!&!!0 (+_N EA ""=:(@&8%9>>PO=V|JR-W.H M965T2JGL"|@0JVD4 MV:R DMM05Z|H9:-- R9%"LXUL98&G|F441+^"GU)"AOK2FP9|F72F.Y1"P_X*Q|V|FEEK_<_E" K_D|B)T@D)"A8#4/>|D-(D18P_?6?0^D2 M#)= |JD^~^=JIES2V\U_)>Y%C,@ZN Y;#AM<1;W7R!KIZQX\NTM+YE38M-")S5 M%G79)9."4JBVYT=?SA(N(I?2\$BZA,3K;C?R*C|PY.G,Z(89AR8V-_"E^FP2 M)Y0|E#LTM"HH#1.5T7F=(;OGQG%"BPI^|V7\$NSY+&+P,&BK"-MF3)"V03 M-|J,5%I9|5#GDS_&C_M:K2_!JELE)PNM:A2R9O&5)G(Q\ W|:H>;>,@W^>: MNRJ|JORU6%LT="E^ZNSI1D=IW=F+&?9S_R D6S",SZ9M7@XOXW0F1HU|D MZ|3|_T>R8PMW0C_.0L;K7\$N WZ MIS7|"U!+ P04 ""|[Y8?5Y,FV1#_!0^&_!A+W=OFLA5TA7EP6|K?>MGT?AA7_S@=?*VM+ C|+ XJ5|1|P| MXNQ\$?,&N KX|R!#8Y'M@,<@UJ5&? +&7@'8"=CL|A#G:&MTENFD2E@>M\$;9|%:5TTN8+O MH)=DHW#DHC/M^!PWHT|Q6%RLA0VV|J?R_0&*==(MVLN MN#5MLH|>0,YAR_? C5F?7OCT4DRZ\$&R^K-W.N)1_&Y, R_4_J@|A1.*_&M;JA|,Q7%2|663Q|XLN87BSSV?+_JHHI=#G);Y|6_4(R#C_P:(CD+U0 MF? BL|J1C9LF^>=\$+E.Q4T#4>+041V2_ [9<^9M#*#M5UWZ23=V^"V:G/ZLW#XCW7'E'0# K=D&H&PO=V|JR-W.H965THYTT#B5ZD67_!55SH&?)&U- "-=%I"125(UB#L3"Y5 M18WM|JH+H6@-'O^CB) R"&DH\$SB)_A&9%L#&<^"-K|I|JH^KT\$+ML8C_!A MX(D517\$#)(EJ6L 6S'.J4;9'!>52 TDP(IRM^&,^74Q?O [XS:51|E; M=E^*N,Y#%N/ 0&U^M^@:G|J|6_&GLSABO:>>#C2"8_!>O/G>;RXYJ6\$G^<M@V6FC\$GCG#+(:Y/W_I) M!*\$X1E|V M"S|TMY"G7U-D4K)RD5;_|P|J7JUAE|^"B4Q6M\$!_T*0_+9*S^FXBR:N MWN>ZIBG\$N';9JSW@YV|2SX<@M@Q,B!_O/OD#_*VV6EX;2P9NMN[|]O-@(| M&*CTKU_PD_ \.QU@IQ?WJFW?LA7 MU.5+7GP|I.L|G|?G;EU>RQJIXN%HOR_C';IN4?|V|6^Y^4VK>J7Q61I M/A59^G|HM-TLF.^+Q39=[V;7EX? W/A37E_ESM5\$GOL<@%\$SYOMVQ2Z;Y"J7 MLV#V|L;|>QJVK^<QN+Y^2E?9759|>O1O_U*61|K#>IOMRG6^<XKL|J7LY^!" M+0-> #HI_K+7LO6SM^<*KWG^?9 BW_O9?7K4BG^GWSV65;Y0JQ72?8KG>O_Z:_R-BU:#FT U8TX|U M&_0=@3<- ^+E")L&X;E'B)H&AZXO7OM^.'\$RK=+KRR)_8|NJ;M?SB<_4/K M^GRM=_N|#!_JZ'WKG7?>^_5F4P>YO%Q4|2?8H|&O?YKGYHL;5| MR|Z(JM+=? NEHOZAI?NP^>^O^#7,_"JFWML^4X>|/2PD_L_M|>?>N>^<@ MZL|=W0U^NCR>#^L<_/-|D^LR7.VX;4)-K-N""W\$H_/MOM=1|5V7;C|4 MU%_Y(M^65+Z-C+R-G+S MUE7V45U:45WU=EVZ\$A#PB02ID P(P;B&,Q41HOR_& M0184R'8\$9SXX&)QX=|X;1FW+LE81-T+|Y9017|KNGT|8;.*L3C|@M%R'B= M+^(Z'R3'3B;3K|;55FQ.PR_=\$/UU-E/Z\$!#PB02ID P(P;+8PR6\$V6!)3(X M2)A\$PA0(9@0GV/77=GJT'FB:&E=E+|J7^"TEXV\$W7TA"%@L^7W8R 26K,X&@ M,T'0B>!LZ-RG:YV>5FM|^F^_EL'/6U0FH32% (IFQH'I^")D\$#1H4(29-0 MFD+1S!|I^Q8X#8@|)W#K@&Q?YYTB==@YLV> @B:1)*4RB;1!=MWX)HJBP!=790FH32%(IFADB| MN|13|Q90EC7*V>B=;DV9Y>0<|KDX1L/_%@>?7.P98&?B);|FV2H;|E% MXJ2|<-,&CT D34)I^D4SXZ+=79|,E22@Q@|*DU".0M,\$&G\$SCMBMSM+_WK M-0CGK|LD"JF_M"8:"|F|>/>+B;DL6A|X3"G_[6/8FX?9>:(VV|5OLE7W|SO MT-W33|Z'K'C47&8-_%V|PT+&\$(I4DH3%9H9BT V3!1.F"0|7.FC>B>5^36 MHF@:ELJ4#)=0)0FH32% HIDATFZ2N1<+G|*V,NW'F-N/F:GC?;|) |TW>+&=6!UQ4P44|J)K\$G5UV3TH^5;\$FAWI(\$*U;_0I%,T.D/20?7|D|)0)* MHE2S4;4=MA|H&#R'E&Z8?6.@HEJPTZ|D;VH5QMPLS(\-)L_KKQ;W19;MUKL5 MV7/H4AZ4)J\$TA:*9D='6D4|5R,FA|A%*DU".0M,_.SNT>PS"%W.&1%VE-8! MB&S|([D51U&H%2|),QBAME^XV6<=H(XQXZ^4^<)(Y0FH32%HF1T08QG^K2 M,X0Z1BA-0FD*13-#I!UC_+2, [1K+HF\$011F\$@G5E\$)|@U)U)XV6_6Y#2C2SM M^2@|CY@T1486B|NTB+2ABMR&RL^YY@+_+V_P?>7053@H3;#H9F2T#8RF*N;H/X| M2I- 0FD+1S!|I_Q>+^&_B+I*WY|W|P0A8|9UW9PV6Y8DUO2GHF0A|YN\$C+2+ MBMPNJILE3CH*_V_P\$(ONMT#I"D4S(Z.|7S15S68\$-7U0FH32% (IFA|BU4_&M(I^V4)_0W731/Z MW39=|:QQN(&#F|R-TB0U*4RB;&1KM J.IRC0C|V\$TB24IE T,T3:'D;CRS0C MNVJ2<TOK%A%)"QA)K7PMR|);1;3X(62)8|P96VF1%;|E3A-GF1^HNA4)J\$T MA:9^UQIFRBF|MH44+| (I4DH3%#H9HBT7Q3CJS:%74"YKZCJ%EY1,F80=A^R MV+=O#B%D0HB^Y0ZA79=PNZZ3>:D.W\$?8/'8A*Z^06D*13-#I7VCF#I>4T - M|)0FH32%HIDAT@92C*7%;|I\$BLG7 H5>1V)T23_>UEHIM!%;FPC/KVQ!:_ MD0FV(R.G_&'K3|)HQWA+R7;YKQOIV[W4?8?#XA*|06D*13-CU=IB<|(|K- &M;)&WV<1NLSF%Q3:4XKQ99N^VD333B&\$RMHG0P|N)/Q|M@6^UTEZEQ9A9V560IK|Y;0A59,R24 5)8'WSH&3|F^C\$VJ3%;LV/(N<=#/N(PX= MHE";A-(4BF;&300.>*|JSQCJ-Z\$T";4I%,T,D?;|?AJSY@HY(RL&U@<E7^O M>M3-(<36G/2&WXO|Z|LTC;5?B|U_|2_^_KMW|URLUO<|Z0"ZK >E22A-H6AF M(+2C)*>JY8RAWA%*DU":0M,\$&GO&(&OY8R)O32%O8\$G(8NL1)|R,+&OJ>_ MDD6BKSXC;CW|P.W VDGA'.?AQ@T>@="U|A-H6AF8+1KC+QE?Z9G819?<P(C M%);MH8|&;KVH(E1)|XJLV5_MK1*WM^JD^AW-"Q"%2@-(6BF;'1=C"9J|L\$S M@11#*\$%Y;0I%;T/4>F|^"+/A- @:DUG611*6+5A)"JTESL(5<3ZUDP3;T2 MM|6R<1|ITP?=<(I/2)2F4#33SF87?&ZGJNA<OGTAE'A-(6BF2^2OG Y0J\$M=-I^JK|>4F(JOJ4Q(J9MV|I@&5M|Q|N&@|7WV;_%0#@^U+|SY_WE6OC|<^ MONLUS|F_<GPR/C_&S?|Q6U O^<#^"W5X?Z|QUY=Z2|I|GQ:K|:|T-MGG^E#^ M? _W7*Q7C<75?YT>+K|KWE5Y=O#CX|9 I>5>T^|JY7KV|V!_@2^<^+IS M_3|02P,\$% @NX#^6(#+=,^?>^1^<1D |D |X;|JW;W)K&ULM5AM;|LV\$XKA%#H4+;|HMYLI|:|V-*#M@|LO,CZ8=@ M1|9MHI+HDK3=^N1DBQ=&_J,V&?;EEJCG>:B|XUUT-SU2|I5O.1;|>@YX5? &9M MA=A=.0Y/MSA^W^8|7,@G;|R).0MVSA|QS!;E:0#|I/\$?LWP7.Z%F0>NT<\$.3T|J(KYO)I9KGHC.G.%4 DD?PYX MB;- *BMB^/JG_6AHOC7E\$"|J|H6LQ^9FC2VPPENTS0=@/Z.M M-X-"I9?2C= P;""I|J\$TCT7-*_)@UR4E2_ZOMB|8|D7P:H+7)P1|\$/R: MX/_L#D#""YVA| FE^8|E>VEXV(DT'SZ\$!\$PA99|ZJ+T2LF6 M;#6.BCW@LFG M1+X_?X?<^"X"|X|U;_&_0|LM25\$&3LOO8RP0R?""7BXC|I|MQ_6T^<\$&.R M3 ::3QTAWT)I.6F|XZ+T7MB1Q_6*#@<P,C|Y.Y2;#8I-BB2&Q3G""CC|D/HI6;5)5S&CDJG^_QSFT(70ED?JT;L M|6PR#<OJH^+I+ENX%G^<U08HH-.0QLV(LZ586-E&CE0T\$57H%|@83>U\$Z788Y;|7D* K| MB;O4H\$WE;*>5PRY1GC<|XNM#HGH^YLEB^<BHP;HP<#QJ9|G|M&9,A|[I(DS M^1;%%L B76"=#I*Y;^O@3 5G,|P|VY|1|O\$4I69-4^<P@ M_J'S:A:;%0M,.76#81W#H3W2@6A%#C85(I-JL5&UQ)1:-T3GQ@T.MA|1#&B MAJW,C_<^1? OJ?D^0P6!+K6ODN0&"/^J N%"G|PMEF6YV ML|CF/_NXF52+C.HEIM2ZD3@W:3|K8|@M^SJA8;54M,J7\$#=[.AX& 7,EP1 MHHO>|QXZ4&6A|JH6:M,|IZ|*%+0UO- 1&6DTQIEYIAMRADR|RG=#Z* M86K6S9SZNIS.|M87|&H)->NQFFN7H|.S?#44OT^L0PH,KR66|GV2\$|/57F MZD;073E(?!:"T+RW&#*TPDP|Y|,U|C>|)THS9HIOWS_P|02P,\$% @NX#^ M6B#P#NDE!|1@!D |X;|JW;W)K&ULM5AM

M;JLV\$/XKA*8,+<!)HMYL9;!!E*Q*#@26L.0V8=<@VCJ;0B516F[?>C7BQ+ M,J,U&?>J]GG>4[!(^ ^FQTI^!)W)]JR]*LQ:P@6W@ \;FX8W)FM2KK)(. <>S1*##9SXP, ^BG60\$BK\$ MGPd<>6>,2E>6E'XI'Y 6<!,NWP26(E2@LBO JQ F19*CV^>J)&[!,D=L%P01_ DK7858VI=>:P(2M4W-/C+] XY)=Z*YKRZA,=VQ@&VBU MYX)F#5F^09;D]3?YUFQ\$ARIUU 2G(3A#@<O<\$P6T(I(O=;\!J"][T6_(90N6]5 MOE<%;%Q%!%C- &CXB5*E6#JXK=KJAROY*"/@/LFGB>2)Q3T<(-# ^>F=1LM' MJ)=C >AM!((D*7GGWU^B-#;- ^_0&Y3D2#9)4QEC/K.\$?%(2QEHUQJYK8X3 MUEQ2TW.QVRX.U]16)*.Q*CC"MZ3CK?>.R?MK9U3PUWUN(B=CQS;130<-?_ MJ-1\$-J]HKLJ= _V<]P?KUFZ\$[5%P\$SWW"]_TBH2[9; EU16FF_9/_\A*/) M C+<@CRKJM:ZGUBU3W14OR KFALEQ^'-@!C,6//^# _EFUY3K%(IUBL2:Q7G^" M-CC>F/KIGBHO7^Jv7 Jb7@/@6E)- EJG9TE/S<[ZT]D5:U6)=.OT8.<8.*^4^1IA72^2J]19158MUJ?5#=#IG&A%,IX- M7-4/N'F1#Q2PJ7U1-"A@?F!W+GJS'PJ8%YB3)_+IN3;'X/71[V('3.GE* _9 M1TVG6]15+=.EUH_ N6[#_FME ZU9G5:U2*M:KSNM'Z)S88=2Y/Q;!!U9?Z@Z MM8/U:WQ@Q7K4=GCKMJH9 FZ07Y+V#;).4IA(TW9YD3&CM4JYWHB:_%U59=4 M")I5PQV0-> 2)JO*16G26F@[?PO_@502P,\$% @ NX#^6.XYD 'I @ M10D !D IX;"]IW;W)K&ULK59=;JHP%/TK5E9- MG<3(IZ&C*#+Q-6W3NB&[;@_ 3'DRX)%8=FJD.M/OUly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|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v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f9<=5.3L];ZR^L% (SGJS8KQ&_B^*HB\$3^ M7^&'0'9'=M=ED7) WO#RAG+JZ^@?Q2VGHX^U;]N+ [E^Q]0B7L.HICV7WY MV.*OWI<^>)-IVJ]J3ZTCGOZR2^>,"GJDEF\$Y=>4O!>JW8CMGME\$5M]7]"JEF M^X:S]@GD?>L_CjJ-GG5?T==T>F06- Z8K_(M7XKSF;SSV]ZC]C6]=>.>ZCW?Z0% MC_MKZOY+>#V^NXJG0BM-VYO2^DN.3N77+1I&G=;VMZE)F#1\$Q)5!OZBG MU_9>I^W- N7O0VG49MYU;_f9E.3DXB:VJ

)J4@AIMV ?>""8 M[1?]H:."AG=9436U) !7DQ?.S5)F87*FAHG4(N) L-Q9FS]*=#HS/W#Q.R6 MLKQYV\$^C)"&B8/&59HJ]6S%[M.-1 \)* [_FBF3YA2W3I,XCLNB?M8PGH@EM M"EBQ #8L0_KR+BF+4&5X3P0ZL5 Jj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~?JMW_L0%NAPMMD=%Y->80^ (&*/U38_4*DG]BJC] OHI^<QJ^V^A8""!JIT5W10^5%P>@!MM86D&IM M5-.48I^ VT)MK2TL7;7AOG6=I40)AVMMPJ-Y^&H?(OFO/4UE36TLX)Y06VL+ M2;4V*FMJG\$ [H2:IE_!C5JX<5WG_40^X9^>(>P>L^>7WAT?I!:-2%03:BM M2>XDNA>5-35.H40AVP.M1OR*ZSH/L_.E]"&Y_*P51#TJ]->0KA*^0H M" [7W:86D3\$5E38VS=2:GIF85GM:LT"(TVRVCID M..!^&Z-USKNT"/@CB=PI2G?E*9.PBX=>ZGH7OP9U,Q M1,=>4N99M^Y^H_PADVN>41)SF)Q@+T+VW*!=*M_&J^1^4Z3;ZM;PO=VJR-W-H965TGWNNBI=D1RKGE@3#B;+(7.LH2F7KEI+@C+& MRIGK]_M_- \>4_ .8IEW+>?"P*S2@GUQ*(L1_Q_#_TE3&PGCN<!=>50Y4];#C<=> MK_&2W)]M]Z6T)KE8FA[LJ.)D.75NO/YR.ME_L6I7J1L;O!_3.S-M- G'Z9D*\$D50;!0Q_&S(CC)DAF.9#]>G4(0VQ^?VD?FFI@Y=IK.A.L&TTZN) M.W01A:X8/I&:#^1RL_Z6"*?N+MB4V"AR4%DJ+O">+##^+*RW_6.6A00"= M=H)?>2QJ00@:(@/P4LCAI4A&F\$046PXMV2NTU<@<C6.QU)LD314H^2_2_OY6 M#?FBW_R36RUAE /QY>82005LX^&X)5(0EL JW0!WOC&S.P&LL.W2:\$(TI M4^L@X.XVU0;1I&=E_JG* K@37^X7F"/9 M"S_JYIUW%(0IT^RD54I]3\$0!>|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v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|BZ)>BL>_L3U>V@N!>E>G.Z+I]L6I/60K_4 I52A-G+9#) _JHF6=MEGKV M9M^BY%P=+SE0UQ_*8U :A!(\$E^91-%_IVO7TSMH:PJEB=-VB\$0%-7^07INFORMVO4_5 M).S)^UFJU^4VA%M)POHC4%I^H34I]ST4RA:~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a2Q!>4_GM@<^9YL9(< MOX]U.AIOH:VT_JETGP.IA;RMDI\YR5V(S-48&6K\$INO\$MW#_F64!|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~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`^UU&^:I2Q_>+;B^VW+G^Y MDE5F%I=Q^I28D^Y^I^02B^HID_U%:I4\$V^:@94.Z&^!=5JL;.@M^)*BZXD:? @3 MJH:A7410Q6J^F^E33H^L.U00RH9D(U^ZK94,U!>7%@U+4FUS1Q;X!#^-R ZO M&513.FUTDS:I+;U.(I0A^;K14_Y_.B94XLZ^#*=4U_ M4\$V!;B14TZ^:#M4,J^9^-0NJV5#-06GEK!;M37+_)^P30UNOZ&^2ZV^[-/71+74]^!^=A>L^E3AD3!S? M,K(26+PF&Q;RH+)=HIYN^S^IHFO- 44TIB+VCQI\$S=^#YTI^&-1.J65#-AFH.M2MM^MG-P-VN^A:OT^NV1V^#AN_7AW9SI^U2P^~\^/T.MBO7M>D^TNJ>-V6KIS= M7=X+?G23^3L;KK@? ^9QC^F_1>VH!|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~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

40+>N\J:~&9->F5C0Z;9Z0R;"*~R5T M^N^U=Q^T20ZFX%\$L=B77031MT4U+=UM0EO)=BJ2.Q#L^KIN"?=>SJR16J5ZKE MQ96JIDBTAOUL@.];05\AL;8S%(DCL0Z268-D1C8+&16
L0^Y3D2-S8U5>B@ M2(H5.U5):E5VJ)K1P=~^@FIV&^0\#L3.8Y@>|J\ MHR:|2.Y>|K- ML1A5UH\JNPUPA5>0UG >P\ #L\YZ5128K)>@>ENJPSSC; M8=
3\VFEE2AR93\182HF53\B516T05>~*SZT>49>R>8&8R:ODHH|E|<~'P2|ML YL^>=D- (17T:9-0!M%<^#AYA30!<^#K80Q\WAV?>D>K^G JELKM2Z?>~|I&C?>N.S\DXW#>7:#
l+>~^C\$X\$DK^U>4>@V+>W+H71-5>XK-P=O6:CQU.C|I|>~&LW1.M|T2|(DH^BKY8\150649V9U>7%#&~71X5-78N?EY1XZ M3V?>N9 MLK30QX\45L#10 @+N_EBR:T..;P0_L8 9
>@PO=VIR:W-H M965TOCVP\$BT+>|0B/9^VVZ\$?B2ER);R.G*1.66T^O/O3R7.N:EISO^/O.50@)\ M*3#A.V\$X)8&@Y3N8<<+2C^T %>N;~'9'B)=Q@ M8'N?D/5A
8'Z&BZT^>P|X|90+>F&A1?>|R|>@>U^*=~^&Y/C(4%3);%>=JLRNRLR^ M1\$+K@>Q|O|>@>@>BE^#^2Y1M^ ^DPI^>5+-34014706@>^V|>+>^R110>?%>HRA@>=K|IYI.M|7/2
|T1M2D|PUTI=>J K|K|EP3+M&BH?>@>^O4IO V70^ MY&X&Z|NUT M<~%QO4 W^#~\$Y@>E+>@>^Y8H4@>Y8EODS^~^R1I2OYC@MPD6 MY02+>8\$URA3690|I?>= 4 &08?>
O2;C=U|>@>N|W@>F|J|3T:3;1LO LU @>5 (9_ZEN4DDQ4)>4TX39TUA MGK1\$;8)%L%B2V^~@.WK.@U?7?F-LMD\$RRR^19: FN4:527;=3Y.ET6=>\$.s
Mh\$NY_B_X U>|>IEN\$-85BBBA=>~^?W6#>~#-M4QO:C.MP^M.72L W#5B1X\JGOMNV2P+M;(+%EL :Q22|_2I?>W\$K1K08|J15M.@J6FP+K5FL@Y.._Q%27\$7IUF^C4=B2
M(8/1L1H:C|I7M1LOWZP|R/X,9);+>+R^IWOQWSL M^RZ_LUI0PMP49+K6)RI6=>DICV>_JE|LZMHL2VT9D7W+9H?OKPV=|:|SRZ6
M3;3("EIL^ZU9K^W3Z7>WG;T?>7^9A:52HM^V_ODTT^Q?>BP1VR16_K_YV MQ^PEW\$F57P16*9\I7F4E^E..OSL7JT/BF_MU.?>K2\$K V+&A;8C@>~^N^V_WA_Q6
UD4IDYVP<@>IOWIDP|P<~^?ZROMIU_HH M1Y^M^OMIN4(P14P9R;+>2L7#COIO_I_P P102P.\$%> NX#^<6BMCQ?<M^ DOX_ID_IJ:~IW^WK^ULQ5G;N.V\$T/5
M0ET4^9I:~\$G\G\3H&L|F^|>~|P7|I22CQ2\$MCFU9=>S^G\$+>|>X E19>5?>=H M\$S_8NG_PYYOQ^_JOI^7RFUH^|>X^B^F|UBRU7I^YK@J6L&J|(B80XVYVD^NF M50N7+66P.
T:16YU|>|>H^KOY^E.TVL|LP5_0719|T@>^B7Y10|W|E|:~B1B&322|9Y6|A0^*T6.7I ME^>O|D_>~R1 3XO5<~^IY=PWHY@>~M^L|L2|Z;99^S%EDC3&M^0^1^OZS.._L(K>O
MTC+!@>2^%V19CQ2OQC2971%CCXK^LLO 0 M%>0 \$3\$-(F^*~!\$PMR1PE0980+H^BSI1D^TD=B^I^U^-W1VKE1U)E:LP#_M^92H KD|9_+S3_I
<~|16|&4M->9Z24_>=W+M1Y7Z\$X33%(E1|GB|I|>=&L%Q5 MG&A^77_614FGO?I^A%>D51^~^5\$4>3M9E|<^E^M^JOL\$SQD2IRNK6A.M65<6>8\$.._UGXG9GQAI?>+
XAD45PW<4ASWJ|D1UT9K+ MOH-O^>Q5VZB>70|>28Q14F0)K5_11Y6FSGM^A-2=>=;=>GONOE?|I^KK\$+>U M2BKW1J|1H8K50C^>3QS(8&J_>@>MH16?H7;6%5F>D>=0^/9 ?
^MVU|I9:2 MD|IM9NX-|5>|>76FT|@>N|O>_AIV|>~|HH20_JX>FIYXTM^K\$K^I:7U^X-2EU6G;@>NM3E|4OU6AV=I_M A;|37.TW_7FDZ_7W4>7G08=HHH?>X#AA5D|X&O^A%8?
P>|P^>~#2=NJO:~\$5J>1-<A^J\$FU+>W1+J0E M61AE6MIEFZ7WTS:~%I\$>S^RBEW;@>V^K.WIN EM^>3|J3V9G7H^DABUZN^MH=51 MNIPM|VXK58>V=|4|AC2J^|K973EJ;
<~|J&67|C@>1U@>B6PO?6_VWY^+FJ8O M&+1W^U:~?4FPA5:GJ7Q)H.T.WY:UVW^Q^<~15_6I>L56_IU:>^&K/M7=>XN_I M\$LS&PO=VIR:W-H965T2?5)9P^&W= M
M^Y>9|3W9Y\$K\$A\$5%>5%615RM<K131UO\$S181_>JPRX<5C>W:MXXK<^&X\$ M7^NB-WE_U?7P.SNXG61A&.MLJ_|C/9JNXI:V_6UPU|T:0L|Z&9%\$3| MSH95W
N8|1>3>FEA|I|3|9&?2\$..%UB|8@>L#^6>@>E^|U|>W1^A&Q?>~6 MG%ZET@>+WUP_LKYSOZ_LU=U3^5%> NX#>+33Q_O1(^DNXZ>9&|EY>Z4_?ABTUZ^Z
M|S\$K9P^>+C38R+>6H012ZBA5C)^%56&MGLPD7H3>3<~>Z-N34\$1S^>F3C@>I;Q4)DN3 M_~(7%>A8&2>U2D\$PBZH4^>0=Y1L|KR^M=H@>-+1*L_!0\$1Z^&^T
MSWYB>RT8454RD>+>BT9_A7I_VV#;~?>3XOY^R-Q KCVY_0T&068^Q M2^~1 B8>~>C|>M=>_R/|B|XV13|L-F2-LEF+9^5TM2KMH0AYZ^?C#>#>+ MLC^>X2XQJO8 2Y.I
(@N9H_L-G_*1.XAU,BP(\$>0<~L:LIH7|@>U-O7T38_M.EA?V_W4^ISG6%=>)CF4.3001^>KUN^SIH@_&PO=VIR:W-H965T-1G|VX>~|1.0A1Z^G(FY|96J=W4MF6Z)066-
WQ^&+Q95_\$.Q)Q1D5N>XX3V>6\$FSK|KJDK19C04N64D3N19%D46^Q9DPI?Y19K2<<~ MTLU6Z0EL=O^A#>GDZN_>G8^1W^DM^1.4LZ0L.NY|E|=I^>S3I_*#G(DV>D
M(WG@>~\$&K.YY>@>9D9RD2C@>~N3^1HU|I^E=IQUX^%Y M%\$S|_M^TAH+>#|ATKRIATHDS7R;T2|)^G5K1^5XRU|>5>3?T9P^MT1G@>ZW6.15 M3|2F^16Z1E|R..?>
9>B0+>2E9IF\$<=FEEXO\$>N2W^O^>UJYCA=8UK^ZEGE^@>QRW.O=>X7R<~M^2^0^O9^X^>X5^>=C^>1^L;HTJ8- WP\$&W212R|L.Z:X) S.A.G13N<~I MF500R201>V(M?OW%#9W?
35H/218/298.1^6E;~#2M^Q^FEAB25-T|H>R1>#> M\$P^>~^&+>#~:~M12C&@I8\$1^>DOIIY^C@>Z^>C^>O/Q|>C^B_YD^~#>+ @C\$S)
M.2PVL87^V#^>2.VL>|&+>O.CE\$KQZA7CD_I^%>X^HC(Y^Y+N<4Z8DF@>M>(&P.MA&_0T.2)B)1^>@OBZ@?*=|JXD M40|11E?246Y%2^IMT^#2P95<9>~|H(TV\$ M7D?32Y3D=>~
^~YJGER^>~&)>4^CWR\$N(15DW^O(AZ^1HO|J1O^QV^U|>~M<~>BQV^>SBR M^Q^L_OVOQ>=>@>^HXIZ_/A8J9H|>9|JY/S96^>?%>A71^>|34YXVQ^>9I2+>X
M2+>|D|>+(\$S5MG|I)(7|>C^>+>VBOQ959I|U7|H3..==>Q^NO^H|E9@>ROG9@>O%25-|JXHOJ|1^>X@>HM|B^>R^R;1&@>#O MUYRKXT|>~C^B_!4\$1\$|10 (>N_EH@TW+7|7@>0+09 9
>@>P O=M^IR-W-H965T3J^P#W\XSN^*6|HHH^?>I|EY^BU|MEXX^>~>D<<~&3^>R|>? M=-47#DU2YH3^+>8\$1>1>FK>=>~>?>T| LO@>S0T76.?>
2E24AC+>B&58%|J^4WS\$W\$>@>XN^R>KRZ%>~.P9P4HOX85|E^A=O4_R_3^>B.W^2|E|M^ND NC11<442>~>(&?>P0578?(P1AUG^29I?>7C<3X^X<^>WV5Y+>@TF#A>N_MR
4YJVK9M^>6R_00+>#L=P7S+0Q3E&KP<3^>ZL\$|H1U/V7_-I20812|M@& M^?003%U_H^G/|>_@N0U<3\$>G3O_>_DS;W@A^4114HON|246TA15?+>N7<~M4 KO1M4(6#Z^IMT|?
%#>~T(4^>W1X(22|>EQ|I154Z^>M28Y|L-DF6&^>K)Q7%0W^OOUX1YF<53.JI^S=6D1 M&4^?%|1%6>~>P XGS|S9:HU1\$=MH|AK\$>5\$>42B0B^>N5Q&8-0&0/&~
M8\$X8EUIU?O^A<~>52_>?>TO1^>E|LDBPO1-9^0UBG(7OG^O6^>M\$D66R2+>#%>M^DUKB|JIBR+>B^>E(RCQC/M=>~>1\$9+>~|4G79FP|S_2C\$S1R1WKY&~?>QJ&V|U^>X^X
M^7#~>3^?7C^>7&F=>D=C^Y+E=6>E1:87Z;NB=AO_M79_7W_JBC^B^>1C|A^>I=W^#>~#LZ5|FL4V6_W^>N|S70|U>~MG^M.URH8-MZ,RD XC5W M&=VOYGPL4IYN7>83U:~?
V^X410K9<~WWO708_XF 9 M^>P=O^VIR-W-H965T1^@>LPI:~8B4H;~>^DNW\$R^>~Y^F+>A&1_J^>|>@|I9Z M6|>~>J^>C^Y|C_#RE^>U4VMQF=>+|~^
>I2M.Y#>=SRGPDV^E:U/B^>8>0\$1KY7 M@_5ZJ^>8CEU3ZO>=>#B/5I=>^T^E^>1 WSM^>XCMIK^%MI<~5J^>JRX=>=+>(6Z4.OW M5FB|QUA.5B.FSVJQ^?>
U>~>S)N8^>A^6W\$SKH9U&E\$(SXR\$5;GCH&^>L|J4TB^>U MNN<~>P<~\$N|JNSAF5 ND/RWP0|>P^WN^>=5A@>#RR1<~J+>BX18 M<~>|E^>FXX^>X|L^>E^>
|J@>~|I^PORK^>S^R^>A5ZL+0|30|^I|2_>|D^>(4&^4 M9&E^P|V^P^>P^53^>D1^>PY^>~\$0<~&13M^>Q|C^XJ^>H+>~^I^H=>K\$D5P.X5@>78T.O5 M&=N54^>~LOM0SAV|EVX^>AF@>Q
5P^>P_3+Z&4E_PU=HAFKJ_VJ9AM<~MZ^?ZB|6I_ZX#6^>~\$>~Q->#>+>1>+>25JFSQ046CVFKM^>M5:C51US|J6WBURU1^>5X2^>4J|D|2\$>8C&5&57^>I=6+>~MG?
VRB8#_>J^>Z^>W=|V|B|?2<~^YB@PIEF@FY.0=>=>(P80P^>+>XOZ3FW^>A3K& M.EBARU8^>E^>6K&C1PIXW^>T+>H^K+>J2^>O&S;U^>K^>P_+>J\$2 EQ|10^Y^*3^>8Y>~!>7+6)W7R
M^>Y<~Z_>2.8:(Q=@>I@3823959.A6IYY#>=S)O-O2YMQG|I)9>(+>M\$M77& M:F.Z.Q_HL0?U=1H^>U|G\$>R3RX2.02^>SNK^>WD43Z9^>
M615N^>K7AC&6J>D|TRV+>+>6^DT^S|JN^>_>P|>P|>@>S^>E^>S^>U^>_#>+>#>_Q4RI0.W> M3EV@97G+8D^>3^>Q7OQ89+>669E>2\$>~#^|W|>ZDC(DY^>+>PQ%>_I^>IB^>~^1^>S^>#B^>IKUU!_I
M00T=>K7TZ|J_40:3\$0>2+UH2ZT^>F|>=O04ZEXM^>+>C^>Z#B9@>MBT|1.1LT M^>3O0;08BDSIU+Q-4>UO-7LYN5^>P0WG1^>G|G|LM5@>I@>O5T5G>~AGIWH|JNL M_TYK^>)\$SI=YIF
2:6\$2P^>Q=C.S.6612_1>99YA5O9D<~>5>YV M1V:(HY\$3>V69U)Q|T^>H\$A4OQ^>V|T2(K26Y^>M^>AWNO\$O-FM=VYC=DER+>+^>K+>_M3L2=>_?HWK(7HN@*?2Y|Y=L0_1/1>9M^>J^>@>V|B^>N(N(6^>
(^HE?G5^>K2K|L+3X M&E:98SUS_U6MM?>4W@S05|I|J7U|B\$46U|P4G\$0342XK26^>~>C^>BN@>N^>N6N MWULW@>W K5.
(F^>W)DEI>7^>|1QX\$>Y=UJMMF2XLW.P4G@BZ^>08+>3;D0U^>EQ@>Y M^>P^>D|O|Y|>+>E1^>T^>W^>G+>6_Q=02P.\$%>@ NX#^<6|BOB|I_P_80P_ID M
|X^>I^>W^>W^K&LQX\$>M;~>C^>X\$>KX5NYT2D|A^>D8H M^>12^>DQ|N3U^>H^>M7NA1\$>~>C^>D\$K^>M^>IQC\$901M>?>8010L6R5D6^>18^>G:21G|L130K%>P0\$>H^>I11VW-<~MGIUADEOAT^S-
>#AD^>TE^>C^>O^>K^>+~^>1_>@>+>~^>R^>MW<~>(#62R7E7K^>#88\$7^>CR MJ9A0Q^>KEH1DD^>Q^>O53SXE(O1@>#>#>C^>MN=0=6^>VM80I4>B+EOK\$5IU42H^>|XOW|7|T:TO^>~|4P9_4H2N1Q9>20LED.(5
ME01L\$>4>+>~>V4\$>~^>TJ6P^>~>U70K^>L BL|^>7W MBML>~>P.M+>P^>X^>T^>M^>N^>R?>|6D&ZEP^>~^>F^>DVZ5\$>I@>(2OP_>=L@KJT5^>FQZ8|NTBA?>)=9X2JYV
MB<~>+>@>~>R^>~>Q^>M1(4Z05.67P03V^>S^>+>I|J@>E|L|>7-7.4&~>M5387>~>?>A\$D1^>M^>|DZ|G3^>2#>A+Y4^>S<~12SSH^>7\$|B|AFL^>~>6V1_6GV0^>MTG|FV?>~O|I M9KE<~^A3G^>20-
~^>@>=V^>C|VRL=>~^>V7: F7B0A/ZN@>|S|1^>OY7K2|G^>D^>Y..T@_MOS\$POTG.KYT>_3I|N^>PZ|SQ#91^>G.6F\$5.3.3.5.5>#HC^>G.%>~>7^>OPC^>M52^>XWG3S?>7WE5L7QWM1X^>F+>%71|_U6.\$?>
ODI|Y^>FL^>?3+>+>H^>F67PELH+>MZM87W^>U^>C^>Q^>+>+>U-0 BN03+>+>Q^>~I|N^>H^>R^>RZ063|LZ=>#1.5V79>C^>N|J^>M0|H_KX+>N|Z|I6^>2JCM^>I0^>IG^>PSBG61DMLF04^>3X^>Y_K/BSV>1
|63L M5FV_16I6Q^>0.L64|CN2(ZV@>+>EH+>+>CM3-T2B08H^>P^>NGV?>|>WHJFWIS5^>K^>M^>~>778J^>X|K^>OZ^>N^>J^>R^>J^>G^>=H2HS^>TOU:3C\$>90 BC5SEI\$9RWB-HL^>82U:~
M6+15V^>X^>O^>CJN_5%~>I^>Y^>EB^>66Q_4^>5?>=GX1\$^>?^>OZ>2U2OZZRO>~>PG4I^>M^>@>6@>2O^>H^>+>V^>C^>1^>#8^>C^>O^>A|>5^>2&~>6&5^>7^>+>A&L5^>1^>M^>~>+>@>S^>P^>UB7L
M=106|14^>EW_1E^>T9P514^>O|J|>P5^>U^>VIR-W-H965T19:RC^>S^>P^>~>S19^>LYE^>K8U^>B^>Z^>P^>INX4^>5^>O^>H^>U3V7=5@>D W5F^>6^>UK8 M@>W^>M-
ARGRKN2TPQ04|B4YGH\$^>A9WKZ:3%>IR=GGZ_01AAIX(I=I|I|2F@>R\$S MEW?Q:IKXP0?>OOV8VBX+>+>RCP@>V@>_CT.7T^>M^>H^>M^>W^>?>INE^>1^>4^>C^>G^>(SEB_>M^>@>~^>\$.>6\$&~>I9D3FE.N-
T^>7X>+>V42NC3|VLHV98|&F8W-^>)^>C^>B^>F8-OG_2Q M^>A2|?>~>8^>F4^>~>^>40I/9^>N^>M^>A^>28|SEN^>M^>3^>C^>BF@>I^>O^>P^>+>ZUBFP5^>Z_1 MM1U=8^>K^>~>3^>WFM^>6|1KBXVJ>1-
X9RPUK^>2@>N19@>O|WOG^>C^>=(>G94^>5 M#8>UQ:VY^>^>^>BV6^>*(OHT?>6G^>=>#>|>#>Z^>4>A>OM_VX^>M^>W^>P^>N^>P^>E^>Q7EP5M^>W5 MAYOIE<~>K^>Y^>=O^>U^>VX4^>4^>VRIM1.2\$^>P@>6.
(DHK#3=>+>~>ULK9>?>I|LV>? M^>4(MBA9P1^>N^>VG^>H^>G&G3^>K2H\$2^>J^>P^>1^>C^>K1^>E2^>D1W15^>D^>(4V9>=BP^>M.27=1 BY_Y^>V8&+>U^>H^>V^>H-
1309F<~SNEREO^>F^>BQ=7@>+>3759<~>6%>C1I|U M9^>D YU944^>T_?>78^>~>88K@>615%>Y^>C^>O^>~>W4^>Y^>Y^>W^>M^>M3|D2WF6^>G^>BVLV03^>4^>Z^>@>9+3@>I@>DG^>(&^>I^>SFSC^>XO@>U^>|I 6?
QXXR.X8F5> M^>2|N^>C|G<~>V_0=>R^>O^>M^>I^>2U6|N1^>88.KJNYX7=H DJ.OXO3?>~>C^>QV^>K^>RBK|.^>I8\$16^>U^>WYJ M\$M\$1^>|S90=@>(PE^>51(T@>LH^>69^>L.ZSP8B^>X_0ECK.V9@>MH^>#-
E7^>NA MOQ^>M^>4W^>O@>~>W6^>~>609H;5?>9U8O^>Y^>F^>I02>~>L^>T^>I^>5.MMI(413FKFK^>~>ZJ8G^>T1_5^>Q?
MX7250C^>1^>2X^>~>5K^>M^>T4^>58>~>CW^>_Q11|3T>~>IFXVZ^>4L^>09\$1^>1^>6^>S^>N+>FV^>H12QP^>71R M=I2(J\$U\$>G|HJWY4)2U=>~>REYN^>J387L M^>3^>T=77YEWV^>FV9.6W-D=4<4L5_QH5
MJEBSN5W^>I9?2@>DOH40C^>K_SGP858NYUT>1^>XDY|J|>L4C<~>8YD^>Y:MN0BITU^>M^>8|8UFXG412^>|N|S|C^>_>(YZG+55TK6^>S^>F1WW^>~^>+>U^>~>7^>|C^>A|?>7^>D_J^>J^>W_Q#1#^>7^>I7Z8G0-
&P^>FZIBUO>A^>H4R448^>Z^>~>ML(7^>D^>+>1^>T^>B|AID2501^>TAVIOE^>_J00: M2@>EJ|A^>|Z2VTS+>~^>I^>H^>M^>~>UEPH@3_>U+W8L(7|4.S43>~>QJTEF81^>8Y<~>C^>=N^>T^>C^>M^>|>O|>S^>DQ.D+>W70-
M^>D^>QTEZ^>K^>G2G<~>=H^>#.(8Z^>S^>M7\$S@>I^>EQM3?>LQ7|02P.\$%>@ NX#^<6M4^>~>V5Y3 P E@>X_ID_1X^>I^>W^>W^K&ULM5=>M_L|P%>TK51@02^>~>I7ZOK1OMI4
4.5&M&CP@>KSDMKM^>P|>F^>T^>C^>+>@>PGS9HN M^>P^>R^>P^>E187I\$Q\$>~>Q^KYTYV7^>R3^>81^>|S^>+>Y^>I^>W^>G63+>X7N1N5+0C^>@>DG^>~^>I^>R^>G\$F7^>N|I|F^>M^>A^>8R8_V M^>J^>|>C^>~^>M5^>PKP=J^>C+>#B
M^>J^>HA3@>_>Y^>F@>~^>+>#>~>K^>K^>X|0|>@>I^>D@>E2^>E^>131\$6^>%P|O@>_6^>M^>V3^>M^>B^>M^>F1.GS^>S^>ZOE^>~^>S1_4^>~>6&E^>C_4AQ0B^>M|U|L^>~>R^>F7UZARR0A|HEI>~>I% M^>
H3^>E^>W^>P^>N|>D3|I^>K^>S^KO|J^>E^>Q^>7?2^>F^>YCA^>W^>X^>M^>T2Z6-01=FYK<2OM^>2^>O^>+>Z|CW^>~>S^>3&W^>~>LQIROQ8^>~^>C^>M^>Z^>U^>P^>L^>V^>N^>F|Y|I^>L^>P^K^>~^>CY^>M^>YD^>C^>F.8.OKVD2^>NP
F7|L^>O^>=NG5^>G55\$M^>T|J0^>V^>M^>C^>^>R^>F^>U^>E^>U^>O^>L^>O1T18 M<~>4BP|TT^>Q^>689S^>U^>W^>9_P1YX^>M^>X^>=2O^>@>AZH|I1^>~>I^>P^>L^>~>US585J8H M^>SE|CN^>~^>W^>^>M^>X^>WZAI=>#0BE
~>3|P^>2WPL^>89>~>1^>L^>W^>#ZW^>5.728BL_MILRH4E:4JLQJM4_35^>DL<~5^>GZR+>#>W^>D9ENI^>~>7AE1N72^>~>U|I+>|J@>CLIKO MXTKH7|ZW&7FG9^>G5\$5M.T|I|U_AWJ=)79)=?>
GAT.D0V19XJ3E=LA3KN MP0=M^>I|C|A.O.5<7W>35>5>7MJ0X&^>~>HLL6 O P_~>I^>D^>X^>I^>W^>K&U^>LM^>M^>1^>P^>S_>BA40^>F@>F^>SZ^>~>M+>~>#>~>S^>Hos^>~>C^>~>K&Y^>8P79|D/CP
M^>V^>D^>I9&EY^>B16&WG_K^>S|ZYN:G.@>I^>O^>2CT|4|L|GQ|I(2^>S^>T^>31^>C^>+>ISO^>M^>O|I|L^>NPDP^>V-W.G_>~>E^>M^>Q^>M1^>9M8380BS\$|V>Z\$6C^>168ZW<~>WB0W|Y.O|>K^>2^>8^>Y>~>8C|9FZPE?>
4B M^>.(D|J^>~>A.G^>=T^>F\$>+>DA5O^>H7|7#S.\$4\$>~>~>M^>T^>S^>A^>G|U^>Q^>D^>

-B720S3;8T.P.M6BP^0^X9XK>|9|;G;V#P=0JK16IX* _\$VYKK3N<IQ_%1CO|I\$M=U^C.FO>E&HFEK012_M_U;#Y>A>S^;^AU50V^52W+;6Y-65Z.QNV)AK6.G|Q>.HA^'63;X|4NE!_M LRC\$E^F&ZT=755172^;8P=11>WGI_U;3+6ME;6;0U|Q7N|N|K|V|_O.\$_MHRF^W6;M_B_M_RE;Y017V;7+U45=V6HU6E|ZS<_0J<2%1R|2Y^V;C|K|C|LMN?>^|_D(R5|C0_L 8E%\$SVOY083|YH&#EY^F=7<#3^S^U\$X+3|B9N^MR@_M^M.C|8(|+&+&+<L|B0@PP\$A2P0|B(|@HS>@)O;EK^E(F|F|C&|_<= 8J|3B420_M^0&9#>0%5^T|K?>^<E^<AVI- T^P29\$9#>@)=3G-|0%|P0EY+|QND54+|FVN.MP./W.35^G^?/?52^=QYOZ|F7R26HKOLERK<1_+>V;7UB|;HC8V;17^<= M|1I\$7AM/NFHOP^4A; IG6%|X|USF8=Z- <|2_>|0V0LS_N-5N99^@<0B4_M^;|GB (<K0^Y;B.4F^6%>6;9KHUV@_M 3|B|S^=6%>H65|_1^>F=6-2_M|A@SN^|_1RD^|Y4K0P42Z|_V|B5_U@|178U|R#&#>X59X9;1^>34BH8; LI.M|HZEKEM-34_0Q4M^ZTR|WR8\$;*_<=\$\$S\$X4_OZZ^V|U.D7X|PL8&D8|J0\$E=M_M0(MD0B|3%CY^<GH9\$5=<^|_RQHU|R(R#^|17|2ZP4F6Z>A2|M.W6\$23DC8^>M7F3- 3|T|_1^>S^U+>33&|0|_OC.V^>F+>ZG83R1^|_1C\$|_0|>F72|BZX_2.Z0^>E|F0HAP3_3^KG^X9U|UV43N;6_O=|B|M|7|E|&+&+&+Q|N60_-DAS@>|_1ENM;Z_X095442QF5\$R|K8^BM^L&W|_1^>F|>_<= MB)=2B0A|T@FEE|G+<W4_>5%<(D|F?&1_88DE@P2_VAO|3|_13XH|MO_6M?<2>DDY\$X^<E|<3^>W|B^M^M|YU|G(R&E|DY|9V3? <2>2&D8|C|RJAM^5Y^M\$K\$V^P^>64D-|DKR3|1.T|20DF.M9|8_RE|C|B|_R2LAL%3+|ZQ;A9|D1D0F;D|E^>=1T;TD\$S|F4Y_75=339|6V^<_M^Y\$>=5;20DF8A^;_G4W_+>F\$|@>|D&E5M^T2|JR3_>B|3|B|X^F9AHT|1^>M8\$S^<1&Y\$^|_109R3|ZD_M\$M<S|H\$|>1|/(6U5+>779+D|)_Q^R=7>|S^O8=M;1+>2M>;2|T\$S- KYX^YGS8^>E;Q9B4@6F_QTP=<>>G|7C|ZM3R&R^#0_M\$S@>_<|_1|>2>YKTM_Z|H\$|1|@N+T|N\$S=<^O|W+>2G_Q_S^<|>U@|^|*|H_M\$|IEG|E4^Y-E|U\$S^<|>3>DAH? <=<D|W_PNX2^<S^EY9|ZD&F&W|&S-2|DD\$C_7M7;3.FEW_<Q|_0;5ZFE^Q29OET_2CYC>=>9N%G(SM+>R^E|YFV^B8?^_S_MKG^<G+>2E+2D;GMTV|_#>G0;E3X=>|0|9Y_199^<4 8F^F^|Q8E;2EDH9^;0|I.N.M|IRIV_E.62|DM1^&#Z;H|OR1W+|S|8B_+<KW>+G|E(529@O|D|B=X9VR4.I|L|H3_MAOX99^>V4(T)|X|L|I^&#Z^4!7.D99^<L|K78X|V|V^>IVR4^>DOK5N15.6 MRMYP^C|UO|1|U|L&7|U|&#|DE^P|R9OG0F|Y>0DGBY8|C=GI>0?9|CET|_M=B|H;|S\$F9^>63|T@AJN1_M^A2|ACG>=C;R2|H|U|RT^R|M+G87|Q|1|>_M<0|W=V^<Y4^<1^>_&#N_<R|C|V|I=GI^&#>6-2|JR|&#K|L_HN|<1|OQ|U+>P04_M^<|_<|Y8|T|I|J^>B^<8-0^<^<|_<A|>+U|96Q\$+>W=OHZ>7>K7R2N|C|I?_F=AM-OMU_M^<V|M_Q\$+? S^X|C|Z|>72ECM7A^>U|T95U7|>+&#<NKK1W|B|X3^>X6S^V^KJ|G^<_M|U|+Y_D.P2P^<H\$SA^<A^>C^<YOA^>^|I^>D|P<0>G-0|G00Y|G|O_T^<_&#A_M|B3(N^<R|F6|H^<9^<K0_U|> <=<@>|<I|ROX\$9\$=S_Q^H^9M0_IV0+>@=<@>P|Z0X_M^<?&S_Q^H+>H+>B|W\$;_M4M|>C>Q^>V3^|I\$>@>O|J+>I^>HMI^<H+>ZBT>@>O|J+>I^>H_M|B+>ZBT>@>O|J+>I^>I|0|S@>=4>1

Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } /* word-wrap: break-word; */ } .report td.pl.a a { cursor: pointer; display: block; width: 200px; width: 200px; } .report td.pl div.a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report rc { background-color: #f0f0f0; } /* Even rows... */ .report re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } .XML 107 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.html5383291true1230false5 falsefalseR1.htm0000001 - Document - Cover PageSheethttp://www.hologic.com/role/CoverPageCover PageCover1 falsefalseR2.htm0000002 - Statement - Consolidated Statements of IncomeSheethttp://www.hologic.com/role/ConsolidatedStatementsOfIncomeConsolidated Statements of IncomeStatements2 falsefalseR3.htm0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss)Sheethttp://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossConsolidated Statements of Comprehensive Income (Loss)Statements3 falsefalseR4.htm0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)Sheethttp://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParentheticalConsolidated Statements of Comprehensive Loss (Parenthetical)Statements4 falsefalseR5.htm0000005 - Statement - Consolidated Balance SheetsSheethttp://www.hologic.com/role/ConsolidatedBalanceSheetsConsolidated Balance SheetsStatements5 falsefalseR6.htm0000006 - Statement - Consolidated Balance Sheets (Parenthetical)Sheethttp://www.hologic.com/role/ConsolidatedBalanceSheetsParentheticalConsolidated Balance Sheets (Parenthetical)Statements6 falsefalseR7.htm0000007 - Statement - Consolidated Statements of Stockholders' EquitySheethttp://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquityConsolidated Statements of Stockholders' EquityStatements7 falsefalseR8.htm0000008 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsConsolidated Statements of Cash FlowsStatements8 falsefalseR9.htm0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)Sheethttp://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsParentheticalConsolidated Statements of Cash Flows (Parenthetical)Statements9 falsefalseR10.htm0000010 - Disclosure - Basis of PresentationSheethttp://www.hologic.com/role/BasisOfPresentationBasis of PresentationNotes10 falsefalseR11.htm0000012 - Disclosure - LeasesSheethttp://www.hologic.com/role/LeasesLeasesNotes11 falsefalseR12.htm0000013 - Disclosure - Fair Value MeasurementsSheethttp://www.hologic.com/role/FairValueMeasurementsFair Value MeasurementsNotes12 falsefalseR13.htm0000014 - Disclosure - Business CombinationsSheethttp://www.hologic.com/role/BusinessCombinationsBusiness CombinationsNotes13 falsefalseR14.htm0000015 - Disclosure - Strategic InvestmentSheethttp://www.hologic.com/role/StrategicInvestmentStrategic InvestmentNotes14 falsefalseR15.htm0000016 - Disclosure - DispositionSheethttp://www.hologic.com/role/DispositionDispositionNotes15 falsefalseR16.htm0000017 - Disclosure - RestructuringSheethttp://www.hologic.com/role/RestructuringRestructuringNotes16 falsefalseR17.htm0000018 - Disclosure - Borrowings and Credit ArrangementsSheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsBorrowings and Credit ArrangementsNotes17 falsefalseR18.htm0000019 - Disclosure - Trade Receivables and Allowance for Credit LossesSheethttp://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesTrade Receivables and Allowance for Credit LossesNotes18 falsefalseR19.htm0000020 - Disclosure - DerivativesSheethttp://www.hologic.com/role/DerivativesDerivativesNotes19 falsefalseR20.htm0000021 - Disclosure - Commitments and ContingenciesSheethttp://www.hologic.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes20 falsefalseR21.htm0000022 - Disclosure - Net Income (Loss) Per ShareSheethttp://www.hologic.com/role/NetIncomeLossPerShareNet Income (Loss) Per ShareNotes21 falsefalseR22.htm0000023 - Disclosure - Stock-Based CompensationSheethttp://www.hologic.com/role/StockBasedCompensationStock-Based CompensationNotes22 falsefalseR23.htm0000024 - Disclosure - Other Balance Sheet InformationSheethttp://www.hologic.com/role/OtherBalanceSheetInformationOther Balance Sheet InformationNotes23 falsefalseR24.htm0000025 - Disclosure - Business Segments and Geographic InformationSheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformationBusiness Segments and Geographic InformationNotes24 falsefalseR25.htm0000026 - Disclosure - Income TaxesSheethttp://www.hologic.com/role/IncomeTaxesIncome TaxesNotes25 falsefalseR26.htm0000027 - Disclosure - Intangible Assets and GoodwillSheethttp://www.hologic.com/role/IntangibleAssetsandGoodwillIntangible Assets and GoodwillNotes26 falsefalseR27.htm0000028 - Disclosure - Product WarrantiesSheethttp://www.hologic.com/role/ProductWarrantiesProduct WarrantiesNotes27 falsefalseR28.htm0000029 - Disclosure - Accumulated Other Comprehensive Income (Loss)Sheethttp://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossAccumulated Other Comprehensive Income (Loss)Notes28 falsefalseR29.htm0000030 - Disclosure - Share RepurchaseSheethttp://www.hologic.com/role/ShareRepurchaseShare RepurchaseNotes29 falsefalseR30.htm0000031 - Disclosure - New Accounting PronouncementsSheethttp://www.hologic.com/role/NewAccountingPronouncementsNew Accounting PronouncementsNotes30 falsefalseR31.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes31 falsefalseR32.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes32 falsefalseR33.htm9954471 - Disclosure - Basis of Presentation (Policies)Sheethttp://www.hologic.com/role/BasisOfPresentationPoliciesBasis of Presentation (Policies)PoliciesSheethttp://www.hologic.com/role/NewAccountingPronouncements33 falsefalseR34.htm9954472 - Disclosure - Revenue from Contract with Customer (Policies)Sheethttp://www.hologic.com/role/RevenuefromContractwithCustomerPoliciesRevenue from Contract with Customer (Policies)PoliciesSheethttp://www.hologic.com/role/NewAccountingPronouncements34 falsefalseR35.htm9954473 - Disclosure - New Accounting Pronouncements (Policies)Sheethttp://www.hologic.com/role/NewAccountingPronouncementsPoliciesNew Accounting Pronouncements (Policies)PoliciesSheethttp://www.hologic.com/role/NewAccountingPronouncements35 falsefalseR36.htm9954474 - Disclosure - Revenue (Tables)Sheethttp://www.hologic.com/role/RevenueTablesRevenue (Tables)Tables36 falsefalseR37.htm9954475 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.hologic.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)TablesSheethttp://www.hologic.com/role/FairValueMeasurements37 falsefalseR38.htm9954476 - Disclosure - Disposition (Tables)Sheethttp://www.hologic.com/role/DispositionTablesDisposition (Tables)TablesSheethttp://www.hologic.com/role/Disposition38 falsefalseR39.htm9954477 - Disclosure - Borrowings and Credit Arrangements (Tables)Sheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsTablesBorrowings and Credit Arrangements (Tables)TablesSheethttp://www.hologic.com/role/BorrowingsandCreditArrangements39 falsefalseR40.htm9954478 - Disclosure - Trade Receivables and Allowance for Credit Losses (Tables)Sheethttp://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesTablesTrade Receivables and Allowance for Credit Losses (Tables)TablesSheethttp://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLosses40 falsefalseR41.htm9954479 - Disclosure - Derivatives (Tables)Sheethttp://www.hologic.com/role/DerivativesTablesDerivatives (Tables)TablesSheethttp://www.hologic.com/role/Derivatives41 falsefalseR42.htm9954480 - Disclosure - Net Income (Loss) Per Share (Tables)Sheethttp://www.hologic.com/role/NetIncomeLossPerShareTablesNet Income (Loss) Per Share (Tables)TablesSheethttp://www.hologic.com/role/NetIncomeLossPerShare42 falsefalseR43.htm9954481 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.hologic.com/role/StockBasedCompensationTablesStock-Based Compensation (Tables)TablesSheethttp://www.hologic.com/role/StockBasedCompensation43 falsefalseR44.htm9954482 - Disclosure - Other Balance Sheet Information (Tables)Sheethttp://www.hologic.com/role/OtherBalanceSheetInformationTablesOther Balance Sheet Information (Tables)TablesSheethttp://www.hologic.com/role/OtherBalanceSheetInformation44 falsefalseR45.htm9954483 - Disclosure - Business Segments and Geographic Information (Tables)Sheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformationTablesBusiness Segments and Geographic Information (Tables)TablesSheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformation45 falsefalseR46.htm9954484 - Disclosure - Intangible Assets and Goodwill (Tables)Sheethttp://www.hologic.com/role/IntangibleAssetsandGoodwillTablesIntangible Assets and Goodwill (Tables)TablesSheethttp://www.hologic.com/role/IntangibleAssetsandGoodwill46 falsefalseR47.htm9954485 - Disclosure - Product Warranties (Tables)Sheethttp://www.hologic.com/role/ProductWarrantiesTablesProduct Warranties (Tables)TablesSheethttp://www.hologic.com/role/ProductWarranties47 falsefalseR48.htm9954486 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)Sheethttp://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossTablesAccumulated Other Comprehensive Income (Loss) (Tables)TablesSheethttp://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLoss48 falsefalseR49.htm9954487 - Disclosure - Basis of Presentation (Details)Sheethttp://www.hologic.com/role/BasisOfPresentationDetailsBasis of Presentation (Details)DetailsSheethttp://www.hologic.com/role/BasisOfPresentationPolicies49 falsefalseR50.htm9954488 - Disclosure - Revenue - Business Revenue (Details)Sheethttp://www.hologic.com/role/RevenueBusinessRevenueDetailsRevenue - Business Revenue (Details)Details50 falsefalseR51.htm9954489 - Disclosure - Revenue - Geographical Revenue (Details)Sheethttp://www.hologic.com/role/RevenueGeographicalRevenueDetailsRevenue - Geographical Revenue (Details)Details51 falsefalseR52.htm9954490 - Disclosure - Revenue - Revenue by Type (Details)Sheethttp://www.hologic.com/role/RevenueRevenuebyTypeDetailsRevenue - Revenue by Type (Details)Details52 falsefalseR53.htm9954491 - Disclosure - Revenue - Narrative (Details)Sheethttp://www.hologic.com/role/RevenueNarrativeDetailsRevenue - Narrative (Details)Details53 falsefalseR54.htm9954492 - Disclosure - Revenue - Remaining Performance Obligation (Details)Sheethttp://www.hologic.com/role/RevenueRemainingPerformanceObligationDetailsRevenue - Remaining Performance Obligation (Details)Details54 falsefalseR55.htm9954493 - Disclosure - Leases - Additional Lease Information (Details)Sheethttp://www.hologic.com/role/LeasesAdditionalLeaseInformationDetailsLeases - Additional Lease Information (Details)Details55 falsefalseR56.htm9954494 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)Sheethttp://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetailFair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)Details56 falsefalseR57.htm9954495 - Disclosure - Fair Value Measurements - Roll Forward (Details)Sheethttp://www.hologic.com/role/FairValueMeasurementsRollForwardDetailsFair Value Measurements - Roll Forward (Details)Details57 falsefalseR58.htm9954496 - Disclosure - Fair Value Measurements - Additional Information (Detail)Sheethttp://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetailFair Value Measurements - Additional Information (Detail)Details58 falsefalseR59.htm9954497 - Disclosure - Fair Value Measurements - Cash and Cash Equivalents (Details)Sheethttp://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetailsFair Value Measurements - Cash and Cash Equivalents (Details)Details59 falsefalseR60.htm9954498 - Disclosure - Fair Value Measurements - Available for Sale Debt Securities (Details)Sheethttp://www.hologic.com/role/FairValueMeasurementsAvailableforSaleDebtSecuritiesDetailsFair Value Measurements - Available for Sale Debt Securities (Details)Details60 falsefalseR61.htm9954499 - Disclosure - Business Combination (Details)Sheethttp://www.hologic.com/role/BusinessCombinationDetailsBusiness Combination (Details)DetailsSheethttp://www.hologic.com/role/BusinessCombinations61 falsefalseR62.htm9954500 - Disclosure - Strategic Investment (Details)Sheethttp://www.hologic.com/role/StrategicInvestmentDetailsStrategic Investment (Details)DetailsSheethttp://www.hologic.com/role/StrategicInvestment62 falsefalseR63.htm9954501 - Disclosure - Disposition - Additional Information (Details)Sheethttp://www.hologic.com/role/DispositionAdditionalInformationDetailsDisposition - Additional Information (Details)Details63 falsefalseR64.htm9954502 - Disclosure - Disposition - Schedule of Disposition Related Income Statement Information (Details)Sheethttp://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetailsDisposition - Schedule of Disposition Related Income Statement Information (Details)Details64 falsefalseR65.htm9954503 - Disclosure - Restructuring (Details)Sheethttp://www.hologic.com/role/RestructuringDetailsRestructuring (Details)DetailsSheethttp://www.hologic.com/role/Restructuring65 falsefalseR66.htm9954504 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail)Sheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsDetailBorrowings and Credit Arrangements - Company's Borrowings (Detail)Details66 falsefalseR67.htm9954505 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail)Sheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetailBorrowings and Credit Arrangements - Additional Information (Detail)Details67 falsefalseR68.htm9954506 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details)Sheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetailsBorrowings and Credit Arrangements - Interest Expense Credit Agreement (Details)Details68 falsefalseR69.htm9954507 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details)Notesheethttp://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetailsBorrowings and Credit Arrangements - Interest Expense Senior Notes (Details)Details69 falsefalseR70.htm9954508 - Disclosure - Trade Receivables and Allowance for Credit Losses (Details)Sheethttp://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesDetailsTrade Receivables and Allowance for Credit Losses (Details)DetailsSheethttp://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesTables70 falsefalseR71.htm9954509 - Disclosure - Derivatives - Additional Information (Details)Sheethttp://www.hologic.com/role/DerivativesAdditionalInformationDetailsDerivatives - Additional Information (Details)Details71 falsefalseR72.htm9954510 - Disclosure - Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details)Sheethttp://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetailsDerivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details)Details72 falsefalseR73.htm9954511 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments

(Details)Sheethttp://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetailsDerivatives - Fair Value of Derivative Financial Instruments (Details)Details73 falsefalseR74.htm9954512 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCl

(Details)Sheethttp://www.hologic.com/role/DerivativesGainLossonFairValueHedgesRecognizedinAOClDetailsDerivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCl (Details)Details74 falsefalseR75.htm9954513 - Disclosure - Net Income (Loss) Per Share (Detail)Sheethttp://www.hologic.com/role/NetIncomeLossPerShareDetailNet Income (Loss) Per Share (Detail)Detailshttp://www.hologic.com/role/NetIncomeLossPerShareTables75 falsefalseR76.htm9954514 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations

(Detail)Sheethttp://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseinConsolidatedStatementsofOperationsDetailStock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)Details76 falsefalseR77.htm9954515 - Disclosure - Stock-Based Compensation - Additional Information (Detail)Sheethttp://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetailStock-Based Compensation - Additional Information (Detail)Details77 falsefalseR78.htm9954516 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options

(Detail)Sheethttp://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetailStock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)Details78 falsefalseR79.htm9954517 - Disclosure - Other Balance Sheet Information - Inventories (Detail)Sheethttp://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetailOther Balance Sheet Information - Inventories (Detail)Details79 falsefalseR80.htm9954518 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment

(Detail)Sheethttp://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetailOther Balance Sheet Information - Property, Plant and Equipment (Detail)Details80 falsefalseR81.htm9954519 - Disclosure - Other Balance Sheet Information - Additional Information

(Detail)Sheethttp://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetailOther Balance Sheet Information - Additional Information (Detail)Details81 falsefalseR82.htm9954520 - Disclosure - Business Segments and Geographic Information - Additional Information

(Detail)Sheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetailBusiness Segments and Geographic Information - Additional Information (Detail)Details82 falsefalseR83.htm9954521 - Disclosure - Business Segments and Geographic Information - Segment Information

(Detail)Sheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetailBusiness Segments and Geographic Information - Segment Information (Detail)Details83 falsefalseR84.htm9954522 - Disclosure - Business Segments and Geographic Information - Revenues by Geography

(Detail)Sheethttp://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetailBusiness Segments and Geographic Information - Revenues by Geography (Detail)Details84 falsefalseR85.htm9954523 - Disclosure - Income Taxes (Details)Sheethttp://www.hologic.com/role/IncomeTaxesDetailsIncome Taxes (Details)Detailshttp://www.hologic.com/role/IncomeTaxes85 falsefalseR86.htm9954524 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets

(Detail)Sheethttp://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetailIntangible Assets and Goodwill - Schedule of Intangible Assets (Detail)Details86 falsefalseR87.htm9954525 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense

(Detail)Sheethttp://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetailIntangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)Details87 falsefalseR88.htm9954526 - Disclosure - Intangible Assets and Goodwill - Additional Information

(Details)Sheethttp://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetailsIntangible Assets and Goodwill - Additional Information (Details)Details88 falsefalseR89.htm9954527 - Disclosure - Product Warranties - Product Warranties - Product Warranty Activity

(Detail)Sheethttp://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetailProduct Warranties - Product Warranty Activity (Detail)Details89 falsefalseR90.htm9954528 - Disclosure - Accumulated Other Comprehensive Income (Loss)

(Detail)Sheethttp://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetailAccumulated Other Comprehensive Income (Loss) (Detail)Detailshttp://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossTables90 falsefalseR91.htm9954529 - Disclosure - Share Repurchase

(Details)Sheethttp://www.hologic.com/role/ShareRepurchaseDetailsShare Repurchase (Details)Detailshttp://www.hologic.com/role/ShareRepurchase91 falsefalseAll ReportsBookAll Reports holx-20240629.htmholx-20240629.xsdholx-20240629.cal.xmlholx-20240629_def.xmlholx-20240629_lab.xmlholx-20240629_pre.xmlhttp://fasb.org/us-gaap/2023http://xbrl.sec.gov/dei/2023http://xbrl.sec.gov/ecd/2023truetrue JSON 110 MetaLinks.json IDEA: XBRL DOCUMENT "c-1", "instance": { "holx-20240629.htm": { "nsr": { "holx": "http://www.hologic.com/20240629", "dts": { "inline": { "local": { "holx-20240629.htm" } }, "schema": { "local": { "holx-20240629.xsd" } }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/ltr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ltr/role/net-2009-12-16.xsd", "http://www.xbrl.org/ltr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fashb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fashb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fashb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fashb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fashb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fashb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" } }, "calculationLink": { "local": { "holx-20240629.cal.xml" } }, "definitionLink": { "local": { "holx-20240629_def.xml" } }, "labelLink": { "local": { "holx-20240629_lab.xml" } }, "presentationLink": { "local": { "holx-20240629_pre.xml" } }, "keyStandard": 297, "keyCustom": 32, "axisStandard": 31, "axisCustom": 0, "memberStandard": 53, "memberCustom": 54, "hidden": { "total": 11, "http://fasb.org/us-gaap/2023": 5, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 538, "entityCount": 1, "segmentCount": 123, "elementCount": 669, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1280, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 10 }, "report": { "R1": { "role": "http://www.hologic.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:Security12bTitle", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:Security12bTitle", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofIncome", "longName": "0000002 - Statement - Consolidated Statements of Income", "shortName": "Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss", "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical", "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)", "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "longName": "0000005 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofStockholdersEquity", "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-21", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "td", "tr": "table", "div": "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.hologic.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000009 - Statement - Consolidated Statements of Cash Flows (Parenthetical)", "shortName": "Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-100", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "link:footnote", "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-100", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "link:footnote", "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.hologic.com/role/BasisofPresentation", "longName": "0000010 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.hologic.com/role/Leases", "longName": "0000012 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:LesseeFinanceLeasesTextBlock", "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": "null", "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:LesseeFinanceLeasesTextBlock", "span": "div", "body", "html": "1", "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.hologic.com/role/FairValueMeasurements", "longName": "0000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-

```

gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.hologic.com/role/BusinessCombinations", "longName": "0000014 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.hologic.com/role/StrategicInvestment", "longName": "0000015 - Disclosure - Strategic Investment", "shortName": "Strategic Investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.hologic.com/role/Disposition", "longName": "0000016 - Disclosure - Disposition", "shortName": "Disposition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.hologic.com/role/Restructuring", "longName": "0000017 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.hologic.com/role/BorrowingsandCreditArrangements", "longName": "0000018 - Disclosure - Borrowings and Credit Arrangements", "shortName": "Borrowings and Credit Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLosses", "longName": "0000019 - Disclosure - Trade Receivables and Allowance for Credit Losses", "shortName": "Trade Receivables and Allowance for Credit Losses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.hologic.com/role/Derivatives", "longName": "0000020 - Disclosure - Derivatives", "shortName": "Derivatives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativesAndFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.hologic.com/role/CommitmentsandContingencies", "longName": "0000021 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.hologic.com/role/NetIncomeLossPerShare", "longName": "0000022 - Disclosure - Net Income (Loss) Per Share", "shortName": "Net Income (Loss) Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.hologic.com/role/StockBasedCompensation", "longName": "0000023 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.hologic.com/role/OtherBalanceSheetInformation", "longName": "0000024 - Disclosure - Other Balance Sheet Information", "shortName": "Other Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "holx:DetailsOfCertainBalanceSheetAccountsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "holx:DetailsOfCertainBalanceSheetAccountsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.hologic.com/role/BusinessSegmentsandGeographicInformation", "longName": "0000025 - Disclosure - Business Segments and Geographic Information", "shortName": "Business Segments and Geographic Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.hologic.com/role/IncomeTaxes", "longName": "0000026 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "context
```

"lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R34": { "role": "http://www.hologic.com/role/RevenuefromContractwithCustomerPolicies", "longName": "9954472 - Disclosure - Revenue from Contract with Customer (Policies)", "shortName": "Revenue from Contract with Customer (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueRecognitionPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R35": { "role": "http://www.hologic.com/role/NewAccountingPronouncementsPolicies", "longName": "9954473 - Disclosure - New Accounting Pronouncements (Policies)", "shortName": "New Accounting Pronouncements (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R36": { "role": "http://www.hologic.com/role/RevenueTables", "longName": "9954474 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R37": { "role": "http://www.hologic.com/role/FairValueMeasurementsTables", "longName": "9954475 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R38": { "role": "http://www.hologic.com/role/DispositionTables", "longName": "9954476 - Disclosure - Disposition (Tables)", "shortName": "Disposition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R39": { "role": "http://www.hologic.com/role/BorrowingsandCreditArrangementsTables", "longName": "9954477 - Disclosure - Borrowings and Credit Arrangements (Tables)", "shortName": "Borrowings and Credit Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R40": { "role": "http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesTables", "longName": "9954478 - Disclosure - Trade Receivables and Allowance for Credit Losses (Tables)", "shortName": "Trade Receivables and Allowance for Credit Losses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R41": { "role": "http://www.hologic.com/role/DerivativesTables", "longName": "9954479 - Disclosure - Derivatives (Tables)", "shortName": "Derivatives (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R42": { "role": "http://www.hologic.com/role/NetIncomeLossPerShareTables", "longName": "9954480 - Disclosure - Net Income (Loss) Per Share (Tables)", "shortName": "Net Income (Loss) Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R43": { "role": "http://www.hologic.com/role/StockBasedCompensationTables", "longName": "9954481 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R44": { "role": "http://www.hologic.com/role/OtherBalanceSheetInformationTables", "longName": "9954482 - Disclosure - Other Balance Sheet Information (Tables)", "shortName": "Other Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOffInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R45": { "role": "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationTables", "longName": "9954483 - Disclosure - Business Segments and Geographic Information (Tables)", "shortName": "Business Segments and Geographic Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "R46": { "role": "http://www.hologic.com/role/IntangibleAssetsandGoodwillTables", "longName": "9954484 - Disclosure - Intangible Assets and Goodwill (Tables)", "shortName": "Intangible Assets and Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Schedule

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

"unique": true } }, "R71": { "role": "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "longName": "9954509 - Disclosure - Derivatives - Additional Information (Details)", "shortName": "Derivatives - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-378", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "uniqueAnchor": { "contextRef": "c-382", "name": "holx:NotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "unique": true } }, "R72": { "role": "http://www.hologic.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativeContractsDetails", "longName": "9954510 - Disclosure - Derivatives - Schedule Of Change In Fair Value Of Derivative Contracts (Details)", "shortName": "Derivatives - Schedule Of Change In Fair Value Of Derivative Contracts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "longName": "9954511 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments (Details)", "shortName": "Derivatives - Fair Value of Derivative Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-399", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-399", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInAOCIDetails", "longName": "9954512 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details)", "shortName": "Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.hologic.com/role/NetIncomeLossPerShareDetail", "longName": "9954513 - Disclosure - Net Income (Loss) Per Share (Detail)", "shortName": "Net Income (Loss) Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "unique": true } }, "R76": { "role": "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsofOperationsDetail", "longName": "9954514 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "uniqueAnchor": { "contextRef": "c-409", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "unique": true } }, "R77": { "role": "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "longName": "9954515 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-425", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-425", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail", "longName": "9954516 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)", "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail", "longName": "9954517 - Disclosure - Other Balance Sheet Information - Inventories (Detail)", "shortName": "Other Balance Sheet Information - Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R80": { "role": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail", "longName": "9954518 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment (Detail)", "shortName": "Other Balance Sheet Information - Property, Plant and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-14", "name": "holx:ManufacturingEquipmentAndSoftware", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "c-14", "name": "holx:ManufacturingEquipmentAndSoftware", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"

"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetail", "longName": "9954525 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)", "shortName": "Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "longName": "9954526 - Disclosure - Intangible Assets and Goodwill - Additional Information (Details)", "shortName": "Intangible Assets and Goodwill - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-492", "name": "us-gaap:AssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "unique": true } }, "R89": { "role": "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail", "longName": "9954527 - Disclosure - Product Warranties - Product Warranty Activity (Detail)", "shortName": "Product Warranties - Product Warranty Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "longName": "9954528 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Detail)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:OCIBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "unique": true } }, "R91": { "role": "http://www.hologic.com/role/ShareRepurchaseDetails", "longName": "9954529 - Disclosure - Share Repurchase (Details)", "shortName": "Share Repurchase (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-11", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-11", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "holx-20240629.htm", "first": true, "unique": true } }, "tag": { "holx_A2021RevolverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "A2021RevolverMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2021 Revolver", "label": "2021 Revolver [Member]", "documentation": "2021 Revolver" } } }, "auth_ref": [] }, "holx_A2021TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "A2021TermLoanMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2021 Term Loan", "label": "2021 Term Loan [Member]", "documentation": "2021 Term Loan" } } }, "auth_ref": [] }, "holx_A2028And2029SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "A2028And2029SeniorNotesMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "2028 and 2029 Senior Notes [Member]", "documentation": "2028 and 2029 Senior Notes" } } }, "auth_ref": [] }, "holx_A2028SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "A2028SeniorNotesMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2028 Senior Notes", "label": "2028 Senior Notes [Member]", "documentation": "2028 Senior Notes [Member]" } } }, "auth_ref": [] }, "holx_A2029SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "A2029SeniorNotesMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "2029 Senior Notes", "label": "2029 Senior Notes [Member]", "documentation": "2029 Senior Notes" } } }, "auth_ref": [] }, "holx_AcceleratedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AcceleratedAmortization", "crdr": "debit", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated amortization", "label": "Accelerated amortization", "documentation": "Accelerated amortization" } } }, "auth_ref": [] }, "holx_AcceleratedShareRepurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AcceleratedShareRepurchaseAgreement", "crdr": "debit", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated share repurchase agreement", "label": "Accelerated share repurchase agreement", "documentation": "Accelerated share repurchase agreement" } } }, "auth_ref": [] }, "holx_AcceleratedShareRepurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AcceleratedShareRepurchaseAgreementMember", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchase Agreement", "label": "Accelerated Share Repurchase Agreement [Member]", "documentation": "Accelerated Share Repurchase Agreement" } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "crdr": "debit", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement." } } }, "auth_ref": ["r175"] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r34", "r817"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, less reserves", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r322", "r323"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r36"] }, "us-gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesMember", "presentation": ["http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": ["r36"] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": ["r8", "r21", "r45", "r927", "r928", "r929"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": ["http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Less \u20132013 accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r66", "r216", "r654"] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r231", "r238", "r239", "r554", "r789", "r927"] }, "holx_AccumulatedOtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AccumulatedOtherComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income [Abstract]", "label": "Accumulated Other Comprehensive Income [Abstract]", "documentation": "Accumulated Other Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain

members defined in one or many axes to the table." } } }, "auth_ref": ["r237", "r238", "r586", "r588", "r589", "r590", "r591", "r592"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r44", "r45", "r141", "r223", "r651", "r684", "r687"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."} } } }, "auth_ref": ["r237", "r238", "r586", "r588", "r589", "r590", "r591", "r592"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } } }, "auth_ref": ["r6", "r21", "r45", "r562", "r565", "r601", "r680", "r681", "r927", "r928", "r929", "r938", "r939", "r940"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail"], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } } }, "auth_ref": ["r7", "r21", "r45", "r238", "r239", "r588", "r589", "r590", "r591", "r592", "r927"] }, "holx_AccessaHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AccessaHealthMember", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accessa Health", "label": "Accessa Health [Member]", "documentation": "Accessa Health" } } } }, "auth_ref": [] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } } }, "auth_ref": ["r158"] }, "holx_AcquiredIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AcquiredIntangibleAssetsMember", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Total acquired intangible assets", "label": "Acquired intangible assets [Member]", "documentation": "Acquired intangible assets [Member]" } } } }, "auth_ref": ["ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } } }, "auth_ref": ["r869"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } } }, "auth_ref": ["r131", "r817", "r1000"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } } }, "auth_ref": ["r524", "r525", "r526", "r695", "r938", "r939", "r940", "r987", "r1002"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation Amount", "label": "Adjustment to Compensation Amount" } } } }, "auth_ref": ["r875"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation", "label": "Adjustment to Compensation [Axis]" } } } }, "auth_ref": ["r875"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } } }, "auth_ref": ["r875"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to PEO Compensation, Footnote [Text Block]" } } } }, "auth_ref": ["r875"] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } } }, "auth_ref": ["r13", "r63"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } } }, "auth_ref": ["r72", "r73", "r490"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } } }, "auth_ref": ["r840", "r851", "r861", "r886"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } } }, "auth_ref": ["r843", "r854", "r864", "r889"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } } }, "auth_ref": ["r875"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } } }, "auth_ref": ["r882"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } } }, "auth_ref": ["r847", "r855", "r865", "r882", "r890", "r894", "r902"] }, "holx_AllOtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AllOtherCountriesMember", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail"], "lang": { "en-us": { "role": { "terseLabel": "Rest of World", "label": "All Other Countries [Member]", "documentation": "All other countries." } } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } } }, "auth_ref": ["r900"] }, "us-gaap-AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Balanceu00a0at Beginning of Period", "periodEndLabel": "Balanceu00a0at End of Period", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } } }, "auth_ref": ["r224", "r324", "r366"] }, "us-gaap-AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease", "presentation": ["http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Write-offs, Payments and Foreign Exchange", "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable." } } } }, "auth_ref": ["r965"] }, "us-gaap-AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": ["http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of acquired intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": ["r13", "r58", "r63"] }, "holx_AnnualIncrementalRevenueGrowthPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "AnnualIncrementalRevenueGrowthPeriod", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Annual incremental revenue growth period", "label": "Annual Incremental Revenue Growth Period", "documentation": "Annual Incremental Revenue Growth Period" } } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fash.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average anti-dilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth_ref": ["r283"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fash.org/us-

gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r51"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r51"] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Asia-Pacific", "label": "Asia Pacific [Member]" } } }, "auth_ref": ["r1003", "r1004", "r1005", "r1006"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset and equipment impairment charges", "verboseLabel": "Asset impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r13", "r64"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Identifiable assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r188", "r220", "r250", "r292", "r307", "r313", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r552", "r555", "r581", "r647", "r720", "r817", "r831", "r975", "r976", "r993"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r212", "r226", "r250", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r552", "r555", "r581", "r817", "r975", "r976", "r993"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Assets held-for-sale - current assets", "totalLabel": "Disposal Group, Including Discontinued Operation, Assets", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166", "r210", "r211"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsAvailableforSaleDebtSecuritiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total available-for-sale securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r327", "r373", "r641", "r947"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r897"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r898"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "auth_ref": ["r893"] }, "ecd_AwardTmgHwMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHwMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r893"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r893"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r893"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r893"] }, "ecd_AwardTmgPredtrmdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r893"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r896"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r895"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r894"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r894"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": ["r88", "r93"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Related Disclosures [Abstract]", "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.hologic.com/role/BasisofPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "holx_BioZorbMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "BioZorbMember", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "BioZorb", "label": "BioZorb [Member]", "documentation": "BioZorb" } } }, "auth_ref": [] }, "holx_BloodScreeningMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "BloodScreeningMember", "presentation": ["http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Blood Screening", "label": "Blood Screening [Member]", "documentation": "Blood Screening [Member]" } } }, "auth_ref": [] }, "holx_BreastHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "BreastHealthMember", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Breast Health", "label": "Breast Health [Member]", "documentation": "Breast health." } } }, "auth_ref": [] }, "holx_BreastImagingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "BreastImagingMember", "presentation": ["http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Breast Imaging", "label": "Breast Imaging [Member]", "documentation": "Breast Imaging [Member]" } } }, "auth_ref": [] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail"], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": ["r164"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.hologic.com/role/BasisofPresentationDetails",

"http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r548", "r813", "r814"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.hologic.com/role/BasisofPresentationDetails", "http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r75", "r76", "r548", "r813", "r814"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r548"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BasisofPresentationDetails", "http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r1", "r2", "r17"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent consideration - fair value adjustments", "terseLabel": "Contingent consideration - fair value adjustments", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset." } } }, "auth_ref": ["r551", "r933"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration - fair value adjustments", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r551", "r933"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r3", "r79", "r550"] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/BusinessCombinations"], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r180", "r549"] }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCustomerRelationships": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCustomerRelationships", "crdr": "debit", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships", "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "holx_CapitalEquipmentComponentsandSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "CapitalEquipmentComponentsandSoftwareMember", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capital equipment, components and software", "label": "Capital Equipment, Components and Software [Member]", "documentation": "Capital Equipment, Components and Software [Member]" } } }, "auth_ref": [] }, "holx_CapitalizedsoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "CapitalizedsoftwareMember", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized software embedded in products", "label": "Capitalized software [Member]", "documentation": "Capitalized software [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cost", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r50", "r214", "r782"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "verboseLabel": "Fair Value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "holx_CashAndCashEquivalentsUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "CashAndCashEquivalentsUnrealizedGain", "crdr": "credit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Cash and Cash Equivalents, Unrealized Gain", "documentation": "Cash and Cash Equivalents, Unrealized Gain" } } }, "auth_ref": [] }, "holx_CashAndCashEquivalentsUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "CashAndCashEquivalentsUnrealizedLoss", "crdr": "debit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses", "label": "Cash and Cash Equivalents, Unrealized Loss", "documentation": "Cash and Cash Equivalents, Unrealized Loss" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r50", "r153", "r247"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "TotalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r4", "r153"] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "presentation": ["http://www.hologic.com/role/DispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash Divested from Deconsolidation", "label": "Cash Divested from Deconsolidation", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": ["r151"] }, "us-gaap_CashFlowHedgeDerivativeInstrumentAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgeDerivativeInstrumentAssetsAtFairValue", "crdr": "debit", "presentation": ["http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedge Derivative Instrument Assets at Fair Value", "verboseLabel": "Cash Flow Hedge Derivative Instrument Assets at Fair Value", "label": "Cash Flow Hedge Derivative Instrument Assets at Fair Value", "documentation": "Fair value of all asset derivatives designated as cash flow hedging instruments." } } }, "auth_ref": ["r92"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r214"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": ["r873"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r874"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],

```

lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r874" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" ] }, "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r170", "r823", "r824", "r825", "r828" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingencies", "http://www.hologic.com/role/CommitmentsAndContingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r168", "r408", "r409", "r767", "r972" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ] }, "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r819", "r820", "r821", "r823", "r824", "r825", "r828", "r938", "r939", "r987", "r999", "r1002" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r130" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r130", "r708" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r130" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ] }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r130", "r650", "r817" ] }, "us-gaap_CommonStockValueVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r879" ] }, "us-gaap_CommonStockValueVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r878" ] }, "us-gaap_CommonStockValueVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r880" ] }, "us-gaap_CommonStockValueVsTotalShareholderReturnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r877" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ] }, "lang": { "en-us": { "role": { "terseLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r46", "r234", "r236", "r243", "r643", "r660" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLoss" ] }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r140", "r242", "r642", "r658" ] }, "us-gaap_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail" ] }, "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r252", "r294", "r305", "r306", "r307", "r308", "r309", "r311", "r315", "r422", "r423", "r424", "r425", "r427", "r428", "r430", "r432", "r433", "r975", "r976" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.hologic.com/role/BasisofPresentationPolicies" ] }, "lang": { "en-us": { "role": { "terseLabel": "Principal of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r82", "r790" ] }, "us-gaap_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ConsumablesMember", "presentation": [ "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Disposables", "label": "Consumables [Member]", "documentation": "Consumables [Member]" } } }, "auth_ref": [ ] }, "us-gaap_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" ] }, "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration" } } }, "auth_ref": [ ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.hologic.com/role/RevenueNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r480" ] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail" ] }, "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r944" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ] }, "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r147", "r634" ] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap
```

"http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r78"] }, "holyx_CytologyPerinatalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "CytologyPerinatalMember", "presentation": ["http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cytology & Perinatal", "label": "Cytology & Perinatal [Member]", "documentation": "Cytology & Perinatal [Member]" } } }, "auth_ref": [] }, "holyx_DanburyClosureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "DanburyClosureMember", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Danbury closure", "label": "Danbury closure [Member]", "documentation": "Danbury closure" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Borrowings and Credit Arrangements", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r169", "r248", "r435", "r441", "r442", "r443", "r444", "r445", "r446", "r451", "r458", "r459", "r461"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r31", "r127", "r128", "r189", "r190", "r252", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r595", "r798", "r799", "r800", "r802", "r935"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r108", "r110", "r436", "r595", "r799", "r800"] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of debt instrument", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": ["r449", "r580", "r799", "r800"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r38", "r437"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r252", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r595", "r798", "r799", "r800", "r801", "r802", "r935"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r39", "r252", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r595", "r798", "r799", "r800", "r801", "r802", "r935"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r39", "r68", "r69", "r107", "r108", "r110", "r113", "r172", "r173", "r252", "r436", "r437", "r438", "r439", "r440", "r442", "r447", "r448", "r449", "r450", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r595", "r798", "r799", "r800", "r801", "r802", "r935"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959"] }, "holyx_December112020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "December112020Member", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "December 11, 2020", "label": "December 11, 2020 [Member]", "documentation": "December 11, 2020" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r13", "r179", "r200", "r543", "r544", "r937"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred income tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r529", "r530", "r648"] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue, net of current portion", "label": "Deferred Revenue, Noncurrent", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r925"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r13", "r65"] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r13"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedinAOCIDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r700", "r701", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r735", "r736", "r738", "r741", "r742", "r743", "r744", "r755", "r756", "r760", "r761", "r819", "r821"] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": ["http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": ["r29", "r91", "r139", "r227", "r788"] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": ["http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount of realized gain (loss) recognized in income", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": ["r985"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedinAOCIDetails"]

```
"http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredonRecurringBasisDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments [Axis]", "label": "Derivative Instruments [Axis]", "documentation": "Information by type of derivative contract." } }, "auth_ref": [ "r89", "r92", "r94", "r97", "r700", "r701", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r735", "r736", "r737", "r738", "r741", "r742", "r743", "r744", "r755", "r756", "r760", "r761", "r788", "r819" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [ ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [ ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedinAOCIDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } }, "auth_ref": [ "r23", "r89", "r94", "r97", "r100", "r101", "r559" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedinAOCIDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [ "r559" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } }, "auth_ref": [ "r96", "r913" ] }, "us-gaap_DerivativeLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [ "r568" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } }, "auth_ref": [ "r983", "r984" ] }, "us-gaap_DerivativeTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } }, "auth_ref": [ "r23", "r84", "r85", "r86", "r87", "r90", "r94", "r98", "r99", "r101", "r568" ] }, "us-gaap_DerivativeVariableInterestRate": { "xbrlType": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeVariableInterestRate", "presentation": [ "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable interest rate", "label": "Derivative, Variable Interest Rate", "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative." } }, "auth_ref": [ ] }, "us-gaap_DerivativesAndFairValueTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesAndFairValueTextBlock", "presentation": [ "http://www.hologic.com/role/Derivatives" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives", "label": "Derivatives and Fair Value [Text Block]", "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities." } }, "auth_ref": [ "r184", "r185" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative instruments designated as a cash flow hedge", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } }, "auth_ref": [ "r23" ] }, "holx_DetailsOfCertainBalanceSheetAccountsTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "DetailsOfCertainBalanceSheetAccountsTextBlock", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Other Balance Sheet Information", "label": "Details Of Certain Balance Sheet Accounts [Text Block]", "documentation": "Details of certain balance sheet accounts." } }, "auth_ref": [ ] }, "holx_DevelopedTechnologyMember": { "xbrlType": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "DevelopedTechnologyMember", "presentation": [ "http://www.hologic.com/role/intangibleAssetsandGoodwillScheduledtoIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Developed Technology [Member]", "documentation": "Developed technology." } }, "auth_ref": [ ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostics", "label": "Diagnostics [Member]", "documentation": "Diagnostics." } }, "auth_ref": [ ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } }, "auth_ref": [ "r479", "r803", "r804", "r805", "r806", "r807", "r808", "r809" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } }, "auth_ref": [ "r479", "r803", "r804", "r805", "r806", "r807", "r808", "r809" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.hologic.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } }, "auth_ref": [ "r977" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.hologic.com/role/StockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } }, "auth_ref": [ "r488", "r493", "r520", "r521", "r523", "r815" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]", "documentation": "Share-based payment arrangements." } }, "auth_ref": [ ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } }, "auth_ref": [ ] }, "us-gaap_DisposalGroupDisposedOffBySaleNotDiscontinuedOperationsMember": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOffBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "
```

"http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Accounts Payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "crdr": "credit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationCash", "crdr": "debit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Disposal Group, Including Discontinued Operation, Cash", "documentation": "Amount of currency on hand, demand deposits with banks or financial institutions, and other kinds of accounts that have the general characteristics of demand deposits, held by a disposal group." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://www.hologic.com/role/DispositionAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sales price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "holx_DisposalGroupIncludingDiscontinuedOperationContraAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "DisposalGroupIncludingDiscontinuedOperationContraAssets", "crdr": "credit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "documentation": "Disposal Group, Including Discontinued Operation, Contra Assets" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "crdr": "debit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory", "label": "Disposal Group, Including Discontinued Operation, Inventory", "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets", "crdr": "debit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/Disposition"], "lang": { "en-us": { "role": { "terseLabel": "Disposition", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r116", "r162"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r813", "r814"] }, "holx_DisposalGroupsIncludingDiscontinuedOperationsandCollaborativeAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "DisposalGroupsIncludingDiscontinuedOperationsandCollaborativeAgreementAbstract", "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]", "documentation": "Disposal Groups, Including Discontinued Operations and Collaborative Agreement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r835"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r868"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": ["http://www.hologic.com/role/CoverPage"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-O, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome"], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per common share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r244", "r262", "r263", "r264", "r265", "r266", "r273", "r275", "r280", "r281", "r282", "r286", "r572", "r573", "r644", "r661", "r793"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r244", "r262", "r263", "r264", "r265", "r266", "r275", "r280", "r281", "r282", "r286", "r572", "r573", "r644", "r661", "r793"] }, "holx_EarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "EarningsPerShareLineItems", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Line Items]", "label": "Earnings Per Share [Line Items]", "documentation": "Earnings Per Share [Line Items]" } } }, "auth_ref": [] }, "holx_EarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "EarningsPerShareTable", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Table]", "label": "Earnings Per Share [Table]", "documentation": "Earnings Per Share [Table]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss) Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r272", "r283", "r284", "r285"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r585"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.hologic.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Company's effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r532"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r522"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",

"nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period for recognition of unrecognized stock-based compensation, years", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r522": 1 }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Stock option plans", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { "holx_EndomagneticsLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "EndomagneticsLtdMember", "presentation": { "http://www.hologic.com/role/BasisofPresentationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Endomag", "label": "Endomagnetics Ltd [Member]", "documentation": "Endomagnetics Ltd" } } }, "auth_ref": { "normalizedStringItemType": { "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "normalizedStringItemType": { "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { "centralIndexKeyItemType": { "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r833": 1 }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r833": 1 }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemtype", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r907": 1 }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r833": 1 }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r833": 1 }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r833": 1 }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemtype", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.hologic.com/role/CoverPage": { "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r833": 1 }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": { "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": { "holx_EquipmentUnderCustomerUsageAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "EquipmentUnderCustomerUsageAgreements", "presentation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Equipment under customer usage agreements", "label": "Equipment Under Customer Usage Agreements", "documentation": "Gross amount at the balance sheet date of long-lived, depreciable asset that are equipment placed at customer locations for which title is not transferred to the Company's customers." } } }, "auth_ref": { "us-gaap_EquityAbstract": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": { "http://www.hologic.com/role/StrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": { "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": { "r22": "r206", "r237", "r238", "r239", "r253", "r254", "r255", "r259", "r267", "r269", "r287", "r362", "r365", "r477", "r524", "r525", "r526", "r536", "r537", "r561", "r562", "r563", "r564", "r565", "r567", "r571", "r586", "r588", "r589", "r590", "r591", "r592", "r601", "r680", "r681", "r682", "r695", "r747" } } }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": { "http://www.hologic.com/role/StrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Investment, Name [Domain]" } } }, "auth_ref": { "r356", "r357", "r359" } } }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": { "http://www.hologic.com/role/StrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Ownership Percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": { "r356": 1 }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "presentation": { "http://www.hologic.com/role/StrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": { "r302", "r355", "r922", "r963" } } }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "presentation": { "http://www.hologic.com/role/StrategicInvestmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": { "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": { "http://www.hologic.com/role/StrategicInvestment": { "lang": { "en-us": { "role": { "terseLabel": "Strategic Investment", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": { "r205", "r358", "r361", "r908" } } }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": { "r876" } } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": { "r840", "r851", "r861", "r886" } } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": { "r837", "r848", "r858", "r883" } } }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": { "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail": { "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": { "r1003", "r1004", "r1005", "r1006" } } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Executive Category", "label": "Executive Category [Axis]" } } }, "auth_ref": { "r882" } } }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "label": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "documentation": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" } } }, "auth_ref": { "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredOnRecurringBasisDetail": { "lang": { "en-us": { "role": { "terseLabel": "Asset Class

"Domain": "us-gaap", "label": "Asset Class [Axis]", "documentation": "Class of asset.", "auth_ref": "r25", "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": "r102", "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": "r102", "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": "r102", "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": "r449", "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": "r449", "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Inputs, Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": "r449", "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs [Level 2]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": "r449", "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs [Level 3]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": "r449", "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations", "presentation": "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Obligations, Fair Value Disclosure", "documentation": "Fair value of obligations measured on a recurring basis." } } }, "auth_ref": "r102", "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": "http://www.hologic.com/role/FairValueMeasurements", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": "r185", "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "presentation": "http://www.hologic.com/role/FairValueMeasurementsRollForwardDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": "r579", "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "presentation": "http://www.hologic.com/role/FairValueMeasurementsRollForwardDetails", "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration recorded at acquisition", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": "r103", "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "presentation": "http://www.hologic.com/role/FairValueMeasurementsRollForwardDetails", "lang": { "en-us": { "role": { "terseLabel": "Payments", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": "r103", "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityValue", "presentation": "http://www.hologic.com/role/FairValueMeasurementsRollForwardDetails", "lang": { "en-us": { "role": { "terseLabel": "Beginning balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": "r25", "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": "r449", "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "presentation": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]", "label": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": "r102", "us-gaap_FairValueDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": "r88", "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "presentation": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0, "presentation": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Finance lease obligations", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": "r600", "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "presentation": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0, "presentation": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Finance lease obligations, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": "r600", "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "presentation": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail", "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 7.0, "presentation": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail", "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": "r599", "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation":

Label 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } }, "auth_ref": ["r160"] } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Remainder of Fiscal 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } } }, "auth_ref": [] } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } }, "auth_ref": ["r160"] } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } }, "auth_ref": ["r160"] } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofEstimatedAmortizationExpenseDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Fiscal 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."} } } }, "auth_ref": ["r160"] } }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": "http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } } }, "auth_ref": ["r388", "r390", "r391", "r393", "r635", "r639"] } }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "crdr": "debit", "presentation": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets, fair value", "label": "Finite-Lived Intangible Assets, Fair Value Disclosure", "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } } }, "auth_ref": ["r988"] } }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } } }, "auth_ref": ["r159", "r639"] } }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": "http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth_ref": ["r635"] } }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": "http://www.hologic.com/role/BusinessCombinationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail" } }, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } } }, "auth_ref": ["r59", "r62"] } }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangibles", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } } }, "auth_ref": ["r159", "r635"] } }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": "http://www.hologic.com/role/IncomeTaxDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Foreign Tax Authority", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity under the entity's country of domicile." } } } }, "auth_ref": [] } }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Forward foreign currency contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } } }, "auth_ref": ["r788", "r810", "r816"] } }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativeContractsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Forward foreign currency contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } } }, "auth_ref": ["r714", "r718", "r723", "r737", "r743", "r758", "r759", "r760", "r821"] } }, "us-gaap_ForeignExchangeOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeOptionMember", "presentation": "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativeContractsDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Option", "label": "Foreign currency option contracts", "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option)."} } } }, "auth_ref": [] } }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"} } } }, "auth_ref": ["r844", "r855", "r865", "r890"] } }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount"} } } }, "auth_ref": ["r844", "r855", "r865", "r890"] } }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount"} } } }, "auth_ref": ["r844", "r855", "r865", "r890"] } }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"} } } }, "auth_ref": ["r844", "r855", "r865", "r890"] } }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" } }, "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name"} } } }, "auth_ref": ["r844", "r855", "r865", "r890"] } }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForwardContractsMember", "presentation": "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" } }, "lang": { "en-us": { "role": { "terseLabel": "Forward Contracts", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } } }, "auth_ref": ["r986"] } }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "

```

"order": 1.0, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r146", "r250", "r292", "r306", "r312", "r315", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r581", "r794", "r975" ] }, "us-gaap_GuaranteesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Guarantees [Abstract]", "label": "Guarantees [Abstract]", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r934", "r969" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets", "label": "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r934", "r969" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Impairment of intangible assets and equipment", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r934", "r969" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Impairment, assets held-for-use", "label": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r13", "r64", "r165" ] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail", "lang": { "en-us": { "role": { "terseLabel": "In-process research and development", "label": "In Process Research and Development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r10", "r142", "r192", "r292", "r306", "r312", "r315", "r645", "r656", "r794" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r813", "r814" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsParentetical", "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r813", "r814" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r16", "r27", "r32", "r117", "r118", "r119", "r120", "r121", "r122", "r124", "r125", "r126", "r167" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r394", "r400", "r731" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail", "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r400", "r731" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r18" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ ] }, "us-gaap_IncomeTaxContingencyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyLineItems", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ ] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r19", "r74", "r177", "r178" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r251", "r528", "r533", "r534", "r535", "r541", "r545", "r546", "r547", "r693" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/IncomeTaxesDetails", "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r197", "r203", "r268", "r269", "r300", "r531", "r542", "r662" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r12" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap_NetCash
```

"weight": 1.0, "order": 12.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": { "r12" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r777" }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r12" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions", "label": "Increase (Decrease) in Operating Capital [Abstract]", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": { "r276", "r277", "r278", "r282", "r492" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": { "r389", "r392" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": { "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r988" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": { "r60", "r161" }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual [Axis]", "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions." } } }, "auth_ref": { "r5" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.hologic.com/role/IntangibleAssetsandGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets and Goodwill", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": { "r387" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": { "r57", "r61" }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" }, "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": { "r109", "r195", "r240", "r296", "r594", "r732", "r829", "r1001" }, "us-gaap_InterestExpenseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseBorrowings", "crdr": "debit", "presentation": { "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Borrowings", "documentation": "Aggregate amount of interest expense on all borrowings." } } }, "auth_ref": { "r194" }, "holx_InterestRateSwap2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InterestRateSwap2023Member", "presentation": { "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 2023", "label": "Interest Rate Swap, 2023 [Member]", "documentation": "Interest Rate Swap, 2023" } } }, "auth_ref": { "r194" }, "holx_InterestRateSwap2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InterestRateSwap2024Member", "presentation": { "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, 2024", "label": "Interest Rate Swap, 2024 [Member]", "documentation": "Interest Rate Swap, 2024" } } }, "auth_ref": { "r194" }, "holx_InterestRateSwapAgreementOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InterestRateSwapAgreementOneMember", "presentation": { "http://www.hologic.com/20240629", "localname": "InterestRateSwapAgreementOneMember", "presentation": { "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Agreement One", "label": "Interest Rate Swap, Agreement One [Member]", "documentation": "Interest Rate Swap, Agreement One" } } }, "auth_ref": { "r194" }, "holx_InterestRateSwapAgreementTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InterestRateSwapAgreementTwoMember", "presentation": { "http://www.hologic.com/20240629", "localname": "InterestRateSwapAgreementTwoMember", "presentation": { "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap, Agreement Two", "label": "Interest Rate Swap, Agreement Two [Member]", "documentation": "Interest Rate Swap, Agreement Two" } } }, "auth_ref": { "r194" }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "lang": { "en-us": { "role": { "terseLabel": "Interest rate swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": { "r779", "r826", "r827" }, "holx_InternalusesoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InternalusesoftwareMember", "presentation": { "http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleoffIntangibleAssetsDetail", "lang": { "en-us": { "role": { "terseLabel": "Internal-use software", "label": "Internal-use software [Member]", "documentation": "Internal-use software [Member]", "auth_ref": { "r779", "r826", "r827" } } } } }

"holx_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InternationalMember", "presentation": ["http://www.hologic.com/role/RevenueBusinessRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International [Member]", "documentation": "International [Member]" } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Intersegment", "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": ["r294", "r305", "r306", "r307", "r308", "r309", "r311", "r315"] }, "holx_InterventionalBreastSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "InterventionalBreastSolutionsMember", "presentation": ["http://www.hologic.com/role/RevenueBusinessRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Interventional Breast Solutions", "label": "Interventional Breast Solutions [Member]", "documentation": "Interventional Breast Solutions [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r157", "r785"] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r225", "r783", "r817"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r157", "r787"] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": ["r157", "r786"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome"] }, "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": ["r149", "r295"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r577"] }, "holx_JWMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "JWMedicalMember", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "JW Medical", "label": "JW Medical [Member]", "documentation": "JW Medical" } } }, "auth_ref": [] }, "holx_KarleenObertonMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "KarleenObertonMember", "presentation": ["http://xbrl.sec.gov/cdr/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "label": "Karleen Oberton [Member]", "documentation": "Karleen Oberton" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": ["r923"] }, "holx_LeaseRevenuePercentageOfTotalRevenue": { "xbrltype": "pureItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "LeaseRevenuePercentageOfTotalRevenue", "presentation": ["http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Lease revenue as a percentage of total (percentage)", "label": "Lease Revenue, Percentage Of Total Revenue", "documentation": "Lease Revenue, Percentage Of Total Revenue" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsGross", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements, Gross", "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r164"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": ["http://www.hologic.com/role/Leases"] }, "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": ["r598"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.hologic.com/role/Leases"] }, "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r598"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders'2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r135", "r191", "r653", "r817", "r936", "r964", "r990"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS'2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r37", "r213", "r250", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r553", "r555", "r556", "r581", "r817", "r975", "r993", "r994"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.hologic.com/role/DispositionScheduleofDispositionRelatedIncomeStatementInformationDetails"] }, "lang": { "en-us": { "role": { "totalLabel": "Disposal Group, Including Discontinued Operation, Liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r5", "r117", "r123", "r166", "r210", "r211"] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"] }, "lang": { "en-us": { "role": { "terseLabel": "Assets held-for-sale - current liabilities", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r5", "r117", "r123", "r163", "r166", "r210", "r211"] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate at end of period", "label": "Line of Credit Facility, Interest Rate At Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": ["r35"] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": ["r35"] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility borrowings", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r35"] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseCreditAgreementDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility

"label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." }, { "auth_ref": "r35", "r935" }, { "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": "http://www.hologic.com/role/TradeReceivablesAndAllowanceforCreditLosses", "lang": { "en-us": { "role": { "terseLabel": "Trade Receivables and Allowance for Credit Losses", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]" } } }, "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." }, { "auth_ref": "r946", "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": "http://www.hologic.com/role/CoverPage", "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": "r1", "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "parentTag": null, "weight": null, "order": null, "root": true }, { "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "lang": { "en-us": { "role": { "totalLabel": "Total debt obligations", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": "r31", "r190", "r448", "r462", "r799", "r800", "r997" }, { "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "verboseLabel": "Current portion of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": "r221", "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of current portion", "verboseLabel": "Total long-term debt obligations", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": "r222", "holx_LongTermDebtObligationsWithoutConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "LongTermDebtObligationsWithoutConvertibleNotes", "crdr": "credit", "calculation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 }, "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "lang": { "en-us": { "role": { "terseLabel": "Long term debt obligations, excluding convertible notes", "label": "Long Term Debt Obligations Without Convertible Notes", "documentation": "Long term debt obligations without convertible notes." } } }, "auth_ref": "r1", "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": "r39", "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompansBorrowingsDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": "r39", "r67", "holx_ManufacturingEquipmentAndSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ManufacturingEquipmentAndSoftware", "crdr": "debit", "calculation": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantandEquipmentGross", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail", "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Manufacturing Equipment And Software", "documentation": "Gross amount as of the balance sheet date of long-lived, depreciable assets that include manufacturing and other equipment with finite lives used to produce goods and services, and computer equipment and software." } } }, "auth_ref": "r1", "holx_MarketBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MarketBasedAwardsMember", "presentation": "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Market Based Awards", "label": "Market Based Awards [Member]", "documentation": "Market Based Awards [Member]" } } }, "auth_ref": "r1", "holx_MaverixMedicalLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MaverixMedicalLLCMember", "presentation": "http://www.hologic.com/role/StrategicInvestmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Maverix Medical LLC", "label": "Maverix Medical LLC [Member]", "documentation": "Maverix Medical LLC" } } }, "auth_ref": "r1", "holx_MaximumTargetNumberOfSharesIssuedBasedOnStockPerformanceInPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MaximumTargetNumberOfSharesIssuedBasedOnStockPerformanceInPercent", "presentation": "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Maximum eligible percentage to receive target number of shares of company's common stock", "label": "Maximum Target Number Of Shares Issued Based On Stock Performance In Percent", "documentation": "Maximum target number percentage of shares issued based on stock performance." } } }, "auth_ref": "r1", "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": "r874", "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": "r874", "holx_MinimumTargetNumberOfSharesIssuedOnStockPerformanceInPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MinimumTargetNumberOfSharesIssuedOnStockPerformanceInPercent", "presentation": "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Minimum eligible percentage to receive target number of shares of company's common stock", "label": "Minimum Target Number Of Shares Issued On Stock Performance In Percent", "documentation": "Minimum target number percentage of shares that would be issued based on stock price performance." } } }, "auth_ref": "r1", "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value [Flag]", "label": "MNPI Disclosure Timed for Compensation Value", "documentation": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": "r893", "holx_MobidiagMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MobidiagMember", "presentation": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail", "http://www.hologic.com/role/RestructuringDetails", "lang": { "en-us": { "role": { "terseLabel": "Mobidiag", "label": "Mobidiag [Member]", "documentation": "Mobidiag" } } }, "auth_ref": "r1", "holx_MolecularDiagnosticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "MolecularDiagnosticsMember", "presentation": "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Molecular Diagnostics", "label": "Molecular Diagnostics [Member]", "documentation": "Molecular Diagnostics [Member]" } } }, "auth_ref": "r1", "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": { "en-us": { "role": { "terseLabel": "Money Market Funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": "r978", "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward", "presentation": "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail", "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]", "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": "r1", "ecd_MtrTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrTermsOfTrdArrTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": "r901", "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2

"NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r153", "r154", "r155"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net Income (Loss) Attributable to Parent", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r143", "r155", "r193", "r211", "r232", "r235", "r239", "r250", "r258", "r262", "r263", "r264", "r265", "r268", "r269", "r279", "r292", "r306", "r312", "r315", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r573", "r581", "r657", "r728", "r745", "r746", "r794", "r829", "r975"] }, "holx_NetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "NetIncome", "crdr": "credit", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" }, "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Net income", "documentation": "Net income attributable to Hologic" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": { "http://www.hologic.com/role/NewAccountingPronouncements" }, "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": ["r201", "r202", "r204", "r208", "r256", "r257", "r260", "r261", "r270", "r271", "r363", "r364", "r538", "r539", "r540", "r566", "r570", "r574", "r575", "r576", "r582", "r583", "r584", "r596", "r597", "r602", "r636", "r637", "r638", "r683", "r684", "r685", "r686", "r687"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.hologic.com/role/NewAccountingPronouncementsPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "New Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r874"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r844", "r855", "r865", "r882", "r890"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r872"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r871"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r882"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r901"] }, "ecd_NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r901"] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": { "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesScheduleOfChangeInFairValueOfDerivativeContractsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": ["r23"] }, "holx_NormediMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "NormediMember", "presentation": { "http://www.hologic.com/role/BusinessCombinationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Normedi", "label": "Normedi [Member]", "documentation": "Normedi" } } }, "auth_ref": [] }, "holx_NotationalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "NotationalAmount", "crdr": "debit", "presentation": { "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Notational Amount", "label": "Notational Amount", "documentation": "Notational Amount" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": { "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r945"] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "presentation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r45"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "lang": { "en-us": { "role": { "totalLabel": "Operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "verboseLabel": "Income (loss) from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r292", "r306", "r312", "r315", "r794"] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureTextBlock", "presentation": { "http://www.hologic.com/role/BasisOfPresentation" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r115", "r182", "r688", "r689"] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "presentation": { "http://www.hologic.com/role/RestructuringDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Lease asset impairment charges", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": ["r934", "r970"] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": { "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": ["r88", "r100"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r219"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r230"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), net", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r228", "r229"] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": { "http://www.hologic.com/role/DerivativesGainLossFromFairValueHedgesRecognizedinAOCI": { "lang": { "en-us": { "role": { "terseLabel": "Amount of gain (loss) recognized in other comprehensive income, net of taxes", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": ["r228", "r229", "r557", "r558", "r560"] },

```

OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetTaxExcludingAmountsReclassifiedFromAOICI": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetTaxExcludingAmountsReclassifiedFromAOICI", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "terseLabel": "Changes in foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation adjustment, net tax, excluding amounts reclassified from AOICI", "documentation": "Other Comprehensive Income (Loss), Foreign Currency Translation adjustment, net tax, excluding amounts reclassified from AOICI" } } } }, "auth_ref": [ ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income activity", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "auth_ref": [ "r22", "r30", "r233", "r236", "r242", "r586", "r587", "r592", "r642", "r658", "r927", "r928" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity", "auth_ref": [ "r11", "r20", "r183", "r233", "r236" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "auth_ref": [ "r40" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other adjustments and non-cash items", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "auth_ref": [ "r155" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "auth_ref": [ "r150" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount", "auth_ref": [ "r874" ] }, "holx_OtherTypeofRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "OtherTypeofRevenueMember", "presentation": { "http://www.hologic.com/role/RevenueRevenuebyTypeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Type of Revenue [Member]", "documentation": "Other Type of Revenue [Member]", "auth_ref": [ ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount", "auth_ref": [ "r842", "r853", "r863", "r888" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Recovery Compensation Amount", "label": "Outstanding Recovery Compensation Amount", "auth_ref": [ "r845", "r856", "r866", "r891" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name", "auth_ref": [ "r845", "r856", "r866", "r891" ] }, "holx_PSUFreeCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PSUFreeCashFlowMember", "presentation": { "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PSU Free Cash Flow [Member]", "label": "PSU Free Cash Flow [Member]", "documentation": "PSU Free Cash Flow [Member]", "auth_ref": [ ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "auth_ref": [ "r870" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.hologic.com/role/BusinessCombinationDetails": "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "auth_ref": [ "r10" ] }, "holx_PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of minimum tax withholdings on net share settlements of equity awards", "label": "Payment For Tax Withholding Related To Vested And Released Restricted Stock Units", "documentation": "The payment of minimum statutory tax withholdings to taxing authorities on the behalf of employees from the net share settlement upon vesting of restricted stock units. This payment is not an expense of the Company nor an operating activity.", "auth_ref": [ ] }, "holx_PaymentOfDeferredAcquisitionConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PaymentOfDeferredAcquisitionConsideration", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of deferred acquisition consideration", "label": "Payment of deferred acquisition consideration", "auth_ref": [ ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other activity", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "auth_ref": [ "r911", "r931" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Repurchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period.", "auth_ref": [ "r48" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intellectual property", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "auth_ref": [ "r152" ] }, "us-gaap_PaymentsToAcquireOtherInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireOtherInvestments", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Strategic investments", "label": "Payments to Acquire Other Investments", "documentation": "Amount of cash outflow to acquire investments classified as other.", "auth_ref": [ "r151" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": { "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail": { "lang": { "en-us":
```

"PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": { "r871" }, "holx_PercentageOfRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PercentageOfRevenues", "presentation": { "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Percentage Of Revenues", "documentation": "Percentage of revenues." } } }, "auth_ref": { "r871" }, "holx_PercentageOfShareRepurchaseProgram": { "xbrltype": "percentItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PercentageOfShareRepurchaseProgram", "presentation": { "http://www.hologic.com/role/ShareRepurchaseDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Percentage of share repurchase program", "label": "Percentage of share repurchase program", "documentation": "Percentage of share repurchase program." } } }, "auth_ref": { "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": { "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Performance Shares", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": { "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r129", "r464" } } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r129", "r708" } } }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheetsParentetical" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": { "r129", "r464" } } }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.01 par value lu2013 1,623 shares authorized: 0 shares issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r129", "r649", "r817" } } }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r926" } } }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": { "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": { "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid income taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r784", "r796", "r966" } } }, "holx_PrincipalAmountOfBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "PrincipalAmountOfBorrowings", "crdr": "credit", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Borrowed principal", "label": "Principal Amount Of Borrowings", "documentation": "Represents the aggregate outstanding principal of amounts borrowed under the Credit Agreement." } } }, "auth_ref": { "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Sale of business, net of cash disposed", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": { "r47" } } }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock pursuant to employee stock plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": { "r9", "r26" } } }, "holx_ProceedsFromSwap": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ProceedsFromSwap", "crdr": "debit", "presentation": { "http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Proceeds from swap", "label": "Proceeds from swap", "documentation": "Proceeds from swap" } } }, "auth_ref": { "holx_ProceedsReceivedFromGovernmentGrantsForCapacityExpansion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ProceedsReceivedFromGovernmentGrantsForCapacityExpansion", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the Department of Defense", "label": "Proceeds received from government grants for capacity expansion", "documentation": "Proceeds received from government grants for capacity expansion" } } }, "auth_ref": { "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" }, "lang": { "en-us": { "role": { "terseLabel": "Product", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": { "r803" } } }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": { "r317", "r634", "r674", "r675", "r676", "r677", "r678", "r679", "r780", "r803", "r818", "r914", "r973", "r974", "r977", "r998" } } }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "presentation": { "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" }, "lang": { "en-us": { "role": { "terseLabel": "PeriodStartLabel": "Balanceu00a0at Beginningu00a0of Period", "periodEndLabel": "Balanceu00a0at Endu00a0ofu00a0Period", "label": "Standard and Extended Product Warranty Accrual", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": { "r111", "r414", "r418", "r421" } } }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": { "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" }, "lang": { "en-us": { "role": { "negatedLabel": "Settlements/ Adjustments", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": { "r419" } } }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": { "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Provisions", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": { "r420" } } }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": { "http://www.hologic.com/role/ProductWarranties" }, "lang": { "en-us": { "role": { "terseLabel": "Product Warranties", "label": "Product Warranty Disclosure [Text Block]", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": { "r410", "r411", "r412", "r413", "r415", "r416" } } }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": { "r317", "r634", "r674", "r675", "r676", "r677", "r678", "r679", "r780", "r803", "r818", "r914", "r973", "r974", "r977", "r998" } } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r15" } } }, "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, fair value", "label": "Property, Plant, and Equipment, Fair Value Disclosure", "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r988" } } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" }, "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r164", "r215", "r655" } } }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentMember", "presentation": { "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets",

"http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantandEquipmentDetail"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r15", "r646", "r655", "r817"], "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationTables"], "lang": { "en-us": { "role": { "terseLabel": "Other Balance Sheet Information of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r15"], "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r164"], "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": ["http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Loss", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r245", "r369"], "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r870"], "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r870"], "holx_RSUPSUSUMSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "RSUPSUSUMSMember", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "RSU, PSU, MSU", "label": "RSU, PSU, MSU [Member]", "documentation": "RSU, PSU, MSU [Member]" } } }, "auth_ref": ["us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": ["ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r837", "r848", "r858", "r883"], "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Repayments of Debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r932"], "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r49", "r691"], "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": ["r114", "r527", "r995"], "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": ["ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r838", "r849", "r859", "r884"], "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r839", "r850", "r860", "r885"], "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r846", "r857", "r867", "r892"], "holx_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "RestOfWorldMember", "presentation": ["http://www.hologic.com/role/RevenueGeographicalRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Rest of World", "label": "Rest of World [Member]", "documentation": "Rest of World [Member]" } } }, "auth_ref": ["us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units, net of shares withheld for employee taxes (in shares)", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": ["us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": ["us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Vesting of restricted stock units, net of shares withheld for employee taxes", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": ["us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/Restructuring"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities Disclosure", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r396", "r397", "r399", "r402", "r407"], "us-gaap_RestructuringAndRelatedCostExpectedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringAndRelatedCostExpectedCost", "crdr": "debit", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected cost", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": ["r398", "r401", "r404", "r406"], "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "calculation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r13", "r403", "r404", "r971"], "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r398", "r399", "r400", "r401", "r404", "r405", "r406"], "us-gaap_RestructuringCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostsAbstract", "lang": { "en-us": { "role": { "label": "Restructuring Costs [Abstract]" } } }, "auth_ref": ["us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanAxis", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan" } } }, "auth_ref": ["us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringPlanDomain", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": ["us-gaap_RestructuringReserveAcceleratedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringReserveAcceleratedDepreciation", "crdr": "debit", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated depreciation", "label": "Restructuring and Related Cost, Accelerated Depreciation", "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan." } } }, "auth_ref": ["us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r132", "r174", "r652", "r683", "r687", "r692", "r709", "r817"], "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r206", "r253", "r254", "r255", "r259", "r267", "r269", "r362", "r365", "r524", "r525", "r526", "r536", "r537", "r561", "r563", "r564", "r567", "r571", "r680", "r682", "r695", "r1002"], "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": ["us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer,

Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": ["r293", "r294", "r305", "r310", "r311", "r317", "r319", "r321", "r478", "r479", "r634"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.hologic.com/role/RevenueFromContractWithCustomerPolicies"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r729", "r778", "r791"] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.hologic.com/role/RevenueNarrativeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r198"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": ["http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r199"] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": ["http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r199"] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": ["http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Percentage", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": ["r912"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r241", "r250", "r293", "r294", "r305", "r310", "r311", "r317", "r319", "r321", "r360", "r422", "r423", "r425", "r426", "r427", "r429", "r431", "r433", "r434", "r581", "r645", "r975"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfIncome"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues [Abstract]", "auth_ref": [] }, "holx_RevolverMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "RevolverMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Revolver", "label": "Revolver [Member]", "documentation": "Revolver [Member]" } } }, "auth_ref": [] }, "holx_RightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "RightOfUseAssetMember", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Right of use asset [Member]", "label": "Right of use asset [Member]", "documentation": "Right of use asset" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r901"] }, "ecd_Rule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"] }, "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r901"] }, "holx_SSIUltrasoundImagingBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "SSIUltrasoundImagingBusinessMember", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsParentetical", "http://www.hologic.com/role/DispositionAdditionalInformationDetails", "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails", "http://www.hologic.com/role/Role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "SSI Ultrasound Imaging Business", "label": "SSI Ultrasound Imaging Business [Member]", "documentation": "SSI Ultrasound Imaging Business" } } }, "auth_ref": [] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScenarioPlanMember", "presentation": ["http://www.hologic.com/role/BasisOfPresentationDetails", "http://www.hologic.com/role/BusinessCombinationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Agreement", "label": "Scenario, Plan [Member]", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.hologic.com/role/BasisOfPresentationDetails", "http://www.hologic.com/role/BusinessCombinationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": ["r270", "r487", "r909", "r941"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://www.hologic.com/role/TradeReceivablesandAllowanceforCreditLossesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r43"] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Changes in Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r45", "r991", "r992"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.hologic.com/role/BusinessCombinationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": ["r75", "r76", "r548"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.hologic.com/role/DerivativesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOI) and reclassified into earnings." } } }, "auth_ref": ["r95"] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Company's Borrowings", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-term instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "presentation": ["http://www.hologic.com/role/DerivativesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Assets at Fair Value", "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]", "documentation": "Tabular disclosure of derivative assets at fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": ["http://www.hologic.com/role/DerivativesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r89", "r94", "r559"] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": ["http://www.hologic.com/role/DispositionTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income from Operation of Disposed Business", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r16", "r27", "r32", "r117", "r118", "r119", "r120", "r121", "r122", "r124", "r125", "r126", "r167"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Basic and Diluted Share Amounts", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r942"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.hologic.com/role/StrategicInvestmentDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": ["r356", "r357", "r359"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": ["http://www.hologic.com/role/StrategicInvestmentDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r250", "r356", "r357", "r359", "r360", "r581"] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": ["http://www.hologic.com/role/StrategicInvestmentDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a)

the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": ["r211", "r250", "r356", "r357", "r359", "r360", "r581"] }, "us-gaap_ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r577", "r578"] }, "us-gaap_ScheduleOffFairValueOffBalanceSheetRisksTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffFairValueOffBalanceSheetRisksTable", "presentation": ["http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Off-balance Sheet Risks [Table]", "label": "Schedule of Fair Value, off-Balance-Sheet Risks [Table]", "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition." } } }, "auth_ref": ["r105", "r187"] }, "us-gaap_ScheduleOffFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffFiniteLivedIntangibleAssetsTable", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r59", "r62", "r635"] }, "us-gaap_ScheduleOffFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r59", "r62"] }, "holx_ScheduleOfGeographicalSegmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ScheduleOfGeographicalSegmentsLineItems", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Geographical Segments [Line Items]", "label": "Schedule Of Geographical Segments [Line Items]", "documentation": "Schedule Of Geographical Segments [Line Items]" } } }, "auth_ref": [] }, "holx_ScheduleOfGeographicalSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ScheduleOfGeographicalSegmentsTable", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Geographical Segments [Table]", "label": "Schedule Of Geographical Segments [Table]", "documentation": "Schedule Of Geographical Segments [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOffIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": ["r28", "r161"] }, "holx_ScheduleOfInterestExpenseUnderConvertibleNotesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ScheduleOfInterestExpenseUnderConvertibleNotesTableTextBlock", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense Under Convertible Notes", "label": "Schedule Of Interest Expense Under Convertible Notes [Table Text Block]", "documentation": "Schedule of interest expense under convertible notes." } } }, "auth_ref": [] }, "holx_ScheduleOfInterestExpenseUnderCreditAgreementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ScheduleOfInterestExpenseUnderCreditAgreementsTableTextBlock", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Interest Expense Under Credit Agreement", "label": "Schedule Of Interest Expense Under Credit Agreements [Table Text Block]", "documentation": "Schedule Of Interest Expense Under Credit Agreements" } } }, "auth_ref": [] }, "us-gaap_ScheduleOffInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOffInventoryCurrentTableTextBlock", "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Other Balance Sheet Information of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r33", "r136", "r137", "r138"] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": ["http://www.hologic.com/role/ProductWarrantiesTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Product Warranty Activity", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r417"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": ["http://www.hologic.com/role/RestructuringDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost, the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": ["r398", "r399", "r400", "r401", "r404", "r405", "r406"] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTableTextBlock", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Revenues by Geography", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r55", "r145"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail", "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r52", "r53", "r54", "r56"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTableTextBlock", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r52", "r53", "r54", "r56"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r489", "r491", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519"] }, "holx_ScheduleOfShareBasedCompensationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ScheduleOfShareBasedCompensationExpenseTableTextBlock", "presentation": ["http://www.hologic.com/role/StockBasedCompensationTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation Expense in Consolidated Statements of Operations", "label": "Schedule Of Share Based Compensation Expense [Table Text Block]", "documentation": "Schedule of share-based compensation expense." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": ["http://www.hologic.com/role/StockBasedCompensationTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Assumptions Utilized to Value Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r176"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.hologic.com/role/IntangibleAssetsandGoodwillTables"] }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r62"] }, "holx_SecuredTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "SecuredTermLoanMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"] }, "lang": { "en-us": { "role": { "terseLabel": "Secured Term Loan", "label": "Secured Term Loan [Member]", "documentation": "Secured Term Loan" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.hologic.com/role/CoverPage"] }, "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r832"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.hologic.com/role/CoverPage"] }, "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r834"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r289", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [

"http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r319", "r320", "r697", "r698", "r699", "r752", "r753", "r754", "r762", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r781", "r804", "r821", "r977", "r998"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "holx_SegmentReportingDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "SegmentReportingDisclosureLineItems", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Disclosure [Line Items]", "label": "Segment Reporting Disclosure [Line Items]", "documentation": "Segment Reporting Disclosure [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformation"], "lang": { "en-us": { "role": { "terseLabel": "Business Segments and Geographic Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r288", "r289", "r290", "r291", "r292", "r304", "r309", "r313", "r314", "r315", "r316", "r317", "r318", "r321"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome"], "lang": { "en-us": { "role": { "terseLabel": "Selling and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": ["r144"] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotes", "crdr": "credit", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Senior notes", "label": "Senior Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation with maturities initially due after one year or beyond the operating cycle if longer. Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": ["r112", "r997"] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "holx_September222022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "September222022Member", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "September 22, 2022", "label": "September 22, 2022 [Member]", "documentation": "September 22, 2022" } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceMember", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofIncome", "http://www.hologic.com/role/RevenueRevenuebyTypeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Service", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r803"] }, "us-gaap_SeveranceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts", "crdr": "debit", "presentation": ["http://www.hologic.com/role/RestructuringDetails"], "lang": { "en-us": { "role": { "terseLabel": "Severance costs", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r13"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsofCashFlows", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsofOperationsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r12"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Shares granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r508"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r508"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r505", "r506"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r518"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "crdr": "debit", "presentation": ["http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term." } } }, "auth_ref": ["r517"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": ["http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": ["r516"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsofOperationsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r489", "r491", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": ["r979"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r511"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-

gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation, stock options outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r497", "r498"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average exercise price of options outstanding (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r497", "r498"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average exercise prices (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r501"] }, "us-gaap_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramAxis", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareRepurchaseProgramDomain", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of the share repurchase program." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedtoValueStockOptionsDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r515"] }, "holx_ShareBasedCompensationArrangementRestrictedStockVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ShareBasedCompensationArrangementRestrictedStockVestingPeriod", "presentation": ["http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Performance stock units vesting period", "label": "Shared Based Compensation Arrangement Restricted Stock Vesting Period", "documentation": "Period of time that must lapse in order for the restricted stock units to vest." } } }, "auth_ref": [] }, "holx_ShareRepurchasePlanLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ShareRepurchasePlanLineItems", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "share repurchase plan [Line Items]", "label": "share repurchase plan [Line Items]", "documentation": "[Line Items] for share repurchase plan [Table]" } } }, "auth_ref": [] }, "holx_ShareRepurchasePlanTable": { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "ShareRepurchasePlanTable", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "share repurchase plan [Table]", "label": "share repurchase plan [Table]", "documentation": "share repurchase plan [Table]" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": ["r22"] }, "holx_SkeletalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "SkeletalHealthMember", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Skeletal Health", "label": "Skeletal Health [Member]", "documentation": "Skeletal health." } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r209", "r289", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r315", "r321", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r395", "r401", "r406", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r797", "r914", "r998"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r22", "r42", "r206", "r237", "r238", "r239", "r253", "r254", "r255", "r259", "r267", "r269", "r287", "r362", "r365", "r477", "r524", "r525", "r526", "r536", "r537", "r561", "r562", "r563", "r564", "r565", "r567", "r571", "r586", "r588", "r589", "r590", "r591", "r592", "r601", "r680", "r681", "r682", "r695", "r747"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": ["http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r319", "r320", "r697", "r698", "r699", "r752", "r753", "r754", "r762", "r766", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r781", "r804", "r821", "r977", "r998"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsParentetical", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r253", "r254", "r255", "r287", "r634", "r690", "r696", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r725", "r727", "r729", "r730", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r747", "r822"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": ["http://www.hologic.com/role/BasisOfPresentationDetails", "http://www.hologic.com/role/BusinessCombinationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": ["r270", "r487", "r909", "r910", "r941"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfCashFlowsParentetical", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": ["r253", "r254", "r255", "r287", "r634", "r690", "r696", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r721", "r722", "r723", "r724", "r725", "r727", "r729", "r730", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r747", "r822"] }, "ecd_StkPrCOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrCOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r841", "r852", "r862", "r887"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": ["http://www.hologic.com/role/NetIncomeLossPerShareDetail"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Stock Options and stock units", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": ["r943"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued under the employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r22", "r129", "r130", "r174"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r22", "r129", "r130", "r174", "r502"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued under the employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r22", "r129", "r130", "r174"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r22", "r42", "r174"] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [

"http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Authorized Amount", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchased During Period, Shares", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r22", "r129", "r130", "r174", "r691", "r747", "r763"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchased During Period, Value", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r22", "r129", "r130", "r174", "r695", "r747", "r763", "r830"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": "http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r130", "r133", "r134", "r156", "r710", "r726", "r748", "r749", "r817", "r831", "r936", "r964", "r990", "r1002"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r80", "r81", "r83", "r206", "r207", "r238", "r253", "r254", "r255", "r259", "r267", "r362", "r365", "r477", "r524", "r525", "r526", "r536", "r537", "r561", "r562", "r563", "r564", "r565", "r567", "r571", "r586", "r588", "r592", "r601", "r681", "r682", "r694", "r710", "r726", "r748", "r749", "r764", "r830", "r936", "r964", "r990", "r1002"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.hologic.com/role/ShareRepurchase"], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r171", "r249", "r463", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r477", "r569", "r750", "r751", "r765"] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsegmentsAxis", "presentation": ["http://www.hologic.com/role/OtherBalanceSheetInformationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": ["http://www.hologic.com/role/BasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": ["r593", "r603"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": ["http://www.hologic.com/role/BasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": ["r593", "r603"] }, "us-gaap_SubsequentEventsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyTextBlock", "presentation": ["http://www.hologic.com/role/BasisofPresentationPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events Consideration", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r881"] }, "us-gaap_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "TermLoanMember", "presentation": ["http://www.hologic.com/role/BorrowingsandCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsandCreditArrangementsCompaniesBorrowingsDetail"], "lang": { "en-us": { "role": { "terseLabel": "Term Loan", "label": "Term Loan [Member]", "documentation": "Term Loan [Member]", "documentation": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount", "crdr": "debit", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount", "crdr": "debit", "presentation": ["http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]", "documentation": "Trade Names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r77"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement", "label": "Trading Arrangement [Axis]", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": ["r900"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]", "documentation": "Trading Symbol", "label": "Trading Symbol", "documentation": "Transfers and servicing of financial instruments types of financial instruments domain", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments Domain", "presentation": ["http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.hologic.com/role/DerivativesFairValueofDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r460", "r475", "r568", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r659", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r959", "r960", "r961", "r962"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date", "documentation": "Duration of the trading arrangement", "label": "Trading Arrangement Duration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration", "documentation": "Individual title of the trading arrangement", "label": "Trading Arrangement, Individual Title", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title", "documentation": "Aggregate available amount of securities", "label": "Trading Arrangement, Securities Aggregate Available Amount", "presentation": ["http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date", "documentation": "Treasury stock common member", "label": "Treasury Stock Common Member", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r70"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheetsParentHetical": "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r70"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.hologic.com/role/ShareRepurchaseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r22", "r130", "r174"] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": ["http://www.hologic.com/role/ConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost \u2013 2013 68,731 and 58,231 shares, respectively", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": ["r41", "r70", "r71"] }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

"TreasuryStockValueAcquiredParValueMethod", "crdr": "debit", "presentation": "I", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us"; { "role": "negatedTerseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Par Value Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method." } }, "auth_ref": "r22", "r70", "r174", "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": "I", "http://www.hologic.com/role/BusinessSegmentsandGeographicInformationRevenuesbyGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "lang": "en-us"; { "role": "terseLabel": "United States", "label": "UNITED STATES" } }, "auth_ref": "us-gaap_USTreasurySecuritiesMember"; { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": "I", "http://www.hologic.com/role/FairValueMeasurementsCashandCashEquivalentsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetail", "lang": "en-us"; { "role": "terseLabel": "US Treasury Securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } }, "auth_ref": "r792", "r810", "r996"; { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": "en-us"; { "role": "terseLabel": "Ultrasound imaging assets, equipment", "label": "Ultrasound imaging assets, equipment", "documentation": "Ultrasound imaging assets, equipment", "auth_ref": "holx_UltrasoundImagingAssetsDevelopedTechnologyMember"; { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "UltrasoundImagingAssetsDevelopedTechnologyMember", "presentation": "I", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": "en-us"; { "role": "terseLabel": "ultrasound imaging assets, developed technology", "label": "Ultrasound imaging assets, developed technology [Member]", "documentation": "Ultrasound imaging assets, developed technology", "auth_ref": "holx_UltrasoundImagingAssetsEquipmentMember"; { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "UltrasoundImagingAssetsEquipmentMember", "presentation": "I", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "lang": "en-us"; { "role": "terseLabel": "Ultrasound imaging assets, equipment", "label": "Ultrasound imaging assets, equipment", "documentation": "Ultrasound imaging assets, equipment", "auth_ref": "holx_UltrasoundImagingAssetsMember"; { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/20240629", "localname": "UltrasoundImagingAssetsMember", "presentation": "I", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": "en-us"; { "role": "terseLabel": "Ultrasound imaging assets", "label": "Ultrasound imaging assets [Member]", "documentation": "Ultrasound imaging assets", "auth_ref": "ecd_UndrlygSecurityMktPriceChngPct"; { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": "I", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us"; { "role": "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent", "auth_ref": "r899"; { "xbrltype": "us-gaap_UnrealizedGainLossOnDerivatives"; { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": "I", "http://www.hologic.com/role/DerivativesScheduleOfChangeinFairValueOfDerivativeContractsDetails", "lang": "en-us"; { "role": "terseLabel": "Amount of unrealized gain (loss) recognized in income", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } }, "auth_ref": "r13", "r741", "r742", "r743", "r744", "r757"; { "xbrltype": "us-gaap_ValuationTechniqueAxis"; { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": "I", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": "en-us"; { "role": "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } }, "auth_ref": "r24"; { "xbrltype": "us-gaap_ValuationTechniqueDiscountedCashFlowMember"; { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": "I", "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": "en-us"; { "role": "terseLabel": "Valuation Technique, Discounted Cash Flow", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } }, "auth_ref": "r989"; { "xbrltype": "us-gaap_ValuationTechniqueDomain"; { "xbrltype": "domainItemType", "nsuri": "http://www.hologic.com/role/IntangibleAssetsandGoodwillAdditionalInformationDetails", "lang": "en-us"; { "role": "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } }, "auth_ref": "r24"; { "xbrltype": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"; { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.hologic.com/role/NetIncomeLossPerShareDetail"; { "parentTag": null, "weight": null, "order": null, "root": true }; { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/NetIncomeLossPerShareDetail", "lang": "en-us"; { "role": "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPS), determined based on the timing of issuance of shares or units in the period." } }, "auth_ref": "r274", "r282"; { "xbrltype": "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"; { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": "I", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "lang": "en-us"; { "role": "terseLabel": "Weighted average number of shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "auth_ref": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"; { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.hologic.com/role/NetIncomeLossPerShareDetail"; { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 }; { "xbrltype": "stringItemType", "nsuri": "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/NetIncomeLossPerShareDetail", "lang": "en-us"; { "role": "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } }, "auth_ref": "r273", "r282"; { "xbrltype": "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"; { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": "I", "http://www.hologic.com/role/NetIncomeLossPerShareDetail", "lang": "en-us"; { "role": "terseLabel": "Weighted-average anti-dilutive shares related to", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "auth_ref": "std_ref"; { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481913/940-20-25-1", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a), (b), (c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i), (j), (k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5", "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1", "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15", "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19", "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2", "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2", "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2", "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A", "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3", "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b), (d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3", "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D", "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15", "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1", "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

YSGTU|4G|TIDFS858:IV@Z#BRU:01,4A:H=3MO:N-\$PG6:X55B:M4+16P6:M4%4YBM@#CMT:2N=200=M@VJ_90-Z2NMZNO@UW U14L,1LD5L Q1T1F+ MPU-
Z#:#H=;2,Q2CJ^E\$!&F^J^S2YMWJV_#M9?>B+D4I&C(WI.^#+Q+3?7 M1|@C15DVIN*)9/PT13%EF:HY&@&F1=96%#6FXTA!#:#* 1B|&J61UHL\$N M?
EWK#K3#1GMJ|J^HJ|V1KFE^J1PRR8AVZ>#=#78.#Y:VD1&A)AX>TXP2A4D..J|* MHCRLE/MJZ:1>WJ6:5JH>O&T FX:98^CP65D<@IH+543:N3\$8N1U.IKH2
U>=>SRD:GCMJ|U6^<-IC8N1\$SWU.Z5Y810K^TZK:UVZ:P74 M2#94Z9Y10MTFT M>O N|*U>9N0CJ:JL3HJVX^TJ/KUY:FE@JN|D7J:2IMBB Y^U+Z^7T1XPDP:5B*
0N7N1=>H(02Y13K M^X)01?>OSPOXKTA45:ADP5TA)A^L/J.Y_9G "65J1MIKOSDR+E=MS_EO9 M21R757LJL=H.&ZBWU 2V+52A4MPIB1+19BON6&RDS9G^A=5PY3*6JHAR
M9S8J\$<8F-M R-C=1&2CZ80_5W(C^VGO:J)IGT^<A:01LH1#XT\$E\$<N0/VDX2 M&W:R^R^IYWA^5#U1=LMC2I7_YFN/QDZIEJ12KBR4L^>+<5^<^<-X*2EZOEF:7 M1OB>BS_BB?
#=>BZ\$S2:1L|IK>H1FL2=C6(U_1^5^<-&BCUHY?(@/01#&?TJ\$S M8QV6W+<=<C4VX^&R^<W5<3 XFG>+& 71M9QX65\$<XJ:ITLC(6^SCHWL#XPP/E MC_8B9^
S#103X1IWDU:N/FEQ\$ACEX P.C15#E1@1:1N5Y61MT^ M21_5I>E B_ZVLP^*6K1KJLJHWY7^JL 10M(C3WU^5R+& TGQY:J2B1J15
MOI@XANQ61P\$0\$WJ1|0M8R791HG^:018+X=9P6?)>.(O6B1N^X^<X^K0\$<M+>DYDY2481RZHYB TD231 "9.#Z7Z_8B8WNXY:MLZ90PP65TD1QX&_*1^M
MD^<Z8W>O>PRZ60_1A78 "M M2@<9#K917+GK9:ME7Z5:5M1=RE<^"V12=I7^H..HLB6_4#01%<E\$3PI_#0 MTC>J20U?
^X.YWSR06M&C.#PANJ2IOQ^<8_7<IDG:Q^OY.C1#H#>U10^RP1_#A M#:#RMMEB&#<Z2G82RU:14)ZFW_SCSH2?1^QK1P>=>A1+&+& B9C0WJZ:1<@>SWQYVF MXR8(0PV2)2^F&^<-
J7A1JL1B1^8.Y01V>LDH(I1^N1V^T^>YCY|B#..>)> MWO^?Y7+&F^JIG/4:0^+<S+<154=891<1O&6^&A ROM+P|J=6#3(6-22D1XBGULT")>6%..K.Y&QVOU ^T9<#:# 7.M.H1Q+<F96
1..LPZNBS4P_0UXG0@1^&Y:3^3F0HYTIS:ELX1_)-WXX&P8 M^%1@21@94>1.O2^<YF M8|G14|IE83&A98&XIOH^00^2AAB^JMLRP2^<ATU+>7(ZP:3 M-
G8^>@#H^P8^PQ|TCL^<^>1>5HPYO1A^Q^1D.0R^OPX^WX8B_#62ZT2^?F_MAS:== 33A01W51^<6N1UEXG@T+1^IYI&4\$1XE@<6^QN@<=>"N9E=PDF-XSKO^3.B M9K\$Y^FU>|Y_<=>MCS\$G^>OCC|<OR=S3^<KYSN0#<1^J^>20X+UZY M^GS^<6&5G1E_M=OYIF378<X^RR-^>#>U1@:(E-X8DSUD-WDF&IX>^>)D^M
M.9S1H71LBTS&:1%6WNVJ:097^E^@>^YXFOG-B.Q^RDNU1A_5|VEN^<H^W^P2FO/HI=V.Z>EEGCIY^628Y3)LDMMHY&@#RQL2 M/OP4C&EKS&BDE8_1JQ_&F^0%<6>J|U-
9^2SD811939NJ-OT.V(7X21^N4 MYHX_H^?MNS9+6D=>8GR14JG9^7 W_IDE>R:7S UF&I10<=<=<P.Y^T MGX M+0#0J^<=>NB?7>4S1M=J8.1
J35A|U>L78S^>_&Q&31221LD&SGZOG M^#WINMD&9G:Y^TC^>O4AK5+1C Z5Z1>:iV519LZ1+1#0A_1W:B.CF^<+ MBP45@|YK+J|JIDGM@QN7FRC9_OKG?0JY^*8JT
T^#N1LB7C1\$G1 @<SC&W/0 MAVYNB2JAOT^JQO>+<V23+>J-W.VN4_1V_55DNPFDI^YOC:HS(O^<+>2^?1 M:OCM^6HJ9>T63>S+>_D31J9DDP9TO>?>9^6^<M
M.^%<@>30^6LROTLN@<W^<C^>BXL1^>=>VDDI&5="80JO1K^<6^<KZNI&1|D5X M@Z\$2^?1>@<H=I-L M^>=>SGM+<8B.DXN=N82#<8B9\$1^1^28XVUD&S&61FM69V^>
M171MJ+J&619S>=>VM_10MC@_Y3PV)H/JTK-W2V2V(2>G8P8V:IR3P8BNVHF6D1^*=1D6Q51T1D^K> M=<^T.V.RZU^<#<^<4^M^>TR=2C<^<H-K9V)S^<QNS5^MHE&11%
GH.T1ZYN+Q.L.N1N.SN4#<B_86V6^T^ MUIBP=<SB?K6#<2>:U=UY?KATN/Z04^PS.CDM+3W^1MU1_1^7QWDZ2HX_O M^<F&NPVY^<M^>+<1RV^>7=1M&P^<P=IGZ80@<8HG.YY9.3I:1
1.M.31_1YC1^3BX\$SOELO=>TATS/N4^<+D#<@>VY1O1@<=<=<SS.WK2%1K^<A&&F\$3^<AQ>D MJOXN7Y%<B:RT65>=>X1+Y M:&=<U^>VU7O1109W^<A14G3C1CTJ+ZQO?>+D^<F^<Q^7E:TX^<
M^<K1XHG@<IKYSA^<T1XIEIMVU1_@<7+NW?BBP^<#<4=KYOS:5.7CN/E1624FORC M^SL_>60^<VBOG\$<@N\$6>1E-#<J-LG-N1ONEIS5^>.2NOZ99^TTR_@<4NO0%>JW2 MT^IYI^1K6C@<JLJ>:
IKR\$<CV^<A&Y&W1&(<A^<V1108\$M^<M&P&K\$<M.O^F1E_#<JSJVL BN(XP2DRP^DMYIH^<#<=<U8+<F^<F=V0^1^2 J1^<ML^<EJ|@I23^1^W\$MT^<
I801=<8_01D2^<L:BC&UV^<1_<SKKK^<C^<V79+<1^<W M^<1^>1+<@<#<W>:N1LHDH5R3V3M^>6:1^<8CC@<W^<X&Y^<V3@6ZRF^<RV&C&=<MNGC1\$OULES>IQ1<^<T^?>
9VUZ1O1^<LBKTP:6C^<1_<OWOXE^<8^<VN^<#<^<TGR@< MRCM(CCEW^<J33^<7=<D01CIG1Q1O^<ST^<2LXB1^<ZPKEDJ^<M^<K5P:1^<IWW1L1 M1>=W7^<J14+<1^<+28C^<1^<IDCIF5N1L^>^<
I7Y3^<7E1N^<1D>3G^<V^<BR(6Z.O& M^<RTCHC/1591^<1^<7C^<1^<V^<+Z^<7H3F.9GFOVRAUG E/548<^<R16IM1J2L OH4E^<MP_<A4014@I&E1A:0&K?E17> H-L3/RYTY V^<H<1^<TO-<QD-
5V6<1S&@<X=<X^<MDNT17^<670 X2^<MTR\$^<1^<V^<M4U\$^<366G/CLJ24>E^<ZU1.E7^<@<41HMPA^<#<B4D^<W/AH^<FU01Q@<#<80R^<J^<M^<WV^<UW^<979^<+>8 M^<1Y1YFDDIOF@<Z1I
10Q5C7^<R=<2B>8WE-1IUGP^<XD5M^<4^<H.EAK_<S=< MEF1M^<O1ONFT1E^<O=Y(24^<?^<I@<F=<B&81J2^<IDL5U^<UO6F@<F1^<YU^<M^<W1(2^<1^<92^<1^<O+>
Y4ZBS\$12.B>18N^<X2^<MDYLDDED^<?>1PN+<@<P#<DE0^<R M^<QNC^<P2^<7=<G>B^<H^<UBJ41^<_<GSX.O.G^<VY(1/3F/E^<X1

[illegible]

[illegible]

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

N+OM57H6+L7:6-CPWL'R'IC, M6U|>LYAE3T\$.:=!0\$RQ7A2ZIVG>VHCl-<8G5MfEPH_R3J31P1.11#(A'1A_M'('f(=)S9V0M2>=f2MEX-X65F<R@+JF@#&YU.RNjZ=8PH64:<\$X'M7->.<JL^<(U>W>K140:@MB%>X5>2XKJ62QR*&\$KJ5#K7,H#TWO1@2.Oi5 M8Y%5^010>DH/MR 00:@9#D7MIH876K1'2UV'63'03J.R?+2\$2-6.UC=MT5K7=1P\$S'PMRfH.K'62R2ZY.<@X'@'48DM1YQV(H#M3N<.&G4.8)>=W4M=FCY1L1T0JPC59QZULXJ0U>YMQ4N#B8(OM0)0?CP4*>>AQ'D6'fJ4ZC-MJAA.F\$Rb^<0QJ'U'ALF9M.LTN#45'U+R@A6Q'VYX'VY#Nf/5>4.\$O'A'D7P'M<:>.<Y%>'Q86Q<f(0U(X+JLH+R080\$WSL#JQO>O'YMHX923+4.9PSB?2.MHTXA.5QB#><>Y%>9ZGH\$K6:9)SYZ:U#^". W")@/,.S.R.6R1@5N4\$A-PY.M.S&92<NNY&.*X)5X07^C.L'W3MfLFOG+AVR9I>L17^5:IR%Z6L;fW1_M2=H^<H2^>..8E9Jf68L+J4<#5)-#f&C#225Nf^<K=NBWfC3f36'4G5<5'>..fH+098 IZ7U'1MM'1#0<55R60f1<+&f8f;RRH+T@P63fJfB)&fJ'8W6M-\$fJMQ>fT6fH75H5 MP%Y>225fPG=8):OFC'KP DY203^125N?>=INTV#Kf(1 M4R@JN.BV33\$ M@H=X\$2M.36C_H\$=WU'W'f7_08fBfBfR+J+25@fHf85fY@f85H BD)=A-M.D(80\$G73N\$WKf(=J^>+fWJZ7-U7_ZL6.\$H2V'4Q06L2.O1<:-PGRJ44EJ5f@T9IAG68f+M2T9QAI>2I8U5.O>T0^Df&7YR<S.NfM1fEQFV72fTY_R8Jf&fY53.Mf#0=fYfNk+XW_O;U^X?#f3RH2D?D9Q\$ L?M\$Xf9EG(<>@S%GH9BW*:@)Nf?B860fLXfY=!:@Af'f'fE_L#_M.LfJ3^6;fL'P>Z)-fT>S!+>O'A.A5=fTE%@fOUfUX'U5F&f97+V4XfV=3ENA#f-

[illegible][illegible]

[illegible]

[illegible]

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

gaap:TradeNamesMember 2023-12-312024-03-30 0000859737 us-gaap:DevelopedTechnologyRightsMember 2024-03-30 0000859737 us-gaap:TradeNamesMember 2024-03-30 0000859737 holx:MobidiagMember holx:RightOffUseAssetMember 2023-10-012023-12-30 0000859737 holx:MobidiagMember us-gaap:InProcessResearchAndDevelopmentMember 2023-12-312024-03-30 0000859737 holx:MobidiagMember us-gaap:InProcessResearchAndDevelopmentMember 2024-06-29 0000859737 us-gaap:InProcessResearchAndDevelopmentMember 2023-04-022023-07-01 0000859737 us-gaap:InProcessResearchAndDevelopmentMember 2023-07-01 0000859737 holx:UltrasoundImagingAssetsMember 2023-04-022023-07-01 0000859737 holx:UltrasoundImagingAssetsDevelopedTechnologyMember 2023-04-022023-07-01 0000859737 holx:UltrasoundImagingAssetsEquipmentMember 2023-04-022023-07-01 0000859737 holx:SSIUltrasoundImagingBusinessMember 2023-12-30 0000859737 us-gaap:CashMember 2024-06-29 0000859737 us-gaap:CashMember 2023-10-012024-06-29 0000859737 us-gaap:CashAndCashEquivalentsMember us-gaap:CashMember 2024-06-29 0000859737 us-gaap:MoneyMarketFundsMember 2023-10-012024-06-29 0000859737 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember 2024-06-29 0000859737 us-gaap:USTreasurySecuritiesMember 2023-10-012024-06-29 0000859737 us-gaap:CashAndCashEquivalentsMember us-gaap:USTreasurySecuritiesMember 2024-06-29 0000859737 us-gaap:CommercialPaperMember 2023-10-012024-06-29 0000859737 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2024-06-29 0000859737 us-gaap:CashAndCashEquivalentsMember 2024-06-29 0000859737 holx:CreditAgreementMember 2024-06-29 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2024-06-29 0000859737 holx:A2029SeniorNotesMember us-gaap:SeniorNotesMember 2024-06-29 0000859737 holx:A2028SeniorNotesMember 2024-06-29 0000859737 holx:A2029SeniorNotesMember 2024-06-29 0000859737 holx:JWMedicalMember 2023-07-032023-07-03 0000859737 holx:JWMedicalMember us-gaap:CustomerRelationshipsMember 2023-07-032023-07-03 0000859737 holx:NormediMember 2023-04-032023-04-03 0000859737 holx:NormediMember 2023-04-03 0000859737 holx:NormediMember us-gaap:CustomerRelationshipsMember 2023-04-032023-04-03 0000859737 holx:AccessaHealthMember 2020-08-23 0000859737 holx:AccessaHealthMember 2020-08-232020-08-23 0000859737 holx:MaverixMedicalLLCMember 2023-11-13 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:SSIUltrasoundImagingBusinessMember 2023-09-28 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:SSIUltrasoundImagingBusinessMember 2023-09-282023-09-28 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:SSIUltrasoundImagingBusinessMember 2023-07-022023-09-30 0000859737 holx:MobidiagMember 2023-10-012023-12-30 0000859737 holx:MobidiagMember 2024-06-29 0000859737 holx:MobidiagMember 2024-03-312024-06-29 0000859737 holx:MobidiagMember 2023-10-012024-06-29 0000859737 holx:DanburyClosureMember 2024-03-312024-06-29 0000859737 holx:DanburyClosureMember 2023-10-012024-06-29 0000859737 holx:DanburyClosureMember 2023-04-022023-07-01 0000859737 holx:DanburyClosureMember 2022-09-252023-07-01 0000859737 holx:DanburyClosureMember 2024-06-29 0000859737 holx:TermLoanMember 2024-06-29 0000859737 holx:TermLoanMember 2023-09-30 0000859737 holx:A2028SeniorNotesMember 2024-06-29 0000859737 holx:A2028SeniorNotesMember 2023-09-30 0000859737 holx:A2029SeniorNotesMember 2024-06-29 0000859737 holx:A2029SeniorNotesMember 2023-09-30 0000859737 holx:A2021TermLoanMember holx:SecuredTermLoanMember 2021-09-27 0000859737 holx:A2021TermLoanMember holx:SecuredTermLoanMember 2024-06-29 0000859737 holx:A2021TermLoanMember holx:SecuredTermLoanMember 2023-10-012023-12-30 0000859737 holx:CreditAgreementMember 2024-03-312024-06-29 0000859737 holx:CreditAgreementMember 2023-04-022023-07-01 0000859737 holx:CreditAgreementMember 2023-10-012024-06-29 0000859737 holx:CreditAgreementMember 2022-09-252023-07-01 0000859737 holx:CreditAgreementMember 2023-07-01 0000859737 holx:InterestRateSwapAgreementOneMember 2024-06-29 0000859737 holx:InterestRateSwapAgreementTwoMember 2024-06-29 0000859737 us-gaap:InterestRateSwapMember 2024-03-312024-06-29 0000859737 us-gaap:InterestRateSwapMember 2023-10-012024-06-29 0000859737 us-gaap:InterestRateSwapMember 2023-04-022023-07-01 0000859737 us-gaap:InterestRateSwapMember 2022-09-252023-07-01 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2024-03-312024-06-29 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2023-04-022023-07-01 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2023-10-012024-06-29 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2022-09-252023-07-01 0000859737 holx:A2029SeniorNotesMember us-gaap:SeniorNotesMember 2024-03-312024-06-29 0000859737 holx:A2029SeniorNotesMember us-gaap:SeniorNotesMember 2023-04-022023-07-01 0000859737 holx:A2029SeniorNotesMember us-gaap:SeniorNotesMember 2022-09-252023-07-01 0000859737 holx:A2028And2029SeniorNotesMember us-gaap:SeniorNotesMember 2024-03-312024-06-29 0000859737 holx:A2028And2029SeniorNotesMember us-gaap:SeniorNotesMember 2023-10-012024-06-29 0000859737 holx:A2028And2029SeniorNotesMember us-gaap:SeniorNotesMember 2022-09-252023-07-01 0000859737 us-gaap:InterestRateSwapMember 2022-08-25 0000859737 holx:InterestRateSwap2024Member 2023-03-23 0000859737 holx:InterestRateSwap2023Member 2023-03-23 0000859737 holx:InterestRateSwap2023Member 2024-06-29 0000859737 us-gaap:ForwardContractsMember 2024-06-29 0000859737 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-03-312024-06-29 0000859737 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-04-022023-07-01 0000859737 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-10-012024-06-29 0000859737 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2022-09-252023-07-01 0000859737 us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2024-03-312024-06-29 0000859737 us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2023-10-012024-06-29 0000859737 us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2022-09-252023-07-01 0000859737 us-gaap:NondesignatedMember 2024-03-312024-06-29 0000859737 us-gaap:NondesignatedMember 2023-04-022023-07-01 0000859737 us-gaap:NondesignatedMember 2023-10-012024-06-29 0000859737 us-gaap:NondesignatedMember 2022-09-252023-07-01 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000859737 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-29 0000859737 us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-30 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NondesignatedMember 2023-09-30 0000859737 us-gaap:NondesignatedMember 2024-06-29 0000859737 us-gaap:NondesignatedMember 2023-09-30 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2023-09-30 0000859737 us-gaap:StockCompensationPlanMember 2024-03-312024-06-29 0000859737 us-gaap:StockCompensationPlanMember 2023-04-022023-07-01 0000859737 us-gaap:StockCompensationPlanMember 2023-10-012024-06-29 0000859737 us-gaap:StockCompensationPlanMember 2022-09-252023-07-01 0000859737 us-gaap:CostOfSalesMember 2024-03-312024-06-29 0000859737 us-gaap:CostOfSalesMember 2023-04-022023-07-01 0000859737 us-gaap:CostOfSalesMember 2023-10-012024-06-29 0000859737 us-gaap:CostOfSalesMember 2022-09-252023-07-01 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2024-03-312024-06-29 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-022023-07-01 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-012024-06-29 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2022-09-252023-07-01 0000859737 us-gaap:SellingAndMarketingExpenseMember 2024-03-312024-06-29 0000859737 us-gaap:SellingAndMarketingExpenseMember 2023-04-022023-07-01 0000859737 us-gaap:SellingAndMarketingExpenseMember 2023-10-012024-06-29 0000859737 us-gaap:SellingAndMarketingExpenseMember 2022-09-252023-07-01 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2024-03-312024-06-29 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-022023-07-01 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-012024-06-29 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2022-09-252023-07-01 0000859737 us-gaap:EmployeeStockOptionMember 2023-10-012024-06-29 0000859737 us-gaap:EmployeeStockOptionMember 2022-09-252023-07-01 0000859737 us-gaap:EmployeeStockOptionMember 2024-06-29 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2023-10-012024-06-29 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2023-04-022023-07-01 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2022-09-252023-07-01 0000859737 us-gaap:PerformanceSharesMember 2023-10-012024-06-29 0000859737 us-gaap:PerformanceSharesMember 2022-09-252023-07-01 0000859737 holx:MarketBasedAwardsMember 2023-10-012024-06-29 0000859737 holx:PSUFreeCashFlowMember 2023-10-012024-06-29 0000859737 holx:PSUFreeCashFlowMember 2022-09-252023-07-01 0000859737 holx:MarketBasedAwardsMember 2022-09-252023-07-01 0000859737 holx:RSUPlanRSUMember 2024-06-29 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2024-06-29 0000859737 us-gaap:PropertyPlantAndEquipmentMember holx:MobidiagMember 2023-04-022023-07-01 0000859737 us-gaap:PropertyPlantAndEquipmentMember holx:SSIUltrasoundImagingBusinessMember 2023-04-022023-07-01 0000859737 2023-10-012024-03-30 0000859737 us-gaap:IntersegmentEliminationMember 2023-04-022023-07-01 0000859737 us-gaap:IntersegmentEliminationMember 2023-10-012024-06-29 0000859737 us-gaap:IntersegmentEliminationMember 2023-09-30 0000859737 us-gaap:IntersegmentEliminationMember 2024-03-312024-06-29 0000859737 us-gaap:CorporateMember 2024-03-312024-06-29 0000859737 us-gaap:CorporateMember 2023-04-022023-07-01 0000859737 us-gaap:CorporateMember 2023-10-012024-06-29 0000859737 us-gaap:CorporateMember 2022-09-252023-07-01 0000859737 holx:DiagnosticsMember 2024-06-29 0000859737 holx:DiagnosticsMember 2023-09-30 0000859737 holx:BreastHealthMember 2024-06-29 0000859737 holx:BreastHealthMember 2023-09-30 0000859737 holx:GynSurgicalMember 2024-06-29 0000859737 holx:GynSurgicalMember 2023-09-30 0000859737 holx:SkeletalHealthMember 2024-06-29 0000859737 holx:SkeletalHealthMember 2023-09-30 0000859737 us-gaap:CorporateMember 2024-06-29 0000859737 us-gaap:CorporateMember 2023-09-30 0000859737 holx:AllOtherCountriesMember 2024-03-312024-06-29 0000859737 holx:AllOtherCountriesMember 2023-10-012024-06-29 0000859737 holx:AllOtherCountriesMember 2022-09-252023-07-01 0000859737 us-gaap:ForeignCountryMember 2024-03-312024-06-29 0000859737 holx:DevelopedTechnologyMember 2024-06-29 0000859737 holx:DevelopedTechnologyMember 2023-09-30 0000859737 us-gaap:InProcessResearchAndDevelopmentMember 2024-06-29 0000859737 us-gaap:InProcessResearchAndDevelopmentMember 2023-09-30 0000859737 holx:CustomerRelationshipsContractsMember 2024-06-29 0000859737 holx:CustomerRelationshipsContractsMember 2023-09-30 0000859737 us-gaap:TradeNamesMember 2023-09-30 0000859737 holx:AcquiredIntangibleAssetsMember 2024-06-29 0000859737 holx:AcquiredIntangibleAssetsMember 2023-09-30 0000859737 holx:InternalUseSoftwareMember 2024-06-29 0000859737 holx:InternalUseSoftwareMember 2023-09-30 0000859737 holx:CapitalizedSoftwareMember 2024-06-29 0000859737 holx:CapitalizedSoftwareMember 2023-09-30 0000859737 holx:BioZorbMember 2023-12-312024-03-30 0000859737 holx:BioZorbMember us-gaap:DevelopedTechnologyRightsMember 2023-12-312024-03-30 0000859737 holx:BioZorbMember us-gaap:TradeNamesMember 2023-12-312024-03-30 0000859737 holx:BioZorbMember us-gaap:DevelopedTechnologyRightsMember 2024-03-312024-06-29 0000859737 holx:BioZorbMember us-gaap:TradeNamesMember 2024-03-312024-06-29 0000859737 holx:MobidiagMember us-gaap:InProcessResearchAndDevelopmentMember 2023-10-012023-12-30 0000859737 holx:MobidiagMember 2023-12-30 0000859737 holx:MobidiagMember us-gaap:CustomerRelationshipsMember 2023-12-30 0000859737 holx:MobidiagMember us-gaap:TradeNamesMember 2023-12-30 0000859737 us-gaap:InProcessResearchAndDevelopmentMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-07-01 0000859737 us-gaap:InProcessResearchAndDevelopmentMember 2023-04-022023-07-01 0000859737 us-gaap:DevelopedTechnologyRightsMember 2023-04-022023-07-01 0000859737 us-gaap:CustomerRelationshipsMember 2023-04-022023-07-01 0000859737 us-gaap:EquipmentMember 2023-04-022023-07-01 0000859737 holx:SSIUltrasoundImagingBusinessMember holx:UltrasoundImagingAssetsMember 2023-04-022023-07-01 0000859737 holx:SSIUltrasoundImagingBusinessMember holx:UltrasoundImagingAssetsDevelopedTechnologyMember 2023-04-022023-07-01 0000859737 holx:SSIUltrasoundImagingBusinessMember holx:CapitalEquipmentComponentsAndSoftwareMember 2023-04-022023-07-01 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-03-30 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-312024-06-29 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-10-012024-06-29 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-10-012024-06-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-29 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-29 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-01 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-24 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-24 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-24 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-022023-07-01 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-022023-07-01 0000859737 us-gaap:InterestRateSwapMember

gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-022023-07-01 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-252023-07-01 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-252023-07-01 0000859737 us-gaap:InterestRateSwapMembers-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-252023-07-01 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-07-01 0000859737 us-gaap:InterestRateSwapMembers-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-01 0000859737 holx:September222022Member 2022-09-23 0000859737 holx:December112020Member 2024-06-29 0000859737 holx:September222022Member 2024-03-312024-06-29 0000859737 holx:September222022Member 2023-10-012024-06-29 0000859737
holx:September222022Member 2024-06-29 0000859737 2023-11-06 0000859737 2023-11-15 0000859737 2023-11-17 0000859737 2023-11-172023-11-17 0000859737 2024-02-272024-02-27 0000859737 holx:KarleenObertonMember 2023-10-012024-06-29 0000859737 holx:KarleenObertonMember 2024-03-312024-06-29 0000859737
holx:KarleenObertonMember 2024-06-29 shares iso4217:USD iso4217:USD shares pure holx:Segmentfalse2024Q30000859737-09-28P3MPYYPYPYPYPYP150D10-0true2024-06-29false1-36214HOLEGIC-INCDE04-2902449250 Campus Drive,Marlborough,MA01752(508)263-2900Common Stock,\$0.01 par valueHOLEXNASDAQYesYesLarge Accelerated
Filterfalsefalsefalse2322719068112000007991000000246720000025229000002002000001853000005751000000101140000098440000030423000003085100000298200
1700000124000006200000210000034800000490000031630000036610000010175000001033300000214400000.014000006526000005359000002840000032500000803000000
7000000.0240700000121000006435000003305000004462000005260000032600000165100000194500000-405000006109000003654000000.83-0.162.581.480.82-
0.162.571.47234604000246908000236373000247319000236466000246908000238081000249393000194500000-40500000610900000365400000-
2800000110000017400000130200000100000-29000001200000-17000003000003700000-9300000-5600000-250000048000008100000124600000192000000.0-
35700000619000000.049000000.002439100000272250000062850000062560000066550000061760000015840000017530000010550000031600000011900000039970000004184
13950000014760000049509000005016900000889010000091393000002985330003000000.060426000001600300000-23820000051401000-
12515000000487200000267000103000001030000051400023000000.023000000.017100010200000010200000205000002050000018740000018740000011090000011090000013
273300000529400000-
26315000005092500000173000790000079000001800020000020000023200000232000002185000002185000008900000890000062600050000000.050000000.02996760003000
11840000053566000-268150000053008000006400033000003300000150005000005000001770001130000011300000169000001690000040500000-
405000004800000480000014240001141000001141000002999320003000000.061225000001965700000-11360000054990000-
27956000005182000000400000030000030000019000000.019000000.09060000090600000-34000000.0-
34000000.032410002404000002404000002999400003000000.061112000002056300000-14760000058231000-
303600000050169000001240005000000.05000000.04320001620000016200000287000002870000024650000024650000028800000288000002161000155900000155900000100
118800000665952000-359190000046538000007900032000003200000160001000001000001650001000000.01000000.02580000025800000169900000169900000-18200000-
18200000-100000000.0142800010000000.003007560003000000.061976000002472700000-137000000.067380000-
3691900000484440000024000120000012000007000300000300000000001460000014600000194500000194500000-2500000-
25000001351000101000000.0101000000.0300780003000000.062131000002667200000-13950000068731000-
37929000004950900000610900000365400000752000006670000015920000018120000066910000060600000-52300000-100200000448000002238000001700000-12400000-
32400000-30600000250000051000000.0471000004850000073900000-153000004200000-2460000026500000-
2030000058500000107000001990000046000000.0918200000792500000-
31300000065000000.05550000002050000043900000422000004250000010000000.010000000.00160000089000000000-185300000-
961000002781000001130000002600000760000080000007768000002636000002520000033770000016600000237700000290000023000001051800000-
27260000023000001700000-316600000425500000275570000023395000002439100000276500000033200000Basis of Presentation<div style="text-align:justify;text-indent:27pt">The unaudited consolidated financial statements of Hologic, Inc. ("Hologic" or the "Company") presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the "SEC") for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles ("GAAP") for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 30, 2023 included in the Company's annual report on Form 10-K filed with the SEC on November 21, 2023. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company's financial position, results of operations and cash flows for the periods presented.</div><div style="text-align:justify;text-indent:27pt">&

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<table border=

[illegible]

[illegible]

[illegible]

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;></td><td style="background-color:#cfeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.042,3</td><td style="background-color:#cfeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cfeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"></td><td style="background-color:#cfeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.085,1</td><td style="background-color:#cfeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div>733000004890000012220000079700000471000001260000002454000006530000031070000024020000062000000.03022000007900000079000001070000001070000032</div><div><div style="text-align:justify;text-indent:27pt">Lessor Activity - Leases where Hologic is the Lessor</div><div>Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company's consolidated revenue for all periods presented.</div><div><div style="text-align:justify;text-indent:27pt">Lessor Activity - Leases where Hologic is the Lessor</div><div>Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating lease and performance obligations for disposables, reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. Sales-type leases are immaterial. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented less than 3% of the Company's consolidated revenue for all periods presented.</div><div>0.03</div><div>Fair Value Measurements</div><div style="text-align:justify;text-indent:27pt">Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis</div><div style="text-align:justify;text-indent:27pt">
</div><div style="text-align:justify;text-indent:27pt">The Company has investments in money market funds, United States Treasury bills and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents on the Consolidated Balance Sheets.</div><div><div style="text-align:justify;text-indent:27pt">
</div><div><div style="text-align:justify;text-indent:27pt">The Company also has investments in derivative instruments comprised of interest rate swaps and forward foreign currency contracts, which are valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs.</div><div><div style="text-align:justify;text-indent:27pt">
</div></div></div><div style="text-align:justify;text-indent:27pt">The following table summarizes certain fair value information at June 29, 2024 and September 30, 2023 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments.</div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;text-align:center;text-bottom:1pt;text-align:justify;text-indent:27pt"><tr><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<div><table><tr><td colspan=

</div>

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

2025-01-10 10:10:10

[The following text is extremely dense and appears to be a mix of random characters and symbols, likely representing a corrupted or encrypted document. It contains no meaningful information.]

[illegible]

[illegible]

M/Z!\$G7!WGT69%_QK32@TAID=X.9B-ME-L/ZNV*S_7M;D!=C/KT&+OZ+(J;+&?X++9@!B@OU2|^R)Z,&JC\$67:P.E4-M!P!5!;T6*RY;;;FS-KK-M!9>O/XD*LI%O?E^%V(%?_L@YKV.JSL#P9DU2?SLQ15L2Y9>|D)+2AWB+V.M.PU\,\$0-M!B-'R0.U!_Y<CM-!-T!^&/8EE7_6^@^DTC1OKP?CQXU==E3Q4!MV!FN=T!|R_HZSS6<.<%9&7Q8\$E^75A^)>V+D&C!10E%Z6T<(^0>/UOR-Y.M^0M9KL5/@E3K4BB#IV_2SOUY5=!*E\$^\$+L7-ZG%=5U^\$HC5?=F@(MBY+;3J_-M(E5>?<@)E7^IG|^3?/6A?^J;-%5NNL;J6;TEY4H^5BUHFC&11=*6#7\$(Q%%_MD\$1A"GD<=>@DBF4@0=\$JLV\$^L792=(G10@@_+65;T(J\$*#*AH+X%#_D!+^-BEY-H+\$.5=@0\X542!^Q1)?P0!44#^MJB?+G=Z=-4TXFM_SX3WK.3#|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